Dear Colleagues and Guests:

Welcome to the 161st Annual Meeting of the American Psychiatric Association. Our Annual Meeting is the largest psychiatric meeting in the world, and we have planned a full and exciting week of educational, networking, and social opportunities for you.

Our theme this year is “Our Voice in Action: Advancing Science, Care, and the Profession,” and the meeting itself is organized around these areas. There are many outstanding scientific presentations, addressing the newest advances and their influence on patient care. Dr. Thomas Insel, Director of the National Institute of Mental Health and his staff have planned an extensive track of sessions integrating research and clinical care, scheduled throughout the meeting. World famous scientists will present their latest research, and there will be multiple opportunities for small group discussions with senior clinicians and educators. Additionally, sessions address subspecialties such as geriatric psychiatry, addictions, forensic psychiatry, and consultation-liaison psychiatry, as well as child and adolescent care. There are workshops and symposia on issues such as mental health care for returning military, college mental health, practical psychopharmacology, new directions in psychotherapy, electronic health records, and ethics, to list only a few. You can test yourselves at the “Focus: Live” sessions or watch “MindGames,” a Jeopardy-like contest for residents, and of course, find time to enjoy the many wonderful museums, sites, and restaurants of my home town, Washington, D.C.

Please join me at the Opening Session Sunday from 5:00 p.m. to 6:30 p.m., when we officially welcome world leaders and all attendees, and plan to attend the Convocation of Distinguished Fellows Monday at 5:30 p.m., when we will honor colleagues being inducted as Fellows, the APA award winners. The William C. Menninger Memorial lecture will be presented at the Convocation by Dr. Oliver Sacks, neurologist and acclaimed author of Awakenings, The Man Who Mistook His Wife for a Hat, and Musicophilia.

Producing such a rich and full meeting demands much work, and a strong collaboration between members and staff. I especially appreciate the efforts of Dr. David Baron and the members of the Scientific Program Committee, and the many APA staff who are dedicated to the success of this outstanding meeting.

Have a wonderful week!

Sincerely,

Carolyn Robinowitz, M.D.
APA President
Dear APA Members and Guests:

Welcome to Washington, D.C., and the 161st Annual Meeting of the American Psychiatric Association. I anticipate that this terrific city, and its fantastic weather, will provide a perfect setting for the scientific presentations we have planned. As you read through the Program Book, you will notice a number of sessions related to the theme “Our Voice in Action: Advancing Science, Care, and the Profession,” chosen by our President, Dr. Carolyn B. Robinowitz. Let me draw your attention to just a few of the many exciting sessions presented this week, including several Presidential Symposia, which will be presented Monday-Wednesday, from 2:00 p.m.-5:00 p.m.

The Business Meeting and the Opening Session will be held at the Washington Convention Center on Sunday, May 4. The Convocation of Distinguished Fellows also will be held there, on Monday evening, May 5, 5:30 p.m. - 6:30 p.m. During the Convocation, Oliver Sacks, M.D. will present the William C. Menninger Memorial Lecture.

A great way to begin this year’s meeting is to attend the “Advances in Series,” which will focus on the latest advances in neuropsychiatry and clinical neurosciences, C-L psychiatry and psychosomatic medicine, geriatric psychiatry, and psychiatric disorders. We have also combined the Master Educator Consultations, Discussion Groups, and Research Consultations into Small Interactive Sessions, consisting of 15 clinically-based seminars with outstanding clinician educators. These sessions are held Monday through Wednesday.

This year, we have a special series of sessions that will be presented in collaboration with the National Institute of Mental Health. Outstanding leaders in psychiatry and neuroscience research will present across formats from lectures to symposia and workshops. The APA is extremely appreciative of their support of these sessions. For detailed information on the sessions, please consult the separate program on this series, which is included in your registration packet.

It is extremely important that you fill out and return the evaluation forms for this meeting. The members of the Scientific Program Committee are interested in your opinion regarding the quality of the content of the Annual Meeting. The information we obtain will be used to plan next year’s Annual Meeting. Once again, welcome to Washington, D.C. I look forward to sharing a week of exciting and professionally rewarding activities with you.

Sincerely,

David Baron, Ms.Ed., D.O.
KEY LOCATIONS
WASHINGTON, DC CONVENTION CENTER

<table>
<thead>
<tr>
<th>Location</th>
<th>Room/Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Journal of Psychiatry and Psychiatric Services</td>
<td>APPI Bookstore, Hall B, Ground Level</td>
</tr>
<tr>
<td>APA Communications Center</td>
<td>Room 206/Level Two</td>
</tr>
<tr>
<td>APA Meetings and Conventions Office</td>
<td>Room 209A, Level Two</td>
</tr>
<tr>
<td>APA Member Center</td>
<td>Hall B, Lower Level</td>
</tr>
<tr>
<td>APA Scientific Programs Office</td>
<td>Room 203A, Level Two</td>
</tr>
<tr>
<td>Audiotape and CD Sales</td>
<td>East Lobby, Level One</td>
</tr>
<tr>
<td>A/V Preview Room</td>
<td>Room 204A, Level Two</td>
</tr>
<tr>
<td>CME Course Enrollment</td>
<td>Hall B, Lower Level</td>
</tr>
<tr>
<td>CME Certificate of Attendance</td>
<td>Hall B, Lower Level</td>
</tr>
<tr>
<td>Daily Bulletin</td>
<td>Room 206, Level Two</td>
</tr>
<tr>
<td>Exhibit Registration Office</td>
<td>Show Office A, Concourse, Lower Level One</td>
</tr>
<tr>
<td>Exhibits/Publishers’ Bookfair</td>
<td>Halls A-C, Lower Level</td>
</tr>
<tr>
<td>Housing Desk</td>
<td>East Lobby, Level One</td>
</tr>
<tr>
<td>Lost &amp; Found Room</td>
<td>Room 209A, Level Two</td>
</tr>
<tr>
<td>Message Center</td>
<td>East Lobby, Level One</td>
</tr>
<tr>
<td>On-Site Job Bank and Placement Center</td>
<td>APA Member Center, Hall B, Lower Level</td>
</tr>
<tr>
<td>Registration</td>
<td>Hall B, Ground Level</td>
</tr>
</tbody>
</table>

FIRST AID
Located in Exhibit Hall A, Lower Level Two, Washington Convention Center, Hours of operation: Monday, April 28, through Thursday, May 8, and opens 30 minutes prior to show opening and closes 30 minutes after the last event of the evening.

COURTESY SHUTTLE BUS SERVICE
Service will begin on Saturday, May 3, at approximately 7:00 a.m., and will operate daily throughout the meeting commensurate with the scientific program schedule and will conclude on Thursday, May 8, at 6:00 p.m. The Washington Convention Center will serve as the “hub” for all shuttle bus routes. The Shuttle Bus Desk will be located in the South Lobby, L Street Level, Washington Convention Center. A detailed Shuttle Bus Schedule is included in your registration packet and will be posted in the lobbies of participating hotels. Refer to the city map on page XVII-XI for the location of hotels in relation to the Washington Convention Center.

EXHIBITS
Commercial and educational exhibits will be located in Exhibit Halls A-C, Ground Level, Washington Convention Center, along with the Publishers’ Bookfair and the APA Member Center. For your convenience, the Publishers’ Bookfair and APA Member Center will be open Saturday, May 3, 10:00 a.m.-5:00 p.m. Educational and commercial exhibit hours are: Sunday, May 4, 10:00 a.m.-4:30 p.m.; Monday, May 5, and Tuesday, May 6, 10:00 a.m.-5:00 p.m.; and the final day, Wednesday, May 7, 10:00 a.m.-3:00 p.m.

MESSAGE CENTER
Located in East Lobby, Level One, Washington Convention Center and open during registration hours (with the exception of Thursday, May 8, when the Center will be open until 5:00 p.m.). Messages can be left and picked up at the Message Center. Registrants whose names appear on the monitors should pick up their messages at the Message Center.

APA JOB BANK
Visit the APA on-site Job Bank at APA 2008! The online APA Job Bank will power the popular on-site Job Bank providing improved tools for both employers and candidates at the APA’s Annual Meeting. Candidates and employers are encouraged to activate their resume and job postings in advance of the meeting for best results. For more information on the Job Bank, visit www.psych.org/jobbank.

APA COMMUNICATIONS OFFICE & PRESS ROOM
Located in Room 206/Level Two, Washington Convention Center. Hours of operation: Saturday, May 3, 11:00 a.m.-5:00 p.m.; Sunday-Wednesday, May 4-7, 8:00 a.m.-6:00 p.m.; and Thursday, May 8, 8:00 a.m.-2:00 p.m. This room is for the use of registered press only and credentialed public relations representatives only.

DAILY BULLETIN
The Daily Bulletin accepts written requests from APA members for publicity of component, committee, and allied group events as space allows. Four issues are published. The issue for Saturday/Sunday is printed in advance. Copy for the Monday, Tuesday, and Wednesday/Thursday issues can be dropped off in Room 14 A/B, Mezzanine Level, by 12 noon prior to the date of publication.

RESIDENTS’ RESOURCE CENTER
Located in the Columbia Rooms, North Tower, Lobby Level, of the Marriott Washington Hotel. The Residents’ Resource Center will be open from 7:00 a.m. to 6:00 p.m., Sunday, May 20, through Wednesday, May 23. Daily activities are scheduled for residents (such as the orientation, Residents Only Discussion Groups, and Resident Summits) and medical students. Meet and network with your colleagues and leaders in psychiatry. Resources specifically for residents and medical students are available here.

AIRPORT AND LUGGAGE CHECK-IN
You can now check in at the Washington Convention Center and bypass the airport lines! This unique service allows you to check your bags and receive your boarding pass at the Washington Convention Center, leaving you more time to visit the exhibits and attend sessions. It’s safe and secure: The first TSA-approved remote skycap service; Agents are highly trained and credentialed to issue boarding passes and print bag tags on demand. Participating Airlines (Domestic Flights Only): Alaska, American, Continental, Delta, JetBlue, Northwest, and United. Rates: $10 per passenger. Normal airline baggage constraints apply. Hours of operation: Wednesday and Thursday, May 7-8, 8:00 a.m.-1:00 p.m., in the main lobby of the Washington Convention Center. Flights may be checked in anytime the day of departure. Luggage must be checked a minimum of three hours before scheduled flight departure.
TOURS
Stop by the Tour Desk, East Lobby, Level One to purchase or pick up tickets to local tours.

REGISTRATION
Admission to all sessions by registration badge
Located in Exhibit Hall A, Ground Level, Washington Convention Center. Hours of operation: Friday, 12 noon-5:00 p.m.; Saturday, 7:30 a.m.-5:00 p.m.; Sunday, 7:30 a.m.-5:00 p.m.; Monday, 7:30 a.m.-5:30 p.m.; Tuesday, 7:30 a.m.-6:00 p.m.; Wednesday, 7:30 a.m.-5:00 p.m.; and Thursday, 7:30 a.m.-2:00 p.m.

On-Site Registration Fee Schedule:

**APA MEMBERS**
- Full-Time Registration (North American Members).............$295
- Full-Time Registration (International Members)...............$295-$520*
- Members-in-Training (Member Class MT)..........................$ 85
- Daily Registration (North American Members)...................$150
- Daily Registration (International Members)......................$275
- Medical Students..............................................................no charge
* Fee determined by country’s gross national income according to the World Bank.

**NONMEMBERS**
- Full-Time Registration ......................................................$880
- Nonmember Residents, Students, Advocacy
- Group Members, or Mental Health Chaplains .....................$120
- Daily Registration (all Nonmember categories)...............$470
- Medical Students..............................................................no charge

**GUEST REGISTRATION**
- One only per full-time registrant........................................$120
- Only one guest is allowed to register with each full-time meeting registrant. The guest must reside in the same household and be able to receive mail at the same address. APA members cannot register as a “guest”; they must register as an APA member. ID may be required.
- One-Day Exhibit Hall Only Pass (18 and older)....................20.00
  (Only paid registrant can purchase an exhibit hall pass)

On-site fees can be paid by U.S. dollar cash, check, money order, American Express, VISA, or MasterCard. Registration fees are waived only for CME Course Faculty, APA Honorary Fellows (does not include APA Distinguished Fellows/Fellows/Life Fellows/Distinguished Life Fellows), medical students (with proper identification), District Branch Executive Staff (who are not APA members), active members of the Association of Mental Health Clergy (with proper identification), and nonmember program participants (only for the day(s) they present, except for industry-supported symposium presenters who must pay the fee).

Nonmember psychiatric residents and other full-time students must present documentation to register in their respective category and qualify for the reduced fee. (Examples include: a valid full-time [12 + hours per semester] student ID; a letter from your instructor or director of training verifying your status as a psychiatric resident; or similar documentation.)

Note: There are no exemptions or reduced fees available for CME courses. The registration fee covers admission to all sessions (except courses), shuttle buses, and includes a badge and copy of the Program Book, APA Member Center Guide, and New Research Program and Abstracts Books, and for most categories, a copy of the Syllabus.

REGISTRATION BADGES
Badges are required for all sessions including the Opening Session and exhibit hall. Only an APA member badge will admit you to the Business Meeting.

**Badge Color Codes:**
- Blue-Members
- Yellow-Nonmembers
- Silver-Press
- Red-Exhibitors
- Green-APA Staff
- Clear-Temporary Personnel

Registered exhibitors will receive red badges, which allow access only to their exhibit booth in the exhibit hall and to ride the shuttle bus. If an exhibitor wants to attend sessions, he/she must register for the meeting and pay the appropriate fee.

CME COURSE ENROLLMENT
Ticket purchase required for CME Courses
Located in Exhibit Hall A, Ground Level, Washington Convention Center. Hours of operation are the same as registration. Tickets not sold in advance will be available online at the on-site fee after April 20, and on-site at the Course Enrollment Area beginning at 12 noon on May 2. You must be registered for the meeting before you can enroll in courses.

APA ART ASSOCIATION
Located in the L Street Bridge, Level Two, Washington Convention Center and open during the commercial exhibit hours, the exhibit includes paintings, photography, ceramics, and crafts created by APA members and/or their spouses/significant others. Stop by for information on joining the APA Art Association.

APA ALLIANCE BOOTH
Located in the East Lobby, Level One, Washington Convention Center. Hours of operation: Saturday, May 3, through Wednesday, May 7, 9:00 a.m.-5:00 p.m. Stop by the booth to obtain information on the Alliance’s program schedule and information on membership.

APA PERIODICALS
Editorial staff of The American Journal of Psychiatry, Psychiatric Services, Academic Psychiatry, Journal of Neuropsychiatry and Clinical Neurosciences, Psychosomatics, and APA’s CME journal, Focus, will be on hand to demonstrate online access for subscribers, and answer questions regarding submissions. Visitors can also purchase or renew subscriptions to all APA/APPI journals at the booth. Complimentary copies of Psychiatric News will be available at stands located throughout the Washington Convention Center. Persons who wish to contact editors or reporters of Psychiatric News are asked to leave a message on the message board in the Annual Meetings Office located in Room 209A, Level Two. Written announcements, suggestions for articles, letters to the editor, or other material for the newspaper’s consideration may be left with staff at the Periodicals Exhibit.
CONTINUING MEDICAL EDUCATION

Educational Objectives: At the conclusion of this meeting, participants will be able to:

- Review new research findings in the fields of psychiatry and neuroscience and address gaps in knowledge.
- Acquire new knowledge and skills in clinical psychiatry, which can be utilized to improve patient care.
- Identify and remove barriers to the transfer of new knowledge for their practice, including provision of culturally competent care for diverse populations.
- Assess a variety of treatment choices, including psychotherapeutic and pharmacological options; and
- Recognize mental health service delivery issues, including barriers to care.

The APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA designates this educational activity for a maximum of 66 AMA PRA Category 1 Credits.™ Physicians should only claim credit commensurate with the extent of their participation in the activity.

Please note: Most portions of the scientific program, as outlined below, have been approved for CME credit. The scientific sessions on the official Annual Meeting program, with some exceptions, meet the criteria for AMA PRA Category 1 Credit.™ Sessions in the following program formats are designated as category 1:

Advances in… Series, Case Conferences, CME Courses, Focus Live, Forums, Industry-Supported Symposia, Lectures, Presidential Symposia, Scientific and Clinical Reports, Small Interactive Sessions, Symposia, and Workshops. Other scientific sessions not listed may be reported as category 2 (Debates and New Research Poster Sessions). Scientific sessions are open to all Annual Meeting registrants, except for the Case Conferences, which are open to APA members only.

PLEASE NOTE: APA MEMBERS ARE REQUIRED TO MAINTAIN THEIR OWN RECORDS OF CME HOURS. REPORTING OF CME CREDIT IS ON AN HONOR BASIS.

To document CME credit earned at the Annual Meeting, participants should maintain a list of sessions they attended. Credit is earned on an hour-for-hour basis. A page for listing your sessions and credits is provided in the syllabus.

The Certificate of Attendance (or copy) may be forwarded to other organizations requiring verification of participation in the APA Annual Meeting.

The APA requires members to participate in a total of 150 credits of CME activities within a three-year reporting period. At least 60 credits must be in AMA PRA Category 1 Credit.™ activities. CME report forms may be obtained from the Department of CME at the APA or online at www.psych.org. A CME Certificate of Compliance is awarded to APA Members who complete the report. Staff will be available in the APA Member Center to answer any of your questions about CME.

ANNUAL MEETING EVALUATION

The Annual Meeting Scientific Program Committee needs your recommendations and evaluations to plan next year’s Annual Meeting. The General Evaluation is available online at the CME Certificate of Attendance Booth located in Hall B, Lower Level, Washington Convention Center.

By completing the General Evaluation, you will receive a personalized Certificate of Attendance. The certificate can be obtained either on-site by visiting the CME Certificate of Attendance Booth OR attendees may access the web-based evaluation from their own computer during or after the meeting by visiting www.psych.org and browse the Lifelong Learning & CME section. PLEASE NOTE: APA NO LONGER OFFERS PAPER GENERAL EVALUATION FORMS FOR THE ANNUAL MEETING.

SESSION CAPACITY

So that all in attendance may benefit, we ask your assistance when overcrowding occurs:

- Please find seating as far forward as possible.
- Move to the center of the row and fill all seats so that chairs are available on aisles for additional attendees.
- Overcrowding of meeting rooms may subject the session to shutdown by the Fire Marshal; therefore, we urge all attendees to locate seating rather than stand in aisles or against walls.
- If space does not permit you to attend a session, an audiotape of that session may be available. Please check the order form included in your registration packet.

AUDIO RECORDINGS OF SESSIONS

Audiotapes and CDs of most sessions are available shortly after each session concludes and may be purchased at the Mobiltape Booth located in East Lobby, Level One, Washington Convention Center.

SMOKING POLICY

There will be NO SMOKING in scientific sessions or in the exhibit hall. Smoking will only be permitted in designated areas.

TAPE RECORDING AND VISUAL REPRODUCTION POLICIES

Audiotape recording is only permitted for personal use. Registrants are welcome to use their own small, portable audiotape recorders to record any session except Case Conferences, unless prohibited by the presenters. Larger, professional tape recorders are not permitted except for use by registered members of the working press in accordance with APA Press Policies. APA has authorized a professional taping firm to audiotape sessions. Badges of personnel representing this firm will clearly identify them. Registrants are not permitted to photograph (including with cell phone cameras) or videotape any session because the intrusive nature of the recording may disrupt the session.
**FUTURE APA MEETINGS**

**APA ANNUAL MEETINGS**

- 2009 May 16-21  San Francisco, CA
- 2010 May 22-27  New Orleans, LA
- 2011 May 14-19  Honolulu, HI

**INSTITUTES ON PSYCHIATRIC SERVICES**

- 2008 October 2-5  Chicago, IL
- 2009 October 8-11  New York, NY
- 2010 October 14-17  Boston, MA
- 2011 October 27-30  San Francisco, CA

Preliminary Programs for the 2008 Institute on Psychiatric Services are included in the registration packet.

---

**GUIDE TO THE PROGRAM BOOK**

Below you will find the table of contents for ease in locating information about this meeting. A topic index is included to assist you with finding sessions of interest. The individual program for each day's sessions is listed by start time with the formats listed alphabetically under those times. **NOTE: You can also create your own personal schedule by using the online itinerary planner. Visit APA's homepage [www.psych.org](http://www.psych.org) and click on the 2008 Annual Meeting link.**

Then click on the link under the scientific session information heading and follow the instructions.

If you have any questions about this book or the scientific sessions, please feel free to stop by the Scientific Programs Office in Room 203A, Level Two, Washington Convention Center. Hours of operation: Friday, 9:00 a.m.-5:00 p.m.; Saturday, 7:00 a.m.-5:00 p.m.; Sunday, 7:00 a.m.-5:00 p.m.; Monday, 7:00 a.m.-6:00 p.m.; Tuesday, 7:00 a.m.-5:30 p.m.; Wednesday, 7:00 a.m.-5:30 p.m.; and Thursday, 7:00 a.m.-5:30 p.m. All APA staff will be wearing green badges. Please feel free to direct your questions to them.

---

**TABLE OF CONTENTS**

- Floor Plans for Washington Convention Center, Grand Hyatt, Washington, DC, Renaissance Washington, DC Hotel, and City Maps and Accommodations ................................................................. VI-XIII
- Local Information ........................................................................................................ XIV-XV
- Special Acknowledgments ........................................................................................ XVI-XVIII
- Format Descriptions .................................................................................................... XIX
- Disclosure Information .............................................................................................. XX-L
- APA's Online Library of 2008 Annual Meeting Sessions .......................................................... I
- Saturday Sessions ........................................................................................................ 1-4
- Sunday Sessions ........................................................................................................... 5-10
- 2008 Presidents of Allied Organizations ........................................................................... 11-14
- Join the APA Today ....................................................................................................... 15
- 2008 Institute on Psychiatric Service ................................................................................... 16
- Monday Sessions .......................................................................................................... 17-41
- Audiotape and CD Sales Information ............................................................................ 42
- Tuesday Sessions .......................................................................................................... 43-66
- Wednesday Sessions .................................................................................................... 67-86
- Thursday Sessions ...................................................................................................... 87-98
- Call for 2009 Annual Meeting Papers ............................................................................. 99
- Topic Index .................................................................................................................. 100-115
- Participant Index ......................................................................................................... 116-121
- American Psychiatric Publishing, Inc. ............................................................................... 122-123
- Industry-Supported Symposia ....................................................................................... 124-135

News reports or summaries of APA presentations contained in these program materials may not be published or broadcast before the local time and date of the presentation.

Refer to the APA Exhibits Guide for information on: Exhibits, Publishers’ Bookfair, and Dining Facilities in the Washington Convention Center.

The information provided and views expressed by presenters on this program are not necessarily those of the American Psychiatric Association, nor does the American Psychiatric Association warrant the accuracy of any information reported.

©American Psychiatric Association
WASHINGTON CONVENTION CENTER
Level 2
Meeting Rooms 201-210
Hall D
WASHINGTON CONVENTION CENTER

Level 3
Meeting Rooms 301-306
Ballrooms

MT. VERNON PLACE, BELOW
With its ideal mid-Atlantic location and comprehensive air and rail service, it's easy to get to Washington, DC. Thanks to a quick and efficient Metrorail subway system, friendly tour guides and broad, welcoming streets, it's also easy to navigate the Nation's Capital once you're here.

Visitors can fly into one of Washington, DC's three airports, ride a train into magnificent Union Station or navigate the region's network of major highways for a speedy arrival and easy conveyance downtown.

Once in town, hop aboard a site-seeing trolley, travel across town on Metro or on the DC Circulator, or take to the scenic Potomac River to experience the cityscape from a different angle. Either way, you will be delighted…and inspired.

**Area Transportation**

**Metro:**
Metrorail and Metrobus are the safest, cleanest and most efficient ways to get around Washington, DC. For a comprehensive map of our Metrorail subway system and hours of operation go to: [www.washington.org](http://www.washington.org) and click on Getting Around.

**DC Circulator:**
As mentioned above, another easy and economical way to get around our city is by riding the DC Circulator! The Circulator’s buses are unlike any other public transit around town- with low floors, big windows, and multiple doors for easy on-and-off service. For complete information on this convenient way to get around the city- please go to: [www.dccirculator.com](http://www.dccirculator.com)

**Taxi:**
Taxi fares within the District are based on the number of zones traveled not metered rates. Taxi fares from inside DC or Reagan National Airport to outside DC are based on mileage. Airport fares may vary due to exact route taken, congestion, and cab assigned at airport. Average taxi fares from the Walter E. Washington Convention Center to some of the more popular areas of the city:

- Georgetown - $8.80
- National Mall - $6.50
- U.S. Capitol - $6.50
- National Zoo - $8.80

To obtain average taxi fares from any DC location go to: [http://citizenatlas.dc.gov/atlasapps/taxifare.aspx](http://citizenatlas.dc.gov/atlasapps/taxifare.aspx)

**Weather**
Experience the glory of all four seasons here in Washington, DC. Warm weather usually prevails from April until October. May is the perfect time to visit with highs in the 70s and lows in the upper 50s.

**What to see and do**

Never before has Washington, DC provided so much to do in so many places. Culture, heritage, nationally- acclaimed theatre, FREE musical concerts, festivals, world-renowned shopping and all the inspiring monuments and museums you expect, offer ideal touring choices. Start at the National Mall and take in one of the 11 free museums or
take a monlight tour of the monuments. For a complete listing of attractions—go to: washington.org click on What to Do, then Attractions.

But Washington, DC is much more than a city of monuments and museums. It is a thriving cultural capital where opera, jazz and classical music lovers can find a tempting lineup of performances. For more information on Performing Arts—please go to: www.washington.org click on What to Do, then Performing Arts & Entertainment.

For a comprehensive listing of our calendar of events go to: www.washington.org click on Events.

To make your sightseeing plans early visit www.washington.org or call a Visitor Service Specialist at (800) 422-8644.

WHERE TO SHOP
If shopping is on your mind, DC is the place to go! From upscale boutiques in Georgetown and great to Bohemian shopping in Adams Morgan and world-famous outlet complexes, Washington, DC is a shopper's paradise. For shopping suggestions go to: www.washington.org click on Visitor Information then Where to Shop.

WHERE TO EAT
Washington, DC has become a true culinary capital thanks to neighborhood revitalization, ingenious chefs and serious foodies, including the millions of visitors who dine alongside lobbyists, politicians, journalists and celebrities in the District's top dining rooms. In recent years, a dizzying number of new eateries have opened up alongside perennial favorites. A quick tour of the city—any part of the city—reveals big name national chains as well as some of the best signature restaurants in the country. For a comprehensive list of restaurants in the DC Metro area go to: www.washington.org click on Visitor Information then Where to Eat.

AIRPORT INFORMATION

Washington, DC is serviced by three airports. Almost all major domestic and international airlines can be found at one of the three airports below:

**Dulles International Airport (IAD)**
Located approximately 26 miles west of DC (35 - 45 minutes)
Taxi: approximately $50.00 to downtown DC
Shared transportation: Super Shuttle
Travelers can take the Washington Flyer Coach bus to the West Falls Church Metro station for $9.00. Buses run every 30 minutes. For more info visit: http://www.metwashairports.com/Dulles/

**Ronald Reagan National Airport (DCA)**
Located approximately four miles south of DC (10 – 15 minutes)
Taxi: approximately $15.00 to downtown DC
Shared transportation: Super Shuttle
Reagan National Airport has its own Metro station* on the Yellow and Blue Line.
For more info visit: http://www.mwaa.com/national/

**Baltimore/Washington International Thurgood Marshall Airport (BWI)**
Located approximately 30 miles north of DC (40 – 50 minutes)
Taxi: approximately $60.00 to downtown DC
Shared transportation: Super Shuttle and Travelers can take the BWI Express Bus to the Greenbelt Metro station for $3.00. Buses run every 40 minutes. Travelers can also take the MARC Train from the BWI Rail Station to Union Station in Washington, DC – also a Metro station and Amtrak station – for $6.00.
For more info visit: http://www.bwiairport.com/

**AIRLINES**

**Ronald Reagan National Airport (DCA)**

**Dulles International Airport (IAD)**

**Baltimore Washington International Airport (BWI)**
Air Canada, Air Greenland, Air Jamaica, AirTran, American, America West, British Airways, Continental, Delta, Icelandair, Midwest Airlines, North American Airlines, Northwest, Southwest, United, USA 3000, US Airways.
The American Psychiatric Association expresses its deep appreciation for the following:

**Abbott Laboratories:** and support of the Industry-Supported Symposium, “Pediatric and Adolescent ADHD: Back to the Basics”, Saturday May 3, 6:00 p.m.

**American Academy of Psychiatry and the Law:** co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 4, 2:30 p.m.

**American Association of Chairs of Departments of Psychiatry:** support of the APA/AACDP Research Mentorship Award.

**American Association of Psychiatric Administrators:** co-support of the Administrative Psychiatry Award Lecture, Monday, May 5.

**American Psychiatric Association / Hurricane Disaster Relief Fund:** Support of the Disaster Psychiatry Fellowship.

**American Psychiatric Foundation:** support of the APIRE Practice Research Network.; Caucus/Committee of Hispanic Psychiatrists’ Forum and Reception, Tuesday, May 6, 5:30 p.m.; Award for Research in Psychiatry, Tuesday, May 6.

**Association of Professional Chaplains:** partial support of the Oskar Pfister Award Lecture, Monday, May 7.

**Association of Women Psychiatrists:** support of the joint AWP/APA Women’s Caucus reception and meeting, Monday, May 5, 7:30 p.m.; and co-support of the Alexandra Symonds Award Lecture, Tuesday, May 6, 9:00 a.m.

**AstraZeneca Pharmaceuticals:** support of the Industry-Supported Symposium, “Treatment of Children and Adolescents with Psychiatric Disorder: The Raising Use of Antipsychotics”, Sunday, May 4, 1:30 p.m.; “Novel Perspectives Toward a better understanding of Major Depressive Disorder”, Wednesday, May 7, 7:00 p.m. support of the President’s Dessert and Reception; and the Solomon Carter Fuller Award Lecture, Monday, May 21, 9:00 a.m.; and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; APA Fellowship on Public Psychiatry.

**Bristol-Myers Squibb:** co-support of the Industry-Supported Symposia, “Treatment of Children and Adolescents with Psychiatric Disorder: The Rising Use of Antipsychotics”, Sunday, May 4, 1:30 p.m.; “Toward a Better Understanding of Treatment-Resistant Depression”, Wednesday, May 7, 7:00 p.m. support of the President’s Dessert and Reception; and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 3, 7:00 p.m.; APA Fellowship on Public Psychiatry.

**Bristol-Myers Squibb Sweden:** support of Global Psychiatry: A Session for U.S. and International Residents, Sunday, May 4, 2:00 p.m.

**Center for Mental Health Services:** support of the APIRE Practice Research Network (PRN); and the APA’s HIV-related education programs and materials.

**Center for Substance Abuse Treatment:** support of the APIRE Practice Research Network (PRN); and an audience response system for the course, “Office-Based Buprenorphine Treatment of Opioid-Dependent Patients.”

**Eisai, Inc.:** support of the Industry-Supported Symposium, “Plaques & Tangles: Applying Genetics and Molecular Targets to Unravel Strategies for Alzheimer’s Disease”, Wednesday and Thursday, May 7and 8, 7:00 am.

**Eli Lilly and Company:** support of the Industry-Supported Symposia, “Improving Depression Treatments: Bridging the Gap Between Research and Clinical Practice”, Monday, May 21, 7:00 p.m.; “Understanding the Complexity of Bipolar Mixed Episodes”, Tuesday, May 22, 7:00 p.m.; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; and the Simon Bolivar Award Lecture, Saturday, May 19, 6:30 p.m.; 11:00 a.m.; support of the Adolf Meyer Award Lecture; the APA/Lilly Psychiatric Research Fellowship; the symposium entitled, “The Lancet Series on Global Mental Health,” Monday, May 5, 2008, 7:00 p.m.; and the APA/Lilly Resident Research Awards.

**Estate of Agnes Purcell McGavin:** support of the Agnes Purcell McGavin Awards for Distinguished Career Achievement in Child and Adolescent psychiatry, and for Prevention.

**Estate of Dorothy C. Kempf:** support of APIRE/Kempf Fund Award for Research Development in Psychobiological Psychiatry Awards.

**Estate of Kun-Po Soo, M.D. Ph.D.:** Support of the Kun-Po Soo Award Lecture, May 7

**Estate of Judd Marmor, M.D.:** support of the Judd Marmor Award Lecture, Tuesday, May 6, 2:00pm - 3:30pm
SPECIAL ACKNOWLEDGMENTS

Forest Laboratories, Inc.: support of the Industry-Supported Symposia, “Recent Advances in Alzheimer’s Disease: Expert Opinions of Current and Emerging Theories”, Saturday, May 3, 12:30 p.m.; “Mood Disturbance in Younger and Mid-life Women: Defining Treatment Strategies”, Sunday, May 4, 7:00 p.m. and support of the registration portfolios.

GlaxoSmithKline: partial support of the APA/GlaxoSmithKline Fellowship Program and reception.

Harding Foundation: partial support of the Oskar Pfister Award Lecture, Monday, May 7.

Ittleson Foundation: support of the Blanche F. Ittleson Award for Research in Child Psychiatry.

Janssen Pharmaceutical and Research Foundation: support of the Industry-Supported Symposium, Schizophrenia: “The Complexity of Real-World Care”, Tuesday, May 6, 7:00 p.m. partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 3, 7:00 p.m.; the support of the Committee of Asian-American Psychiatrists recruitment reception; and the American Psychiatric Institute for Research and Education/Janssen Resident Psychiatric Research Scholars.

Jazz Pharmaceuticals: support of the Industry-Supported Symposium, “Organizing the Evidence: Obsessive Compulsive Related Disorders: New Perspectives Toward DSM-V”, Tuesday May 6, 7:00 p.m.

McNeil Pediatrics Division of McNeil-PPC, Inc.: support of the Industry-Supported Symposium, “Advances in Neuroimaging and Genetics in ADHD”, Sunday, May 4, 8:00 a.m.

Merck & Co., Inc.: support of the APA/Merck & Co., Inc. Early Academic Career Research Award

National Institute of Mental Health (NIMH): co-support of the APA/NIMH Vestermark Psychiatry Educator Award Lecture, Tuesday, May 6, 11:00 a.m.; and the Research Colloquium for Junior Investigators; support of the American Psychiatric Institute for Research in Education (APIRE) Annual Meeting activities for research trainees; the Program for Minority Research Training in Psychiatry (PMRTP); and the Special Annual Meeting Program Track., “Cutting-Edge Science, State-of-the-Art Treatment”


Organon a part of Shering-Plough: support of the Industry-Supported Symposia, “Individualizing Treatment Plans for Total Health in Patients with Bipolar Disorder”; Wednesday, May 7, 7:00 p.m.; Genetics, Brain imaging and Pharmacology: Clinical Implications for Therapeutic Choices in Psychiatric Disorders”; Monday and Tuesday, May 5 and 6, 7:00 a.m.


Pfizer, Inc.: support of the Industry-Supported Symposia, “Comprehensive Care for Long-Term Patient with Schizophrenia Treatment the Whole Patient”, Saturday, May 3, 12:30 p.m.; “Recent Advances in the Diagnosis and Treatment of Fibromyalgia”, Sunday May 4, 8:00 a.m.; Understanding Bipolar Disorder: Quality and Clinical Conundrums”, Monday and Tuesday, May 5&6, 7:00 a.m.; “Beyond Pain to Fibrofog and Sleep Impairments: Implications for Neurocircuitry and Treatments in Fibromyalgia”, Wednesday, May 7, 7:00p.m. partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 20, 7:00 p.m.; and the Simon Bolivar Award Lecture, Saturday, May 19, 6:30 p.m.

Professional Risk Management Services, Inc.: co-support of the Manfred S. Guttmacher Award Lecture, Sunday, May 21, 2:30 p.m.; and partial support of the Alumni Reception, Tuesday May 22, 6:00 p.m.

Sanofi Aventis: support of the Industry-Supported Symposium “Addressing Unmet Clinical Needs in Severe Depression: Translating the Latest Findings”, Saturday May 3, 6:00 p.m., “Understanding the Endocannabinoid System: Key Links Between Mind, Body and Neuro Psychiatry”, Tuesday, May 6, 7:00 p.m.

Shire US, Inc.: support of the Industry-Supported Symposia, “Advancing Science and Practice in the Management of ADHD from Child to Adult: An Interactive Case Presentation”, Wednesday, May 7, 7:00 p.m.; “How Comorbid is ADHD? Results from epidemiological and clinical Studies”, Sunday, May 20, 7:00 p.m.; the Residents’ Session, “Meet the Experts: Sunny-Side Up,” Monday, May 5, 7:00 a.m.; the APA/Shire Child and Adolescent Psychiatry Fellowships; and partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 3, 7:00 p.m.

Substance Abuse and Mental Health Services Administration (CMHS, CSAP, CSAT): sponsorship of the APA/SAMHSA Minority Fellowship Program.

Takeda Pharmaceuticals North America, Inc.: support of the Industry-Supported Symposia, “Are Cognition and Sleep/Wake Disorder Caused by Too Much Arousal, Too Little Arousal or Both?” Monday and Tuesday, May 5 and 6, 7:00 a.m.

University of Nebraska: support of the Frank J. Menolascino Award for Psychiatric Services for persons with Mental Retardation/Developmental Disabilities.
Vanda Pharmaceuticals Inc.: support of the Industry Supported Symposium, “Genetics in Psychiatry: Opportunities and Obstacles in Schizophrenia”, Sunday, May 4, 1:30 pm

Wyeth Pharmaceuticals: support of the Industry-Supported Symposia, “Psychiatric Issues in Women Through the Adult Life-Cycle”, Saturday, May 3, 12:30 p.m.; “An Interactive Symposium: Unlocking the Combination: Moving Toward a Better Understanding of Major Depressive Disorder”, Sunday May 4, 1:30 p.m. : support of the APIRE/Wyeth Pharmaceuticals M.D., Ph.D., Research Fellowship; the Jeanne Spurlock, M.D. Congressional Fellowship; partial support of the American Psychiatric Foundation Annual Benefit, Saturday, May 3, 7:00 p.m.; and co-support of the Alexandra Symonds Award Lecture, Monday, May 22, 11:00 a.m.
ADVANCES IN.....SERIES
These three-hour and thirty-minute sessions are intended to highlight important new advances occurring in the field of psychiatry involving selected disorders or treatments. The sessions are chaired by editors of recent textbooks published by the American Psychiatric Publishing, Inc (APPI) and feature selected chapter authors from these texts. The books discussed at these sessions may be purchased at the APPI bookstore or online at www.appi.org.

CASE CONFERENCES
During these 90-minute or three-hour sessions, clinical material is presented by videotape or the treating therapist. One or more experts then discuss the case. Some cases will review the progress of psychotherapy in two successive sessions. THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES
Courses are designed to emphasize learning experiences that actively involve participants and include the opportunity for informal exchange with the faculty. Offered in four-hour (half-day), six-hour (full-day), and eight-hour (full-day) sessions, courses either review basic concepts in a special subject area or present advanced material on a circumscribed topic. Participants must purchase tickets to attend.

DEBATES
Experts in the field, including psychiatrists and nonpsychiatrists will debate a controversial topic in psychiatry. The debate format allows for members to hear both pro and con views about important, interesting and timely concerns for our members. Someone who has expertise in the topic area moderates the debate. A portion of the time is allocated for questions from the audience to the presenters with active participation by participants.

FOCUS LIVE
These 90-minute sessions allow participants to test their knowledge using an interactive Audience Response System (ARS), offering a new and entertaining way to learn. ARS sessions can make a group of 300 feel like they are having a small group consultation with an expert clinician. Experts, who served as guest editors of FOCUS, will lead lively multiple choice question-based discussions, and the audience will enter their answers with hand-held devices. Results are instantly tallied and projected on the screen.

FORUMS
These are flexible presentations that afford an opportunity to highlight and select topics that are of timely interest to psychiatrists. Speakers and panel members are chosen for their expertise and leadership in the field.

LECTURES
Lectures feature a small number of distinguished speakers discussing scientific and cultural topics, many of which will extend our understanding beyond the usual limits of clinical psychiatry. The Scientific Program Committee invites the lecturers.

NEW RESEARCH
This format allows for presentation of the very recent findings. The three types of presentations include: Posters, which are visual, self-explanatory presentations; Young Investigators' Posters, with presentations from young investigators, residents, medical students, and research or clinical fellows; and Young Investigators' Oral/Slide which are fifteen-minute presentations with three minutes for discussion.

SCIENTIFIC AND CLINICAL REPORT SESSIONS
Scientific and Clinical Reports are oral presentations of papers prepared for submission before publication. In this 90-minute format, reports are grouped by topic, with floor discussion from the audience following the presentation of each paper. There is no formal discussant.

SMALL INTERACTIVE SESSIONS
This 90-minute format allows small groups to meet informally with either selected experts in psychiatry to discuss topics chosen by the expert obtain consultations around problems in research from senior researchers; or hear clinically-based seminars presented by outstanding educators. Some of these are reserved for residents only. These sessions are limited to 25 participants on a first-come, first-served basis.

SYMPOSIA
Symposia are three-hour sessions consisting of four to six presentations that are thematically linked and focus on a specific topic relevant to clinical psychiatry. They are designed to provide comprehensive treatment of a topic or discussion of the topic from several points of view by the participants and stimulate discussion with the audience. Some symposia are supported by industry and are designated as "Industry-Supported Symposia" in this Program Book.

WORKSHOPS
Workshops are 90-minute sessions that typically involve brief presentations from individual panel members, followed by the opportunity to apply to home in small groups, practice new techniques to build skills, and for lively and informative discussion. This format provides for highly interactive audience participation. Media Workshops are three-hour sessions in which a feature-length film is shown and discussed.
The American Psychiatric Association requires disclosure, by presenters at CME activities, of any significant financial or other affiliation with commercial organization(s) that may have a direct or indirect interest in the subject matter of the scientific program. A "financial interest" may include, but is not limited to, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An "affiliation" may include holding a position on an advisory committee or some other role or benefit to a supporting organization.

Under the ACCME Standards for Commercial Support the existence of such relationships may constitute a conflict of interest; and the prospective audience must be informed of the presenter's affiliation with every commercial supporter by an acknowledgement in the printed program and verbal or visual disclosure to participants at the session (disclosure by slide or overhead is required if audiovisual equipment is used for the presentation). This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgments about the presentation. The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose.

The presenters on the following pages have indicated that either they or an immediate family member has a significant interest or other affiliation with a commercial supporter of this meeting and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial services(s). The presenter's name and the company's name are listed. The nature of the presenter's relationship with the disclosed company is indicated by the following: stock/other financial options, consultant, grant/research support, full-time employee, speaker's bureau, other financial interest or business relationships (specify). A full disclosure index of companies has been provided as a tool to indicate the abbreviated name and full name of the company.

The second group of presenters, beginning on page XLVII, have indicated neither they nor an immediate family member has any significant relationship to disclose. Voting members of the Board of Trustees, Assembly officers, and members of the Scientific Program Committee cannot receive honoraria or travel reimbursement for participating in Industry-Supported Symposia.
<table>
<thead>
<tr>
<th>Abbreviated Name</th>
<th>Manufacturer(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott</td>
<td>Abbott Laboratories</td>
</tr>
<tr>
<td>Acadia</td>
<td>Acadia Pharmaceuticals</td>
</tr>
<tr>
<td>AFSP</td>
<td>AFSP</td>
</tr>
<tr>
<td>Alkermes</td>
<td>Alkermes (Cambridge, MA)</td>
</tr>
<tr>
<td>Allergan</td>
<td>Allergan</td>
</tr>
<tr>
<td>Alza</td>
<td>Alza Corporation</td>
</tr>
<tr>
<td>Amgen</td>
<td>Amgen</td>
</tr>
<tr>
<td>Apotex</td>
<td>Apotex</td>
</tr>
<tr>
<td>Arena</td>
<td>Arena Pharmaceuticals</td>
</tr>
<tr>
<td>Asahi</td>
<td>Asahi</td>
</tr>
<tr>
<td>Aspect Medical Systems</td>
<td>Aspect Medical Systems, Inc.</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>AstraZeneca Pharmaceuticals</td>
</tr>
<tr>
<td>AstraZeneca Canada</td>
<td>AstraZeneca Pharmaceuticals Canada</td>
</tr>
<tr>
<td>Aventis</td>
<td>Aventis Pharmaceuticals</td>
</tr>
<tr>
<td>Aztezion</td>
<td>Aztezion</td>
</tr>
<tr>
<td>Barr</td>
<td>Barr Laboratories</td>
</tr>
<tr>
<td>Bayer</td>
<td>Bayer AG Corporation, Pharmaceutical Division</td>
</tr>
<tr>
<td>Bayer</td>
<td>Bayer Corporation, Pharmaceutical Division</td>
</tr>
<tr>
<td>Berlex</td>
<td>Berlex Laboratories, Inc.</td>
</tr>
<tr>
<td>Biogen</td>
<td>Biogen</td>
</tr>
<tr>
<td>Biovail</td>
<td>Biovail Laboratories, Inc.</td>
</tr>
<tr>
<td>BMS</td>
<td>Bristol-Meyer Squibb</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>Boehringer Ingelheim Pharmaceuticals</td>
</tr>
<tr>
<td>Boots</td>
<td>Boots Pharmaceuticals</td>
</tr>
<tr>
<td>Brief Assessment of Cognition</td>
<td>Brief Assessment of Cognition (BACS)</td>
</tr>
<tr>
<td>Burroughs-Wellcome</td>
<td>Burroughs-Wellcome Pharmaceutical Company</td>
</tr>
<tr>
<td>CABF</td>
<td>Child and Adolescent Bipolar Foundation</td>
</tr>
<tr>
<td>Caraco</td>
<td>Caraco Pharmaceutical, LTD</td>
</tr>
<tr>
<td>Cedrooth</td>
<td>Cedrooth</td>
</tr>
<tr>
<td>Celltech</td>
<td>Celltech Pharmaceuticals, Ltd.</td>
</tr>
<tr>
<td>Celltech Medica</td>
<td>Celltech Medica</td>
</tr>
<tr>
<td>Celsion</td>
<td>Celsion</td>
</tr>
<tr>
<td>Cephalon</td>
<td>Cephalon Inc.</td>
</tr>
<tr>
<td>Ciba Geigy</td>
<td>Ciba Geigy Corporation, Pharmaceutical Division</td>
</tr>
<tr>
<td>Circa Dia</td>
<td>Circa Dia</td>
</tr>
<tr>
<td>CMHC Systems</td>
<td>CMHC Systems</td>
</tr>
<tr>
<td>CoCensys</td>
<td>CoCensys</td>
</tr>
<tr>
<td>Collegium</td>
<td>Collegium</td>
</tr>
<tr>
<td>Compellis</td>
<td>Compellis</td>
</tr>
<tr>
<td>Corecept Therapeutics</td>
<td>Corecept Therapeutics, Inc.</td>
</tr>
<tr>
<td>Cortex</td>
<td>Cortex Pharmaceutical</td>
</tr>
<tr>
<td>Creative Educational Concepts</td>
<td>Creative Educational Concepts</td>
</tr>
<tr>
<td>Cypress</td>
<td>Cypress</td>
</tr>
<tr>
<td>Cypress Allergan</td>
<td>Cypress Allergan</td>
</tr>
<tr>
<td>Cypress Bioscience</td>
<td>Cypress Bioscience</td>
</tr>
<tr>
<td>Dana Foundation</td>
<td>Dana Foundation</td>
</tr>
<tr>
<td>Designer Genes</td>
<td>Designer Genes Inc.</td>
</tr>
<tr>
<td>Dista</td>
<td>Dista Products Company</td>
</tr>
<tr>
<td>Dista</td>
<td>Dista Products, a Division of Eli Lilly Company</td>
</tr>
</tbody>
</table>
## DISCLOSURE INDEX OF COMPANIES

<table>
<thead>
<tr>
<th>Abbreviated Name</th>
<th>Manufacturer(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Abuse Sciences</td>
<td>Drug Abuse Sciences</td>
</tr>
<tr>
<td>Duloxetine</td>
<td>Duloxetine</td>
</tr>
<tr>
<td>Dunphar</td>
<td>Dunphar</td>
</tr>
<tr>
<td>DuPont</td>
<td>DuPont</td>
</tr>
<tr>
<td>Dupont Pharma</td>
<td>Dupont Pharma</td>
</tr>
<tr>
<td>Eccles Institute of Human Genetics</td>
<td>Eccles Institute of Human Genetics</td>
</tr>
<tr>
<td>EEG Spectrum International</td>
<td>EEG Spectrum International</td>
</tr>
<tr>
<td>Eisai</td>
<td>Eisai Inc.</td>
</tr>
<tr>
<td>Eisai America</td>
<td>Eisai America, Inc.</td>
</tr>
<tr>
<td>Elan</td>
<td>Elan Pharmaceuticals</td>
</tr>
<tr>
<td>Eli Lilly</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Eli Lilly Canada</td>
<td>Eli Lilly and Company Canada</td>
</tr>
<tr>
<td>Eli Lilly BMS</td>
<td>Eli Lilly BMS</td>
</tr>
<tr>
<td>Embera NeuroTherapeutics</td>
<td>Embera NeuroTherapeutics, Inc.</td>
</tr>
<tr>
<td>EPIX</td>
<td>EPIX</td>
</tr>
<tr>
<td>Eunoe</td>
<td>Eunoe</td>
</tr>
<tr>
<td>Excerpta Medica Asia</td>
<td>Excerpta Medica Asia</td>
</tr>
<tr>
<td>Faxmed</td>
<td>Faxmed, Inc</td>
</tr>
<tr>
<td>Forest Laboratories</td>
<td>Forest Laboratories, Inc.</td>
</tr>
<tr>
<td>Forest Research Institute</td>
<td>Forest Research Institute</td>
</tr>
<tr>
<td>Fujisawa Institute of America</td>
<td>Fujisawa Institute of America</td>
</tr>
<tr>
<td>Gilead Sciences</td>
<td>Gilead Sciences</td>
</tr>
<tr>
<td>Glaxo</td>
<td>Glaxo Pharmaceuticals</td>
</tr>
<tr>
<td>Glaxo-Wellcome</td>
<td>Glaxo-Wellcome</td>
</tr>
<tr>
<td>Gilead</td>
<td>Gilead</td>
</tr>
<tr>
<td>GSK</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>GSK</td>
<td>GlaxoSmithKline Beecham Healthcare</td>
</tr>
<tr>
<td>GSK</td>
<td>GlaxoSmithKline Beecham Pharmaceuticals</td>
</tr>
<tr>
<td>GSK</td>
<td>GlaxoSmithKline R&amp;D</td>
</tr>
<tr>
<td>GSK Canada</td>
<td>GlaxoSmithKline Canada</td>
</tr>
<tr>
<td>Guilford Publications</td>
<td>Guilford Publications</td>
</tr>
<tr>
<td>Healthcare Technology Systems</td>
<td>Healthcare Technology Systems</td>
</tr>
<tr>
<td>Hoffman-LaRoche</td>
<td>Hoffman-LaRoche Pharmaceuticals</td>
</tr>
<tr>
<td>Humana</td>
<td>Humana</td>
</tr>
<tr>
<td>ICI</td>
<td>ICI</td>
</tr>
<tr>
<td>ICOS</td>
<td>ICOS</td>
</tr>
<tr>
<td>Immune Response</td>
<td>Immune Response</td>
</tr>
<tr>
<td>Innapharma</td>
<td>Innapharma</td>
</tr>
<tr>
<td>International Clinical Research</td>
<td>International Clinical Research</td>
</tr>
<tr>
<td>IVAX</td>
<td>IVAX</td>
</tr>
<tr>
<td>Janssen</td>
<td>Janssen Pharmaceutica Inc.</td>
</tr>
<tr>
<td>Janssen Canada</td>
<td>Janssen Pharmaceutica Inc. Canada</td>
</tr>
<tr>
<td>Janssen Cilag</td>
<td>Janssen Cilag</td>
</tr>
<tr>
<td>Janssen Research Foundation</td>
<td>Janssen Research Foundation</td>
</tr>
<tr>
<td>Janssen-Cilag</td>
<td>Janssen-Cilag Pharmaceutica Inc.</td>
</tr>
<tr>
<td>Janssen-Ortho</td>
<td>Janssen-Ortho Pharmaceutica Inc.</td>
</tr>
<tr>
<td>Jazz</td>
<td>Jazz Pharmaceutical</td>
</tr>
<tr>
<td>Johnson and Johnson</td>
<td>Johnson and Johnson PRD</td>
</tr>
<tr>
<td>Abbreviated Name</td>
<td>Manufacturer(s)</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Kali-Duphar</td>
<td>Kali-Duphar Laboratories, Inc.</td>
</tr>
<tr>
<td>King</td>
<td>King Pharmaceuticals</td>
</tr>
<tr>
<td>Knoll</td>
<td>Knoll Pharmaceuticals</td>
</tr>
<tr>
<td>Lichtwer</td>
<td>Lichtwer Pharma</td>
</tr>
<tr>
<td>Lichtwer</td>
<td>Lichtwer Pharma GmbH</td>
</tr>
<tr>
<td>Lilly Research Laboratories</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company</td>
</tr>
<tr>
<td>LIPHA</td>
<td>LIPHA Pharmaceuticals</td>
</tr>
<tr>
<td>Lifebook Company</td>
<td>Lifebook Company, Inc.</td>
</tr>
<tr>
<td>LP</td>
<td>LP</td>
</tr>
<tr>
<td>Lundbeck</td>
<td>Lundbeck</td>
</tr>
<tr>
<td>Lundbeck Canada</td>
<td>Lundbeck Canada</td>
</tr>
<tr>
<td>Mallinckrodt</td>
<td>Mallinckrodt Pharmaceuticals</td>
</tr>
<tr>
<td>Marinus</td>
<td>Marinus Pharmaceuticals</td>
</tr>
<tr>
<td>Marion-Merrell Dow</td>
<td>Marion-Merrell Dow</td>
</tr>
<tr>
<td>MATRICS Battery</td>
<td>MATRICS Battery (BACS Symbol Coding)</td>
</tr>
<tr>
<td>Mayne</td>
<td>Mayne Pharma</td>
</tr>
<tr>
<td>McNeil Pediatrics</td>
<td>McNeil Pharmaceuticals</td>
</tr>
<tr>
<td>McNeil Pediatrics</td>
<td>McNeil Consumer Healthcare</td>
</tr>
<tr>
<td>MedAvante</td>
<td>MedAvante</td>
</tr>
<tr>
<td>Medscape</td>
<td>Medscape, LLC</td>
</tr>
<tr>
<td>Medtronics</td>
<td>Medtronic, Inc.</td>
</tr>
<tr>
<td>Medtronics</td>
<td>Medtronics</td>
</tr>
<tr>
<td>Merck</td>
<td>Merck &amp; Co., Inc.</td>
</tr>
<tr>
<td>Merck Sharp &amp; Dohme</td>
<td>Merck Sharp &amp;a Dohme</td>
</tr>
<tr>
<td>Mitsubishi-Tokyo</td>
<td>Mitsubishi-Tokyo, Inc.</td>
</tr>
<tr>
<td>Myriad Genetics</td>
<td>Myriad Genetics, Inc.</td>
</tr>
<tr>
<td>NARSAD</td>
<td>National Alliance for Research in Schizophrenia and Affective Disorders</td>
</tr>
<tr>
<td>Neurochem</td>
<td>Neurochem</td>
</tr>
<tr>
<td>Neurocrine Biosciences</td>
<td>Neurocrine</td>
</tr>
<tr>
<td>Neuromolecular</td>
<td>Neuromolecular, Inc.</td>
</tr>
<tr>
<td>Neuronetics</td>
<td>Neuronetics Inc.</td>
</tr>
<tr>
<td>Novartis</td>
<td>Novartis Pharmaceuticals Corporation</td>
</tr>
<tr>
<td>Otsuka</td>
<td>Otsuka Pharmaceuticals</td>
</tr>
<tr>
<td>Orexigen</td>
<td>Orexigen</td>
</tr>
<tr>
<td>Organon, a part of Schering-Plough</td>
<td>Organon Pharmaceuticals Inc.</td>
</tr>
<tr>
<td>Organon, a part of Schering-Plough</td>
<td>Organon USA</td>
</tr>
<tr>
<td>Orion</td>
<td>Orion</td>
</tr>
<tr>
<td>Ortho McNeil</td>
<td>Ortho McNeil Pediatrics</td>
</tr>
<tr>
<td>Otsuka</td>
<td>Otsuka Pharmaceuticals</td>
</tr>
<tr>
<td>Ovation</td>
<td>Ovation Pharmaceuticals</td>
</tr>
<tr>
<td>Pam Lab</td>
<td>Pam Lab LLC</td>
</tr>
<tr>
<td>Par Laboratories</td>
<td>Par Laboratories</td>
</tr>
<tr>
<td>Pfizer</td>
<td>Pfizer Inc.</td>
</tr>
<tr>
<td>Pfizer Canada</td>
<td>Pfizer Canada</td>
</tr>
<tr>
<td>Pharmacia &amp; Upjohn</td>
<td>Pharmacia &amp; Upjohn Company, Inc.</td>
</tr>
<tr>
<td>Pharmastar</td>
<td>Pharmastar</td>
</tr>
<tr>
<td>Pharmavite</td>
<td>Pharmavite</td>
</tr>
<tr>
<td>Prestwick Pharm</td>
<td>Prestwick Pharm</td>
</tr>
<tr>
<td>PRMS</td>
<td>Professional Risk Management Services Inc.</td>
</tr>
<tr>
<td>Abbreviated Name</td>
<td>Manufacturer(s)</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>P&amp;G</td>
<td>Proctor &amp; Gamble</td>
</tr>
<tr>
<td>Psynomics</td>
<td>Psynomics</td>
</tr>
<tr>
<td>Purdue Pharma</td>
<td>Purdue Pharma</td>
</tr>
<tr>
<td>Quintiles</td>
<td>Quintiles</td>
</tr>
<tr>
<td>Reckitt Benckiser</td>
<td>Reckitt Benckiser Pharmaceuticals</td>
</tr>
<tr>
<td>Reliant</td>
<td>Reliant Pharmaceuticals</td>
</tr>
<tr>
<td>Research Institute</td>
<td>Research Institute</td>
</tr>
<tr>
<td>Roche Canada</td>
<td>Roche Group</td>
</tr>
<tr>
<td>Roche Diagnostics</td>
<td>Roche Diagnostics</td>
</tr>
<tr>
<td>Roche Laboratories</td>
<td>Roche Laboratories</td>
</tr>
<tr>
<td>RWJ</td>
<td>Robert Wood Johnson Pharmaceutical</td>
</tr>
<tr>
<td>RWJ Pharmaceutical Research Institute</td>
<td>Robert Wood Johnson Pharmaceutical Research Institute</td>
</tr>
<tr>
<td>Sandoz</td>
<td>Sandoz Pharmaceuticals Corporation</td>
</tr>
<tr>
<td>Sanofi Pharmaceuticals, Inc.</td>
<td>Sanofi Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Sanofi Aventis</td>
<td>Sanofi Aventis</td>
</tr>
<tr>
<td>Sanofi-Pasteur</td>
<td>Sanofi-Pasteur</td>
</tr>
<tr>
<td>Sanofi-Synthelabo</td>
<td>Sanofi-Synthelabo Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Schering</td>
<td>Schering Corporation</td>
</tr>
<tr>
<td>Schering-Plough</td>
<td>Schering-Plough, France</td>
</tr>
<tr>
<td>Schwabe</td>
<td>Schwabe</td>
</tr>
<tr>
<td>Sepracor</td>
<td>Sepracor Inc.</td>
</tr>
<tr>
<td>Servier</td>
<td>Servier</td>
</tr>
<tr>
<td>Shire</td>
<td>Shire US Inc.</td>
</tr>
<tr>
<td>Shire</td>
<td>Shire Pharmaceutical Development, Inc.</td>
</tr>
<tr>
<td>Solvay</td>
<td>Solvay Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Somaxon</td>
<td>Somaxon</td>
</tr>
<tr>
<td>Stanley Foundation</td>
<td>Stanley Foundation</td>
</tr>
<tr>
<td>Stanley Medical Research Institute</td>
<td>Stanley Medical Research Institute</td>
</tr>
<tr>
<td>Sumitomo</td>
<td>Sumitomo</td>
</tr>
<tr>
<td>Supernus</td>
<td>Supernus</td>
</tr>
<tr>
<td>Takeda</td>
<td>Takeda Pharmaceuticals</td>
</tr>
<tr>
<td>Takeda</td>
<td>Takeda Abbott Pharmaceuticals</td>
</tr>
<tr>
<td>Tanox</td>
<td>Tanox</td>
</tr>
<tr>
<td>Teva</td>
<td>Teva Pharmaceuticals</td>
</tr>
<tr>
<td>The Stanley Medical Research Institute</td>
<td>The Stanley Medical Research Institute</td>
</tr>
<tr>
<td>Titan</td>
<td>Titan Pharmaceuticals Inc.</td>
</tr>
<tr>
<td>UCB Pharma</td>
<td>UCB Pharma, Inc.</td>
</tr>
<tr>
<td>Vanda</td>
<td>Vanda Pharmaceuticals</td>
</tr>
<tr>
<td>Variagenics</td>
<td>Variagenics</td>
</tr>
<tr>
<td>Vela</td>
<td>Vela Pharmaceuticals</td>
</tr>
<tr>
<td>Vela</td>
<td>Vela</td>
</tr>
<tr>
<td>Warner Lambert</td>
<td>Warner Lambert</td>
</tr>
<tr>
<td>Watson</td>
<td>Watson</td>
</tr>
<tr>
<td>Wyeth</td>
<td>Wyeth-Ayerst Pharmaceutical Company</td>
</tr>
<tr>
<td>Wyeth</td>
<td>Wyeth-Ayerst Canada</td>
</tr>
<tr>
<td>Wyeth</td>
<td>Wyeth-Ayerst Laboratories</td>
</tr>
<tr>
<td>Wyeth</td>
<td>Wyeth-Ayerst Research, Inc.</td>
</tr>
<tr>
<td>Xenoprotein</td>
<td>Xenoprotein</td>
</tr>
<tr>
<td>Name</td>
<td>Stock/Other Financial Options</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Anissa Abi-Dargham, M.D.</td>
<td></td>
</tr>
<tr>
<td>George S. Alexopoulos, M.D.</td>
<td></td>
</tr>
<tr>
<td>Jonathan E. Alpert, M.D., Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Lori L. Altshuler, M.D.</td>
<td></td>
</tr>
<tr>
<td>Sonia Ancoli-Israel, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Lesley M. Arnold, M.D.</td>
<td></td>
</tr>
<tr>
<td>Amy F. Arnsten, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Louis Aronne, M.D.</td>
<td></td>
</tr>
<tr>
<td>Joan R. Asarnow, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Julian Beezhold, M.D.</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Stock/Other Financial Options</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Donald W. Black, M.D.</td>
<td></td>
</tr>
<tr>
<td>Hilary P. Blumberg, M.D.</td>
<td></td>
</tr>
<tr>
<td>John M. Bradford, M.B., D.P.M.</td>
<td></td>
</tr>
<tr>
<td>Kathleen Brady, M.D., Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Thomas E. Brown, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Peter F. Buckley, M.D.</td>
<td></td>
</tr>
<tr>
<td>Vivien K. Burt, M.D.</td>
<td></td>
</tr>
<tr>
<td>George Bush, M.D.</td>
<td></td>
</tr>
<tr>
<td>Daniel J. Buysse, M.D.</td>
<td></td>
</tr>
<tr>
<td>William E. Callahan, M.D.</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Stock/Other Financial Options</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Gabrielle A. Carlson, M.D.</td>
<td></td>
</tr>
<tr>
<td>Stanley N. Caroff, M.D.</td>
<td></td>
</tr>
<tr>
<td>William T. Carpenter, M.D.</td>
<td></td>
</tr>
<tr>
<td>Linda L. Carpenter, M.D.</td>
<td></td>
</tr>
<tr>
<td>David A. Casey, M.D.</td>
<td></td>
</tr>
<tr>
<td>Ruby C. Castilla-Puentes, M.D. D.P.H.</td>
<td>GSK, Sanofi Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Christina Chambers, Ph.D. M.P.H.</td>
<td></td>
</tr>
<tr>
<td>Daniel J. Clauw, M.D.</td>
<td></td>
</tr>
<tr>
<td>Paula J. Clayton, M.D.</td>
<td></td>
</tr>
<tr>
<td>Anita H. Clayton, M.D.</td>
<td></td>
</tr>
<tr>
<td>Tonya Cohn, M.B., M.S.C.</td>
<td></td>
</tr>
<tr>
<td>David O. Conant-Norville, M.D.</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Stock/Other Financial Options</td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>Robert R. Conley, M.D.</td>
<td></td>
</tr>
<tr>
<td>Vladimir Coric, M.D.</td>
<td></td>
</tr>
<tr>
<td>Christoph U. Correll, M.D.</td>
<td></td>
</tr>
<tr>
<td>Jon Davine, M.D.</td>
<td></td>
</tr>
<tr>
<td>Glen P. Davis, M.D.</td>
<td></td>
</tr>
<tr>
<td>Paola Dazzan</td>
<td></td>
</tr>
<tr>
<td>Melissa Delbello, M.D., M.S.</td>
<td></td>
</tr>
<tr>
<td>Mark Demitrack, M.D.</td>
<td></td>
</tr>
<tr>
<td>David Dinges, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Karl Doghramji, M.D.</td>
<td></td>
</tr>
<tr>
<td>P. Murali Doraiswamy, M.D.</td>
<td></td>
</tr>
<tr>
<td>Darin D. Dougherty, M.D.</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Stock/Other Financial Options</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>----------------------------------------------------</td>
</tr>
<tr>
<td>Steven L. Dubovsky, M.D.</td>
<td></td>
</tr>
<tr>
<td>Broadie Dunlop, M.D.</td>
<td></td>
</tr>
<tr>
<td>James M. Ellison, M.D., M.P.H.</td>
<td></td>
</tr>
<tr>
<td>Graham Emslie, M.D.</td>
<td></td>
</tr>
<tr>
<td>Milton Erman, M.D.</td>
<td>Cephalon, Sanofi Pharmaceuticals, Inc., Forest Laboratories, Neurocrine Biosciences, Pfizer, Sepracor</td>
</tr>
<tr>
<td>Dwight Evans, M.D.</td>
<td></td>
</tr>
<tr>
<td>Peter A. Fahnestock, M.D.</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Stock/Other Financial Options</td>
</tr>
<tr>
<td>-----------------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>Robert L. Findling, M.D.</td>
<td></td>
</tr>
<tr>
<td>Naomi Fineberg, M.A., M.B.B.S</td>
<td>Lundbeck, GSK</td>
</tr>
<tr>
<td>David A. Fishbain, M.D.</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td>Alastair J. Flint, M.B.</td>
<td></td>
</tr>
<tr>
<td>Timothy W. Fong, M.D.</td>
<td></td>
</tr>
<tr>
<td>Brent P. Forester, M.D.</td>
<td>Pfizer, GSK</td>
</tr>
<tr>
<td>Ellen Frank, Ph.D.</td>
<td>Forest Research Institute</td>
</tr>
<tr>
<td>Jean Frazier, M.D.</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td>Marlene P. Freeman, M.D.</td>
<td>Eli Lilly, Reliant, Forest Laboratories</td>
</tr>
<tr>
<td>Oliver Freudeneich, M.D.</td>
<td></td>
</tr>
<tr>
<td>Mark Frye, M.D.</td>
<td>Janssen-Cilag, AstraZeneca, Abbott, BMS, GSK, Otsuka</td>
</tr>
<tr>
<td>Ileana Fumero-Perez, M.D.</td>
<td>Pfizer, BMS</td>
</tr>
<tr>
<td>Sandro Galea, M.D.</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Stock/Other Financial Options</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>James E. Galvin, M.D., M.P.H.</td>
<td></td>
</tr>
<tr>
<td>Alan Gelenberg, M.D.</td>
<td>Vela</td>
</tr>
<tr>
<td>Mark S. George, M.D.</td>
<td>Cyberonics Inc., Aspect Medical Systems, Neuronetics</td>
</tr>
<tr>
<td>Sanacora Gerard, M.D., Ph.D.</td>
<td>Abbott, AstraZeneca, BMS, Pfizer, Lundbeck, Sepracor</td>
</tr>
<tr>
<td>S. Nassir Ghaemi, M.D., M.P.H.</td>
<td></td>
</tr>
<tr>
<td>Michael Gitlin, M.D.</td>
<td></td>
</tr>
<tr>
<td>Donald Goff, M.D.</td>
<td>BMS, Cephalon, Pfizer, Sumitomo, Wyeth</td>
</tr>
<tr>
<td>Joseph F. Goldberg, M.D.</td>
<td>Abbott, AstraZeneca, Eli Lilly, Cephalon, GSK</td>
</tr>
<tr>
<td>Don L. Goldenberg, M.D.</td>
<td>Merek, Abbott, Pfizer, Cypress Eli Lilly</td>
</tr>
<tr>
<td>Fred K. Goodwin, M.D.</td>
<td>AstraZeneca, GSK, Eli Lilly, Pfizer, Wyeth</td>
</tr>
<tr>
<td>Kevin F. Gray, M.D.</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Stock/Other Financial Options</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>John Greist, M.D.</td>
<td></td>
</tr>
<tr>
<td>George T. Grossberg, M.D.</td>
<td></td>
</tr>
<tr>
<td>Robert E. Hales, M.D., M.B.A.</td>
<td></td>
</tr>
<tr>
<td>Philip D. Harvey, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Dan W. Haupt, M.D.</td>
<td></td>
</tr>
<tr>
<td>David C. Henderson, M.D.</td>
<td></td>
</tr>
<tr>
<td>Robert L. Hendren D.O.</td>
<td></td>
</tr>
<tr>
<td>Barry Herman, M.D.</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Robert M. Hirschfeld, M.D.</td>
<td></td>
</tr>
<tr>
<td>Paul Holtzheimer, M.D.</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Stock/Other Financial Options</td>
</tr>
<tr>
<td>--------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Rona Hu, M.D.</td>
<td></td>
</tr>
<tr>
<td>Robert D. Hunt, M.D.</td>
<td></td>
</tr>
<tr>
<td>Waguih W. IsHak, M.D.</td>
<td></td>
</tr>
<tr>
<td>Geetha Jayaram, M.D., M.B.A.</td>
<td></td>
</tr>
<tr>
<td>James W. Jefferson, M.D.</td>
<td>BMS, GSK</td>
</tr>
<tr>
<td>Hadine Joffe, M.D., M.S.C.</td>
<td></td>
</tr>
<tr>
<td>Zohar Joseph, M.D.</td>
<td></td>
</tr>
<tr>
<td>Rene S. Kahn, M.D., Ph.D.</td>
<td></td>
</tr>
<tr>
<td>John M. Kane, M.D.</td>
<td></td>
</tr>
<tr>
<td>Desmond M. Kaplan, M.D.</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Stock/Other Financial Options</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Jordan F. Karp, M.D.</td>
<td></td>
</tr>
<tr>
<td>John W. Kasckow, M.D., Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Nathaniel P. Katz, M.D.</td>
<td></td>
</tr>
<tr>
<td>Richard S. Keefe, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Martin B. Keller, M.D.</td>
<td></td>
</tr>
<tr>
<td>John R. Kelsoe, M.D.</td>
<td>Psynomics</td>
</tr>
<tr>
<td>David Kemp, M.D.</td>
<td></td>
</tr>
<tr>
<td>Ronald C. Kessler, Ph.D.</td>
<td>AstraZeneca, BMS, Eli Lilly, GSK, Pfizer, Santofi Pharmaceuticals, Inc., Wyeth</td>
</tr>
<tr>
<td>David G. Kingdon, M.D.</td>
<td></td>
</tr>
<tr>
<td>Herbert D. Kleber, M.D.</td>
<td>Alkermes</td>
</tr>
<tr>
<td>Robert Kohn, M.D.</td>
<td>NARSAD</td>
</tr>
<tr>
<td>Scott H. Kollins, Ph.D.</td>
<td>Shire, Cephalon, Eli Lilly</td>
</tr>
<tr>
<td>Name</td>
<td>Stock/Other Financial Options</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Alex Kopelowicz, M.D.</td>
<td></td>
</tr>
<tr>
<td>Robert Kowatch, M.D.</td>
<td></td>
</tr>
<tr>
<td>Frank A. Kozel, M.D., M.S.</td>
<td></td>
</tr>
<tr>
<td>Christopher Kratochvil, M.D.</td>
<td></td>
</tr>
<tr>
<td>K. Ranga R. Krishnan, M.D.</td>
<td>Cypress Therapeutics</td>
</tr>
<tr>
<td>Andrew D. Krystal, M.D.</td>
<td>Takeda, Sanofi Pharmaceuticals, Inc., GSK, King, Merck, Cephalon, Eli Lilly, Neurocrine Biosciences Inc., Sepracor, Pfizer, Johnson and Johnson, Organon, a part of Schering-Plough Inc., AstraZeneca</td>
</tr>
<tr>
<td>John H. Krystal, M.D.</td>
<td>Alkermes, BMS, Cypress Eli Lilly, Forest Laboratories, GSK, Janssen Research Foundation, Organon, a part of Schering-Plough, a part of Schering-Plough, Pfizer, Shire, Sumitomo, Takeda, UCB Pharma</td>
</tr>
<tr>
<td>Sanjiv Kumra, M.D.</td>
<td>BMS</td>
</tr>
</tbody>
</table>
**FULL DISCLOSURE INDEX**

<table>
<thead>
<tr>
<th>Name</th>
<th>Stock/Other Financial Options</th>
<th>Consultant</th>
<th>Grant/Research Support</th>
<th>Full-Time Employee</th>
<th>Speaker's Bureau</th>
<th>Other Financial Interest (specify)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elisabeth J. Kunkel, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Forest</td>
<td>laboratories, Pfizer, Wyeth</td>
</tr>
<tr>
<td>David J. Kupfer, M.D.</td>
<td>Servier</td>
<td></td>
<td>Forest Research Institute</td>
<td></td>
<td></td>
<td>Guilford Publications</td>
</tr>
<tr>
<td>John Lauroiello, M.D.</td>
<td>Eli Lilly</td>
<td></td>
<td>Eli Lilly, Pfizer</td>
<td>Janssen Canada</td>
<td></td>
<td>royalties/patient other income</td>
</tr>
<tr>
<td>William Lawson, M.D.</td>
<td>AstraZeneca</td>
<td>AstraZeneca</td>
<td></td>
<td></td>
<td>Abbott, BMS</td>
<td></td>
</tr>
<tr>
<td>Arthur J. Lazarus, M.D., M.B.A.</td>
<td>AstraZeneca</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carlos A. Leon-Andrade, M.D.</td>
<td>GSK, Wyeth</td>
<td></td>
<td></td>
<td></td>
<td>Pfizer</td>
<td></td>
</tr>
<tr>
<td>Petros Levounis, M.D., M.A.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AstraZeneca,</td>
<td>Cephalon, Forest Laboratories, Takeda</td>
</tr>
<tr>
<td>Roberto Lewis-Fernandez, M.D.</td>
<td></td>
<td>Eli Lilly, GSK, Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Israel Liberzon, M.D.</td>
<td>Teva</td>
<td>Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Julio Licinio, M.D.</td>
<td>Teva</td>
<td>Eli Lilly</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jeffrey Lieberman, M.D.</td>
<td>Eli Lilly, Pfizer, GSK, AstraZeneca, Lundbeck, Organon, a part of Schering-Plough, a part of Schering-Plough</td>
<td>Acadia Pharmaceuticals, BMS, GSK, Janssen, Merck, Organon, a part of Schering-Plough Inc., Pfizer</td>
<td></td>
<td></td>
<td>AstraZeneca Advisory Board/ No financial compensation, Eli Lilly Advisory Board/ No financial compensation, GSK Advisory Board/ No financial compensation, Lundbeck Advisory Board/ No financial compensation, Organon, a part of Schering-Plough</td>
<td></td>
</tr>
<tr>
<td>Russell F. Lim, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AstraZeneca</td>
<td></td>
</tr>
<tr>
<td>Leslie P. Lundt, M.D.</td>
<td>Pfizer</td>
<td>Cephalon, Takeda, Sepracor</td>
<td>Cephalon, Sanofi Pharmaceuticals, Inc., GSK, Sepracor, Takeda, Merck, Eli Lilly, Shire</td>
<td>Cephalon, Forest Laboratories, Sanofi Pharmaceuticals, Inc., Wyeth, Sepracor, Pfizer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shari I. Luskin, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Wyeth, AstraZeneca, Forest Laboratories</td>
<td></td>
</tr>
<tr>
<td>Anil K. Malhotra, M.D.</td>
<td>AstraZeneca</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BMS</td>
</tr>
<tr>
<td>Christina V. Mangurian, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>John J. Mann, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>GSK, Novartis</td>
</tr>
<tr>
<td>John S. March, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

XXXVI
<table>
<thead>
<tr>
<th>Name</th>
<th>Stock/Other Financial Options</th>
<th>Consultant</th>
<th>Grant/Research Support</th>
<th>Full-Time Employee</th>
<th>Speaker's Bureau</th>
<th>Other Financial Interest (specify)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen R. Marder, M.D.</td>
<td></td>
<td>BMS, Otsuka, Pfizer, Solvay, Roche Laboratories, Wyeth</td>
<td></td>
<td></td>
<td></td>
<td>BMS Honoraria, Otsuka Honoraria</td>
</tr>
<tr>
<td>Charles R. Marmar, M.D.</td>
<td></td>
<td>Pfizer, Sanofi, Aventis, Aztezian</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prakash Masand, M.D.</td>
<td></td>
<td>Alkermes, BMS, Cephalon, Eli Lilly, Forest Laboratories, GSK, Janssen, Jazz, Organon, a part of Schering-Plough Inc., Ortho McNeil, Pfizer, Solvay, Wyeth</td>
<td>AstraZeneca, BMS, Cephalon, Eli Lilly, Forest Laboratories, GSK, Janssen, Ortho McNeil</td>
<td></td>
<td>AstraZeneca, BMS, Forest Laboratories, GSK, Janssen, Pfizer, Wyeth</td>
<td></td>
</tr>
<tr>
<td>Barbara Mason, Ph.D.</td>
<td></td>
<td>LIPHA, Forest Laboratories</td>
<td>Forest Laboratories, Pfizer</td>
<td></td>
<td></td>
<td>Forest Laboratories</td>
</tr>
<tr>
<td>Sanjay J. Mathew, M.D.</td>
<td></td>
<td>AstraZeneca, Cephalon, Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Helen S. Mayberg, M.D.</td>
<td></td>
<td>Advanced Neuromodulation Systems</td>
<td>NARSAD, Stanley Medical Research Institute, Dana Foundation</td>
<td></td>
<td></td>
<td>Advanced Neuromodulation Systems licensing of intellectual property</td>
</tr>
<tr>
<td>James T. McCracken, M.D.</td>
<td></td>
<td>Eli Lilly, Janssen Research Foundation, Novartis, Pfizer, Shire, Wyeth</td>
<td>BMS, Eli Lilly</td>
<td></td>
<td>UCB Pharma</td>
<td></td>
</tr>
<tr>
<td>Christopher McDougle, M.D.</td>
<td></td>
<td>BMS, Eli Lilly, Janssen</td>
<td>BMS, Janssen</td>
<td></td>
<td></td>
<td>BMS, Janssen</td>
</tr>
<tr>
<td>Patrick McGorry, M.D., Ph.D.</td>
<td></td>
<td>Pfizer, Eli Lilly, Janssen</td>
<td>Janssen, AstraZeneca, BMS, Eli Lilly, Pfizer, Novartis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>James J. McGough, M.D.</td>
<td></td>
<td>Eli Lilly, Shire</td>
<td>Eli Lilly, Janssen, Shire</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melvin G. McInnis, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Roger McIntyre, M.D.</td>
<td></td>
<td>AstraZeneca, Eli Lilly, Janssen, Organon, a part of Schering-Plough, a part of Schering-Plough, Wyeth, Lundbeck, GSK, Oryx, Biowail, Pfizer, BMS, Wyeth</td>
<td>GSK, Merek, Servier, Wyeth, AstraZeneca</td>
<td></td>
<td>AstraZeneca, Eli Lilly, Janssen, Organon, a part of Schering-Plough, a part of Schering-Plough, Wyeth, Lundbeck, GSK, Oryx, Biowail, Pfizer, Prestwick Pharm, Bris</td>
<td></td>
</tr>
<tr>
<td>Francis McMahon, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Herbert Y. Meltzer, M.D.</td>
<td>Acadia Pharmaceuticals</td>
<td>AstraZeneca, Abbott, Acadia Pharmaceuticals, BMS, Eli Lilly, Janssen, Merc, Pfizer</td>
<td>Abbott, AstraZeneca, Eli Lilly, Janssen</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

XXXVII
<table>
<thead>
<tr>
<th>Name</th>
<th>Stock/Other Financial Options</th>
<th>Consultant</th>
<th>Grant/Research Support</th>
<th>Full-Time Employee</th>
<th>Speaker's Bureau</th>
<th>Other Financial Interest (specify)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew A. Menza,</td>
<td></td>
<td>GSK, Eli Lilly, Pfizer, Sepracor, Takeda</td>
<td>AstraZeneca, Boehringer Ingelheim, BMS, GSK, Eli Lilly, Merck, Pfizer, Sanofi Pharmaceuticals, Inc., Sepracor, Takeda, Wyeth-Ayer</td>
<td>Forest Laboratories, BMS, Eli Lilly, Sepracor, Sanofi Pharmaceuticals, Inc., Takeda</td>
<td>Forest Laboratories, BMS, Eli Lilly, Sepracor, Sanofi Pharmaceuticals, Inc., Takeda</td>
<td></td>
</tr>
<tr>
<td>M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jonathan M. Meyer,</td>
<td></td>
<td>BMS, Pfizer</td>
<td></td>
<td>BMS, Pfizer, Janssen-Cilag</td>
<td>Forest Laboratories, Pfizer Advisory Board, Pfizer Advisory Board, Wyeth Advisory Board</td>
<td></td>
</tr>
<tr>
<td>M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barnett S. Meyers,</td>
<td></td>
<td>Cyberonics Inc., Forest Laboratories</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jennifer L.</td>
<td></td>
<td>Pfizer, Shire</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michaels, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eric Mick, S.C.D.</td>
<td></td>
<td>Forest Laboratories</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mark D. Miller,</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jacobo E. Mintzer,</td>
<td></td>
<td>Takeda, Eli Lilly, Forest Laboratories, Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shaila Misri, M.D.</td>
<td></td>
<td>AstraZeneca Canada, GSK, Wyeth, Lundbeck</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jonathan M. Meyer,</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eric M. Morrow,</td>
<td></td>
<td>Forest Laboratories</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M.D., Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benoit H. Mulsant,</td>
<td></td>
<td>Alkermes, AstraZeneca, Eli Lilly, Forest Laboratories, Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M.D., M.S.</td>
<td></td>
<td></td>
<td></td>
<td>AstraZeneca Canada, Pfizer Canada</td>
<td>AstraZeneca Canada, Pfizer Canada</td>
<td></td>
</tr>
<tr>
<td>Philip R. Muskin,</td>
<td></td>
<td>Forest Laboratories</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M.D., M.A.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dominique L.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Musselman, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Husain Mustafa,</td>
<td></td>
<td>AstraZeneca, Abbott, BMS, Janssen</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ziad H. Nahas,</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meera Narasimhan,</td>
<td></td>
<td>BMS, Eli Lilly</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

XXXVIII
<table>
<thead>
<tr>
<th>Name</th>
<th>Stock/Other Financial Options</th>
<th>Consultant</th>
<th>Grant/Research Support</th>
<th>Full-Time Employee</th>
<th>Speaker's Bureau</th>
<th>Other Financial Interest (specify)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Craig Nelson, M.D.</td>
<td></td>
<td>Abbott, Biovail, BMS, Corcept Therapeutics, Eli Lilly, Forest Laboratories, GSK, Novartis, Orexigen, Organon, a part of Schering-Plough Inc., Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Charles B. Nemeroff, M.D., Ph.D.</td>
<td>BMS, Corcept Therapeutics</td>
<td>AstraZeneca, Forest Laboratories, Janssen, Quintiles</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>David N. Neubauer, M.D.</td>
<td></td>
<td>Neurocrine Biosciences Inc., Sanofi Pharmaceuticals, Inc., Takeda</td>
<td></td>
<td></td>
<td>Sanofi Pharmaceuticals, Inc., Takeda</td>
<td></td>
</tr>
<tr>
<td>John W. Newcomer, M.D.</td>
<td></td>
<td>AstraZeneca, Janssen, BMS, GSK, Organon, a part of Schering-Plough Inc., Pfizer, Solvay, Wyeth</td>
<td></td>
<td></td>
<td>BMS, Janssen, NARSAD, Pfizer, Wyeth</td>
<td></td>
</tr>
<tr>
<td>Jeffrey H. Newcorn, M.D.</td>
<td></td>
<td>Cortex, Eli Lilly, Shire, McNeil Pediatrics, Novartis, Pfizer</td>
<td></td>
<td></td>
<td></td>
<td>Novartis, Shire</td>
</tr>
<tr>
<td>Andrew A. Nierenberg, M.D.</td>
<td></td>
<td>Abbott, Eli Lilly Innapharma, Janssen, Jazz, Novartis, Sepracor, Shire</td>
<td></td>
<td></td>
<td>Cederroth, BMS, Eli Lilly Lichtwer GmbH, NARSAD, Cyberonics Inc., Forest Laboratories, Organon, a part of Schering-Plough Inc., RWJ, Wyeth</td>
<td></td>
</tr>
<tr>
<td>Edward V. Nunes, M.D.</td>
<td></td>
<td>Alkermes</td>
<td></td>
<td></td>
<td>Alkermes</td>
<td></td>
</tr>
<tr>
<td>Mary O'Malley, M.D.</td>
<td></td>
<td>Cephalon</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Johnny O'Reardon, M.D.</td>
<td></td>
<td>Neuronetics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mark Olsson, M.D. M.P.H.</td>
<td></td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company, McNeil Pediatrics, Pfizer</td>
<td></td>
<td></td>
<td>AstraZeneca, BMS</td>
<td>Janssen</td>
</tr>
<tr>
<td>Joseph J. Parks, M.D.</td>
<td></td>
<td>Solvay</td>
<td></td>
<td></td>
<td>Eli Lilly</td>
<td></td>
</tr>
<tr>
<td>Teri Pearlstein, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Berlex</td>
<td>Wyeth Advisory Board</td>
</tr>
</tbody>
</table>

XXXIX
## FULL DISCLOSURE INDEX

<table>
<thead>
<tr>
<th>Name</th>
<th>Stock/Other Financial Options</th>
<th>Consultant</th>
<th>Grant/Research Support</th>
<th>Full-Time Employee</th>
<th>Speaker's Bureau</th>
<th>Other Financial Interest (specify)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diana O. Perkins, M.D. M.P.H.</td>
<td></td>
<td>BMS, Eli Lilly AstraZeneca</td>
<td>Janssen, Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td></td>
<td>AstraZeneca, Eli Lilly</td>
<td></td>
</tr>
<tr>
<td>Roy H. Perlis, M.D. M.Sc.</td>
<td></td>
<td>AstraZeneca, BMS, Eli Lilly Pfizer</td>
<td>NARSAD</td>
<td></td>
<td>AstraZeneca, BMS, Eli Lilly, GSK, Pfizer</td>
<td>AstraZeneca Advisory Board, BMS Advisory Board, Eli Lilly Advisory Board, Pfizer Advisory Board</td>
</tr>
<tr>
<td>Eric D. Peselow, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pfizer, Forest Laboratories</td>
<td></td>
</tr>
<tr>
<td>Francois C. Petitjean, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Servier</td>
<td></td>
</tr>
<tr>
<td>Katharine A. Phillips, M.D.</td>
<td></td>
<td></td>
<td>AFSP, Forest Laboratories, UCB Pharma</td>
<td></td>
<td>Guildford Publications</td>
<td>Potential Royalties, Merck Future Writing Honorarium</td>
</tr>
<tr>
<td>Jorge Plutzky, M.D.</td>
<td></td>
<td>GSK, Ono Pharma Pharmaceuticals, Inc., Sanofi, Takeda,</td>
<td></td>
<td></td>
<td>Janssen Speaker Honoraria</td>
<td></td>
</tr>
<tr>
<td>David J. Posey, M.D., M.S.</td>
<td>Shire</td>
<td>BMS, Eli Lilly, Forest Laboratories</td>
<td>Eli Lilly</td>
<td></td>
<td>Janssen</td>
<td></td>
</tr>
<tr>
<td>Robert Post, M.D.</td>
<td></td>
<td>Abbott, AstraZeneca, BMS, GSK</td>
<td></td>
<td></td>
<td>Abbott, AstraZeneca, BMS, GSK</td>
<td></td>
</tr>
<tr>
<td>Steven G. Potkin, M.D.</td>
<td></td>
<td>Acadia, Arena, AstraZeneca, BMS, Janssen, Novartis, Organon, a part of Schering-Plough, a part of Schering-Plough, Otsuka, Pfizer</td>
<td>Sanofi-Synthelabo Pharmaceuticals, Inc., Solvay, Allergan, AstraZeneca, BMS, Lilly Research Laboratories, a division of Eli Lilly and Company Forest Laboratories, Janssen</td>
<td></td>
<td>AstraZeneca, Pfizer, BMS, Novartis</td>
<td></td>
</tr>
<tr>
<td>Annelle B. Primm, M.D., M.P.H.</td>
<td></td>
<td>AstraZeneca, Eli Lilly, Pfizer</td>
<td></td>
<td></td>
<td>AstraZeneca</td>
<td></td>
</tr>
<tr>
<td>Jefferson B. Prince, M.D.</td>
<td></td>
<td>Abbott, McNeil Pediatrics, Novartis, Shire</td>
<td></td>
<td></td>
<td>Janssen</td>
<td></td>
</tr>
<tr>
<td>Andres J. Pumarega, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pfizer, Forest Laboratories</td>
<td></td>
</tr>
<tr>
<td>Peter V. Rabins, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Janssen</td>
<td></td>
</tr>
</tbody>
</table>
### FULL DISCLOSURE INDEX

<table>
<thead>
<tr>
<th>Name</th>
<th>Stock/Other Financial Options</th>
<th>Consultant</th>
<th>Grant/Research Support</th>
<th>Full-Time Employee</th>
<th>Speaker's Bureau</th>
<th>Other Financial Interest (specify)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Natalie L. Rasgon, M.D., Ph.D.</td>
<td></td>
<td>GSK, Wyeth</td>
<td>Abbott, Forest Laboratories, GSK, Wyeth</td>
<td>Abbott, BMS, Forest Laboratories, GlaxoSmithKline, Pfizer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kerry Ressler, M.D., Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Delbert Robinson, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Luis Augusto L. Rohde, M.D., D.Sc.</td>
<td></td>
<td>Eli Lilly Janssen-Cilag, Novartis</td>
<td>Novartis</td>
<td>Novartis, Eli Lilly Janssen-Cilag</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steven P. Roose, M.D.</td>
<td></td>
<td>Forest Laboratories, Eli Lilly, Wyeth</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Richard N. Rosenthal, M.D.</td>
<td></td>
<td>Alkermes, Cephalon</td>
<td>Forest Research Institute, Titan</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stephen Ross, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cephalon Pharmaceuticals</td>
</tr>
<tr>
<td>Thomas Roth, Ph.D.</td>
<td>Abbott, Cephalon, Cypress Elan, Eli Lilly, Purdue Pharma, Roche Laboratories, Sanofi Pharmaceuticals, Inc., Schering, Sepracor, Servier, Shire, Somaxon, Takeda</td>
<td>Aventis, Cephalon, GSK, Neurocrine Biosciences, Pfizer, Sanofi Pharmaceuticals, Inc., Sepracor, Somaxon, Takeda, Wyeth, Xenoprot</td>
<td>Cephalon, Sanofi Pharmaceuticals, Inc., Takeda Abbott Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Matthias Rothermundt, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>A. John Rush, M.D.</td>
<td>Pfizer</td>
<td>AstraZeneca, BMS, Cyberoni, Eli Lilly, Forest Laboratories, GSK, Jazz, Merck, Neuronetics, Ono, Organon, a part of Schering-Plough Inc., Wyeth</td>
<td>Stanley Medical Research Institute</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deirdre Ryan, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AstraZeneca Canada, Wyeth</td>
</tr>
<tr>
<td>Alex N. Sabo, M.D.</td>
<td></td>
<td>AstraZeneca, Cephalon, Eli Lilly Novartis, Perdue, Pfizer, UCB Pharma</td>
<td>Wyeth</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Stock/Other Financial Options</td>
<td>Consultant</td>
<td>Grant/Research Support</td>
<td>Full-Time Employee</td>
<td>Speaker's Bureau</td>
<td>Other Financial Interest (specify)</td>
</tr>
<tr>
<td>-----------------------------------------</td>
<td>------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>--------------------</td>
<td>-----------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Jay A. Salpekar, M.D.</td>
<td></td>
<td>Abbott</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shirlene M. Sampson, M.D. M.S.</td>
<td></td>
<td>Neuronetics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mary Sano, Ph.D.</td>
<td></td>
<td>Aventis, Bayer, Forest Laboratories, GSK, Janssen, Ortho McNeil, Pfizer, Takeda, Novartis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norman Sartorius, M.D., Ph.D.</td>
<td></td>
<td>Servier, Lundbeck</td>
<td></td>
<td></td>
<td></td>
<td>Janssen-Cilag Participation in meetings, Eli Lilly Participated in Scientific Meeting, Pfizer Participated in Scientific Meeting</td>
</tr>
<tr>
<td>Alan F. Schatzberg, M.D.</td>
<td>Corecept Therapeutics</td>
<td>Corecept Therapeutics, Eli Lilly, Neuronetics, Wyeth</td>
<td>GSK</td>
<td></td>
<td></td>
<td>Corecept Therapeutics Advisory Board, Eli Lilly Advisory Board, Wyeth Advisory Board, Forest Laboratories Advisory Board, Abbott Advisory Board, Neuronetics Advisory Board</td>
</tr>
<tr>
<td>S. Charles Schulz, M.D.</td>
<td>AstraZeneca, Eli Lilly</td>
<td>Abbott, Eli Lilly</td>
<td>AstraZeneca</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan Scott, M.D., M.B.</td>
<td>AstraZeneca, BMS, Eli Lilly, GSK, Janssen-Cilag</td>
<td>AstraZeneca, Janssen-Cilag</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michael J. Sernyak, M.D.</td>
<td></td>
<td>Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arie Y. Shalev, M.D.</td>
<td></td>
<td>Lundbeck</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shawn C. Shea, M.D.</td>
<td>Eli Lilly</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yvette I. Sheline, M.D.</td>
<td>Cyberonics Inc., Wyeth</td>
<td></td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Linmarie Sikich, M.D.</td>
<td>Eli Lilly Janssen, BMS, Otsuka, Pfizer, GSK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Helen Blair Simpson, M.D., Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>JazzScientific Advisory Board</td>
</tr>
<tr>
<td>Yusuf Sivrioglu, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pfizer, Novartis</td>
</tr>
<tr>
<td>Name</td>
<td>Stock/Other Financial Options</td>
<td>Consultant</td>
<td>Grant/Research Support</td>
<td>Full-Time Employee</td>
<td>Speaker's Bureau</td>
<td>Other Financial Interest (specify)</td>
</tr>
<tr>
<td>--------------------------</td>
<td>-------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-------------------------</td>
<td>--------------------</td>
<td>------------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>Gary W. Small, M.D.</td>
<td></td>
<td>Abbott, Eisai, Forest Laboratories, Myriad Genetics, Novartis, Ortho McNeil, Pfizer, Takeda</td>
<td></td>
<td></td>
<td>Forest Laboratories, Novartis, Pfizer</td>
<td></td>
</tr>
<tr>
<td>Sean Spence, M.D.</td>
<td></td>
<td>Cephalon, AstraZeneca, Servier, Organon, a part of Schering-Plough Inc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thomas J. Spencer, M.D.</td>
<td></td>
<td></td>
<td>Shire, Eli Lilly, GSK, McNeil Pediatrics, Novartis</td>
<td></td>
<td>GSK, Eli Lilly Novartis, McNeil Pediatrics, Shire</td>
<td>Shire advisory board, Eli Lilly advisory board, GSK advisory board, McNeil Pediatrics advisory board, Novartis advisory board</td>
</tr>
<tr>
<td>Stephen M. Stahl, M.D., Ph.D.</td>
<td>Cypress Neuromolecular</td>
<td>Acadia, AstraZeneca, Biovail, Boehringer Ingelheim, BMS, Cephalon, Cyberonics Inc., Cypress Eli Lilly, GSK, Janssen</td>
<td>Akermes, AstraZeneca, BMS, Cyberonics Inc., Cephalon, Eli Lilly, GSK, Janssen, Jazz, Neurocrine Biosciences Inc., Novartis, Organon</td>
<td></td>
<td>AstraZeneca, Cephalon, Eli Lilly Pfizer, Wyeth</td>
<td>Cypress Bioscience BoardMember, Neuromolecular BoardMember</td>
</tr>
<tr>
<td>Sharon Stanford, M.D.</td>
<td></td>
<td></td>
<td>Eli Lilly Pfizer, Cypress Forest Laboratories, Sanofi-Synthelabo Pharmaceuticals, Inc., Wyeth</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jodi E. Star, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>AstraZeneca, Forest Laboratories</td>
<td></td>
</tr>
<tr>
<td>Vered Stearns</td>
<td></td>
<td>Wyeth</td>
<td></td>
<td></td>
<td>GSK</td>
<td></td>
</tr>
<tr>
<td>David C. Steffens, M.D., M.H.S.C.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Forest Laboratories, Wyeth</td>
<td></td>
</tr>
<tr>
<td>Dan J. Stein, M.D., Ph.D.</td>
<td>GSK, Johnson and Johnson, Lundbeck, Orion, Servier Solvay, Wyeth</td>
<td>AstraZeneca, Eli Lilly, GSK, Janssen, Johnson and Johnson, Lundbeck, Pfizer, Solvay, Wyeth</td>
<td></td>
<td></td>
<td>Lundbeck, Pfizer, Solvay</td>
<td>AstraZeneca Advisory Board, Janssen Advisory Board, Johnson and Johnson Advisory Board, Lundbeck Advisory Board, Pfizer Advisory Board, Wyeth Advisory Board</td>
</tr>
<tr>
<td>Donna E. Stewart, M.D.</td>
<td></td>
<td>Eli Lilly, Wyeth</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eric C. Strain, M.D.</td>
<td></td>
<td>Reckitt Benckiser, Schering, Shire, Titan, GSK</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Stock/Other Financial Options</td>
<td>Consultant</td>
<td>Grant/Research Support</td>
<td>Full-Time Employee</td>
<td>Speaker's Bureau</td>
<td>Other Financial Interest (specify)</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>--------------------</td>
<td>-----------------------------------</td>
<td>----------------------------------------------------------------</td>
</tr>
<tr>
<td>Thomas S. Stroup, M.D., M.P.H.</td>
<td></td>
<td>AstraZeneca, Eli Lilly Janssen, Lundbeck, Pfizer, Solvay</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Craig B. Surman, M.D.</td>
<td></td>
<td>Shire, Takeda</td>
<td>McNeil Pediatrics, Abbott, Merek, Takeda, Pfizer</td>
<td>Novartis, Shire</td>
<td>Shire Educational Grant, Janssen Speaker</td>
<td></td>
</tr>
<tr>
<td>James M. Swanson, M.D.</td>
<td></td>
<td>McNeil Pediatrics, Shire, UCB Pharma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Holly A. Swartz, M.D.</td>
<td></td>
<td>BMS</td>
<td></td>
<td>BMS</td>
<td></td>
<td>AstraZeneca CME Honoraria</td>
</tr>
<tr>
<td>Carol A. Tamminga, M.D.</td>
<td></td>
<td>Acadia, Lilly Research Laboratories, a division of Eli Lilly and Company Lundbeck, Sumitomo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jogin Thakore, M.D.</td>
<td></td>
<td>Eli Lilly</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michael E. Thase, M.D.</td>
<td></td>
<td>AstraZeneca, BMS, Cephalon, Cyberonics Inc., Eli Lilly, GSK, Janssen, Neurontics, Novartis, Organon, a part of Schering-Plough Inc., Sepracor, Shire, Wyeth</td>
<td></td>
<td></td>
<td></td>
<td>AstraZeneca, BMS, Cyberonics Inc., Eli Lilly, GSK, Organon, a part of Schering-Plough Inc., Sanofi Pharmaceuticals, Inc., Wyeth</td>
</tr>
<tr>
<td>John W. Tsuang, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company Abbott, Janssen, Reckitt Benckiser</td>
</tr>
<tr>
<td>Audrey R. Tyrka, M.D., Ph.D.</td>
<td></td>
<td>Cephalon, Cyberonics Inc., Medtronics, Pfizer, Sepracor, UCB Pharma</td>
<td></td>
<td></td>
<td></td>
<td>Wyeth Honorarium, Janssen Research Award</td>
</tr>
<tr>
<td>Eve M. Valera PhD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Shire Honoraria 2006, Eli Lilly Travel Award 2003</td>
</tr>
<tr>
<td>Livia Vavrusova, M.D., Ph.D.</td>
<td></td>
<td>AstraZeneca, Eli Lilly, GSK, Johnson and Johnson, Servier</td>
<td>Lundbeck</td>
<td></td>
<td>AstraZeneca, Eli, GSK, Lilly, Servier</td>
<td></td>
</tr>
<tr>
<td>Dawn I. Velligan, Ph.D.</td>
<td></td>
<td>AstraZeneca, Pfizer</td>
<td>AstraZeneca, Janssen, Organon, a part of Schering-Plough Inc., Pfizer</td>
<td></td>
<td></td>
<td>AstraZeneca, Janssen</td>
</tr>
<tr>
<td>Marcia Verduin, M.D.</td>
<td></td>
<td>BMS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### FULL DISCLOSURE INDEX

<table>
<thead>
<tr>
<th>Name</th>
<th>Stock/Other Financial Options</th>
<th>Consultant</th>
<th>Grant/Research Support</th>
<th>Full-Time Employee</th>
<th>Speaker's Bureau</th>
<th>Other Financial Interest (specify)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eduard Vietu, M.D., Ph.D.</td>
<td></td>
<td>AstraZeneca, BMS, Eli Lilly, GSK, Janssen-Cilag, Merck Sharp &amp; Dohme, Novartis, Organon, a part of Schering-Plough Inc., Otsuka, Pfizer, Sanofi Pharmaceuticals, Inc., Servier,</td>
<td>AstraZeneca, BMS, Eli Lilly, GSK, Janssen-Cilag, Merck Sharp &amp; Dohme, Novartis, Organon, a part of Schering-Plough, a part of Schering-Plough, Ortsuka, Pfizer, Sanofi Pharmaceuticals</td>
<td>AstraZeneca, BMS, Eli Lilly, GSK, Novartis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adele Viguera, M.D.</td>
<td></td>
<td>GSK, Novartis</td>
<td>AstraZeneca, Berlex, Eli Lilly, GSK, Janssen, NARSAD</td>
<td></td>
<td>Eli Lilly, GSK, Novartis, Wyeth</td>
<td></td>
</tr>
<tr>
<td>Karen D. Wagner, M.D., Ph.D.</td>
<td></td>
<td>AstraZeneca, Abbott, BMS, Otsuka</td>
<td></td>
<td></td>
<td>Eli Lilly Advisory Board, Forest Laboratories Advisory board, Janssen Advisory board, Novartis Advisory board</td>
<td></td>
</tr>
<tr>
<td>Peter J. Weiden, M.D.</td>
<td></td>
<td>AstraZeneca, BMS, Janssen, Organon, a part of Schering-Plough, a part of Schering-Plough, Pfizer, Shire, Vanda, Wyeth,</td>
<td>AstraZeneca, BMS, Janssen, Pfizer</td>
<td>AstraZeneca, BMS, Janssen, Pfizer</td>
<td>Pfizer Family Member Consultant</td>
<td></td>
</tr>
<tr>
<td>Daniel Weinberger, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pfizer, Wyeth</td>
<td></td>
</tr>
<tr>
<td>Elyse D. Weiner, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elizabeth B. Weller, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Otuska Scientific Consultant</td>
</tr>
<tr>
<td>Ellen M. Whyte, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Timothy E. Wilens, M.D.</td>
<td></td>
<td>Abbott, Cephalon, Ortho McNeil, Eli Lilly, Merck, Novartis</td>
<td>Abbott, Cephalon, Eli Lilly, Ortho McNeil, Shire</td>
<td>Ortho McNeil, Novartis, Shire</td>
<td></td>
<td></td>
</tr>
<tr>
<td>David A. Williams, Ph.D.</td>
<td></td>
<td>Cypress, Eli Lilly, Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Katherine L. Wisner, M.D., M.S.</td>
<td></td>
<td></td>
<td></td>
<td>Pfizer</td>
<td></td>
<td>GSK</td>
</tr>
<tr>
<td>Stephen Woods, Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sanofi Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Scott W. Woods, M.D.</td>
<td></td>
<td>Otsuka, Schering-Plough,</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allan H. Young, M.D., Ph.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joel Young, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cephalon, Eli Lilly, Novartis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cephalon, Eli Lilly, GSK, McNeil Pediatrics, Sepracor Shire, Takeda,</td>
</tr>
</tbody>
</table>

**XLV**
## FULL DISCLOSURE INDEX

<table>
<thead>
<tr>
<th>Name</th>
<th>Stock/Other Financial Options</th>
<th>Consultant</th>
<th>Grant/Research Support</th>
<th>Full-Time Employee</th>
<th>Speaker's Bureau</th>
<th>Other Financial Interest (specify)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sidney Zisook, M.D.</td>
<td></td>
<td>GSK</td>
<td>Pam Lab</td>
<td></td>
<td></td>
<td>AstraZeneca, Forest Laboratories</td>
</tr>
</tbody>
</table>
The following presenters have indicated they have no significant relationship to disclose or did not provide disclosure information.
The following presenters have indicated they have no significant relationship to disclose or did not provide disclosure information.

Charles J Ndlela M.D. M.P.H.
Vernon Nathaniel M.D.
Syed Naqvi M.D.
Joseph C Napoli M.D.
Surinder S Nand M.D.
Gene A Nakajima M.D.
Wade Myers Ph.D.
Maria Muzik M.D.
Michael F Myers M.D.
Wade Myers M.D.
Carol C Nadelson M.D.
Amaneek D Nagra M.D. M.P.H.
Niru Nahar M.D. M.P.H.
Gene A Nakajima M.D.
MeNaughton L. Nancy M.Ed.
Surinder S Nan D.M.D.
Joseph C Napol M.D.
Sylv Naqvi M.D.
Vernon E. Narrow M.D. M.P.H.
Norrin S Nickel M.D. M.P.H.
Stephen J Petersen Ph.D.
Deborah C Peck M.D.
Roger Pele M.D.
Paul Pendler Psy.D.
Christian D Perring Ph.D.
Cheryl Person M.D.
Eithel S Person M.D.
Linda F Pessar M.D.
Neil Pessar M.D.
John Petet M.D.
Timothy J Petersen Ph.D.
Stephen W Peterson M.D.
Michael K Pfeffer M.D.
Bruce M Pfohl M.D. M.S.
James W Pickett Ph.D.
Sue Pickett-Schenk Ph.D.
Richard C Pillard M.D.
Adam J Savitz M.D. Ph.D.
Andrew J SAXON M.D.
Erminia Scarcella M.D.
David L. Seaga M.D.
David S Schnecht M.D.
Diane H Schirky M.D.
Randolph B Schiffer M.D.
Chester W. Schmidt M.D.
Chester W. Schmidt M.D.
Barbara S Schnieidman M.D. M.P.H.
Michael Schoenbaum Ph.D.
Gary R Schoener M.D.
Robert A Schoevers M.D.
Pim Scholte M.D.
Kenneth G Schooff M.D.
James Q Schubemeil M.D.
Thomas G Schulze M.D.
Harold A Schwartz M.D.
Patricia M Schwartz M.D.
Vctor I Schwartz M.D.
Thomas L Schwenk M.D.
Marcia Scott M.D.
Bruce W Scotton M.D.
James H Sealy, Jr. M.D.
Deborah E Scale B.A. M.A.
Jonathan L Sebat Ph.D.
Ricardo Sein M.D.
Lloyd I Sederer M.D.
Marinly Seide Ph.D.
Larry J Seidman Ph.D.
Roslyn Seligman M.D. B.S.
Dave Sells Ph.D.
Sandra E Sephton Ph.D.
David Shaffer M.D.
Edward R Shapiro M.A. M.D.
Steven S Sharpein M.D.
Janet Shaw B.S. M.B.A.
Jon A Shaw M.D.
Wallace Shaw M.D. Ph.D.
Paula Shear Ph.D.
Beverly A Sheehan M.B.A.
Hong Shen M.D.
Ramakrishnan Shemyoy M.D.
Richard Shepler Ph.D.
Cathy Sherbourne Ph.D.
Joel T Sherriff Ph.D.
Heather L Shibley M.D.
Lina Shihabuddin M.D.
Ellen H Sholevar M.D.
G. Pirooz Sholevar M.D.
Adriana E Shuster M.D. B.A.
Kirsan S Siddiqui M.Ed. B.A.
Adriana E Shuster M.D. B.A.
G. Pirooz Sholevar M.D.
Ellen H Sholevar M.D.
Heather L Shibley M.D.
Richard Shepler Ph.D.
Cathy Sherbourne Ph.D.
Joel T Sherriff Ph.D.
Heather L Shibley M.D.
Lina Shihabuddin M.D.
Ellen H Sholevar M.D.
G. Pirooz Sholevar M.D.
Adriana E Shuster M.D. B.A.
Kirsan S Siddiqui M.Ed. B.A.
Adriana E Shuster M.D. B.A.
G. Pirooz Sholevar M.D.
Ellen H Sholevar M.D.
Heather L Shibley M.D.
Richard Shepler Ph.D.
Cathy Sherbourne Ph.D.
Joel T Sherriff Ph.D.
Heather L Shibley M.D.
Lina Shihabuddin M.D.
Ellen H Sholevar M.D.
G. Pirooz Sholevar M.D.
Adriana E Shuster M.D. B.A.
Kirsan S Siddiqui M.Ed. B.A.
Adriana E Shuster M.D. B.A.
G. Pirooz Sholevar M.D.
Ellen H Sholevar M.D.
Heather L Shibley M.D.
Richard Shepler Ph.D.
Cathy Sherbourne Ph.D.
Joel T Sherriff Ph.D.
Heather L Shibley M.D.
Lina Shihabuddin M.D.
Ellen H Sholevar M.D.
G. Pirooz Sholevar M.D.
Adriana E Shuster M.D. B.A.
Kirsan S Siddiqui M.Ed. B.A.
Adriana E Shuster M.D. B.A.
G. Pirooz Sholevar M.D.
Ellen H Sholevar M.D.
Heather L Shibley M.D.
Richard Shepler Ph.D.
Cathy Sherbourne Ph.D.
Joel T Sherriff Ph.D.
Heather L Shibley M.D.
Lina Shihabuddin M.D.
Ellen H Sholevar M.D.
G. Pirooz Sholevar M.D.
Adriana E Shuster M.D. B.A.
Kirsan S Siddiqui M.Ed. B.A.
Adriana E Shuster M.D. B.A.
G. Pirooz Sholevar M.D.
Ellen H Sholevar M.D.
Heather L Shibley M.D.
161st ANNUAL MEETING
May 3-8, 2008 • Washington, DC

2008 Annual Meeting Online
Your One-Stop Educational eResource Library

- Audio-visual programs available 24/7 from your desktop
- Special attendee on-site pricing available
- Up to 100 hours of new 2008 meeting content
- Review presentations from world renowned faculty
- Earn CME credit
- Free online access for 90+ hours of Industry-Supported Symposia

Visit the booth located in the east lobby, (just off the main entrance to the convention center) for more information.

The APA Annual Meeting Online
www.psych.org/amlibrary

The American Psychiatric Association is accredited by the ACCME to provide continuing medical education for physicians. The APA designates (each of the presentations) in this educational activity for a maximum of 1-3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

www.psych.org
8:00 a.m. Sessions

COURSES 1-4

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 1 8:00 a.m.-12:00 noon
Room 101, Level One, Washington Convention Center
DSM-IV RATING SCALES TO INCREASE THE EFFECTIVENESS OF YOUR PSYCHIATRIC PRACTICE
Co-Directors: Joyce Sprafkin, Ph.D., Kenneth D. Gadow, Ph.D.
Faculty: Deborah Weisbrot M.D.

COURSE 2 8:00 a.m.-12:00 noon
Room 102A, Level One, Washington Convention Center
PSYCHIATRIC CONSULTATION IN LONG-TERM CARE: BASIC COURSE
Director: Abhilash K. Desai, M.D.
Faculty: George Grossberg M.D.

COURSE 3 8:00 a.m.-12:00 noon
Room 148, Level One, Washington Convention Center
DYNAMIC PSYCHOTHERAPY FOR CANCER PATIENTS AND THEIR SPOUSES
Director: Norman L. Straker, M.D.

COURSE 4 8:00 a.m.-12:00 noon
Room 152A, Level One, Washington Convention Center
MANAGEMENT OF PSYCHIATRIC DISORDERS IN PREGNANT AND POSTPARTUM WOMEN
Co-Directors: Shaila Misri, M.D., Diana Carter, M.D.
Faculty: Shari Lusskin M.D., Deirdre Ryan M.D.

9:00 a.m. Sessions

COURSES 5-12

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 5 9:00 a.m.-4:00 p.m.
Room 103A, Level One, Washington Convention Center
EEG NEUROFEEDBACK IN PSYCHIATRY: CLINICAL APPLICATIONS
Co-Directors: Thomas M. Brod, M.D., Michael Cohen, M.D.
Faculty: David Mitnick M.D., Laurence Hirshberg, Ph.D., Siegfried Othmer, B.S., Samuel Roura M.D., Stephen Larsen Ph.D., Stephen E. Buic, M.D.

COURSE 6 9:00 a.m.-4:00 p.m.
Room 103B, Level One, Washington Convention Center
A PRACTICAL APPROACH TO RISK ASSESSMENT
Director: William Campbell, M.D.

COURSE 7 9:00 a.m.-4:00 p.m.
Room 143A/B, Level One, Washington Convention Center
PSYCHIATRIC ASPECTS OF HIV/AIDS: AN UPDATE
Director: Marshall Forstein, M.D.
Faculty: Francisco Fernandez M.D., Gary Simon M.D., Gabrielle Marzani-Nissen M.D., Antoine Douaihy M.D.

COURSE 8 9:00 a.m.-4:00 p.m.
Room 143C, Level One, Washington Convention Center
SPIRITUALITY AND WORLDVIEW IN CLINICAL PRACTICE
Director: Allan M. Josephson, M.D.
Faculty: Mary Dell, M.D., James Griffith M.D., John Petet, M.D.

COURSE 9 9:00 a.m.-4:00 p.m.
Room 151B, Level One, Washington Convention Center
THERAPEUTIC INTERVENTIONS IN EATING DISORDERS: BASIC PRINCIPLES
Director: David C. Jimerson, M.D.
Faculty: Joel Yager, M.D., Michael Devlin, M.D., B. Thomas Walsh, M.D., Katherine Halmi, M.D.
COURSE 10 9:00 a.m.-4:00 p.m.
Room 152B, Level One, Washington Convention Center

KUNDALINI YOGA MEDITATION TECHNIQUES FOR PSYCHIATRIC DISORDERS

Director: David Shannahoff-Khalsa, B.A.

COURSE 11 9:00 a.m.-4:00 p.m.
Room 158A/B, Level One, Washington Convention Center

INTERPERSONAL AND SOCIAL RHYTHM THERAPY FOR BIPOLAR DISORDER

Co-Directors: Ellen Frank, Ph.D., Holly A. Swartz, M.D.
Faculty: Debra Frankel, LIC.S.W.

COURSE 12 9:00 a.m.-4:00 p.m.
Room 159A/B, Level One, Washington Convention Center

NEUROANATOMY OF EMOTIONS: FROM BRAIN TO CLINICAL PRACTICE

Director: Ricardo M. Vela, M.D.
Faculty: Mohammed Milad Ph.D.

INTERNATIONAL MEDICAL GRADUATES RESIDENTS INSTITUTE
9:00 a.m.-4:00 p.m.
Room 150A/B, Level One, Washington Convention Center

International Medical Graduates Residents Institute
(Institute registration required)

12:30 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 1-3

INDUSTRY-SUPPORTED SYMPOSIUM 1
12:30 p.m.-3:30 p.m.
Ballroom A/B, Level Three, Washington Convention Center

PSYCHIATRIC ISSUES IN WOMEN THROUGH THE ADULT LIFE-CYCLE
Supported by: Wyeth Pharmaceuticals

Chp.: Vivien K. Burt, M.D.

A Gender Differences in Anxiety and Mood Disorders in the Population
Kathleen R. Merikangas, Ph.D.

B Cognition and Mood in Perimenopause
Sanjay J. Mathew, M.D.

C Risk Factors for Alcohol Abuse in Women: Recent Research and Implications for Treatment and Prevention
Sharon Wilsnack, Ph.D.

D Post partum Depression: Risk Factors and Treatment
Pedro J. Garrido, Ph.D., Amaro Lakia, Ph.D., Maricarmen Bennasar, Psy.D, Vivien K. Burt, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 2
12:30 p.m.-3:30 p.m.
Grand Ballroom, Ballroom Level, Renaissance Washington

COMPREHENSIVE CARE OF THE LONG-TERM PATIENT WITH SCHIZOPHRENIA: TREATING THE WHOLE PATIENT
Supported by: Pfizer Inc.

Chp.: John W. Newcomer, M.D.

A Tools for Improving Long-Term Medical Health
Peter A. Fahnestock, M.D.

B Recovery From Schizophrenia: Goals and Outcomes for an Emerging and Attainable Therapeutic Goal
Stephen R. Marder, M.D.

C General Medical Health in Schizophrenia: It's More Than Just Weight Gain
John W. Newcomer, M.D.

D Achieving Recovery: Pharmacologic and Psychosocial Approaches
William T. Carpenter, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 3
12:30 p.m.-3:30 p.m.
Independence Ballroom, Independence Level, Grand Hyatt Washington

RECENT ADVANCES IN ALZHEIMER'S DISEASE: EXPERT OPINIONS ON CURRENT AND EMERGING THEORIES
Supported by: Forest Laboratories, Inc.

Chp.: Peter V. Rabins, M.D.

A Advances in the Diagnosis of Alzheimer's Disease
Gary W. Small, M.D.

B Advances in Disease Modification: BAPtists versus TAUists
Leonard Petrucelli, Ph.D.

C Advances in Current Alzheimer's Disease Treatment Guidelines
Peter V. Rabins, M.D.
D Advances in Symptomatic Alzheimer’s Disease Pharmacotherapy
Roy Yaari, M.D.

1:00 p.m. Sessions

COURSES 13-18
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 13 1:00 p.m.-5:00 p.m.
Room 101, Level One, Washington Convention Center
BRAIN STIMULATION THERAPIES IN PSYCHIATRY
Director: Ziad H. Nahas, M.D.
Faculty: Husain Mustafa M.D., Darin Dougherty M.D., Linda Carpenter M.D.

COURSE 14 1:00 p.m.-5:00 p.m.
Room 102A, Level One, Washington Convention Center
PSYCHIATRISTS’ ROLE IN DISASTER MANAGEMENT: LESSONS LEARNED
Director: Richard C. Hall, M.D.
Faculty: Ryan C. Hall, M.D., James R. Rundell, M.D., Daniel K. Winstead, M.D.

COURSE 15 1:00 p.m.-5:00 p.m.
Room 102B, Level One, Washington Convention Center
COGNITIVE-BEHAVIOR THERAPY FOR SCHIZOPHRENIA
Director: Jesse H. Wright, M.D.
Faculty: David Kingdon, M.D., Douglas Turkington, M.D.

COURSE 16 1:00 p.m.-5:00 p.m.
Room 144A, Level One, Washington Convention Center
DREAM TRANSLATION: ONE EMPIRICALLY-BASED APPROACH
Director: Milton Kramer, M.D.

COURSE 17 1:00 p.m.-5:00 p.m.
Room 151A, Level One, Washington Convention Center
PSYCHIATRIC GENOMICS: APPLICATIONS FOR CLINICAL PRACTICE
Director: David A. Mrazek, M.D.
Faculty: John L. Black, M.D., Renato D. Alarcon, M.D.

MOOD DISORDERS IN LATER LIFE
Co-Directors: James M. Ellison, M.D., Yusuf Sivrioglu, M.D.
Faculty: Donald A. Davidoff, Ph.D., Francesca C. Antognini, Ph.D., Brent P. Forester, M.D.

6:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 4-6

INDUSTRY-SUPPORTED SYMPOSIUM 4
6:00 p.m.-9:00 p.m.
Ballroom A/B, Level Three, Washington Convention Center
FIBROMYALGIA: DIAGNOSTIC ADVANCES AND EMERGING PHARMACOLOGIC THERAPIES FOR A COMPLEX, MULTIDIMENSIONAL DISORDER
Supported by: Eli Lilly and Company
Chp.: Daniel J. Clauw, M.D.
A Fibromyalgia: The Pathophysiology of Dysfunctional Pain Processing
Daniel J. Clauw, M.D.
B Emerging Strategies in the Management of Fibromyalgia: A Pathophysiologic Approach to Pharmacotherapy
Daniel J. Clauw, M.D.
C Efficacy of Current Therapeutic Interventions for Fibromyalgia: Unmet Clinical Needs
Lesley M. Arnold, M.D.
D The Fibromyalgia Mystery: Diagnostic Challenges in Patients With a Constellation of Symptoms
Sharon Stanford, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 5
6:00 p.m.-9:00 p.m.
Grand Ballroom, Ballroom Level, Renaissance Washington
ADDRESSING UNMET CLINICAL NEEDS IN SEVERE DEPRESSION: TRANSLATING THE LATEST FINDINGS
Supported by: Sanofi-Aventis
Chp.: Charles B. Nemeroff, M.D.
A Addressing Unmet Needs in Psychotic Depression
Alan F. Schatzberg, M.D.
B Addressing Unmet Needs in Severe Depression  
Charles B. Nemeroff, M.D.

C Neurobiology of Depression  
Kerry Ressler, M.D.

D Addressing Unmet Needs in Refractory Depression  
Dwight Evans, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 6  
6:00 p.m.-9:00 p.m.  
Independence Ballroom, Independence Level, Grand Hyatt  
Washington

PEDIATRIC AND ADOLESCENT ADHD: BACK TO THE BASICS  
Supported by: Abbott Laboratories

Chp.: Timothy E. Wilens, M.D.

A Office-Based Psychosocial Interventions for ADHD  
Aude Henin, Ph.D.

B ADHD Diagnosis and Management: A Road Map to the Latest Guidelines  
Christopher Kratochvil, M.D.

C ADHD Today: New Insights Into Causes and Consequences  
Stephen V. Faraone, Ph.D.

D New Choices, New Challenges: Advances in ADHD Treatment Options  
Timothy E. Wilens, M.D.
8:00 a.m. Sessions

COURSES 19-23

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 19 8:00 a.m.-12:00 noon
Room 102A, Level One, Washington Convention Center

PSYCHIATRIC CONSULTATION IN LONG-TERM CARE: ADVANCED COURSE

Co-Directors: Abhilash K. Desai, M.D., George T. Grossberg, M.D.

COURSE 20 8:00 a.m.-12:00 noon
Room 102B, Level One, Washington Convention Center

COGNITIVE-BEHAVIOR THERAPY FOR SEVERE MENTAL DISORDERS

Co-Directors: Jesse H. Wright, M.D.
Faculty: Douglas Turkington, M.D.

COURSE 21 8:00 a.m.-12:00 noon
Room 144A, Level One, Washington Convention Center

HOW TO GIVE A MORE EFFECTIVE LECTURE: PUNCH, PASSION, AND POLISH

Director: Phillip J. Resnick, M.D.

COURSE 22 8:00 a.m.-12:00 noon
Room 144B, Level One, Washington Convention Center

INTERPERSONAL PSYCHOTHERAPY

Director: John C. Markowitz, M.D.

COURSE 23 8:00 a.m.-12:00 noon
Room 152A, Level One, Washington Convention Center

ADD IN CHILDREN AND ADOLESCENTS

Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D.

INDUSTRY-SUPPORTED SYMPOSIA 7-9

INDUSTRY-SUPPORTED SYMPOSIUM 7
8:00 a.m.-11:00 a.m.
Ballroom A/B, Level Three, Washington Convention Center

TREATING PATIENTS EARLY: UPDATES ON THE CONTROVERSY
Supported by: AstraZeneca Pharmaceuticals

Chp.: S. Charles Schulz, M.D.

A Differentiating Between Prodromal Schizophrenia and Prodromal Bipolar Disorder
Barbara Cornblatt, Ph.D.

B Early Diagnosis of Schizophrenia
Oliver Freudenreich, M.D.

C The Prodromal or Ultra-High Risk Stage of Schizophrenia and Related Psychoses: A Window for Understanding and Intervention
Patrick McGorry, M.D.

D Major Depressive Disorder in Youth: Neurobiology and Treatment
Kathryn Cullen, M.D.

E Medication Treatment for Youth: Is It the Same As for Adults?
S. Charles Schulz, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 8
8:00 a.m.-11:00 a.m.
Grand Ballroom, Ballroom Level, Renaissance Washington

ADVANCES IN NEUROIMAGING AND GENETICS IN ADHD
Supported by: McNeil Pediatrics/Ortho-McNeil Janssen Scientific Affairs, LLC

Chp.: Joseph Biederman, M.D.

A Using MRI to Disentangle the Comorbidity Between ADHD and BPD in Adults
Joseph Biederman, M.D.

B New Genetic Findings on the Overlap Between ADHD and BPD
Eric Mick, Sc.D.

C Pharmacoeimaging Studies of Stimulant Formulations in ADHD Using Positron Emission Tomography (PET)
Thomas J. Spencer, M.D.

(Continued next page)
D A Pharmacoinaging Study of OROS-MPH
Using Functional Magnetic Resonance Imaging (FMRI) in Adults With ADHD
George Bush, M.D.

E New Fronto-Cerebellar Findings in ADHD
Eve M. Valera, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 9
8:00 a.m.-11:00 a.m.
Independence Ballroom, Independence Level, Grand Hyatt Washington

RECENT ADVANCES IN DIAGNOSIS AND
TREATMENT OF FIBROMYALGIA
Supported by: Pfizer Inc.

Chp.: Lesley Arnold, M.D.

A Nonpharmacologic Treatment of Fibromyalgia
Dina Dadabhoy, M.D.

B Overview of Fibromyalgia and Related Conditions
Daniel J. Clauw, M.D.

C The Role of Antidepressants as Analgesics
David A. Fishbain, M.D.

D Pharmacologic Treatment of Fibromyalgia
Don L. Goldenberg, M.D.

E Genetics of Fibromyalgia
Lesley Arnold, M.D.

9:00 a.m. Sessions

COURSES 24-35
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 24 9:00 a.m.-4:00 p.m.
Room 101, Level One, Washington Convention Center
TRANSPERSONAL AND SPIRITUAL ASPECTS OF THE PRACTICE OF PSYCHIATRY
Director: Lewis Mehl-Madrona, M.D.
Faculty: Bruce W. Scotton, M.D., Margaret Williams, M.D.,
Robert L. Crocker, M.D.

COURSE 25 9:00 a.m.-4:00 p.m.
Room 102A, Level One, Washington Convention Center
INTRODUCTION TO COGNITIVE-BEHAVIORAL THERAPY
Co-Directors: Robert M. Goisman, M.D., Philip G. Levendusky, Ph.D.

COURSE 26 9:00 a.m.-4:00 p.m.
Room 103B, Level One, Washington Convention Center
SEEING THE FOREST AND THE TREES: A
BIOPSYCHOSOCIAL APPROACH TO THE ORAL BOARD EXAMINATION
Director: William H. Campbell, M.D.

COURSE 27 9:00 a.m.-4:00 p.m.
Room 144C, Level One, Washington Convention Center
RECOGNITION AND TREATMENT OF SOCIAL PHOBIA: FOCUS ON SHAME AND TEMPERAMENT
Director: Paul B. Bohn, M.D.

COURSE 28 9:00 a.m.-4:00 p.m.
Room 152B, Level One, Washington Convention Center
LOVE, DESIRE, INTIMACY, AND INFIDELITY
Director: Stephen B. Levine, M.D.

COURSE 29 9:00 a.m.-4:00 p.m.
Room 153, Level One, Washington Convention Center
WHAT IS PSYCHIATRY? PHILOSOPHIES AND PRACTICE
Co-Directors: S. Nassir Ghaemi, M.D., David H. Brendel, M.D.

COURSE 30 9:00 a.m.-4:00 p.m.
Room 154A, Level One, Washington Convention Center
THE ASSESSMENT AND TREATMENT OF CHILD SEXUAL ABUSERS
Co-Directors: Gene G. Abel, M.D., John M. Bradford, M.B., D.P.M.
Faculty: Candice A. Osborn, M.A.

COURSE 31 9:00 a.m.-4:00 p.m.
Room 154B, Level One, Washington Convention Center
COGNITIVE THERAPY ON THE FLY
Director: Ari E. Zaretzky, M.D.
SUNDAY

COURSE 32  9:00 a.m.-4:00 p.m.
Room 155, Level One, Washington Convention Center

MONEY MATTERS I: USING THEORY IN CLINICAL PRACTICE

Director: Cecilia M. Mikalac, M.D.

COURSE 33  9:00 a.m.-4:00 p.m.
Room 156, Level One, Washington Convention Center

TRAUMATIC BRAIN INJURY: NEUROPSYCHIATRIC ASSESSMENT

Director: Robert P. Granacher, M.D.

COURSE 34  9:00 a.m.-4:00 p.m.
Room 158A/B, Level One, Washington Convention Center

SPIRITUALITY IN PSYCHIATRY

Director: Michael D. McGee, M.D.
Faculty: Christina Pulchaski, M.D.

COURSE 35  9:00 a.m.-4:00 p.m.
Room 159A/B, Level One, Washington Convention Center

ADVANCED INTERVIEWING TECHNIQUES

Director: Shawn C. Shea, M.D.

10:00 a.m. Session

PRESIDENTIAL AACAP INSTITUTE
10:00 a.m.-5:00 p.m.
Room 202A, Level Two, Washington Convention Center

PRACTICAL PEDIATRIC PSYCHOPHARMACOLOGY

Chp.: Christopher J. Kratochvil, M.D.

A  Evidence-Based Pharmacotherapy for ADHD
Laurence L. Greenhill, M.D.

B  Management of Pediatric Depression
Jefferson B. Prince, M.D.

C  Ten Things a Clinician Needs to Know About Bipolar, Schizophrenia, Autism, and Aggression in Children and Adolescents
Adelaide Sherwood Robb, M.D.

D  Pediatric Anxiety Disorders
John T. Walkup, M.D.

E  Pediatric Psychopharmacology Case Presentations: Practical Applications
Christopher Jon Kratochvil, M.D.

12:30 p.m. Session

BUSINESS MEETING
(Voting Members Only*)

12:30 p.m.-1:30 p.m.
Room 146 A/B/C, Level One, Washington Convention Center

CALL TO ORDER
Carolyn B. Robinowitz, M.D., President

MEMORIAL TO DECEASED MEMBERS

ANNOUNCEMENT OF ELECTION RESULTS
William B. Lawson, M.D., Chairperson, Committee of Tellers

REPORTS TO THE MEMBERSHIP

Secretary-Treasurer: Donna M. Norris, M.D.
Speaker, Assembly: Jeffrey Akaka, M.D.
Speaker-Elect, Assembly: Ronald M. Burd, M.D.
Chairperson, Committee on Bylaws: John O. Gaston, M.D.
Chairperson, Elections Committee: Maria T. Lymberis, M.D.
Chairperson, Ethics Committee: Wade C. Myers, M.D.
Chairperson, Membership Committee: Joseph E.V. Rubin, M.D.
Medical Director and CEO: James H. Scully, Jr., M.D.
Chairpersons of Councils (Written Reports Only)

ANNUAL FORUM

ADJOURNMENT

*Members-in-Training, General Members, Distinguished Fellows, Fellows, Life Fellows, Distinguished Life Fellows, and Life Members. Badge or APA membership card necessary for admission. No cameras or tape recorders will be permitted.

1:00 p.m. Sessions

COURSES 36-39

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 36  1:00 p.m.-5:00 p.m.
Room 102B, Level One, Washington Convention Center

MULTIDISCIPLINARY TREATMENT OF CHRONIC PAIN

Co-Directors: Vladimir Bokarius, M.D., Steven Richeimer, M.D.
SUNDAY

Faculty: Ali Nemat, M.D., Lisa Victor, Ph.D., Yogi Matharu, D.P.M., Mary Kay Wolfe, OTR/L

COURSE 37 1:00 p.m.-5:00 p.m.
Room 144A, Level One, Washington Convention Center

INTRODUCTION TO TRANSCRANIAL MAGNETIC STIMULATION

Director: Ziad H. Nahas, M.D.
Faculty: Mark Demitrack, M.D., Frank A. Kozel, M.D., John O’Reardon, M.D., Shirlene Sampson, M.D.

COURSE 38 1:00 p.m.-5:00 p.m.
Room 144B, Level One, Washington Convention Center

LOSING A PATIENT TO SUICIDE

Directors: Michael F. Myers, M.D.
Faculty: Robert I. Simon, M.D., Carla Fine, M.S., Frank R. Campbell, Ph.D., L.C.S.W.

COURSE 39 1:00 p.m.-5:00 p.m.
Room 152A, Level One, Washington Convention Center

TREATMENT OF SCHIZOPHRENIA

Director: Philip G. Janicak, M.D.
Faculty: Morris B. Goldman, M.D., Rajiv Tandon, M.D., Stephen R. Marder, M.D.

1:30 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 10-12

INDUSTRY-SUPPORTED SYMPOSIUM 10
1:30 p.m.-4:30 p.m.
Ballroom A/B, Level Three, Washington Convention Center

AN INTERACTIVE SYMPOSIUM: UNLOCKING THE COMBINATION MOVING TOWARD A BETTER UNDERSTANDING OF MAJOR DEPRESSIVE DISORDER

Supported by: Wyeth Pharmaceuticals

Chp.: Maurizio Fava, M.D.

A Combining Antidepressants: Is There Evidence for Synergy?
Craig Nelson, M.D.

B The Role of Glutamate in MDD Nonresponsive to Standard Therapies
Sanacora Gerard, M.D.

C Augmentation Strategies in Treatment-Resistant Depression
Maurizio Fava, M.D.

D The Role of Pharmacogenetics in Treatment-Resistant Depression
Roy H. Perlis, M.D.

E Neurostimulation Approaches to Treatment-Resistant Depression
Sarah Lisanby, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 11
1:30 p.m.-4:30 p.m.
Grand Ballroom, Ballroom Level, Renaissance Washington

GENETICS IN PSYCHIATRY: OPPORTUNITES AND OBSTACLES IN SCHIZOPHRENIA

Supported by: Vanda Pharmaceuticals

Chp.: John M. Kane, M.D.
Co-Chp.: Anil K. Malhotra, M.D.

A Transgenic Manipulations of Putative Schizophrenia Susceptibility Genes: A Strategy for Clarifying Linkage/Association Signals and Molecular Pathways
Weidong Li, Ph.D., J. David Jentsch, Ph.D., Alcino Silva, Ph.D., Tyrone D. Cannon

B New Approaches to the Genetics of Psychiatric Disorders
Danielle M. Dick, Ph.D.

C The Pharmacogenetics of Antipsychotic Drug Response
Anil K. Malhotra, M.D.

D Clinical Phenomenology and Response Measure in Genetic Studies
John M. Kane, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 12
1:30 p.m.-4:30 p.m.
Independence Ballroom, Independence Level, Grand Hyatt Washington

TREATMENT OF CHILDREN AND ADOLESCENTS WITH PSYCHIATRIC DISORDERS: THE RISING USE OF ANTIPSYCHOTICS

Supported by: Bristol-Myers Squibb Company

Chp.: Christoph U. Correll, M.D.

A Atypical Antipsychotics in Autism Spectrum and Disruptive Behavior Disorders
Christopher McDougle, M.D.

B Challenges in Pharmacologic Management of Major Psychiatric Disorders in Children and Adolescents: Optimizing Treatment With Minimal Adverse Effects
Christoph U. Correll, M.D.
**SUNDAY**

**2:30 p.m. Session**

**LECTURE 1**

2:30 p.m.-4:00 p.m.
Room 143 A/B/C, Level One
Washington Convention Center

**AAPL/APA’s MANFRED GUTTMACHER AWARD LECTURE**

Douglas Mossman, M.D.

Critique of Pure Risk Assessment

Chp.: Patricia R. Recupero, M.D.

Dr. Mossman is Professor of Psychiatry at the Wright State University Boonshoft School of Medicine, and Administrative Director of the Glenn M. Weaver Institute of Law and Psychiatry at the University of Cincinnati College Of Law. He is a graduate of Oberlin College, the University of Michigan Medical School, and the University of Cincinnati General and Child Psychiatry residency training programs. A frequent lecturer to medical and legal audiences, Dr. Mossman has authored more than 100 publications on ethical issues, medical decision making, violence prediction, statistics, and psychiatric treatment. His 1994 article, “Assessing Predictions of Violence: Being Accurate About Accuracy,” was the first to examine violence predictions using ROC analysis, and has now been cited in more than 250 scientific and legal publications. His scholarship emphasizes using insights from other disciplines, especially mathematics and philosophy, to resolve diagnostic and decision-making problems commonly encountered by mental health clinicians. His recent scholarly projects investigate sex offender recidivism, competence to stand trial, and Bayesian reasoning. Dr. Mossman is a Distinguished Fellow of the American Psychiatric Association and a former councilor of the American Academy of Psychiatry and Law. His hobbies include music, religious studies, and investing.

**5:00 p.m. Session**

**OFFICIAL OPENING SESSION**

5:00 p.m.-6:30 p.m.
Hall D, Level Two, Washington Convention Center

**CALL TO ORDER**

Carolyn B. Robinowitz, M.D., President

**INTRODUCTION OF STAGE GUESTS**

**INTRODUCTION OF CHAIRPERSON OF THE SCIENTIFIC PROGRAM COMMITTEE**

David Baron, D.O.
Chairperson, Scientific Program Committee

**INTRODUCTION OF VISITING DIGNITARIES** (Please refer to pages 11-14 for a listing of the presidents of allied organizations.)

**PRESIDENTIAL ADDRESS**

Carolyn B. Robinowitz, M.D.
To be introduced by Paul Jay Fink, M.D.

**RESPONSE OF THE PRESIDENT-ELECT**

Nada L. Stotland, M.D.
To be introduced by Steven S. Sharfstein, M.D.

**ADJOURNMENT**

**7:00 p.m. Sessions**

**INDUSTRY-SUPPORTED SYMPOSIA 13-15**

**INDUSTRY-SUPPORTED SYMPOSIUM 13**

7:00 p.m.-10:00 p.m.
Ballroom A/B, Level Three, Washington Convention Center

**TANGLED UP IN BLUE: OPTIMIZING TREATMENT OF DEPRESSION IN THE PRESENCE OF COMORBIDITIES**

Supported by: Eli Lilly and Company

Chp.: John Greist, M.D.

A Depression, Physical Symptoms, and Pain: A Roadmap for Psychiatrists
John F. Greden, M.D.

B Depression: Beating the Odds for Remission
John Greist, M.D.

C Depression with Co-Occurring Psychiatric Disorders: Recognition and Management
James W. Jefferson, M.D.

(Continued next page)
SUNDAY

D  At the Clinical Crossroads: Approaches to Negative Symptoms and Cognitive Impairment
   Maria Muzik, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 14
7:00 p.m.-10:00 p.m.
Grand Ballroom, Ballroom Level, Renaissance Washington

MOOD DISTURBANCE IN YOUNGER AND MID-LIFE WOMEN: DEFINING TREATMENT STRATEGIES
Supported by: Forest Laboratories, Inc.
Chp.: Lee S. Cohen, M.D.

A  Bipolar Disorder in Reproductive-Age Women
   Adele Viguera, M.D.

B  Depression During the Transition to Menopause: Old and New Treatment Options
   Claudio N. Soares, M.D.

C  Managing Depression During the Menopause Transition: is Treatment of Hot Flashes and Sleep Disturbance Important?
   Hadine Joffe, M.D.

D  Course and Treatment of Major Depression During Pregnancy: Weighing the Risks
   Lee S. Cohen, M.D.

E  PMDD: Hormonal and Nonhormonal Treatment Strategies
   Teri Pearlstein, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 15
7:00 p.m.-10:00 p.m.
Independence Ballroom, Independence Level, Grand Hyatt Washington
USING A CHRONIC DISEASE MODEL WHEN MANAGING PATIENTS
Supported by: Eli Lilly and Company
Chp.: Robert R. Conley, M.D.

A  Managing Depression in Women Throughout the Phases of Menopause
   Mary O’Malley, M.D.

B  Maintenance Treatment in Patients With Schizophrenia
   Robert R. Conley, M.D.

C  The Need for Chronic Disease Management in Bipolar Disorder
   Roger McIntyre, M.D.

D  When Substance Abuse Impacts Management in Patients With Schizophrenia
   Marcia Verduin, M.D.
<table>
<thead>
<tr>
<th>Organization Name</th>
<th>President/Associate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Academy of Cognitive Therapy</td>
<td>Robert L. Leahy, M.D.</td>
</tr>
<tr>
<td>Academy of Organizational and Occupational Psychiatry</td>
<td>Steven Pflanz, M.D.</td>
</tr>
<tr>
<td>Albanian Psychiatric Society</td>
<td>Professor Anastas Suli</td>
</tr>
<tr>
<td>Algerian Psychiatric Association</td>
<td>Professor Farid Kacha</td>
</tr>
<tr>
<td>American Academy of Addiction Psychiatry</td>
<td>Elinore McCance-Katz, M.D.</td>
</tr>
<tr>
<td>American Academy of Child and Adolescent Psychiatry</td>
<td>Robert L. Hendren, D.O.</td>
</tr>
<tr>
<td>American Academy of Family Physicians</td>
<td>Jim King, M.D.</td>
</tr>
<tr>
<td>American Academy of Neurology</td>
<td>Stephen M. Sergay, MB BCh, FAAN</td>
</tr>
<tr>
<td>American Academy of Psychiatry and the Law</td>
<td>Jeffery S. Janofsky, M.D.</td>
</tr>
<tr>
<td>American Academy of Psychoanalysis and Dynamic Psychiatry</td>
<td>Sherry P. Katz-Bearnot, M.D.</td>
</tr>
<tr>
<td>American Association for the Advancement of Science</td>
<td>James J. McCarthy, M.D.</td>
</tr>
<tr>
<td>American Association of Chairs of Departments of Psychiatry</td>
<td>Peter Buckley, M.D.</td>
</tr>
<tr>
<td>American Association of Community Psychiatrists</td>
<td>Wesley Sowers, M.D.</td>
</tr>
<tr>
<td>American Association of Directors of Psychiatric Residency Training</td>
<td>Deborah Cowley, M.D.</td>
</tr>
<tr>
<td>American Association for Emergency Psychiatry</td>
<td>Avrim B. Fishkind, M.D.</td>
</tr>
<tr>
<td>American Association of Practicing Psychiatrists</td>
<td>Janis G. Chester, M.D.</td>
</tr>
<tr>
<td>American Board of Psychiatry and Neurology, Inc.</td>
<td>Burton V. Reifler, M.D.</td>
</tr>
<tr>
<td>American Association for Social Psychiatry</td>
<td>Beverly Faust, M.D.</td>
</tr>
<tr>
<td>American College of Emergency Physicians</td>
<td>Linda L. Lawrence, M.D.</td>
</tr>
<tr>
<td>American College of Mental Health Administration</td>
<td>Eric N. Goplerud, Ph.D</td>
</tr>
<tr>
<td>American College of Obstetricians and Gynecologists</td>
<td>Kenneth L. Noller, M.D.</td>
</tr>
<tr>
<td>American College of Physicians-American Society of Internal Medicine</td>
<td>Jeffrey P. Harris, M.D.</td>
</tr>
<tr>
<td>American College of Psychiatrists</td>
<td>Robert C. Fernandez, M.D.</td>
</tr>
<tr>
<td>American College of Psychoanalysts</td>
<td>Elise Snyder, M.D.</td>
</tr>
<tr>
<td>American College of Surgeons</td>
<td>Gerald B. Healy, M.D.</td>
</tr>
<tr>
<td>American Group Psychotherapy Association</td>
<td>Connie Concannon, M.S.W.</td>
</tr>
<tr>
<td>American Medical Association</td>
<td>Ronald M. Davis, M.D.</td>
</tr>
<tr>
<td>American Neurological Association</td>
<td>Timothy A. Pedley, M.D.</td>
</tr>
<tr>
<td>American Neuropsychiatric Association</td>
<td>Fred Osiewcz, M.D.</td>
</tr>
<tr>
<td>American Nurses Association</td>
<td>Rebecca M. Patton, MSN, RN</td>
</tr>
<tr>
<td>American Orthopsychiatric Association</td>
<td>David S. Hargrove, Ph.D</td>
</tr>
<tr>
<td>American Psychiatric Association</td>
<td>Kay Brada, M.D.</td>
</tr>
<tr>
<td>American Psychoanalytic Association</td>
<td>K. Lynne Moritz, M.D.</td>
</tr>
<tr>
<td>Organization</td>
<td>President/Chair</td>
</tr>
<tr>
<td>------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Association of Psychiatrists in Nigeria</td>
<td>Professor Taiwo Adamson</td>
</tr>
<tr>
<td>Association of Psychiatrists of Tajikistan</td>
<td>Dr. Abduvakhid Baibabaev</td>
</tr>
<tr>
<td>Association of Reformers in Psych/Former USSR &amp; E/Cen Europe</td>
<td>Professor Toma Tomov</td>
</tr>
<tr>
<td>Association of Women Psychiatrists</td>
<td>Tana Grady-Weliky, M.D.</td>
</tr>
<tr>
<td>Azerbaijan Psychiatric Association</td>
<td>Professor Nadir Ismayilov</td>
</tr>
<tr>
<td>Bangladesh Association of Psychiatrists</td>
<td>Dr. AHM Mustafizur Rahman</td>
</tr>
<tr>
<td>Barbados Association of Psychiatrists</td>
<td>Dr. Sharon Harvey</td>
</tr>
<tr>
<td>Black Psychiatrists of America</td>
<td>Cassandra F. Newkirk, M.D.</td>
</tr>
<tr>
<td>Bolivian Society of Psychiatry</td>
<td>Dra. Rosario Del Carpio Ona</td>
</tr>
<tr>
<td>Brazilian Association of Psychiatry</td>
<td>Dr. Joao Alberto Carvalho</td>
</tr>
<tr>
<td>Bulgarian Psychiatric Association</td>
<td>Dr. Peter Marinov</td>
</tr>
<tr>
<td>Byelorussian Psychiatric Association</td>
<td>Dr. Roman A. Ezregneev</td>
</tr>
<tr>
<td>Canadian Psychiatric Association</td>
<td>Dr. Patrick J. White</td>
</tr>
<tr>
<td>Caribbean Psychiatric Association</td>
<td>Dr. Jacqueline Sharpe</td>
</tr>
<tr>
<td>Chinese Society of Psychiatry</td>
<td>Professor Dongfeng Zhou</td>
</tr>
<tr>
<td>Colombian Society of Psychiatry</td>
<td>Dr. Carlos A. López Jaramillo</td>
</tr>
<tr>
<td>Council of Medical Specialty Societies</td>
<td>Carol D. Berkowitz, M.D.</td>
</tr>
<tr>
<td>Costa Rican Psychiatric Association</td>
<td>Dr. Yanira Obando</td>
</tr>
<tr>
<td>Croatian Psychiatric Association</td>
<td>Professor Ljubomir Hotzig Cuban</td>
</tr>
<tr>
<td>Cyprus Society of Psychiatry</td>
<td>Dr. Argyris Argyriou</td>
</tr>
<tr>
<td>Czech Psychiatric Association</td>
<td>Professor Jiri Raboch</td>
</tr>
<tr>
<td>Danish Psychiatric Society</td>
<td>Dr. Merete Nordentoft</td>
</tr>
<tr>
<td>Danubian Psychiatric Association</td>
<td>Dr. Werner Schoenig</td>
</tr>
<tr>
<td>Depression and Bipolar Support Alliance</td>
<td>Susan R. Bergeson, M.D.</td>
</tr>
<tr>
<td>Ecuador Psychiatric Association</td>
<td>Dr. Jose Cruz Duenas</td>
</tr>
<tr>
<td>Egyptian Psychiatric Association</td>
<td>Professor Ahmed Okaisa</td>
</tr>
<tr>
<td>Estonian Psychiatric Association</td>
<td>Dr. Valdur Janes</td>
</tr>
<tr>
<td>Evolution Psychiatrique Institut</td>
<td>Marcel Riviere</td>
</tr>
<tr>
<td>Finnish Psychiatric Association</td>
<td>Professor Jyrki Korkesia</td>
</tr>
<tr>
<td>Flemish Neurologists &amp; Psychiatrists</td>
<td>Dr. J Peusken</td>
</tr>
<tr>
<td>Foundation for Interdisciplinary Investigation of Communication</td>
<td>Professor Miguel Angel Materazzi</td>
</tr>
<tr>
<td>Francophone Int'l Federation of Psychiatry</td>
<td>Dr. Francis Caroli</td>
</tr>
<tr>
<td>French Association of Psychiatrists in Private Practice</td>
<td>Dr. Olivier Schmitt</td>
</tr>
<tr>
<td>French Association of Psychiatry</td>
<td>Dr. Bernard Gibelbo</td>
</tr>
<tr>
<td>French Scientific Association of Psychiatrists In Public Svc</td>
<td>Professor J.C. Pascal</td>
</tr>
<tr>
<td>Georgian Psychiatric Association</td>
<td>Professor George Naneishvilli</td>
</tr>
<tr>
<td>German Society for Psychiatry, Psychotherapy, and Nervous Disorders</td>
<td>Professor Wolfgang Gaebel</td>
</tr>
<tr>
<td>Ghana Psychiatric Association</td>
<td>Dr. Sammy Hene</td>
</tr>
<tr>
<td>Group for the Advancement of Psychiatry</td>
<td>Louis Flaherty, M.D.</td>
</tr>
<tr>
<td>Hellenic Psychiatric Association</td>
<td>Professor George Christodoulou</td>
</tr>
<tr>
<td>Hellenic Society of Neurology &amp; Psychiatry</td>
<td>Professor Costas Sistefanis</td>
</tr>
<tr>
<td>Honduran Psychiatric Association</td>
<td>Dr. Octavio R. Sanchez-Midence</td>
</tr>
<tr>
<td>Hong Kong College of Psychiatrists</td>
<td>Dr. Hung Ne Fong</td>
</tr>
<tr>
<td>Hungarian Psychiatric Association</td>
<td>Dr. Attila Nemeth</td>
</tr>
<tr>
<td>Icelandic Psychiatric Association</td>
<td>Dr. Magnus Haraldsson</td>
</tr>
<tr>
<td>Independent Psychiatric Association of Russia</td>
<td>Dr. Yuri Sergievitch Savenko</td>
</tr>
<tr>
<td>Indian Association for Social Psychiatry</td>
<td>Professor Roy Abraham Kallivayalili</td>
</tr>
<tr>
<td>Indian Psychiatric Society</td>
<td>Dr. Siva Nambi</td>
</tr>
<tr>
<td>Indo-American Psychiatric Association</td>
<td>Surinder Nand, M.D.</td>
</tr>
<tr>
<td>Indonesian Psychiatric Association</td>
<td>Professor HM Syamsul Hadi</td>
</tr>
<tr>
<td>International Association for Cognitive Psychotherapy</td>
<td>Dr. Robert L. Leahy</td>
</tr>
<tr>
<td>Int'l Association of Ethno-Psychologists</td>
<td>Dr. Valentin Ya. Semke</td>
</tr>
<tr>
<td>International Society of Psychopathology of Expression</td>
<td>Dr. Guy Roux</td>
</tr>
<tr>
<td>Iranian Psychiatric Association</td>
<td>Lebanese Psychiatric Association</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>Professor Ahmad Jalili</td>
<td>Dr. Charles Badoura</td>
</tr>
<tr>
<td>Iraqi Psychiatric Association</td>
<td>Lithuanian Psychiatric Association</td>
</tr>
<tr>
<td>Dr. Mohammad R. Lafta</td>
<td>Professor Algirdas Dominskas</td>
</tr>
<tr>
<td>Irish College of Psychiatrists</td>
<td>Luxembourg Society of Neurology</td>
</tr>
<tr>
<td>Dr. Conilia Walsh</td>
<td>and Psychiatry</td>
</tr>
<tr>
<td>Israel Psychiatric Association</td>
<td>Dr. Christen Jacoby</td>
</tr>
<tr>
<td>Professor Ari Bleich</td>
<td>Mauritius Psychiatric Association</td>
</tr>
<tr>
<td>Italian Association for Research in Schizophrenia</td>
<td>Mexican Psychiatric Association</td>
</tr>
<tr>
<td>Professor Carlo L. Cazzullo</td>
<td>Professor Check Ngen</td>
</tr>
<tr>
<td>Italian Psychiatric Association</td>
<td>Mexican Society of Neurology &amp; Psychiatry</td>
</tr>
<tr>
<td>Professor Engeo Agngha</td>
<td>Dr. Sergio Sanchez-Pintado</td>
</tr>
<tr>
<td>Italian Psychiatric Society</td>
<td>Moroccan Society of Psychiatry</td>
</tr>
<tr>
<td>Professor Mario Maj</td>
<td>Dr. M.F. Benckmann</td>
</tr>
<tr>
<td>Ivory Coast Association of Psychiatry</td>
<td>National Alliance For Research on Schizophrenia and Depression</td>
</tr>
<tr>
<td>Professor Joseph Delafosse</td>
<td>Geoffrey Birckett, M.D.</td>
</tr>
<tr>
<td>Jamaican Psychiatric Association</td>
<td>National Alliance on Mental Illness (NAMI)</td>
</tr>
<tr>
<td>Dr. G. Leveridge</td>
<td>Anand Pandya, M.D.</td>
</tr>
<tr>
<td>Japanese Society of Psychiatry &amp; Neurology</td>
<td>National Association of Psychiatric Health Systems</td>
</tr>
<tr>
<td>Professor Yashio Yamawachi</td>
<td>Jeff Bornstein, M.D.</td>
</tr>
<tr>
<td>Jordan Association of Psychiatrists</td>
<td>National Association of Social Workers, Inc.</td>
</tr>
<tr>
<td>Professor Wann Shmaigat</td>
<td>Elibra Craig de Silva, D.SW</td>
</tr>
<tr>
<td>Kazakh Association of Psychiatrists &amp; Nacologist 47</td>
<td>National Council for Community Behavioral Healthcare</td>
</tr>
<tr>
<td>Professor Joulidzhek Alimkhanov</td>
<td>Ting-Kai Li, M.D.</td>
</tr>
<tr>
<td>Korean Neuropsychiatric Association</td>
<td>National Institute on Drug Abuse, NIH</td>
</tr>
<tr>
<td>Dr. Soo-Churl Cho</td>
<td>Nora D. Volksw, M.D.</td>
</tr>
<tr>
<td>Kuwait Psychiatric Association</td>
<td>National Institute of Mental Health</td>
</tr>
<tr>
<td>Professor Eissam A. Al-Ansari</td>
<td>Thomas R. Insel, M.D.</td>
</tr>
<tr>
<td>Kyrgyz Science &amp; Practical Community of Psychiatrists 1</td>
<td>National Mental Health Association</td>
</tr>
<tr>
<td>Dr. Abijalal Begmatov</td>
<td>David L. Shern, M.D.</td>
</tr>
<tr>
<td>Latin American Psychiatric Association</td>
<td>Netherlands Psychiatric Association</td>
</tr>
<tr>
<td>Dr. Rafael Navarro</td>
<td>Dr. R. van den Boeck</td>
</tr>
<tr>
<td>Latin American Psychiatry Association</td>
<td></td>
</tr>
<tr>
<td>Dr. Cesar Mella Mejias, M.D.</td>
<td></td>
</tr>
<tr>
<td>Latvian Psychiatric Association</td>
<td></td>
</tr>
<tr>
<td>Dr. Elmari Rancans</td>
<td></td>
</tr>
</tbody>
</table>
2008 Presidents of Allied Organizations

Psychiatrists Association of Nepal
Dr. Desh Raj Bahadur Kunwar

Second General Global Alliance of Mental Illness
Dr. Paolo Lucio Morseli

Serbian Psychiatric Association
Professor Svetlana Drezgic-Vukic

Singapore Psychiatric Association
Professor Thiew Chai Ong

Slovak Psychiatric Association
Dr. Varrusova Livia

Sociedad Dominicana de Psiquiatria
Dr. Alejandro Uribe Peguero

Society for Biological Psychiatry
Husseini Manji, M.D.

Society of Neurology, Psychiatry, & Neurosurgery of Chile
Professor Juan Maass

Society of Psychiatrists
Professor Miguel A. Valdes Mier

Society of Psychiatry of Uruguay
Dr. Vicente Pardo

Society of Psychopathology and Mental Health of Dakar
Professor Daouda Sow

Society Settlement of Physically and Mentally Disabled
Professor Daniel Larbi

South African Society of Psychiatrists
Dr. Thabo Rangaka

Spanish Association of Neuropsychiatry
Dr. Alberto Fernandez Liria

Spanish Society of Psychiatry
Dr. Julio Valleso Ruiloba

Sri Lanka Psychiatric Association
Professor Nalaka Mendis

Swedish Psychiatric Association
Dr. Christina Spjut

Swiss Society of Psychiatry and Psychotherapy
Frau Dr. Grazziella Giacometti Bickel

Syndicat des Psychiatres Francais
Dr. Pierre Stael

Syrian Arab Association of Psychiatrists
Professor Mahmoud Abdul-Al

Taiwanese Society of Psychiatry
Professor Ra-Band Lu

The Haitian Society of Psychiatry
Dr. Max Desmiers

The Indonesian Psychiatric Association
Dr. Sasanto Wibisono

The Norwegian Psychiatric Association
Dr. Jan Olav Johannesen

The Psychiatric Association of Austria
Dr. H G Zapotoczky

The Psychiatric Evolution
Professor Jean Garrave

The Royal Australian and New Zealand College of Psychiatrists
Professor Ken Kirkby

The Royal College of Psychiatrists
Professor Sheila Hollins

Tunisian Psychiatric Society
Professor Saida Douki

Turkish American Neuropsychiatric Association
Errol Ucer, M.D.

R. Professor Ulisses
Dr. Nausa Kniijnik Lucion

Romanian League for Mental Health
Professor Bogdana Tudorache

Romanian Psychiatric Association
Dr. Dan Predipeanu

Royal College of Psychiatrists
Professor Sheila Hollins

Royal Society of Mental Medicine of Belgium
Professor A. Seguers

Russian Society of Psychiatrists
Professor Valery Krasnov

SA Society of Psychiatrists
Dr. Eugene Allers

Salvadoran Psychiatric Association
Dr. Miguel Fortin Magana

Saudi Psychiatric Association
Dr. Malek Abumadini

Turkish Neuropsychiatric Society
Professor Peykan Gokalp

Turkmen Scientific Society of Psychiatrists
Dr. Nina Kerimi

Ukraine Scientific Soc of Neurologists, Psychiatrists and Narcologists
Professor Peter Volosby

Ukrainian Psychiatric Association
Professor Victor Shumlyansky

Uzbek Association of Psychiatrists
Dr. Shakh-Zaide Muradalbov

Venezuelan Society of Psychiatry
Dr. Nestor Macias

World Association for Dynamic Psychiatry
Dr. Maria Ammon

World Psychiatric Association
Professor Juan E. Mezzich

Yemen Psychiatrists and Neurologists Association
Dr. Abdellmagid Al-Khalilaidi

Yugoslav Association of Psychiatric Institutions
Professor Ljubica Krasovicek

Yugoslav Psychiatric Association
Professor Mirko Pjeovica

Zambian Neuropsychiatric Association
Professor A. Haworth
How do I qualify?
You may qualify if you:
1. Are a psychiatrist residing in the U.S. or Canada and,
2. Have paid the full-time registration fee for the Annual Meeting ($825.00 Advance, $905.00 on-site)

How do I apply?
1. Stop by one of the APA Membership Booths either in the Registration area (near the Registrar) or in the APA Member Center (Exhibit Hall B, Lower Level) to fill out an APA Membership Application. The application must be submitted on-site during the meeting at one of these locations.
2. Additional documentation—proof of ACGME-AOA or RCPS(C)—approved psychiatry residency training and a current, valid medical license must be received by APA no later than June 30, 2008.

How does the rebate work?
1. Your local psychiatric district branch must approve the application no later than September 30, 2008
2. The difference between the member and non-member rate will be applied towards your pro-rated 2008 national and local dues. The remaining balance of the rebate amount will be sent directly to you, or if you choose, we can apply the remaining balance to your 2009 dues.* It’s up to you!

Why should I join?
Please stop by one of the APA Membership Booths to learn more about the many benefits of APA membership.

* Outstanding dues from previous years may be deducted in some cases.
60th Institute on Psychiatric Services
October 2–5, 2008

Save the date now to attend the American Psychiatric Association’s 60th Institute on Psychiatric Services, APA’s leading educational conference on clinical issues and community mental health to meet the service needs of people with severe mental illness. Check out our website at www.psych.org/IPS.

Chicago

From Patient to Partner: Transforming Systems of Care

This four-day event will feature popular networking events, more than 100 exhibits that complement the educational program, and over 200 expertly-led educational sessions on topics including: Violence, Trauma, and Victimization; Social and Community Psychiatry; Psychopharmacology; Resident and Medical Student Concerns; Disorders; Cross-Cultural and Minority Issues; Psychiatric Administration and Services; Treatment Techniques and Outcome Studies; Cognitive Disorders; Health Service Research; Mood Disorders; Schizophrenia and Other Psychotic Disorders; and much more…

Who Should Attend?
• All APA Members
• Psychiatrists and mental health professionals in community practice or the public sector including state and Veterans Affairs hospitals, community clinics, and jails and prisons
• Psychiatric Administrators
• Mental health professionals interested in social issues that have an impact on patients and their families
• Minority psychiatrists and International Medical Graduates
• Psychiatric Residents (only $60 for advance registration)
• Nonmember Residents and Advocacy Group Members (only $85 for advance registration)
• Medical Students (free registration)

Why Should You Attend?
• This activity has been approved for 30 hours of CME credit and CEUs have been applied for.
• Receive a 40% discount on APA member registration fees
• Network with colleagues at receptions and other events
• Industry-supported lunch and dinner symposia
• Valuable exhibit hall prizes drawn each day

How Will You Benefit?
• Utilize new knowledge and skills in clinical psychiatry that can be used to improve patient care;
• Examine how the current health care system affects patient care;
• Demonstrate and apply new skills useful in clinical and public psychiatry settings;
• Recognize and improve mental health disparities in the community; and
• Assess and evaluate all aspects of recovery; and
• Describe how to transform systems of care.

The Preliminary Program, which includes registration, housing, and travel information will be available in May at www.psych.org/IPS or call 1-888-35-PSYCH and request a copy. Online registration will begin on June 2.

For more information, please contact:
American Psychiatric Association
1000 Wilson Blvd., Suite 1825
Arlington, VA 22209-3901
Phone: 1-888-35-PSYCH
or (703) 907-7300
Fax: (703) 907-1090
E-mail: apa@psych.org
Web: www.psych.org/IPS
7:00 a.m. Sessions

PART 1 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 16-18

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 16, PART 1
7:00 a.m.-8:30 a.m.
Ballroom A/B, Level Three, Washington Convention Center

ARE COGNITION, SLEEP, AND WAKE DISORDERS CAUSED BY TOO MUCH AROUSAL, TOO LITTLE AROUSAL OR BOTH?
Supported by Takeda Pharmaceuticals

Chp.: Daniel J. Buysse, M.D.

A Where Do Increased Arousal and Insomnia Fall Along the Arousal Spectrum?
Leslie P. Lundt, M.D., Meeta Singh, M.D., Stephen M. Stahl, M.D., Ph.D., Daniel J. Buysse, M.D.

B How Do We Best Treat Too Much or Too Little Arousal?
Stephen M. Stahl, M.D., Ph.D., Meeta Singh, M.D., Daniel J. Buysse, M.D., Leslie P. Lundt, M.D.

C What Is Sleepiness Versus Inattentiveness? Can the Arousal Spectrum Answer This Question?
Leslie P. Lundt, M.D., Daniel J. Buysse, M.D., Stephen M. Stahl, M.D., Ph.D., Meeta Singh, M.D.

D Insights Into the Neurobiology of the Arousal Spectrum: The Neurocircuitry Spanning States From “Hypersonnia” to “Hyperarousal”
Meeta Singh, M.D., Daniel J. Buysse, M.D., Leslie P. Lundt, M.D., Stephen M. Stahl, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 17, PART 1
7:00 a.m.-8:30 a.m.
Grand Ballroom, Ballroom Level, Renaissance Washington

UNDERSTANDING BIPOLAR DISORDER: QUALITY AND CLINICAL CONUNDRUMS
Supported by Pfizer Inc

Chp.: Gary Sachs, M.D.

A Community Treatment of Bipolar Depression: Service Utilization and Quality
Alisa Busch, M.D.

B A Historical Overview of Bipolar Disorder
Ileana Fumero-Perez, M.D.

C Evidence-Based Treatment Options for Bipolar Depression
Mark Frye, M.D.

D Reducing Diagnostic Error: Recognition of Bipolar Depression Phenomenology
Gary Sachs, M.D.

E Pathophysiology of Bipolar Depression
Terence A. Ketter, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 18, PART 1
7:00 a.m.-8:30 a.m.
Independence Ballroom, Independence Level, Grand Hyatt Washington

GENETICS, BRAIN IMAGING, AND PHARMACOLOGY: CLINICAL IMPLICATIONS FOR THERAPEUTIC CHOICES IN PSYCHIATRIC DISORDERS
Supported by: Organon Pharmaceuticals USA Inc.

Chp.: Robert E. Hales, M.D.
Co-Chp.: Stuart C. Yudofsky, M.D.

A Receptor Pharmacology, Molecular Imaging, and Clinical Implications in Schizophrenia
Anissa Abi-Dargham, M.D.

B Clinical Implications of Recent Genetics and Neuroimaging Advances in Bipolar Disorder
Kiki Chang, M.D.

C Schizophrenia: The Clinical Importance of Genetics and Structural Brain Imaging
Rene S. Kahn, M.D.

D Effective Treatment of Bipolar Disorder: An Elusive Goal?
Terence A. Ketter, M.D.

RESIDENTS’ SESSION
7:00 a.m.-8:30 a.m.
Renaissance Ballroom East, Ballroom Level, Renaissance Washington

MEET THE EXPERTS: SUNNY-SIDE UP

Chp.: Carolyn B. Robinowitz, M.D.
Co-Chp.: Nada Stotland, M.D.

At this breakfast, nationally-recognized experts will sit at tables with small groups of residents and discuss a variety of career issues and opportunities in psychiatry. Topic areas include: academic psychiatry, addiction psychiatry, administrative psychiatry, child and adolescent psychiatry, cultural

(Continued next page)
competency, ethics, forensic psychiatry, geriatric psychiatry, leadership, neuropsychiatry, psychodynamic psychotherapy, psychosomatic medicine, public and community psychiatry, research, and women's mental health.

8:00 a.m. Sessions

COURSES 40-45

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 40 8:00 a.m.-12 noon
Room 13, Meeting Room Level, Renaissance Washington
REEL PSYCHIATRY

Co-Directors: Luis F. Ramirez, M.D., David J. Robinson, M.D.

COURSE 41 8:00 a.m.-12 noon
Room 14, Meeting Room Level, Renaissance Washington
DSM-IV-TR CULTURAL FORMULATIONS: DIAGNOSIS AND TREATMENT

Director: Russell F. Lim, M.D.

Faculty: Candace Fleming, Ph.D., David C. Henderson, M.D., Francis G. Lu, M.D., Johannes C. Ndlela, M.D., Roberto Lewis-Fernandez, M.D.

COURSE 42 8:00 a.m.-12 noon
Room 15, Meeting Room Level, Renaissance Washington
TREATING MEDICAL STUDENTS AND PHYSICIANS

Directors: Michael F. Myers, M.D., Leah J. Dickstein, M.D.
Faculty: Penelope Ziegler, M.D.

COURSE 43 8:00 a.m.-12 noon
Room 18, Ballroom Level, Renaissance Washington
EXPLORING TECHNOLOGIES IN PSYCHIATRY

Co-Directors: Robert S. Kennedy, M.D., John Luo, M.D.
Faculty: Carlyle Chan, M.D.

COURSE 44 8:00 a.m.-12 noon
Renaissance Ballroom West B, Ballroom Level, Renaissance Washington
ADD IN ADULTS

Director: Thomas E. Brown, Ph.D.
Faculty: Anthony Rostain M.D., Jefferson Prince, M.D.

COURSE 45 8:00 a.m.-12 noon
Congressional Hall B, Ballroom Level, Renaissance Washington
THE DETECTION OF MALINGERED MENTAL ILLNESS

Director: Phillip J. Resnick, M.D.

9:00 a.m. Sessions

CASE CONFERENCE 1
9:00 a.m.-10:30 a.m.
Room 154 A/B, Level One, Washington Convention Center
POSTTRAUMATIC STRESS DISORDER (PTSD): TREATMENT ACROSS PHARMACOLOGY, PSYCHOTHERAPY, AND COLLABORATIVE CARE

Moderator: Robert Uprano, M.D.
Presenters: David M. Benedek, M.D., Douglas F. Zatzick, M.D., Patricia A. Resick, Ph.D., Heather L. Shibley, M.D.
THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

FOCUS LIVE SESSION 1
9:00 a.m.-10:30 a.m.
Room 103A/B, Level One, Washington Convention Center
FOCUS LIVE! MAJOR DEPRESSIVE DISORDER

Moderators: Deborah J. Hales, M.D., Mark H. Rapaport, M.D.
Presenter: Charles Nemeroff, M.D.
Depression accounts for more disability than any other disorder worldwide. It is a significant risk factor for suicide, especially in adolescents, young adults, and the elderly. It is an important risk factor for poor treatment response in patients with cardiovascular disease. There has been a significant increase in our understanding of depression and the efficacy and tolerability of currently available treatments through results of recent studies such as the NIMH-sponsored clinical treatment trial, STAR-D. Combination or augmentation therapies, comprised of more than one antidepressant medication or an antidepressant and a second non-antidepressant, and combination pharmacotherapy/psychotherapy, appear to be associated with better therapeutic responses than monotherapy. Increased side effects often associated with co-prescribing two medications, and the increased cost of treatment with combination psychotherapy and pharmacotherapy or two medications, are major obstacles that prevent their wholesale clinical adoption. Many new findings and research directions have recently emerged that presage rapid changes in clinical practice - in diagnostics, choice of currently available treatments and novel treatment development itself. In FOCUS LIVE sessions expert clinicians lead multiple choice question-based discussions. Participants test their knowledge.
with an interactive Audience Response System, which instantly presents the audience responses as a histogram on the screen. Questions in this session will cover major depressive disorder, including diagnosis, treatment, and new developments.

LECTURES 2-4

LECTURE 2

9:00 a.m.-10:30 a.m.
Room 143 A/B/C, Level One
Washington Convention Center

APA'S ALEXANDRA SYMONDS AWARD LECTURE

Gail E. Robinson, M.D.

What Women Want

Chp.: Melvin Green, M.D.

Dr. Gail Erlick Robinson is a Professor of Psychiatry and Ob/Gyn at the University of Toronto and Director of the Women’s Mental Health Program at the University Health Network, Toronto, Canada. She was Founding Co-Director of the Women’s Mental Health Program at the University of Toronto. In the American Psychiatric Association she is currently the Women’s Caucus Representative and the Chair of the Committee on Family Violence and Abuse. She is a clinician and has designed curricula, taught, done research, published, and acted as an expert witness on issues pertaining to women’s mental health including domestic violence, sexual assault, the adult consequences of child sexual abuse, sexual harassment, stalking and the abuse of patients by healthcare professionals and other authority figures. Her special areas of interest are in psychological aspects of women’s reproductive life and violence against women. She was a co-founder of the Toronto Rape Crisis Centre and the Metropolitan Action Committee on Violence Against Women and Children. She is currently President of the Board of YWCA Toronto. She has received the YWCA Woman of Distinction Award and the Top 100 Most Powerful Women in Canada Award in the Championship category for her work in women’s mental health.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 3

9:00 a.m.-10:30 a.m.
Room 146A/B, Level One
Washington Convention Center

Otto W. Steenfeldt-Foss, M.D.

Planning, Organization, and Evaluation of Mental Health Services – Ideals and Realities

Chp.: Pedro Ruiz, M.D.
Co-Chp.: Renato Alarcon, M.D.

A native of Oslo, Norway, Dr. Steenfeldt-Foss received his MD from the University of Bergen in 1958. His clinical and specialty training led him to the position of Psychiatrist-in-Chief at Oslo City University Hospitals Ulleval and Dikemark. Following completion of his MPH at the Harvard School of Public Health, he served as the Director of Mental Health Services of Norway and periodically as the Director General of Public Health in the Ministry of Health & Social Affairs. He left this post in 1980 to assume his current position as Director and Physician in Chief of University Health Services of Oslo. Dr. Steenfeldt-Foss is a board-certified and practicing specialist in community medicine, general medicine and psychiatry, as well as a certified supervisor in general medicine and psychotherapy. He has been a consultant on mental health to the WHO since 1970 and has also served as a consultant to various national and municipal governments. He is a lecturer at the University of Oslo, President of the Norwegian Psychiatric Association, a WHO Fellow and an official council member on various committees. Dr. Steenfeld-Foss’s clinical, scientific and administrative experience, based on the bio-psycho-social holistic frame of reference, gives him a unique challenge and opportunities to continue his work for securing the dignity and human rights for the individual suffering patient as well as society. Practical experience from the wartime, on-site, in former Yugoslavia, the Soviet Union, including the Baltic States, Turkey, and most recently through the WPA-China Issue, has strengthened his belief and dialogue. Dr. Steenfeldt-Foss is the recipient of the 2005 Jean Delay Prize in Psychiatry, the most prestigious award of the International Association of Psychiatry.

International Psychiatrist Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 4

9:00 a.m.-10:30 a.m.
Room 202A/B, Level Two
Washington Convention Center

Helen Mayberg, M.D.

Deep Brain Stimulation for Treatment Resistant Depression

Collaborative Session with National Institute of Mental Health

Chp.: Daniel Weinberger, M.D.
Co-Chp.: Robin Hurley, M.D.

Dr. Mayberg is Professor of Psychiatry and Neurology at the Emory University School of Medicine. Her studies over the past 20 years have systematically examined neural mechanisms mediating depression pathogenesis in both psychiatric and neurological patient subgroups, as well as antidepressant response to various treatments including pharmacotherapy, cognitive behavioral therapy and placebo with a goal towards identification of neurobiological markers predicting treatment response and optimized treatment selection. Her long-term interest in neural network models of mood regulation in health and disease led to the recent development of a new intervention for treatment resistant patients using deep brain stimulation, a study initiated at the University of Toronto and now continuing at Emory. Dr. Mayberg is a Board Certified Neurologist, trained (Continued next page)
at Columbia’s Neurological Institute in New York, with
fellowship training in nuclear medicine at Johns Hopkins. She
received a BA in Psychobiology from UCLA and an MD from
University of Southern California. She has held previous
academic appointments in Neurology, Psychiatry and Radiology
at John Hopkins School of Medicine, The University of Texas
Health Sciences Center in San Antonio and the University of
Toronto, where she was also the first Sandra Rotman Chair in
Neuropsychiatry. Dr. Mayberg is currently a member of the
NINDS Advisory Council, the American Neurological
Association Council and the Scientific Advisory Board for
NARSAD. She has served on the Clinical Neuroscience and
Biological Psychopathology and the Brain Disorders and Clinical
Neuroscience Study Sections at NIH. She is active in the Society
for Neuroscience, The American College of Neuropsychophar-
macology, the Society of Biological Psychiatry, and the
Organization for Human Brain Mapping. Her research program
has ongoing funding from the NIMH, the Canadian Institute for
Health Research, NARSAD, the Stanley Medical Research
Institute, the Dana Foundation and the Woodruff Fund. She
was the 2007 recipient of NARSAD’s Falcone Prize for
Depression Research.

Frontiers of Science Lecture Series

THIS SESSION WILL BE AUDIOTAPE.

NEW RESEARCH POSTER SESSION 1: YOUNG
INVESTIGATORS’
9:00 a.m.-10:30 a.m.
West Lobby, Level One, Washington Convention Center

For further information on New Research submissions, please
refer to the New Research Program Book included in your
registration packet.

SMALL INTERACTIVE SESSIONS 1-3
9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-
come, first-served basis.

1 Laura W. Roberts, M.D., on Professionalism and Ethics: Q
   & A Self-Study Guide for Mental Health Professionals (Meet
   the Author)
   Room 304, Level Three, Washington Convention Center

2 Nora D. Volkow, M.D., on Addiction and the Brain
   Room 305, Level Three, Washington Convention Center

3 Joan Anzia, M.D., on Graduation and the PGY 4 Resident:
   Clinical and Ethical Challenges in Terminating with Patients at
   the end of Training
   Room 306, Level Three, Washington Convention Center

COURSES 46-51

Course descriptions are available in the CME
Course Brochure included in your registration
packet. Admission by ticket only.

COURSE 46 9:00 a.m.-4:00 p.m.
Room 4, Meeting Room Level, Renaissance Washington

UNDERSTANDING THE PERSON BEHIND THE
ILLNESS: AN APPROACH TO PSYCHODYNAMIC
FORMULATION

Director: William Campbell, M.D.

COURSE 47 9:00 a.m.-4:00 p.m.
Room 5, Meeting Room Level, Renaissance Washington

DAVANLOO’S INTENSIVE SHORT-TERM
DYNAMIC PSYCHOTHERAPY IN CLINICAL
PRACTICE

Co-Directors: James Q. Schubmehl, M.D., Alan Beeber, M.D.

COURSE 48 9:00 a.m.-4:00 p.m.
Room 10/11, Meeting Room Level, Renaissance
Washington

HOPE FOR THE DISTRESSED AND DISRUPTIVE

Director: William H. Swiggart, M.S.
Faculty: Anderson Spickard, M.D., Tobi Fishel, Ph.D., Ronald
Neufeld, B.S., Charles Samenow, M.D., Reid Finlayson, M.D.,
James Pichert, Ph.D., Gerald Hickson, M.D.

COURSE 49 9:00 a.m.-4:00 p.m.
Room 12, Meeting Room Level, Renaissance Washington

TREATING BORDERLINE PERSONALITY
DISORDER WITH THE STEPPS* MODEL (*SYSTEMS
TRAINING FOR EMOTIONAL PREDICTABILITY
AND PROBLEM SOLVING)

Director: Donald W. Black, M.D.
Faculty: Bruce Pfohl, M.D., Nancee Blum, M.S.W.

COURSE 50 9:00 a.m.-4:00 p.m.
Renaissance Ballroom West A, Ballroom Level,
Renaissance Washington

ADVANCES IN NEUROPSYCHIATRY

Co-Directors: C. Edward Coffey, M.D., Jeffrey Cummings, M.D.
Faculty: Mark S. George M.D., Michael Trimble M.D.,
Randolph Schiffer M.D.
MONDAY

COURSE 51 9:00 a.m.-4:00 p.m.
Congressional Hall A, Ballroom Level, Renaissance Washington

PSYCHOTHERAPY FOR PERSONALITY DISORDER
Co-Directors: Frank E. Yeomans, M.D., Otto Kernberg, M.D.
Faculty: John Clarkin Ph.D., Eve Caligor, M.D.

WORKSHOPS

COMPONENTS 1-13

COMPONENT WORKSHOP 1 9:00 a.m.-10:30 a.m.
Room 144A/B, Level One, Washington Convention Center

THE BIGGER PICTURE: PSYCHIATRISTS AS PHYSICIAN ADVOCATES
APA Committee of Residents and Fellows
Chp.: Rachel A. Davis, M.D.
Participant: Jeremy Lazarus, M.D.

COMPONENT WORKSHOP 2 9:00 a.m.-10:30 a.m.
Room 144C, Level One, Washington Convention Center

EARLY CHILDHOOD FEEDING DISORDERS: CROSS-CULTURAL LESSONS IN US AND CHINA COLLABORATION
APA Corresponding Committee on Infancy and Early Childhood
Co-Chps.: Jean M. Thomas, M.D., Irene Chatoor, M.D.
Participant: David Chen, M.D.

COMPONENT WORKSHOP 3 9:00 a.m.-10:30 a.m.
Room 147A, Level One, Washington Convention Center

FROM BEDSIDE TO BALANCE SHEET: THE MANY FACETS OF ADMINISTRATIVE PSYCHIATRY
APA Committee on Psychiatric Administration and Management
Co-Chps.: I. Mark Russakoff, M.D.
Participants: Sy Saeed, M.D., Kenneth Schooff, M.D., Lydia Weisser, D.O., Arthur Lazarus, M.D., Brian Hepburn M.D.

COMPONENT WORKSHOP 4 9:00 a.m.-10:30 a.m.
Room 147B, Level One, Washington Convention Center

THE RIPPLE EFFECT OF PSYCHIATRIC STIGMA IN MEDICAL EDUCATION AND STRATEGIES TO COMBAT IT
APA Corresponding Committee on Medical Student Education
Chp.: Linda F. Pessar, M.D.
Participants: Lowell Tong, M.D., Mark Townsend, M.D.

COMPONENT WORKSHOP 5 9:00 a.m.-10:30 a.m.
Room 150A, Level One, Washington Convention Center

SCHOOL MENTAL HEALTH: CLINICAL ESSENTIALS AND COLLABORATIVE INTERVENTIONS
APA Corresponding Committee on Mental Health and Schools
Chp.: Marcia J. Slattery, M.D.
Participants: Lina Lopez, M.D., Jodi Star, M.D., Hong Shen, M.D., Edgardo Menvielle, M.D.

COMPONENT WORKSHOP 6 9:00 a.m.-10:30 a.m.
Room 150B, Level One, Washington Convention Center

PRACTICAL TIPS ON HOW TO BE A SUCCESSFUL AUTHOR
American Psychiatric Publishing Inc. Editorial Board
Chp.: Robert E. Hales, M.D.
Participants: Glen Gabbard, M.D., John Oldham, M.D., Katharine Phillips, M.D., Donna Stewart, M.D.

COMPONENT WORKSHOP 7 9:00 a.m.-10:30 a.m.
Room 151A, Level One, Washington Convention Center

MENTORING 101: A SURVIVAL GUIDE FOR IMGs
APA Committee on International Medical Graduates
Co-Chps.: Antony Fernandez, M.D., Sanjay Dube, M.D.
Participants: Francis Sanchez M.D., Nady el-Guebaly, M.D., Vinay Kapoor, M.D., Marie-Claude Rigaud, M.D., Alejandra Postlethwaite, M.D.

COMPONENT WORKSHOP 8 9:00 a.m.-10:30 a.m.
Room 151B, Level One, Washington Convention Center

DISASTER PREPAREDNESS AND RESPONSE: STANDARDS FOR CARE BEFORE, DURING, AND AFTER A DISASTER
APA Committee on Psychiatric Dimensions of Disaster
Co-Chps.: Arin Terbakopian, M.D., Albert V. Vogel, M.D.
Participants: Heather Shibley, M.D., Vanessa Hernandez, M.D., Robert Gifford, Ph.D.

COMPONENT WORKSHOP 9 9:00 a.m.-10:30 a.m.
Room 152A, Level One, Washington Convention Center

LOOKING FOR LOVE AND DODGING THE VIRUS
APA Committee on AIDS
Co-Chps.: Pamela Y. Collins, M.D., Khakasa H. Wapenyi, M.D.
Participants: Navdeep Dhaliwal, M.D.
COMPONENT WORKSHOP 10  9:00 a.m.-10:30 a.m.  
Room 158A/B, Level One, Washington Convention Center

THE BEGINNING AND THE END OF TRANSINSTITUTIONALIZATION  
APA Council on Social Issues and Public Psychiatry

Co-Chps: Hunter L. McQuistion, M.D., Tracee M. Burroughs, M.D.  
Participants: Siegel Lauren, Rogelio Samorano, M.D., George Lipman, J.D.

COMPONENT WORKSHOP 11  9:00 a.m.-10:30 a.m.  
Room 159A/B, Level One, Washington Convention Center

PSYCHIATRY AND MANAGED CARE: PATIENT ACCESS, PHYSICIAN AUTONOMY, AND PROFESSIONAL ADVOCACY  
APA Committee on Managed Care

Chp.: Paul H. Wick, M.D.  
Participants: David Nace, M.D., Jonathan Weker, M.D.

COMPONENT WORKSHOP 12  9:00 a.m.-10:30 a.m.  
Room 201, Level Two, Washington Convention Center

THE NEW ORLEANS SCHOOL RECOVERY DISTRICT: WHAT ARE THE RISK, PREDICTIVE, AND PROTECTIVE FACTORS?  
APA Alliance

Chp.: Kay Brada,  
Participant: Carl Bell, M.D.

COMPONENT WORKSHOP 13  9:00 a.m.-10:30 a.m.  
Room 207B, Level Two, Washington Convention Center

ROLE OF INTERNATIONAL HEALTH ORGANIZATIONS IN PROMOTING GLOBAL CHILD AND ADOLESCENT MENTAL HEALTH  
APA Council on Global Psychiatry and the APA Council on Children, Adolescents, and Their Families

Co-Chps: Siham Muntasser, M.D., Eliot Sorel, M.D.  
Participants: Myron Belfer M.D., Professor Sam Tyano, M.D., Tarek Okasha, Rima Salah, Ph.D.

ISSUES 1-13

ISSUE WORKSHOP 1  9:00 a.m.-10:30 a.m.  
Room 101, Level One, Washington Convention Center

PARAPHILIAS, PERSONALITY DISORDERS, AND PHARMACEUTICALS: UNUSUAL SUSPECTS IN PSYCHIATRIC DEFENSE

Chp.: Renee M. Sorrentino, M.D.  
Participants: Susan Hatters Friedman, M.D., Joy Stankowski, M.D.

ISSUE WORKSHOP 2  9:00 a.m.-10:30 a.m.  
Room 102A/B, Level One, Washington Convention Center

MAINTENANCE OF CERTIFICATION FOR DIPLOMATES OF THE AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY

Co-Chps: Patricia W. Tivnan, M.A., Larry R. Faulkner, M.D.  
Participants: Victor Reus, M.D., Naleen Andrade, M.D., Christopher Colenda, M.D.

ISSUE WORKSHOP 3  9:00 a.m.-10:30 a.m.  
Room 141, Level One, Washington Convention Center

MALPRACTICE: A DEFENDANT'S PRIMER

Co-Chps: Abe M. Rychik, J.D., Eugene L. Lowenkopf, M.D.

ISSUE WORKSHOP 4  9:00 a.m.-10:30 a.m.  
Room 142, Level One, Washington Convention Center

CROSS-CULTURAL VALIDATION OF SELF-REPORT QUESTIONNAIRES IN NON-WESTERN POST-CONFLICT SETTINGS

Co-Chps: Peter Ventevogel, M.D., Pim Scholte, M.D.

ISSUE WORKSHOP 5  9:00 a.m.-10:30 a.m.  
Room 148, Level One, Washington Convention Center

MAKING YOUR TALKS MORE INTERACTIVE: THE BETTER WAY!

Chp.: Jon Davine, M.D.

ISSUE WORKSHOP 6  9:00 a.m.-10:30 a.m.  
Room 149A/B, Level One, Washington Convention Center

TREATING THE CHRONICALLY DEPRESSED PATIENT USING THE COGNITIVE-BEHAVIORAL ANALYSIS SYSTEM OF PSYCHOTHERAPY

Co-Chps: Eric Levander, M.D., James P. McCullough, Ph.D.

ISSUE WORKSHOP 7  9:00 a.m.-10:30 a.m.  
Room 152B, Level One, Washington Convention Center

IMPACT OF PATIENT SUICIDE ON PSYCHIATRY RESIDENTS: A WORKSHOP DISCUSSION

Co-Chps: Elizabeth S. Harre, M.D., Christina V. Mangurian, M.D.  
Participants: Aaron Reliford, M.D., Andrew Booty, M.D., Francine Cournos, M.D., Carolyn Douglas, M.D.
ISSUE WORKSHOP 8  9:00 a.m.-10:30 a.m.  
Room 153, Level One, Washington Convention Center  

PSYCHODYNAMIC PSYCHOTHERAPY WITH SELF-DESTRUCTIVE BORDERLINES  
Chp.: Eric M. Plakun, M.D.  
Participant: Edward Shapiro, M.A.  

ISSUE WORKSHOP 9  9:00 a.m.-10:30 a.m.  
Room 155, Level One, Washington Convention Center  

JUMPING OFF A CLIFF, OR THE ROAD NOT TAKEN: ALTERNATIVE CAREER CHOICES AND WHERE THEY LEAD  
Chp.: Deborah Spitz, M.D.  
Participant: Edward Silberman, M.D.  

ISSUE WORKSHOP 10  9:00 a.m.-10:30 a.m.  
Room 156, Level One, Washington Convention Center  

CHRONIC PAIN, PRESCRIPTION OPIOIDS, AND PSYCHIATRY: CONCEPTS, TOOLS, AND RISK MANAGEMENT TO HELP PATIENTS AND IMPROVE OUTCOME  
Co-Chps.: Alex N. Sabo, M.D., John F. Rogers, Esq.  
Participants: Jennifer Michaels, M.D., John Harrington, Ph.D., Donald Burt, M.D.  

ISSUE WORKSHOP 11  9:00 a.m.-10:30 a.m.  
Room 157, Level One, Washington Convention Center  

THE WRATH OF GOD: A FAITH-BASED SURVIVAL PARADIGM (VIDEO INTERVIEWS OF SURVIVORS IN THE EARTHQUAKE REGION OF PAKISTAN)  
Chp.: Samoon Ahmad, M.D.  

ISSUE WORKSHOP 12  9:00 a.m.-10:30 a.m.  
Room 160, Level One, Washington Convention Center  

PSYCHOPATHY AND ADDICTION AMONG CRIMINAL JUSTICE POPULATIONS: NEW DIRECTIONS  
National Institute on Drug Abuse  
Co-Chps.: Wilson M. Compton, III, M.D., Joseph Frascella, Ph.D.  
Participants: Linda Teplin, Ph.D., Scott Henggeler, Ph.D., Kent Kiehl, Ph.D.  

ISSUE WORKSHOP 13  9:00 a.m.-10:30 a.m.  
Room 207A, Level Two, Washington Convention Center  

PSYCHIATRIC SERVICES FOR GIRLS AND WOMEN IN CORRECTIONAL FACILITIES  
Chp.: Cassandra F. Newkirk, M.D.  
Participants: Otis Anderson, III, M.D., Saundra Maass-Robinson, M.D.  

MEDIA 1-2  

MEDIA WORKSHOP 1  9:00 a.m.-12 noon  
Room 140A, Level One, Washington Convention Center  

WHITE LIGHT BLACK RAIN: THE DESTRUCTION OF HIROSHIMA AND NAGASAKI  
Chp.: David Rothstein, M.D.  
Participant: Kennette Benedict, Ph.D.  

MEDIA WORKSHOP 2  9:00 a.m.-12 noon  
Room 140B, Level One, Washington Convention Center  

TSOTS: TOWARD AN UNDERSTANDING OF THE ROOTS OF VIOLENCE, ITS MAINTENANCE, AND ITS TRANSFORMATION  
Chp.: Roslyn Seligman, M.D.  

SYMPOSIA 1-2  

SYMPOSIUM 1  9:00 a.m.-12 noon  
Room 145A, Level One, Washington Convention Center  

EPIGENETIC MECHANISMS OF DEPRESSION AND ANTIDEPRESSANT ACTION  
Chp.: Eric J. Nestler, M.D.  
A Epigenetic Mechanisms in Memory Formation  
David Sweatt, Ph.D.  
B Role of Histone Acetylation and Methylation in Social Defeat Stress  
Eric J. Nestler, M.D.  
C Epigenetic Programming of Gene Expression and Function Via Maternal Care  
Michael Meaney, Ph.D.  
D Antidepressant Activity of Histone Deacetylase Inhibitors  
Schahram Akbarian, M.D., Caroline Connor, Hsien-Sung Huang, Frederick Schroeder  
Discussants: Eric J. Nestler M.D., Schahram Akbarian, M.D., Michael Meaney, Ph.D., David Sweatt, Ph.D.  
THIS SESSION WILL BE AUDIOTAPED.
MONDAY

SYMPOSIUM 2
9:00 a.m.-12 noon
Room 145B, Level One, Washington Convention Center

BUPRENORPHINE FOR OPIOID DEPENDENCE:
RECENT CLINICAL AND RESEARCH FINDINGS

Chp.: Marc Galanter, M.D.

A  Buprenorphine Maintenance for Heroin Addicts
   Eric C. Strain, M.D.

B  Differential Patterns of Buprenorphine Use in the U.S.
   Herbert D. Kleber, M.D.

C  The Use of Buprenorphine in Patients With Chronic
   Pain
   Joseph G. Liberto, M.D., Adam J. Gordon, M.D.

D  Buprenorphine for Detoxification of Opioid-
   Dependent Patients
   Laura F. McNicholas, M.D.

Discussants: Laura F. McNicholas M.D., Eric Strain, M.D.,
   Joseph Liberto, M.D., Herbert Kleber, M.D.,
   Adam Gordon, M.D.

THIS SESSION WILL BE AUDIOTAPED.

9:30 a.m. Sessions

FORUM 1

FORUM 1 9:30 a.m.-11:00 a.m.
Room 146C, Level One, Washington Convention Center

THE DISPOSABLE AMERICAN: LAYOFFS AND
THEIR CONSEQUENCES

Chp.: Louis Uchitell

10:30 a.m. Sessions

ADVANCES IN RESEARCH 1

RESEARCH ADVANCES IN PSYCHIATRY
10:30 a.m.-12:30 p.m.
Ballroom C, Level Three, Washington Convention Center

Chp.: Herbert Pardes, M.D.

Participants: Evelyn Attia, M.D., on Eating Disorders
Helen Mayberg, M.D., on Mood Disorders
Donald Goff, M.D., on Schizophrenia
Pat Sullivan, M.D., on Genetics

11:00 a.m. Sessions

ADVANCES IN MEDICINE 1

HIV/AIDS IN 2008: PROGRESS AND CHALLENGES

11:00 a.m.-12:30 p.m.
Room 147A, Level One, Washington Convention Center

Chp.: James Merikangas
Participant: Anthony Fauci, M.D.

FOCUS LIVE SESSION 2

11:00 am-12:30PM
Room 103A/B, Level One, Washington Convention Center

FOCUS LIVE! SCHIZOPHRENIA

Moderator: Deborah J. Hales, M.D., Mark H. Rapaport, M.D.
Presenter: Peter Buckley, M.D.

Schizophrenia is a chronic, debilitating illness affecting 1% of
adults. The combination of onset in early adulthood and
persistent dysfunction create enormous personal costs.
Symptoms of the illness are variable from person to person, with
positive symptoms of delusions, hallucinations, and thought
disorganization and negative symptoms of blunted affect, social
dysfunction, and lack of motivation, along with cognitive
impairments, and mood disturbance. Treatment planning has the
goals of reducing or eliminating symptoms, maximizing quality
of life, and promoting recovery. The biological basis is known to
include genetic, environmental, and developmental factors. In
this FOCUS LIVE session multiple choice questions covering
current issues in schizophrenia will be presented: assessment of
symptoms and establishment of a diagnosis, treatment plan and
treatment adherence, treating comorbid conditions, psychosocial
treatments and antipsychotic medications, metabolic
disturbances during antipsychotic therapy, complex switching
and combining of medications, and side-effect management
strategies to improve patient outcomes.
In FOCUS LIVE sessions expert clinicians lead multiple choice
question-based discussions. Participants test their knowledge
with an interactive audience response system, which instantly
presents the audience responses as a histogram on the screen.
Questions cover existing knowledge and new developments in
schizophrenia.
LECTURES 5-7

LECTURE 5
11:00 a.m.-12:30 p.m.
Room 143A/B/C, Level One
Washington Convention Center

APA'S BENJAMIN RUSH AWARD LECTURE

Mark S. Micale, M.D.

Psychological Trauma and the Lessons of History

Chp.: Laura D. Hirshbein, M.D.

Mark S. Micale (Ph.D., Yale University, 1987) is professor of the history of science and medicine at the University of Illinois in Urbana-Champaign. He has published widely in psychiatric history, including Approaching Hysteria: Disease and Its Interpretations (1995), Traumatic Pasts: History, Psychiatry, and Trauma in the Modern Age, 1870-1930 (2001), and (with Roy Porter) Discovering the History of Psychiatry (1994). His new book The Male Malady: Masculine Nervous Illness from the Renaissance to Freud is forthcoming with Harvard University Press. He is now researching a new project about “psychiatric globalization.”

LECTURE 6
11:00 a.m.-12:30 p.m.
Room 146A/B, Level One
Washington Convention Center

Solomon Snyder, M.D.

Neurotransmitters, Drugs and the Brain: Historical Perspectives

Collaborative Session With the National Institute of Mental Health

Chp.: Carolyn B. Robinowitz, M.D.
Co-Chp.: Anthony Rothschild, M.D.

Born in Washington, D.C. in December 1938, Dr. Snyder received his undergraduate and medical training at Georgetown University (MD 1962); Research Associate training with Julius Axelrod at the NIH (1963-1965); and psychiatric training at the Johns Hopkins Hospital (1965-1968). In 1966 he joined the faculty of the Johns Hopkins University School of Medicine (Asst Professor Pharmacology, 1966-1968; Associate Professor Pharmacology/Psychiatry (1968-1970); Professor (1970). In 1980 he established the Department of Neuroscience and served as Director (1980-2006). He is presently Distinguished Service Professor of Neuroscience, Pharmacology and Psychiatry. Dr. Snyder is the recipient of numerous professional honors, including the Albert Lasker Award for Basic Biomedical Research (1978), the National Medal of Science (2005), the Albany Medical Prize (2007), the Wolf Foundation Prize in Medicine (1983), the Dickson Prize of the University of Pittsburgh (1983), the Bower Award of the Franklin Institute (1991), the Bristol-Myers Squibb Award for Distinguished Achievement in Neuroscience Research (1996) and the Gerard Prize of the Society for Neuroscience (2000). He is a member of the United States National Academy of Sciences and a Fellow of the American Academy of Arts and Sciences and the American Philosophical Society. He is the author of more than 1000 journal articles and several books including Uses of Marijuana (1971), Madness and the Brain (1974), The Troubled Mind (1976), Biological Aspects of Abnormal Behavior (1980), Drugs and the Brain (1986), and Brainstorming (1989). Many advances in molecular neuroscience have stemmed from Dr. Snyder's identification of receptors for neurotransmitters and drugs and elucidation of the actions of psychotropic agents. The application of Dr. Snyder's techniques has enhanced the development of new agents in the pharmaceutical industry by enabling rapid screening of large numbers of candidate drugs. He has established gases as a new class of neurotransmitters, beginning with his demonstrating the role of nitric oxide in mediating glutamate synaptic transmission and neurotoxicity. His isolation and molecular cloning of nitric oxide synthase led to major insights into the neurotransmitter functions of nitric oxide throughout the body. Distinguished Psychiatrist Lecture Series

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 7
11:00 a.m.-12:30 p.m.
Room 202A/B, Level Two
Washington Convention Center

APA's PATIENT ADVOCACY AWARD LECTURE

Pete Earley

CRAZY: A Father’s Search Through America’s Mental Health Madness

Chp.: Carl Bell, M.D.

In a Washingtonian Magazine cover story entitled, Top Journalists: Washington’s Media Elite, Pete Earley was described as one of a handful of journalists in America who "have the power to introduce new ideas and give them currency.” A former reporter for The Washington Post, he is the author of nine nonfiction books and three novels. His first book, Family of Spies: Inside the John Walker Spy Ring, was a New York Times bestseller and was made into a five hour miniseries shown on CBS television. For his book, The Hot House: Life Inside Leavenworth Prison, Earley spent a full year as a reporter inside a maximum security prison. His book, Circumstantial Evidence helped lead to the release of a black man from death row after he had been wrongly convicted of murdering a white teenager in Alabama. His most recent book, CRAZY: A Father’s Search Through America’s Mental Health Madness, tells two stories. It describes his attempts to help his college age son, Mike, after he becomes ill with bipolar disorder and is arrested. It also describes a year that Earley spent at the Miami Dade County Jail where he followed persons with mental disorders, who had been in jail, out into the community to see (Continued next page)
what sort of services they received. His book was one of two finalists for the Pulitzer Prize in 2007 and has won awards from the National Alliance on Mental Illness, Mental Health America and the Washington Psychiatric Association.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSIONS 1-8

SCIENTIFIC AND CLINICAL REPORT SESSION 1
11:00 a.m.-12:30 p.m.
Room 101, Level One, Washington Convention Center

FORENSIC PSYCHIATRY

Chp.: Britta Ostermeyer, M.D.
Co-Chp.: Dan Cotoman, M.D.

11:00 a.m.
1 The Validity of Psychiatric Impairment Assessment: A Comparison of Two Systems in Clinical Practice
Gordon Davies, M.B.

11:30 a.m.
2 Profile of Perpetrators With Impulsive Violent Behavior
Rob Brouwers, M.D., Karel T.I.Oei, Ph.D., Martin Appelo, Ph.D.

12:00 noon
3 Fathers Who Kill Their Children
Sara West, M.D., Susan Hatters Friedman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 2
11:00 a.m.-12:30 p.m.
Room 142, Level One, Washington Convention Center

WOMEN'S HEALTH AND CHILDREN'S HEALTH

11:00 a.m.
4 Adverse Effects on Gestational and Neonatal Outcomes: From Depression or Antidepressant Drugs?
Katherine Wisner, M.D.

11:30 a.m.
5 Overvaluation of Shape and Weight in Binge-Eating Disorder and Overweight Controls: Refinement of BED as a Diagnostic Construct
Carlos Grilo, Ph.D., Joshua I. Hrabosky, Psy.D., Marney A. White, Ph.D., Kelly C. Allison, Ph.D., Albert J. Stunkard, M.D., Robin M. Masheb, Ph.D.

12:00 noon
6 High Frequency of Undiagnosed Cognitive Disorders in Inner-City Children and Adolescents Hospitalized for Disruptive Behavior
Mark Smith, M.D., Sidney Binks, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 3
11:00 a.m.-12:30 p.m.
Room 147B, Level One, Washington Convention Center

PSYCHIATRIC GENETICS

Chp.: Srijan Sen, M.D.

11:00 a.m.
7 Genes, Memes, and an Infection Model of Mental Illness
Hoyle Leigh, M.D.

11:30 a.m.
8 Combinatorial CYP450 Genotyping for Depressed Inpatients
Gualberto Ruano, M.D., John W. Goethe, M.D., Andreas Windemuth, Ph.D., Bonnie L. Szarek, R.N.

12 noon
9 PharmacoEPIgenetics: Therapeutic and Diagnostic Applications of Chromatin Remodeling Agents in Mental Illness
David Gavin, M.D., Cherise Rosen, Ph.D., Saritha Kartan B.S., Kayla Chase, B.A., Robert Marvin, M.D., Rajiv Sharma, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 4
11:00 a.m.-12:30 p.m.
Room 150A, Level One, Washington Convention Center

SYMPTOMATIC OUTCOMES OF BORDERLINE PERSONALITY DISORDER

Chp.: Jacob Moussai, M.D.

11:00 a.m.
10 Prospective Predictors of Suicidal Behavior in Borderline Personality Disorder
Paul Soloff, M.D., Anthony Fabio, Ph.D.

11:30 a.m.
11 Prediction of Time-to-Attainment of Good Psychosocial Functioning for Borderline Patients Followed Prospectively for Ten Years
Mary Zanarini, Ed.D., Frances R. Frankenburg, M.D., Bradford Reich, M.D.

12 noon
12 The Ten-Year Course of Dissociation Reported by Patients With Borderline Personality Disorder
Mary Zanarini, Ed.D., Frances R. Frankenburg, M.D., Bradford Reich, M.D.

THIS SESSION WILL BE AUDIOTAPED.
SCIENTIFIC AND CLINICAL REPORT SESSION 5
11:00 a.m.-12:30 p.m.
Room 150B, Level One, Washington Convention Center

CHEMICAL DEPENDENCY

Chp.: Susan Stabinsky, M.D.
Co-Chp.: Harvey Stabinsky, M.D.

11:00 a.m.
13 Patient Selection and Matching for Opioid Maintenance Treatment
Ayman Fareed, M.D., Jennifer Casarella, M.D., Richard Amar, M.D., Karen Drexler, M.D.

11:30 a.m.
14 Clinical Assessment in Cocaine Abusing Patients: Association of Alexithymia With Inadequate Parental Attachment
Gianmaria Zita, M.D., Rosamaria Vitale, Psy.D., Elisa Corvaglia, M.D., Angelo Burato, Cristina Catani, Pierluigi Vigezzi, M.D., Edoardo Cozzolino, M.D.

12 noon
15 Difference in Using Wait-and-See Strategy Between Non-Chemical and Chemical Addictions on the Stop Signal Performance
Pinhas Dannon, M.D., Semon Kertzman, M.D, Katherine Lowengrub, M.D., Tali Viste, M.D., Anat Aizer, M.D., Haim Grenspan, M.D., Nina Shliapnikov, M.D., Moshe Birger, M.D., Moshe Kotler, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 6
11:00 a.m.-12:30 p.m.
Room 151A, Level One, Washington Convention Center

CAN EARLY SYMPTOMS PREDICT THE COURSE OF SCHIZOPHRENIA?

Chp.: Derya Iren Akbiyik, M.D., Ph.D.

11:00 a.m.
16 The Predictive Value of First-Rank Symptoms in Patients With Schizophrenia and Other Psychotic Disorders
Linda Grossman, Ph.D., Cherise Rosen, Ph.D., Martin Harrow, Ph.D., Greg Strauss, Ph.D., Megan Butler, B.A.

11:30 a.m.
17 Negative Symptoms and Their Predictors in Schizophrenia Within the Northern Finland 1966 Birth Cohort
Jussi Makinen, Miettunen Jouko, Ph.D., Lauronen E. M.D., Ph.D, Isohanni Matti, M.D., Ph.D, Koponen Hannu, M.D., Ph.D.

12 noon
18 Negative Features of Psychosis Precede Onset of Psychosis in a Prospective General Population Sample of Adolescents
Pirjo H. Maki, M.D., Jouko Miettunen, Ph.D., Marika Kaakinen, B.A., Anja Taanila, Ph.D., Peter B. Jones, M.D., Ph.D., Graham Murray, M.D., Ph.D., I. Moilanen, M.D., Ph.D., M. Joukamaa, M.D., Ph.D., M. Heinimaa, M.D., J. Veijola M.D., Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 7
11:00 a.m.-12:30 p.m.
Room 151B, Level One, Washington Convention Center

CLINICAL DILEMMAS IN SCHIZOPHRENIA

Chp.: Meera Vaswani, Ph.D.

11:00 a.m.
19 Deconstructing First-Episode Psychosis
Cherise Rosen, Ph.D., Robert Marvin, M.D., James Reilly Ph.D., Peter Weiden, M.D., John Sweeney, Ph.D.

11:30 a.m.
20 Pathways Leading to Suicide in Schizophrenia
Antti Alaräisänen, M.B., Johanna Heikkinen, Zuzana Kianickova, M.B., Miettunen Jouko, Ph.D., Räisänen Pirkko, M.D., Ph.D., Matti Isohanni, M.D., Ph.D.

12 noon
21 Recovery in a Subgroup of Patients With Schizophrenia Who Discontinue Antipsychotic Medications: A 15-Year Follow Up
Martin Harrow, Ph.D., Thomas H. Jobe, M.D., Ellen Astrachan-Fletcher, Ph.D., Cherise Rosen, Ph.D., Linda S. Grossman, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 8
11:00 a.m.-12:30 p.m.
Room 152A, Level One, Washington Convention Center

METABOLIC SYNDROME AND EATING BEHAVIOR

Chp.: Daniel P. Chapman, Ph.D.

11:00 a.m.
22 Developing and Implementing a Psychiatric Clinic-Based Metabolic Screening: Part I
Catherine Batesca, M.S.N., Mark E. Schneiderhan, Pharm.D. B.C.P.P., Cherise Rosen, Ph.D., Robert Marvin, M.D., Dennis Beedle, M.D., Ovidio DeLeon, M.D., Gaston Baslet, M.D., Tsing-Yi Koh, Pharm.D., ManYan Yu, Pharm.D., Wendy Ng, Pharm.D. Candidate, Jamie Joseph, Pharm.D., Jeffrey Bishop, Pharm.D.

(Continued next page)
MONDAY

11:30 a.m.
23 Initial Pre-Metabolic Risk of 93 Patients on Second-Generation Antipsychotics: Part 2
Mark Schneiderhan, Pharm.D., Catherine Batscha, A.P.R.N., B.C., Cherise Rosen, Ph.D., Robert Marvin, M.D., Dennis Beedle, M.D., Ovidio DeLeon, M.D., Gaston Baslet, M.D., Tsing-Yi Koh, Pharm.D., ManYan Yu, Pharm.D., Wendy, Pharm.D., Jamie Joseph, Pharm.D., Jennifer Splawski, Pharm.D. Candidate, Jeffrey Bishop, Pharm.D

12 noon
24 A Comparison of the Effects of Modafinil on Olanzapine, Associated Eating Behaviors in Normal Human Subjects
James Roerig, Pharm.D., Kristine Steffen, Pharm.D., James E. Mitchell, M.D., Ross D. Crosby, Ph.D., Blake A. Gosnell, Ph.D.

SMALL INTERACTIVE SESSIONS 4-6

11:00 a.m.-12:30 p.m.
These sessions are limited to 25 participants on a first-come, first-served basis.

4 Eric Hollander, M.D., on Autism and Impulse Control Disorders, Meet the Author
Room 304, Level Three, Washington Convention Center

5 Marcia Goin, M.D., on Career Versus Jobs in Psychiatry
Room 305, Level Three, Washington Convention Center

6 Suzanne Vogel-Scibillia, on The Psychiatrist as Advocate for Family Members and Consumers
Room 306, Level Three, Washington Convention Center

WORKSHOPS

COMPONENTS 14-23

COMPONENT WORKSHOP 14 11:00 a.m.-12:30 p.m.
Room 144C, Level One, Washington Convention Center

ANXIETY, IMPULSIVITY, AND AGGRESSION: DIAGNOSTIC AND TREATMENT DILEMMAS IN INTELLECTUAL DISABILITY
APA Committee on Developmental Disabilities

Chp.: Joel D. Bregman, M.D.
Participants: Stephanie Hamarman, M.D., John de Figueiredo, M.D., Ramakrishnan Shenoy, M.D.

COMPONENT WORKSHOP 15 11:00 a.m.-12:30 p.m.
Room 148, Level One, Washington Convention Center

ASSESSING SUICIDE RISK IN THE GENERAL HOSPITAL: IMPLEMENTING THE 2007 JOINT COMMISSION’S PATIENT SAFETY GOAL
APA Committee on Standards and Survey Procedures

Co-Chps.: Steven R. Daviss, M.D., Angelos Halaris, M.D.
Participant: Geetha Jayaram, M.D., Robert Wise, M.D.

COMPONENT WORKSHOP 16 11:00 a.m.-12:30 p.m.
Room 149A/B, Level One, Washington Convention Center

PSYCHOTHERAPY UPDATE: PSYCHODYNAMIC THERAPY FOR PANIC DISORDER
APA Committee on Psychotherapy by Psychiatrists

Chp.: Eric M. Plakun, M.D.
Participant: Barbara Milrod, M.D.

COMPONENT WORKSHOP 17 11:00 a.m.-12:30 p.m.
Room 154A/B, Level One, Washington Convention Center

ON THE BRINK: UNIVERSAL HEALTH INSURANCE AND MENTAL HEALTH SERVICES
APA Council on Healthcare Systems and Financing

Co-Chps.: Anita S. Everett, M.D., Frederick J. Stoddard, M.D.
Participants: Mary Giliberti, Patrick Runnels, M.D., Joseph English, M.D., Steven Sharfstein, M.D.

COMPONENT WORKSHOP 18 11:00 a.m.-12:30 p.m.
Room 155, Level One, Washington Convention Center

EVALUATING COMPETENCY IN PSYCHOSOMATIC MEDICINE
APA Council on Psychosomatic Medicine

Chp.: Mary Jane Massie, M.D.
Participants: Samuel Sostre, M.D., Thomas Wise, M.D., Lawson Wulsin, M.D.

COMPONENT WORKSHOP 19 11:00 a.m.-12:30 p.m.
Room 158A/B, Level One, Washington Convention Center

REDUCING JUVENILE DELINQUENCY THROUGH PREVENTION
APA Corresponding Committee on Juvenile Justice Issues

Chp.: Stephen B. Billick, M.D.
Participant: Eraka Bath, M.D.
COMPONENT WORKSHOP 20  11:00 a.m.-12:30 p.m.
Room 160, Level One, Washington Convention Center

METHAMPHETAMINE ABUSE IN AMERICAN INDIAN AND ALASKA NATIVE COMMUNITIES: RESTORING HARMONY THROUGH AN INTEGRATED TREATMENT MODEL
APA Committee of American Indian, Alaska Native, and Native Hawaiian Psychiatrists

Chp.: Daniel L. Dickerson, D.O.

COMPONENT WORKSHOP 21  11:00 a.m.-12:30 p.m.
Room 201, Level Two, Washington Convention Center

ETHICAL DILEMMAS IN CLINICAL PRACTICE: ASK THE EXPERTS
APA Ethics Committee

Chp.: Wade Myers, M.D.
Participants: Burton V. Reifler, M.D., William Arroyo, M.D., L. Alan Wright, M.D., Lea DeFrancisci Lis, M.D.

COMPONENT WORKSHOP 22  11:00 a.m.-12:30 p.m.
Room 207A, Level Two, Washington Convention Center

I'M COMING OUT: HELPING YOUR LGBT PATIENTS OUT THE CLOSET DOOR
APA Committee on Gay, Lesbian, and Bisexual Issues

Chp.: Philip A. Bialer, M.D.
Participants: Eugene Lee, M.D., Umee Davac, D.O., Eric Williams, M.D., Serena Volpp, M.D.

COMPONENT WORKSHOP 23  11:00 a.m.-12:30 p.m.
Room 207 B, Level Two, Washington Convention Center

UNNATURAL CAUSES: IS INEQUALITY MAKING US SICK?
APA Committee of Black Psychiatrists

Co-Chps.: Michele Reid, M.D., Melva Green, M.D.
Participants: Napoleon Higgins, Jr., M.D., Cassandra Newkirk, M.D., Rahn Bailey, M.D.

ISSUE WORKSHOP 15  11:00 a.m.-12:30 p.m.
Room 152B, Level One, Washington Convention Center

COMPLEXITIES OF POST-TERMINATION RELATIONSHIPS
Co-Chps.: Malkah T. Notman, M.D.
Participants: Elissa Benedek, M.D., Carl Malmquist, M.D.

ISSUE WORKSHOP 16  11:00 a.m.-12:30 p.m.
Room 153, Level One, Washington Convention Center

TEACHING AND LEARNING MEDICAL-PSYCHIATRIC INTERFACE: A RESIDENCY TRAINING PERSPECTIVE
Co-Chps.: Henry W. Weisman, M.D., Lawrence Kaplan, M.D.
Participants: Natália Ortiz, M.D., Neil Sanuck, M.D., Sheri Hollander, M.D.

ISSUE WORKSHOP 17  11:00 a.m.-12:30 p.m.
Room 156, Level One, Washington Convention Center

INTERNET-ASSOCIATED MENTAL HEALTH PROBLEMS: DESIGNING TREATMENT PLANS BASED ON PSYCHIATRIC NOSOLOGY
Co-Chps.: Daniel J. Pimstone, B.S., Jeffery Wilkins, M.D.
Participants: Jack Kuo, M.D., William Huang, M.D.

ISSUE WORKSHOP 18  11:00 a.m.-12:30 p.m.
Room 157, Level One, Washington Convention Center

DO-NOT-RESUSCITATE ORDERS IN SUICIDAL PATIENTS: CLINICAL, ETHICAL, AND LEGAL DILEMMAS
Chp.: Stephen M. Soltys, M.D.
Participants: Renee Cook, D.O., Philip Pan, M.D., Ross Silverman, J.D.

ISSUE WORKSHOP 19  11:00 a.m.-12:30 p.m.
Room 159A/B, Level One, Washington Convention Center

CHILDREN AND TRAUMA: RESPONDING TO SPECIAL POPULATIONS RANGING FROM MILITARY CHILDREN, TO THOSE EXPOSED TO NATURAL DISASTERS, AND MUCH MORE
Co-Chps.: Heather L. Shibley, M.D., Niru Nahar, M.D.
Participants: Stephen Cozza, M.D., Steven Berkowitz, M.D., Arshad Husain, M.D.

ISSUE WORKSHOP 14  11:00 a.m.-12:30 p.m.
Room 141, Level One, Washington Convention Center

POETS, PSYCHIATRIC TREATMENT, AND THE CREATIVE PROCESS
Chp.: Richard M. Berlin, M.D.
Participants: Barbara Lefcowitz, Ph.D., J.D. Smith, M.A., Vanessa Haley, L.C.S.W
MONDAY

12 noon Sessions

FORUMS 2-5

FORUM 2 12 noon-1:30 p.m.
Room 102 A/B, Level One, Washington Convention Center
THE WORLD ASSOCIATION OF YOUNG PSYCHIATRISTS AND TRAINEES
Chp.: Victor J. Buwalda, M.D.
Presenters: Victor J. Buwalda, M.D., Nitin Gupta, M.D.,
Ruksheda Syeda, M.B.

FORUM 3 12 noon-1:30 p.m.
Room 144A/B, Level One, Washington Convention Center
RESEARCH PLANNING FOR DSM-V
Chp.: Darrel A. Regier, M.D.
Presenters: David J. Kupfer, M.D., Joel E. Dimsdale, M.D.,
David Shaffer, M.D., Kenneth Kendler, M.D., Norman Sartorius, M.D.

FORUM 4 12 noon-1:30 p.m.
Room 146C, Level One, Washington Convention Center
COMPETENCE IN TREATING PATIENTS WITH ADDICTIONS AND CO-OCCURRING PSYCHIATRIC DISORDERS
Chp.: John A. Renner, M.D.
Presenters: Nora Volkow, M.D., Howard Moss, M.D., Bertha Madras, Ph.D.

FORUM 5 12 noon-1:30 p.m.
Auditorium, Meeting Room Level, Renaissance Washington
MUSIC AND MOOD DISORDERS: TCHAIKOVSKY
Chp.: Richard Kogan, M.D.

1:00 p.m. Sessions

COURSES 52-59

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 52 1:00 p.m.-5:00 p.m.
Room 3, Meeting Room Level, Renaissance Washington
ENGAGING RESISTANT AND DIFFICULT-TO-TREAT PATIENTS IN COLLABORATIVE TREATMENT

Director: David Mee-Lee, M.D.

COURSE 53 1:00 p.m.-5:00 p.m.
Rooms 8/9, Meeting Room Level, Renaissance Washington
THE BASICS OF DISASTER PSYCHIATRY
APA Committee on Psychiatric Dimensions of Disaster
Co-Directors: Craig I. Katz M.D., Anand Pandya, M.D.
Faculty: Judith A. Cohen, M.D.

COURSE 54 1:00 p.m.-5:00 p.m.
Room 13, Meeting Room Level, Renaissance Washington
TEACHING PSYCHIATRY? LET HOLLYWOOD HELP!

Director: Steven E. Hyler, M.D.
Faculty: Carol A. Bernstein, M.D., Jeremy R. Butler, M.D.,
Michael B. First, M.D.

COURSE 55 1:00 p.m.-5:00 p.m.
Room 15, Meeting Room Level, Renaissance Washington
FOSTERING A COLLABORATIVE THERAPEUTIC ALLIANCE DURING THE INITIAL ENCOUNTERS WITH A COUPLE: A VIDEO CASE STUDY

Director: Ian E. Alger, M.D.
Faculty: Anita Menfi, R.N., M.A.

COURSE 56 1:00 p.m.-5:00 p.m.
Room 16, Meeting Room Level, Renaissance Washington
RESEARCH AND PUBLISHING ON A SHOESTRING BUDGET

Director: Mantosh J. Dewan, M.D.
Faculty: Stephen V. Faroone, Ph.D., Edward Silberman M.D.,
Michele T. Pato, MD.

COURSE 57 1:00 p.m.-5:00 p.m.
Room 18, Ballroom Level, Renaissance Washington
THE REUNION PROCESS: A NEW FOCUS IN SHORT-TERM DYNAMIC PSYCHOTHERAPY

Director: Steven B. Sandler, M.D.

COURSE 58 1:00 p.m.-5:00 p.m.
Renaissance Ballroom West B, Ballroom Level,
Renaissance Washington
CURRENT CPT CODING AND DOCUMENTATION REQUIREMENTS
Co-Directors: Chester W. Schmidt, Jr., M.D., Tracy R. Gordy, M.D.
COURSE 59 1:00 p.m.-5:00 p.m.  
Congressional Hall B, Ballroom Level, Renaissance Washington  

THE PSYCHIATRIST AS EXPERT WITNESS  

Director: Phillip J. Resnick, M.D.  

NEW RESEARCH POSTER SESSION 2: YOUNG INVESTIGATORS*  
1:00 p.m.-2:30 p.m.  
West Lobby, Level One, Washington Convention Center  

For further information on New Research submissions, please refer to the New Research Program Book included in your registration packet.  

2:00 p.m. Sessions  

FOCUS LIVE SESSION 3  
2:00 p.m.-3:30 p.m.  
Room 103A/B, Level One, Washington Convention Center  

FOCUS LIVE! Obsessive-Compulsive Disorder  

Moderator: Deborah J. Hales, M.D., Mark H. Rapaport, M.D.  
Presenters: John Greist, M.D.  

Obsessive-compulsive disorder (OCD) is often hidden by patients who have insight into the inappropriateness of their obsessional concerns and the excessive rituals they feel compelled to perform. Obsessions are unwanted, intrusive, repetitive ideas, images and impulses. Compulsions are urges to do something to lessen distress from obsessions. Rituals are repetitive purposeful behaviors, typically tied to obsessions and intended to diminish obsessions or the discomfort they cause. Contamination obsessions lead to washing and cleaning rituals; doubt produces checking; aggressive obsessions evoke avoidance of the objects of aggression; and worry about loss produces hoarding. Onset in childhood is common and many suffer lifelong with a few becoming incapacitated by incessant demands of their disorder. Once recognized, treatment with CBT and SSRIs is often helpful, alone or in combination. This multiple choice question based presentation will provide participants with an opportunity to test their knowledge about diagnosis and treatment of this disorder. In FOCUS LIVE! sessions, expert clinicians lead lively multiple choice question-based discussions. Participants test their knowledge with an interactive audience response system, which instantly presents the audience responses as a histogram on the screen. Questions cover existing knowledge on a clinical topic important to practicing general psychiatrists, including diagnosis, treatment, and new developments.  

ADVANCES IN (APPI SERIES) 1  
2:00 p.m.-5:00 pm  
Ballroom C, Level Three, Washington Convention Center  

ADVANCES IN THE TREATMENT OF SUBSTANCE USE DISORDERS  

Chp.: Marc Galanter, M.D.  
Co-Chp.: Herbert D. Kleber, M.D.  

A Assessment of Patients with Substance Use Disorders  
Shelly F. Greenfield, M.D., M.P.H.  

B The Recognition and Treatment of Alcohol Use Disorders  
Kathleen Brady, M.D., Ph.D.  

C Management of Cocaine and Methamphetamine Dependence  
Thomas R. Kosten, M.D.  

D Opioids: Detoxification, Maintenance, and Blockade  
Herbert D. Kleber, M.D.  

E Integrated Office-Based Treatment: Network Therapy  
Marc Galanter, M.D.  

LECTURES 8-10  

LECTURE 8  
2:00 p.m.-3:30 p.m.  
Room 143 A/B/C, Level One, Washington Convention Center  

APA's GEORGE TARJAN AWARD LECTURE  
Albert C. Gaw, M.D.  

Should Psychiatry Embrace a Psycho-spiritual Approach to Patient Care?  

Chp.: Sanjay Dube, M.D.  

Albert Gaw, M.D., was born in the Philippines of Chinese parentage. Dr. Gaw obtained his MD from the University of the East Medical Center in the Philippines; interned at Rochester General Hospital, NY; completed a psychiatric residency at the University of Rochester, Strong Memorial Hospital and a fellowship in Community Psychiatry at Harvard Medical School. An APA Distinguished Life Fellow, Dr. Gaw is a Clinical Professor of Psychiatry at the University of California at San Francisco, Medical Director of San Francisco's Community Behavioral Health Services and was a Speaker of the APA Assembly. Dr. Gaw helped established health and mental program for the Greater Boston's Asian American Community. He has published on Cross-Cultural Psychiatry, including three books: Cross-Cultural Psychiatry; Culture, Ethnicity and Mental Illness; and Concise Guide to Cross-Cultural Psychiatry. At Bedford VA and (Continued next page)
Dr. Caskey attended the University of South Carolina (1956-58) and Duke University Medical School (1958-63). After receiving his M.D. degree, Dr. Caskey remained at Duke as an intern and resident. Dr. Caskey then went to the National Institutes of Health (1965-71) where he was a Research Associate with Nobel Laureate Marshall Nirenberg. His research with Dr. Nirenberg proved the universality of the genetic code for living organisms on earth. Dr. Caskey then became Senior Investigator in the Laboratory of Biochemical Genetics (1967-70) and Head of the Section of Medical Genetics at NHLBI (1970-71). As an independent investigator he discovered the mechanism of code punctuation (stop) to be translated by proteins, not tRNA.

Dr. Caskey joined Baylor College of Medicine in 1971 where he served as Chief of the Section of Medical Genetics (1971-85) and Professor of Medicine and Biochemistry (1971-94). He discovered 11 genetic disease genes during this period. From 1976 to 1994 Dr. Caskey was a Howard Hughes Medical Institute Investigator. Most importantly, he discovered the "triplet repeat" diseases (fragile X and myotonic dystrophy) and the molecular basis of "disease anticipation" (triplet expansion generation to generation). His patent for automation of forensic science use of repeat sequences enabled ABI to use the method worldwide. He served as the first Director of the NIH Genome Center at Baylor College of Medicine. He also served as Director of the Medical Scientist Training Program, Professor of Cell Biology, as the Henry and Emma Meyer Chair in Molecular Genetics, Professor of Molecular Genetics, and Chair of the Department of Molecular and Human Genetics, at Baylor.

Dr. Caskey left academia in 1994 to assume the position of Senior Vice President for Research at Merck Research Laboratories, West Point, Pennsylvania, and Trustee and President of the Merck Genome Research Institute. The development of the adenoviral vector HIV vaccine was achieved by a research team under Dr. Caskey's direction. Dr. Caskey returned to Houston in 2000 and became Founding Director and Chief Executive Officer of Cogene Biotech Ventures and Cogene Ventures, venture capital funds designed to support early-stage biotechnology and life sciences companies using genome technology for drug discovery. In 2007 Dr. Caskey was named Director and Chief Executive Officer of the Brown Foundation Institute of Molecular Medicine and the George & Cynthia Mitchell Distinguished Chair in the Neurosciences. He has served as Chair of the Board of Lexicon Genetics, a Woodlands, Texas biotechnology company, as the company transformed itself from a mouse discovery company to a Nasdaq-listed pharmaceutical corporation. Other recent past Board memberships include the Muscular Dystrophy Association, the Foundation for Biomedical Research, Motorola BioChips, Athersys, Kodiak Technologies, Vical, Xeotron, Etubics, BioHouston, MDS, and Argolyn. He served as Special Advisor to the World Health Organization Hereditary Diseases Program and a member of the World Health Organization's Expert Advisory Panel on Human Genetics. He was President of The Human Genome Organization (HUGO) between 1993-1996. Presently, Dr. Caskey serves as a member of the Science Review Panel for the US Food and Drug Administration. He is Editor of the Annual Review of Medicine. Dr. Caskey is a member of the Academy of Medicine, Engineering and Science of Texas (President of TAMEST 2004-05), a member of the National Academy of Sciences, and the Institute of Medicine.

He is a Fellow of the American Academy of Microbiology, American Association for the Advancement of Science, American College of Medical Genetics, American College of Physicians, and the Royal Society of Medicine. He is a member of the American Society of Human Genetics (President 1990-1991), American Academy of Pharmaceutical Physicians, American Society for Biochemistry and Molecular Biology, American Society for Cell Biology, American Society for Clinical Investigation, American Society of Gene Therapy, American Society for Microbiology, American Medical Association, Association of American Physicians, and the Society for Inherited Metabolic Disorders. Dr. Caskey's most recent award (2007) was the Medical Statesman Award from the Health Access Foundation.
Survival: Reflections on Community Mental Health and Wellness. He has appeared as an expert guest Nightline, CBS Sunday Morning, the News Hour with Jim Lehrer, and the Today Show. He has also lectured internationally on various topics. Dr. Bell graduated from University of Illinois, Chicago Circle, in 1967 and earned his MD from Meharry College in Nashville, Tennessee. He completed his psychiatric residency in 1974 at the Illinois State psychiatric Institute in Chicago, where he worked with children, adolescents and adults.

THIS SESSION WILL BE AUDIOTAPED.

INTERNATIONAL SYMPOSIUM
2:00 p.m.-5:00 p.m.
Room 152A, Level One, Washington Convention Center

THE EMERGENCE OF SUBTHRESHOLD PSYCHIATRY
National Institute on Drug Abuse

Chp.: Ahmed Okasha, Ph.D.
Co-Chp.: Hagop S. Akiskal M.D.

A Clinical Staging of the Schizophrenia Prodrome to Improve Diagnostic Accuracy and Inform Treatment
Kristin S. Cadenhead, M.D.

B The Burden of Sub-Threshold Disorders
Norman Sartorius, M.D., Ph.D.

C The Emergence of Subthreshold Psychiatry
Ahmed Okasha, Ph.D.

D Affective Temperaments as Precursors of Mood Disorders
Hagop S. Akiskal, M.D.

Discussant: Ming T. Tsuang, M.D., Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 3-25

SYMPOSIUM 3 2:00 p.m.-5:00 p.m.
Room 101, Level One, Washington Convention Center

DIAGNOSIS AND TREATMENT OF ADOLESCENTS/YOUNG ADULTS WITH SUBSTANCE USE DISORDER

Chp.: George E. Woody, M.D.
Co-Chp.: Petra Jacobs, M.D.

A Mental Health and Substance Use Treatment Utilization in Adolescents With Substance Use Disorders
Oscar G. Bukstein, M.D., M.P.H., Jack Cornelius, M.D., M.P.H., Annette C. Trunzo, Ph.D., Thomas M. Kelly, Ph.D., D. Scott Wood, Ph.D.

B Psychiatric Disorders in Adolescents With Opioid Use Disorders (OUD) Versus Marijuana/Alcohol Use Disorders
Geetha Subramaniam, M.D.

C Evidence-Based Behavioral and Pharmacological Treatment for Opioid-Dependent Adolescents
Ramon Sollikhat, M.D.

D Brief Strategic Family Therapy (BSFT) for Adolescent Drug Abusers: A Multi-Site Clinical Trial
Michael S. Robbins, Ph.D., José Szapocznik, Ph.D., Viviana Horigian, M.D.

E Buprenorphine Treatment in Opioid-Addicted Adolescents/Young Adults
George E. Woody, M.D., Sabrina Poole, M.A., Geetha Subramaniam, M.D., Michael Bogenschutz, M.D., Ashwin Patkar, M.D., Mark Publicker, M.D., Marc Fishman, M.D., Patrick Abbott, M.D., Robert Kushner, M.D., Karen McCain, R.N., Hilary S. Connery, M.D., Jennifer Potter, Ph.D., Paul Fudala, Ph.D., Victoria Vetter, M.D., Robert Forman, Ph.D., Cynthia Clark, C.R.N.P., Laura McNicholas, M.D., Ph.D., Jack Blaine, M.D., Karen Dugosh, Ph.D., Kevin Lynch, Ph.D.

Discussants: Oscar Bukstein, M.D., Geetha Subramaniam, M.D., Michael Robbins, Ph.D., George Woody, M.D., Lisa Marsch, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 4 2:00 p.m.-5:00 p.m.
Room 102 A/B, Level One, Washington Convention Center

TRAUMATIC STRESS, HORMONES, AND DEPRESSION

Chp.: David Spiegel, M.D.

A The Effects of Depression Type, Length, and Comorbidity on HPA Function
Craig B. Taylor, M.D., David Spiegel, M.D.

B Persistent CSF Oxytocin Reduction After Childhood Abuse
Charles B. Nemeroff, M.D., Larry J. Young, Ph.D., D. Jeffrey Newport, M.D., M.S., Tanja Mletzko, M.S., Andrew H. Miller, M.D., Christine Heim, M.D.

C Stress Sensitivity in Metastatic Breast Cancer: Analysis of Hypothalamic-Pituitary-Adrenal Axis Function
David Spiegel, M.D., Janine Giese-Davis, Ph.D., C. Barr Taylor, M.D., Helena Kraemer, Ph.D.

D Stress, Cortisol, the Serotonin Polymorphism Transporter, and Cognitive Decline
Ruth O’Hara, Ph.D., Carmen Schroder, M.D., Helena Kraemer, Ph.D. Joachim Hallmayer, M.D.

E Mindfulness Meditation Alleviates Fibromyalgia Symptoms and Reduces the Cortisol Awakening Response
Sandra E. Sephton, Ph.D., Inka Weissbecker, Ph.D., Paul Salmon, Ph.D.
Monday

Discussants: Rachel Yehuda, Ph.D., Craig Taylor, M.D., Sandra Sephton, Ph.D., Christine Heim, Ph.D.

This session will be audiotaped.

Symposium 5 2:00 p.m.-5:00 p.m.
Room 140 A, Level One, Washington Convention Center

The Social Responsibility of Universities for the Mental Health of Students and Community Safety

Chp.: Steven S. Sharfstein, M.D.
Co-Chp.: Jerald Kay, M.D.

A Active Minds: Involving Students in Ensuring the Mental Well-Being of Their Peers on Campus
Alison Malmon, M.D.

B The University as a Social Structure
Beverly J. Fauman, M.D.

C The Challenges of College Mental Health
Jerald Kay, M.D.

D Legal and Ethical Issues in Campus Violence
Paul S. Appelbaum, M.D.

E Why are College Mental Health Crises so Difficult to Manage? An Examination of the Challenges to Providing Mental Health Care on College Campuses
Victor I. Schwartz, M.D.,

Discussants: Mary Jane England, M.D., Gary Pavela, J.D., Jerald Kay, M.D., Paul S. Appelbaum, M.D., Victor I. Schwartz, M.D.

This session will be audiotaped.

Symposium 6 2:00 p.m.-5:00 p.m.
Room 140B, Level One, Washington Convention Center

Recent Advances in Prevention Science: Implications for Practice and DSM-V

Chp.: William R. Beardslee, M.D.

A Prevention of Substance Abuse: Evidence From Controlled Trials
J. D. Hawkins, Ph.D., Rick Kosterman, Ph.D., Richard F. Catalano, Ph.D., Sabrina Oesterle, Ph.D.

B Recent Progress In Preventing Schizophrenia
Thomas H. McGlashan, M.D.

C Are Prevention Concepts Appropriate for the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V)?
Wilson M. Compton, III, M.D., William Beardslee, M.D., Harold Goldstein, Ph.D., Robert King, M.D., Thomas McGlashan, M.D., Robert Post, M.D., David Reiss, M.D.

D Prevention of Depression in Youth and Families: Recent Findings and Future Directions
William R. Beardslee, M.D.

Discussants: David Reiss, M.D., Thomas McGlashan, M.D., William R. Beardslee, M.D., J. Hawkins Ph.D., Wilson Compton, III, M.D.

This session will be audiotaped.

Symposium 7 2:00 p.m.-5:00 p.m.
Room 144A/B, Level One, Washington Convention Center

Medical Conundrums: A Guide for Treating the Psychiatrist

Chp.: Brian A. Fallon, M.D.
Co-Chp.: Arthur J. Barsky, M.D.

A A Randomized Trial of Three Psychosocial Treatments for Rheumatoid Arthritis Symptoms
Arthur J. Barsky, M.D., David K. Ahern, Ph.D., E. John Orav, Ph.D., Matthew H. Liang, M.D.

B Chronic Lyme Disease: Helping the Patient Despite the Controversies and Uncertainties
Brian A. Fallon, M.D., John Keilp, M.D., James Moeller, M.D., Kathy Corbera, M.D., Eva Petkova, M.D., Harold Sackeim, M.D.

C Update on Mechanisms and Management of Fibromyalgia
Daniel J. Clauw, M.D.

D Treatment of IBS: A Brain-Gut Disorder
Douglas A. Drossman, M.D.


This session will be audiotaped.

Symposium 8 2:00 p.m.-5:00 p.m.
Room 144C, Level One, Washington Convention Center

Externalizing Disorders of Childhood: A DSM-V Research Agenda

Chp.: David Shaffer, M.D.

A How Cardinal Are Cardinal Symptoms in Pediatric Bipolar Disorder?
Joseph Biederman, M.D., Janet Wozniak, M.D.

B Research on Key Questions Regarding Oppositional Defiant Disorder and Conduct Disorder: Current Status and Recommended Next Steps
Jeffrey D. Burke, Ph.D.

C Adult ADHD
James J. McGough, M.D.
Should Youth With Chronic Irritability Be Diagnosed With Bipolar Disorder?
Ellen Leibenluft, M.D., Melissa Brotman, Ph.D., Daniel Dickstein, M.D., Brendan Rich, Ph.D., Daniel Pine, M.D.

Research Opportunities for ADHD: Is There a Need to Reformulate Criteria in DSM-V?
Luis Augusto L. Rohde, M.D.

Discussants: David Shaffer, M.D., James McGough, M.D., Luis Augusto Rohde, M.D., Jeffrey Burke, Ph.D., Joseph Biederman, M.D.
THIS SESSION WILL BE AUDIOTAPED.

Symposium 9 2:00 p.m.-5:00 p.m.
Room 145A, Level One, Washington Convention Center

Continuation Treatments to Preventing Relapse Following ECT
Chp.: Matthew V. Rudorfer, M.D.
Co-Chp.: Max Fink, M.D.

A Continuation Pharmacotherapy in Preventing Relapse Following ECT
Harold A. Sackeim, Ph.D.

B Effectiveness of ECT in Suicide Risk Reduction in Patients With Major Depression
Joan Prudic, M.D.

C Continuation ECT and Continuation Pharmacotherapy for Relapse Prevention in Major Depression
Charles Kellner, M.D.

D Does Psychosis Predict ECT Response in Major Depression?
Georgios Petrides, M.D.

Discussants: Paula Clayton, M.D., Charles Kellner, M.D., Georgios Petrides, M.D., Harold Sackeim, Ph.D., Joan Prudic, M.D.
THIS SESSION WILL BE AUDIOTAPED.

Symposium 10 2:00 p.m.-5:00 p.m.
Room 145B, Level One, Washington Convention Center

Safety Issues in Child and Adolescent Psychopharmacology: Research Updated and Clinical Implications
Chp.: Benedetto Vitiello, M.D.

A Assessing Safety Outcomes of Treatment of Adolescents With MDD
Emslie Graham, M.D.

B Long-Term Effects of Stimulants in Children with ADHD
James M. Swanson, M.D.

Adverse Effects of Antipsychotic Treatment of Early-Onset Schizophrenia Spectrum Disorders
Linmarie Sikich, M.D., Jean Frazier, M.D., Jack McClellan, M.D., Robert Findling, M.D., Benedetto Vitiello, M.D., Jeffrey Lieberman, M.D.

Discussants: Graham Emslie, M.D., Linmarie Sikich, M.D., Mark Olsson, M.D., James M. Swanson, M.D.
THIS SESSION WILL BE AUDIOTAPED.

Symposium 11 2:00 p.m.-5:00 p.m.
Room 146C, Level One, Washington Convention Center

Depression and Generalized Anxiety: Research Planning for the DSM-V
Chp.: Kenneth S. Kendler, M.D.

A Neurobiological Validators Applied to MDD and GAD
Charles B. Nemeroff, M.D., Elizabeth Martin, M.D.

B Cross-Cultural Aspects of Anxiety and Depression
Dan J. Stein, M.D.

C MDD and GAD: Background and Genetic Relationship
Kenneth S. Kendler, M.D.

D Comorbidity Between DSM-IV Generalized Anxiety Disorder and Major Depression in the National Comorbidity Survey Follow-up
Ronald C. Kessler, Ph.D., John M. Hettema, M.D., Ph.D., Kimberly A. Yonkers, M.D.

E Biological and Treatment Aspects
David J. Kupfer, M.D., Ellen Frank, Ph.D.

Discussants: David Goldberg, D.M., Kenneth Kendler, M.D., David J. Kupfer, M.D., Ronald Kessler Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

Symposium 12 2:00 p.m.-5:00 p.m.
Room 147 A, Level One, Washington Convention Center

Psychiatric Genetics: New Discoveries Knocking at the Clinic Door
Chp.: Francis McMahon, M.D.

A Searching High and Low for Bipolar Disorder Genes
James B. Potash, M.D., M.P.H.

B A Systematic Approach to Association Studies of Schizophrenia
Pablo V. Gejman, M.D. (Continued next page)
C High-Resolution Analysis of Genome Copy Number Variation in Autism Spectrum Disorders
Jonathan L. Sebat, Ph.D.

D Genes Can't Read DSM: Dissecting Genotype-Phenotype Correlations
Thomas G. Schulze, M.D.

Discussants: Thomas G. Schulze, M.D., Pablo Gejman, M.D., James B. Potash, M.D., M.P.H., Jonathan L. Sebat, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 13 2:00 p.m.-5:00 p.m.
Room 147B, Level One, Washington Convention Center

PSYCHOPHARMACOLOGY IN THE ATHLETE
International Society for Sport Psychiatry

Chp.: Antonia L. Baum, M.D.

A The Use of Neuroleptic Medication in Professional Athletes
Douglas L. Geenens, D.O.

B Lithium in the Athlete
Antonia L. Baum, M.D.

D Psycho stimulant Use During Athletic Competition; What Are the Risks and Benefits?
David O. Conant-Norville, M.D.

Discussants: Douglas L. Geenens, D.O., Antonia L. Baum, M.D., David O. Conant-Norville, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 14 2:00 p.m.-5:00 p.m.
Room 149A/B, Level One, Washington Convention Center

SOMATIC PRESENTATIONS OF MENTAL DISORDERS

Chp.: Joel E. Dimsdale, M.D.

A Biological Substrate for Somatoform Disorders
Joel E. Dimsdale, M.D.

B Differential Response to Treatment for Somatoform Disorder Subtypes
Kurt Kroenke, M.D.

C Rethinking Somatoform Disorders in DSM-V: A View From Cultural Psychiatry
Laurence J. Kirmayer, M.D.

D Clinical Course and Treatment of Somatoform Disorders
Winfried Rief, Ph.D.

E The Association of Specific Somatic Syndromes With One Another

Simon Wessely, M.D.

Discussants: Simon Wessely, M.D., Joel E. Dimsdale, M.D., Kurt Kroenke, M.D., Laurence J. Kirmayer, M.D., Winfried Rief, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 15 2:00 p.m.-5:00 p.m.
Room 150A, Level One, Washington Convention Center

GLOBAL GAPS IN PSYCHIATRY: THE MENTAL HEALTH NEEDS OF CHILD SOLDIERS

Chp.: Glen P. Davis, M.D.

A A Long Way Gone: War, Redemption, and Hope Through the Eyes of a Child Soldier
Ishamael Beah, B.A.

B Interventions for Depression Symptoms Among Adolescent Survivors of War and Displacement in Northern Uganda

C The Reintegration of Former Child Soldiers in Northern Uganda
Jeannie Annan, Ph.D.

D Child Soldiers in Mozambique
Jon A. Shaw, M.D.

E Mozambican Child Soldier Life Outcome Study
Neil G. Boothby, Ed.D.

Discussants: Myron Belfer, M.D., Jon Shaw, M.D., Neil Boothby, Ed.D., Michael Wessells, Ph.D., Ishamael Beah, B.A.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 16 2:00 p.m.-5:00 p.m.
Room 150B, Level One, Washington Convention Center

EUROPEAN AND AMERICAN PSYCHIATRY: IDENTITY AND PRIORITIES

Chp.: Pedro Ruiz, M.D.
Co-Chp.: Cyril Hoschel, M.D.

A Current European Perspectives on the Concept of Schizophrenia
Mario Maj, M.D.

B Clinical and Theoretical Psychopathology in the Education of the Future Psychiatrist
Michael Musalek, M.D.
C World Psychiatry: European Contributions
Wolfgang Gaebel, M.D.

Discussants: Eliot Sorel, M.D., Livia Vavrusova, M.D., Michael Muñusle, M.D., Wolfgang Gaebel, M.D., Mario Maj, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 17  2:00 p.m.-5:00 p.m.
Room 151 A, Level One, Washington Convention Center

WOMEN’S HEALTH: STRAIGHT TALK ABOUT TANGLED PROBLEMS PREGNANCY RELATED PSYCHIATRIC ISSUES
Chp.: Gisèle Apter-Danon, M.D.

A Post partum Depression: Effects on the Development of Mother and Child
Alexandra M. Harrison, M.D.

B Dilemmas Concerning Miscarriage and Genetic Terminations
Gail E. Robinson, M.D.

C Antenatal Maternal Mental Health: Blissful Care
Gisèle Apter-Danon, M.D.

D The Myth of the Abortion Trauma Syndrome
Nada L. Stotland, M.D.

Discussants: Carol C. Nadelson, M.D., Gisèle Apter-Danon M.D., Nada L. Stotland, M.D., Alexandra Harrison, M.D., Gail Robinson, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 18  2:00 p.m.-5:00 p.m.
Room 151 B, Level One, Washington Convention Center

THE APPLICATION OF TRANSLATIONAL AFFECTIVE NEUROSCIENCE TO THE UNDERSTANDING OF ANXIETY DISORDERS
Chp.: James Blair, M.D.

A Generalization of Conditioned Fear as a Pathogenic Marker of PTSD
Shmuel Lissek, Ph.D., A. Biggs, S. Rabin, R. Alvarez, B. Cornwell, M. Vythilingham, Daniel Pine, M.D.

B Violence and Victims: Dissociable Dysfunctions in Amygdala-Cortical Interactions in PTSD and Psychopathy
Abigail Marsh, Ph.D., R.J.R. Blair, M.D.

C Differentiating Generalized Social Phobia From Generalized Anxiety Disorder at the Neurocognitive Level
Karina S. Blair, Ph.D., Daniel Pine, M.D.

D Translating Developmental Models of Anxiety to Children
Daniel Pine, M.D.

Discussants: Samantha Crowe, S. Lissek, A. Marsh, D. S. Pine, K.S. Blair M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 19  2:00 p.m.-5:00 p.m.
Room 154 A/B, Level One, Washington Convention Center

COMPARING NOTES: INTERNATIONAL EXPERIENCES IN EVALUATING RESIDENTS’ SKILLS
Chp.: Joan M. Anzia, M.D.
Co-Chp.: Dinesh Bhugra, M.D.

A Trainees’ Assessment at Work Place: The UK Experience
Dinesh Bhugra, M.D.

B Workplace based Assessments in Psychiatric Resident Training in the UK: The Developmental Experience

C Whither Goest We: Supervisors, Residents, and Annual Clinical Skills Exams
John Manring, M.D.

D From ABPN to Psychiatry Residency: Taking on the Challenge of Clinical Skills Examination
Richard F. Summers, M.D.

E In-Training Assessment of Resident Interviewing and Case Presentation Skills in Canada: The McMaster University Approach
Priyanthy Weerasekera, M.D., M.Ed., Karen Saperson, Ch.B., Lawrence Martin, MD.

Discussants: Amit Malik, M.D., Priyanthy Weerasekera, M.D., John Manring, M.D., Richard Summers, M.D., Dinesh Bhugra, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 20  2:00 p.m.-5:00 p.m.
Room 156, Level One, Washington Convention Center

THE PSYCHOSES FUSED: THE KRAEPELINIAN DICHTOMY, A CONTINUUM OR ONE DISORDER: CLINICAL, GENETIC, AND COGNITIVE COMPARISONS
Chp.: Charles R. Lake, M.D.

A “The Psychoses Dissected or Fused: A Correct Diagnosis is Critical for Correct Treatment”
Charles R. Lake, M.D.

(Continued next page)
B Bipolar Disorder and Schizophrenia: Shared Genetic Susceptibility
Wade H. Berrettini, M.D.

C Bipolar Disorder and Schizophrenia From Neuropsychological and Neuroimaging Perspectives
Jon-Kar Zubieta, M.D.

Discussants: Jan Fawcett, M.D., Charles R. Lake, M.D., Jon-Kar Zubieta, M.D., Wade H. Berrettini, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 21 2:00 p.m.-5:00 p.m.
Room 158 A/B, Level One, Washington Convention Center

PHARMACOGENETICS OF TAMOXIFEN AND OTHER CHEMOTHERAPEUTIC AGENTS AND SELECTIVE SEROTONIN REUPTAKE INHIBITORS: DRUG INTERACTIONS AND ALTERATIONS

Chp.: Michelle B. Riba, M.D.
Co-Chp.: John F. Greden, M.D.

A Influence of Drug Interactions and Germline Pharmacogenomics on the Efficacy, Side Effects, and Compliance with Tamoxifen
David A. Flockhart, M.D., James M. Rae, PhD, Daniel F., Hayes, M.D., Anne Nguyen, C.C.R.P., Vered Stearns, M.D., Janet Carpenter, R.N., Ph.D.

B Mood Disorders and Cancer: Implications for Treatment
John F. Greden, M.D.

C Pharmacogenetics in Management of Depression in Cancer Patients
Melvin G. McInnis, M.D.

D Teaching Pharmacogenomics: Finding Space in Our Already Over-Crowded Medical School Curriculum
Tamara L. Gay, M.D.

Discussants: David Flockhart, M.D., Vered Stearns, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 22 2:00 p.m.-5:00 p.m.
Room 159A/B, Level One, Washington Convention Center

MOMENTS OF CHANGE IN PSYCHOTHERAPY: WHAT CAN WE LEARN FROM THE POSITIVE TURNING POINTS OBSERVED IN ADULT AND CHILD TREATMENTS

Chp.: Lenore C. Terr, M.D.

A Change Moments in Therapy
Daniel Stern, M.D.

B Change Moments in Therapy
Ethel S. Person, M.D.

C Magical Moments in Psychotherapy
Lenore C. Terr, M.D.

Discussants: Marcia Kraft Goin, M.D., Lenore Terr, M.D., Ethel Person, M.D., Daniel Stern, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 23 2:00 p.m.-5:00 p.m.
Room 201, Level Two, Washington Convention Center

THE RELATIONSHIPS BETWEEN THE APA ANNUAL MEETING AND THE PHARMACEUTICAL INDUSTRY: HISTORICAL AND CURRENT PERSPECTIVES AND ISSUES

Chp.: Kenneth R. Silk, M.D.
Co-Chp.: Donald M. Hilty, M.D.

A Balancing Science and Support at the APA Annual Meeting
David A. Baron, D.O.

B Differentiating Advertising From Educational Support: A Role for Both
James H. Scully, Jr., M.D.

C The History of the Relationship Between Academia and the Pharmaceutical Industry: What Can the APA Learn?
Kenneth R. Silk, M.D.

D Pharmaceutical Support of the Annual Meeting: Does the Dog Wag the Tail?
Philip R. Muskin, M.D.

Anthony J. Rothschild, M.D.

Discussants: Donald M. Hilty, M.D., Kelli Harding, M.D., David A. Baron, D.O., James H. Scully, Jr., M.D., Philip R. Muskin, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 24 2:00 p.m.-5:00 p.m.
Room 207A, Level Two, Washington Convention Center

THE CHANGING FACE OF TERRORISM: SUICIDE TERRORISM AND RADICALIZATION IN ÉMIGRÉ POPULATIONS

Chp.: Jerrold M. Post, M.D.

A Why Women Kill
Farhana Ali, M.D.

B The Risk of Radicalization and Terrorism in Muslim Émigré Communities
Jerrold M. Post, M.D., Gabriel Sheffer, Ph.D.
5:30 p.m. Sessions

CONVOCATION OF DISTINGUISHED FELLOWS
5:30 p.m.-6:30 p.m.
Hall D, Level Two,
Washington Convention Center

All Distinguished Life Fellows, Distinguished Fellows, Life Fellows, International Fellows, Fellows, members, and registered guests are invited.

Presiding: Carolyn B. Robinowitz, M.D., President

Grand Marshals: Brian B. Doyle, M.D., Susan G. Lazar, M.D.

Marshals: Jeffrey S. Akman, M.D., William B. Lawson, M.D.

INTRODUCTION OF DISTINGUISHED LIFE FELLOWS
Nada L. Stotland, M.D., President-Elect

INDUCTION OF DISTINGUISHED FELLOWS
Nada L. Stotland, M.D.

INTRODUCTION OF FIFTY-YEAR DISTINGUISHED LIFE FELLOWS, FIFTY-YEAR LIFE MEMBERS, AND INTERNATIONAL FELLOWS
Carolyn B. Robinowitz, M.D.

INTRODUCTION OF FELLOWS
Carolyn B. Robinowitz, M.D.

PRESENTATION OF SPECIAL PRESIDENTIAL COMMENDATIONS
Carolyn B. Robinowitz, M.D.

PRESENTATION OF DISTINGUISHED SERVICE AWARDS
Carolyn B. Robinowitz, M.D.

INTRODUCTION OF THE MEMBERSHIP COMMITTEE CHAIRPERSON AND AWARD BOARD CHAIRPERSONS
Carolyn B. Robinowitz, M.D.

PRESENTATION OF AWARDS
Carolyn B. Robinowitz, M.D.

APA/Lilly Resident Research Awards
Human Rights Award
Blanche F. Ittleson Award for Research in Child Psychiatry
APIRE/Kempf Fund Awards for Research Development in Psychobiological Psychiatry
Agnes Purcell McGavin Award
Isaac Ray Award
Jack Weinberg Memorial Award for Geriatric Psychiatry

WILLIAM C. MENNINGER MEMORIAL CONVOCATION LECTURE
Oliver Sacks, M.D.
LECTURE 11
5:30 p.m.-6:30 p.m.
Hall D, Level Two,
Washington Convention Center
WILLIAM C. MENNINGER MEMORIAL LECTURE

Oliver Sacks, M.D.

A thesis offered at APA's 2007 annual meeting by the brilliant mathematician who has suffered for decades from schizophrenia, John Nash, is echoed in the works of another man who has long challenged the one-dimensional assumption that mental or neurological disorders are abnormalities that must be "fixed" through treatment or lived with as a disability. It's not that simple, according to best-selling author and neurologist Oliver Sacks, M.D. "Defects, disorders, diseases," writes Sacks in An Anthropologist on Mars, "can play a paradoxical role, by bringing out latent powers, developments, evolutions, forms of life, that might never be seen, or even be imaginable, in their absence." Sacks will discuss his work and insights at the Convocation of Fellows at APA's 2008 annual meeting on Monday, May 5, at 5:30 p.m. in Hall D, Level 1, at the Washington Convention Center. He is presenting the William C. Menninger Memorial Lecture. Sacks's most recent book, published last fall, is Musicophilia: Tales of Music and the Brain. A music lover himself, Sacks writes about the relationship of music and uncommon brain disorders and how that relationship is marked by power and mystery. He goes beyond the science of the brain as he unfolds the compelling tales of people with different neurological conditions for whom music is or has become a central part of their existence—sometimes to their detriment but most often in paradoxical, healing, or life-changing ways. Sacks, who is probably best known for his books Awakenings, The Man Who Mistook His Wife for a Hat, and An Anthropologist on Mars, was born in 1933 in London into a family of physicians and scientists—including his mother, a surgeon, and his father, a general practitioner. He earned his medical degree at Oxford University and did residencies and fellowship work in the United States. Since 1965 he has lived in New York and practiced neurology. He is now a professor of clinical neurology and clinical psychiatry at Columbia University Medical Center and was named the university's first Columbia Artist. A pivotal event in Sacks's career occurred in 1966. While consulting for a chronic-care hospital in the Bronx, Sacks encountered a group of patients who had spent decades frozen in a statue-like state. He recognized that these patients were survivors of a pandemic of "sleepy sickness" from 1916 to 1927. After treating them with a then-experimental drug, L-dopa, they came back to life. (They later developed tics and seizures as a result of the drug.) He wrote about this experience in his 1973 book Awakenings, later made into a play and movie. Many of the books that Sacks wrote after Awakenings described his experiences with people who had a variety of neurologically based conditions, including Tourette's syndrome, autism, parkinsonism, musical hallucinations, epilepsy, phantom limb syndrome, schizophrenia, and Alzheimer's disease. He has been a subject of three of his books: as a doctor in Migraine, as a patient in A Leg to Stand On, and as a youth growing up in a family of gifted scientists in Uncle Tungsten: Memories of a Chemical Boyhood. The best-selling author has won numerous awards, including a Guggenheim Fellowship for his writings on the neuroanthropology of Tourette's syndrome and the Lewis Thomas Prize by Rockefeller University, which recognizes the scientist as poet. The Institute for Music and Neurologic Function of Beth Abraham Family of Health Services has honored him twice: in 2000, with its Music Has Power Award, and in 2006, in commemoration of his 40th year at Beth Abraham and for his dedication to his patients.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 19-21

INDUSTRY-SUPPORTED SYMPOSIUM 19
7:00 p.m.-10:00 p.m.
Ballroom A/B, Level Three, Washington Convention Center

IS RECOVERY ATTAINABLE IN SCHIZOPHRENIA? BIOLOGICAL, AND PSYCHOLOGIC PERSPECTIVE
Supported by: AstraZeneca Pharmaceuticals

Chp.: Peter J. Weiden, M.D.

A Using Recovery Principles to Define Treatment Goals
Alex Kopelowicz, M.D.

B Psychopharmacology of Recovery: Reducing Burden of Treatment
John Lauriello, M.D.

C What Does the Neurobiology of “First-Episode” Psychosis Tell Us About Treatment Goals for Recovery?
John A. Sweeney, Ph.D.

D Psychopharmacology of Recovery: Reducing the Burden of Disease
Peter J. Weiden, M.D.

C From “Supportive” to Symptom Reduction: Using Cognitive-Behavioral Therapy in Schizophrenia
Shanaya Rathod, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 20
7:00 p.m.-10:00 p.m.
Grand Ballroom, Ballroom Level, Renaissance Washington

NOVEL AND CURRENT ANTIDEPRESSANTS: STATE-OF-THE-ART MANAGEMENT OF DEPRESSION
Supported by: Novartis Pharmaceuticals Corporation

Chp.: Michael E. Thase, M.D.
A Approaches to improve outcomes
Michael Ostacher, M.D., M.P.H., Sarah Baghat, B.A.,
Rebecca Ametrano, B.A., Andrew A. Nierenberg, M.D.

B Disease Burden, Underdiagnosis, and Undertreatment
of Depression
Jordan F. Karp, M.D.

C A Review of the Importance and Treatment of
Residual Symptoms in Depression
Humberto Marin, M.D., Roseanne Dobkin, Ph.D.,
Matthew A. Menza, M.D.

D New Antidepressant Medications and Novel
Mechanism of Action
Michael E. Thase, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 21
7:00 p.m.-10:00 p.m.
Independence Ballroom, Independence Level, Grand Hyatt
Washington

SLEEP AND DISORDERS ACROSS THE LIFE CYCLE:
WHAT PSYCHIATRISTS NEED TO KNOW
Supported by: Sepracor, Inc.

Chp.: Milton Erman, M.D.
High Quality Continues for the 2008 Annual Meeting...

Live recordings will be available for most of the following:

- Lectures
- Advances in... Series
- Presidential Symposia
- Scientific and Clinical Reports
- Symposia
- Debate

CDs and MP3s may be purchased/ordered on site at Mobiltape’s booth at the Washington Convention Center.

Mobiltape Company, Incorporated
24730 Avenue Tibbitts, Suite 170
Valencia, CA 91355
Phone: (661) 295-0504  ■  (800) 369-5718
Fax: (661) 295-8474
Website: www.mobiltape.com
FOCUS is the best system for recertification, self-assessment, and lifelong learning in psychiatry. In one package FOCUS provides a comprehensive review of current clinical practice based on the content outlined by the ABPN recertification exam. Each issue offers Clinical Reviews, a Patient Management Exercise, Seminal Articles, and a CME quiz. Twenty AMA PRA Category 1 Credits™ are available per year for the issue quizzes, and an additional 20 hours can be earned through completion of the end-of-year Self-Assessment Exam. All current and back issues are available online. You can earn CME credits by taking the exams from the current issue, or even the nonexpired exams from any past issue that was published during your subscription period.

The FOCUS Self-Assessment Exam is an annual 100-question, multiple-choice supplement written by practicing psychiatrists and academic experts that allows you to earn 20 AMA PRA Category 1 Credits™ and the opportunity to anonymously compare your knowledge to that of your peers either online or on paper. Each question is similar to those used in board-type exams. The FOCUS Self-Assessment Exam is listed by the ABPN as an approved self-assessment activity that fulfills the requirement of psychiatrists applying for and taking the recertification examination.

FOCUS addresses the core content in psychiatry in 4-year cycles. Each issue briefs you on new developments and reviews the current state of practice in that topic area through:

- A comprehensive review article summarizing current research
- A clinical synthesis article written by a leading expert in the field
- A patient management exercise and ask-the-expert column
- Recent influential works selected by experts in the field
TUESDAY, MAY 6, 2008
161ST ANNUAL MEETING

7:00 a.m. Sessions

PART 2 OF INDUSTRY-SUPPORTED BREAKFAST SYMPOSIA 16-18

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 16, PART 2
7:00 a.m.-8:30 a.m.
Ballroom A/B, Level 3, Washington Convention Center
ARE COGNITION, SLEEP, AND WAKE DISORDERS CAUSED BY TOO MUCH AROUSAL, TOO LITTLE AROUSAL OR BOTH?
Supported by: Takeda Pharmaceuticals

Chp.: Daniel J. Buysse, M.D.

A Where Do Increased Arousal and Insomnia Fall Along the Arousal Spectrum?
Leslie P. Lundt, M.D., Meeta Singh, M.D., Stephen M. Stahl, M.D., Ph.D., Daniel J. Buysse, M.D.

B How Do We Best Treat Too Much or Too Little Arousal?
Stephen M. Stahl, M.D., Ph.D., Meeta Singh, M.D., Daniel J. Buysse, M.D., Leslie P. Lundt, M.D.

C What is Sleepiness Versus Inattentiveness? Can the Arousal Spectrum Answer This Question?
Leslie P. Lundt, M.D., Daniel J. Buysse, M.D., Stephen M. Stahl, M.D., Ph.D., Meeta Singh, M.D.

D Insights Into the Neurobiology of the Arousal Spectrum: the Neurocircuitry Spanning States From Hypersomnia to “Hyperarousal”
Meeta Singh, M.D.; Daniel J. Buysse, MD; Leslie P. Lundt, M.D., Stephen M. Stahl, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 17, PART 2
7:00 a.m.-8:30 a.m.
Grand Ballroom, Ballroom Level, Renaissance

UNDERSTANDING BIPOLAR DISORDER: QUALITY AND CONUNDRUMS
Supported by: Pfizer Inc

Chp.: Gary Sachs, M.D.

A Community Treatment of Bipolar Depression: Service Utilization and Quality
Alisa Busch, M.D.

B A Historical Overview of Bipolar Disorder
Ileana Fumero-Perez, M.D.

C Evidence-Based Treatment Options for Bipolar Depression
Mark Frye, M.D.

D Reducing Diagnostic Error: Recognition of Bipolar Depression Phenomenology
Gary Sachs, M.D.

E Pathophysiology of Bipolar Depression
Terence A. Ketter, M.D.

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 18, PART 2
7:00 a.m.-8:30 a.m.
Independence Ballroom A-E, Level 5B, Grand Hyatt

GENETICS, BRAIN IMAGING, AND PHARMACOLOGY: CLINICAL IMPLICATIONS FOR THERAPEUTIC CHOICES IN PSYCHIATRIC DISORDERS
Supported by: Organon, a part of Schering-Plough

Chp.: Robert E. Hales, M.D.
Co-Chp.: Stuart C. Yudofsky, M.D.

A Receptor Pharmacology, Molecular Imaging, and, Clinical Implications in Schizophrenia
Anissa Abi-Dargham, M.D.

B Clinical Implications of Recent Genetics and Neuroimaging Advances in Bipolar Disorder
Kiki Chang, M.D.

C Schizophrenia: The Clinical Importance of Genetics and Structural Brain Imaging
Rene S. Kahn, M.D.

D Effective Treatment of Bipolar Disorder: An Elusive Goal?
Terence A. Ketter, M.D.

8:00 a.m. Sessions

COURSES 60-65
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 60 8:00 a.m.-12 noon
Room 5, Meeting Room Level, Renaissance Washington

SHORT-TERM PSYCHODYNAMIC SUPPORTIVE PSYCHOTHERAPY FOR DEPRESSION

Director: Henricus Van, M.D.
Faculty: Gerda van Aalst, M.D., Robert Schoevers, Ph.D., Simone Kool, M.D., Frans F. de Jonghe, M.D., Ph.D., Marielle Hendriksen, M.A.

COURSE 61 8:00 a.m.-12 noon
Rooms 8/9, Meeting Room Level, Renaissance Washington

DISASTER PSYCHIATRY: TERRORISM, TRAUMA, AND THINGS TO DO

Director: Joseph C. Napoli, M.D.
Faculty: Michael Blumenfield, M.D.

COURSE 62 8:00 a.m.-12 noon
Room 10/11, Meeting Room Level, Renaissance Washington

CREATIVE USE OF BOUNDARY CROSSING IN THERAPY

Director: Gail E. Robinson, M.D.
Faculty: Gary R. Schoener, M.A., Howard E. Book, M.D., Linda M. Jorgenson, M.A.

COURSE 63 8:00 a.m.-12 noon
Room 12, Meeting Room Level, Renaissance Washington

IMPROVING YOUR PRESENTATION SKILLS: A COACHING APPROACH

Director: Luis F. Ramirez, M.D.

COURSE 64 8:00 a.m.-12 noon
Renaissance Ballroom West A, Ballroom Level, Renaissance Washington

THE EVALUATION, IDENTIFICATION, AND TREATMENT OF THE MAJOR DEMENTIAS

Co-Directors: Raymond A. Faber, M.D., Kevin F. Gray, M.D.
Faculty: Randolph B. Schiffer, M.D.

COURSE 65 8:00 a.m.-12 noon
Congressional Hall B, Ballroom Level, Renaissance Washington

RISK ASSESSMENT FOR VIOLENCE

Director: Phillip J. Resnick, M.D.
**LECTURE 13**
9:00 a.m.-10:30 a.m.
Room 143 A/B/C, Level One
Washington Convention Center

**CELLULAR PLASTICITY CASCADES: A WINDOW INTO MOOD DISORDERS**

Husseini K. Manji, M.D.

**Chp.:** Hagop Akiskal, M.D.

Husseini K. Manji, M.D. is Chief, Laboratory of Molecular Pathophysiology & Experimental Therapeutics, NIMH, and Director of the NIMH Mood and Anxiety Disorders Program, the largest program of its kind in the world. He is also a visiting professor in the Department of Psychiatry at Duke University. Dr. Manji received his B.S. (Biochemistry) and M.D. from the University of British Columbia. Following psychiatry residency training, he completed fellowship training in psychopharmacology at the NIMH and obtained extensive additional training in cellular and molecular biology at the NIDDK. The major focus of his ongoing research is the investigation of disease- and treatment-induced changes in gene and protein expression profiles that regulate synaptic and neural plasticity in mood disorders. His work has helped to conceptualize these illnesses as genetically-influenced disorders of synaptic plasticity, and has led to the investigation of novel therapeutics for refractory mood disorders. Dr. Manji is a previous recipient of numerous research awards, including the A. E. Bennett Award for Neuropsychiatric Research, the Ziskind-Sommerfield Award for Neuropsychiatric Research, the NARSAD Mood Disorders Prize (Falcone Prize), the Mogens Schou Distinguished Research Award, the American College of Neuropsychopharmacology (ACNP)’s Joel Elkes award for distinguished research, the Canadian Association of Professors in Psychiatry Award, the Henry and Page Laughlin Distinguished Teacher Award, the Brown University School of Medicine Distinguished Researcher Award, and the NIMH award for excellence in clinical care and research. In addition to his research endeavors, Dr. Manji is also actively involved in medical and neuroscience education endeavors, and has served as a member of the National Board of Medical Examiners (NMBE) Behavioral Science Test Committee, the Howard Hughes Medical Institute Research Scholars Program Selection and Advisory Committee, and numerous national curriculum committees. He has developed and co-directs the NIH Foundation for the Advanced Education in the Sciences Graduate Course in the Neurobiology of Mental Illness, and has received both the NIMH Mentor of the Year and NIMH Supervisor of the Year awards. He has published extensively on the molecular and cellular neurobiology of severe mood disorders and their treatments, editor of Neuropsychopharmacology Reviews: The Next Generation of Progress, deputy editor of Biological Psychiatry, associate editor of the journal Bipolar Disorders, and sits on the editorial board of numerous journals. He is a Councilor of the ACNP, chairs the ACNP’s Task Force on New Medication Development, and is president-elect of the Society of Biological Psychiatry.

**Frontiers of Science Lecture Series**

**THIS SESSION WILL BE AUDIOTAPED.**

**LECTURE 14**
9:00 a.m.-10:30 a.m.
Room 146A/B, Level One,
Washington Convention Center

**Mario Maj, M.D.**

**CONFLICTS AND INTEREST IN PSYCHIATRIC PRACTICE AND RESEARCH**

**Chp.:** Juan Mezzich, M.D.

Mario Maj is Full Professor of Psychiatry and Chairman of the Department of Psychiatry of the University of Naples. Since 1983, he has been collaborating with the World Health Organization (WHO), being active as a researcher and an educator in sub-Saharan Africa, South-East Asia, and Latin America. From 1989 to 1991, he has been responsible for the WHO Programme on the Neuropsychiatric Aspects of HIV Infection at WHO Headquarters in Geneva. He is President-Elect of the World Psychiatric Association. He has been President of the European Psychiatric Association (2003-2004) and of the Italian Psychiatric Association (2000-2002). He is member of the Italian High Council of Medicine. He has published papers in 51 different journals indexed in the Current Contents, including all the psychiatric journals indexed in the Current Contents-Life Sciences, and several major journals in the fields of neurosciences, basic sciences, and general medicine. According to the Institute for Scientific Information (ISI), he is the Italian psychiatrist with the highest number of citations in the period 1981-2005.

**International Psychiatrist Lecture Series**

**THIS SESSION WILL BE AUDIOTAPED.**

**LECTURE 15**
9:00 a.m.-10:30 a.m.
Hall D, Level Two,
Washington Convention Center

**Thomas Insel, M.D.**

**RETHINKING MENTAL DISORDERS: HOW RESEARCH WILL CHANGE PRACTICE**

Collaborative Session With the National Institute of Mental Health

**Chp.:** Christine Marx, M.D.

Thomas R. Insel, M.D., is Director of the National Institute of Mental Health (NIMH), the component of the National Institutes of Health charged with generating the knowledge needed to understand, treat, and prevent mental disorders. With a budget of over $1.4 billion, the NIMH leads the nation’s research on disorders that affect an estimated 44 million Americans, including one in five children. Immediately prior to his appointment as director, which marks his return to NIMH after an eight-year hiatus, Dr. Insel was Professor of Psychiatry at Emory University. There, he was founding director of the Center for Behavioral Neuroscience, one of the largest science and technology centers funded by the National Science Foundation and, concurrently, director of an NIH-funded Center for Autism Research.
From 1994 to 1999, he was Director of the Yerkes Regional Primate Research Center in Atlanta. While at Emory, Dr. Insel continued the line of research he had initiated at NIMH, studying the neurobiology of complex social behaviors in animals. Early in his NIMH research career, which extended from 1979 to 1994, Dr. Insel conducted clinical research on obsessive-compulsive disorder, conducting some of the first treatment trials for OCD using the selective serotonin reuptake inhibitors (SSRI) class of medications. He has published over 200 scientific articles and four books, including the Neurobiology of Parental Care (with Michael Numan) in 2003. Dr. Insel has served on numerous academic, scientific, and professional committees, including 10 editorial boards. He is a member of the Institute of Medicine, a fellow of the American College of Neuropsychopharmacology, and is a recipient of several awards. Dr. Insel graduated from the combined B.A.-M.D. program at Boston University in 1974. He did his internship at Berkshire Medical Center, Pittsfield, Massachusetts, and his residency at the Langley Porter Neuropsychiatric Institute at the University of California, San Francisco.

**Frontiers of Science Lecture Series**

**THIS SESSION WILL BE AUDIOTAPED.**

**SMALL INTERACTIVE SESSIONS 7-9**

9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

7 Ralph Leo, M.D., on An Overview of the Role of Psychiatrists in Pain Medicine: Treating the Complex Pain Patient *(Meet the Author)*

Room 304, Level Three, Washington Convention Center

8 Jonathan Borus, M.D., on Career Issues for the Academic Psychiatrist *(Meet the Author)*

Room 305, Level Three, Washington Convention Center

9 Helen Mayberg, M.D., on How Neuroimaging Has Changed Our View of Depression

Room 306, Level Three, Washington Convention Center

**WORKSHOPS**

**COMPONENTS 24-33**

**COMPONENT WORKSHOP 24**  9:00 a.m.-10:30 a.m.

Room 142, Level One, Washington Convention Center

**LETHAL BEAUTY: THE GOLDEN GATE BRIDGE**

*APA Northern California Psychiatric Society*

Chp.: Mel I. Blaustein, M.D.

Participant: Mary Zablotny

**COMPONENT WORKSHOP 25**  9:00 a.m.-10:30 a.m.

Room 147A, Level One, Washington Convention Center

**DRUG ABUSE IN ATHLETES: THE CHALLENGES OF PREVENTION AND TREATMENT**

*APA Council on Addiction Psychiatry*

Chp.: Evaristo Akerele, M.D

Participants: Herbert Kleber, M.D., Edward Nunes, M.D., Richard Rosenthal M.D.

**COMPONENT WORKSHOP 26**  9:00 a.m.-10:30 a.m.

Room 147B, Level One, Washington Convention Center

**WORKPLACE PSYCHIATRY 101**

*APA Corresponding Committee on Psychiatry in the Workplace*

Chp.: Jeffrey P. Kahn, M.D.

Participants: Steven Pfianz M.D., Alan Langlieb M.D., Andrea Stolar M.D.

**COMPONENT WORKSHOP 27**  9:00 a.m.-10:30 a.m.

Room 148, Level One, Washington Convention Center

**BETTER LUCK TOMORROW: GAMBLING IN ASIAN-AMERICANS**

*APA Committee of Asian-American Psychiatrists*

Chp.: Mona H. Gill, M.D.

Participants: Dan Tzuan, M.D., Timothy W. Fong, M.D., Shirley Liu, B.A.

**COMPONENT WORKSHOP 28**  9:00 a.m.-10:30 a.m.

Room 154A/B, Level One, Washington Convention Center

**AMERICAN PSYCHIATRY: CARE QUALITY, ACCESS, ETHICS, AND ADVOCACY**

*APA Council on Quality Care*

Co-Chps.: Eliot Sorel, M.D., Daniel K. Winstead, M.D.

Participants: Donna Norris, M.D., Francis Lu, M.D., Steven Moffic, M.D., James H. Scully, Jr., M.D.

**COMPONENT WORKSHOP 29**  9:00 a.m.-10:30 a.m.

Room 155, Level One, Washington Convention Center

**DOES CULTURE MATTER? A DEBATE ON THE UNDERUSE AND OVERUSE OF CULTURAL DIFFERENCES IN PSYCHIATRY**

*APA/SAMHSA and APA/AstraZeneca Minority Fellowships*

Co-Chps.: Natalie Weder, M.D., Liwei I Hua, M.D.

Participants: Vikram Kambampati, M.D., Jacob Moussai, M.D., Jennifer Le, M.D., Kehinde Ogundipe, M.D., Melissa Ochoa-Perez, M.D., Iman Hypolite, M.D., Icelini Garcia-Sosa, M.D.

**COMPONENT WORKSHOP 30**  9:00 a.m.-10:30 a.m.

Room 156, Level One, Washington Convention Center

**NOVEL CAREERS IN PSYCHIATRY: WOMEN WHO HAVE MADE THEIR OWN WAY**

*APA Committee on Women*

Co-Chps.: April H. Morciglio, M.D., Jamae C. Campbell, M.D.

Participants: Melva Green, Francine Cournos, M.D., Janet Taylor, M.D.
<table>
<thead>
<tr>
<th>Component Workshop 31</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 159A/B, Level One, Washington Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Electronic Health Records in Psychiatry: Experiences of Early Adopters</strong></td>
<td></td>
<td>APA Corresponding Committee on Electronic Health Records</td>
</tr>
<tr>
<td>Chp.: Farrell H. Braziel, M.D.</td>
<td>Participants: Laura Fochtman M.D., Suzanne Albrecht M.D., John Boronow, M.D., Peter Fore, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Component Workshop 32</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 207A, Level Two, Washington Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demystifying the System: Eliminating Barriers to Effective Treatment of Mentally Ill in Jails and Prisons</strong></td>
<td></td>
<td>APA Corresponding Committee on Jails and Prisons</td>
</tr>
<tr>
<td>Chp.: Henry C. Weinstein, M.D.</td>
<td>Participants: Avram Mack, M.D., Erik Roskes, M.D., Tom Hamilton, Cassandra Newkirk, M.D., William Arroyo, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Component Workshop 33</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 207B, Level Two, Washington Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Disaster Preparation and Mental Health Response: Roles for District Branch Emergency Committees</strong></td>
<td></td>
<td>APA Washington Psychiatric Society</td>
</tr>
<tr>
<td>Co-Chps.: Julia Z. Frank, M.D., Cheryl Person, M.D.</td>
<td>Participants: Stephen Peterson, M.D., Catherine May, M.D., Enrico Suardi, M.D., Erminia Scarcella, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 20</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 101, Level One, Washington Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Off-Label Use of Psychotropic Medications in Consultation-Liaison Psychiatry: Medico-Legal Issues</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Ramaswamy Viswanathan, M.D.</td>
<td>Participants: Rebecca Brendel, M.D., John McIntyre, M.D., Paul S. Appelbaum, M.D., James Levenson, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 21</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 103A/B, Level One, Washington Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pearls and Pitfalls in Negotiating Your First Job</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Molly K. McVoy, M.D.</td>
<td>Participant: William Campbell, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 22</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 141, Level One, Washington Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vietnam Veterans and the Iraq War: Is the Past Ever the Past?</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-Chps.: Laura C. Kordon, M.D., Eric T. Glessner, L.C.S.W.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 23</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 144A/B, Level One, Washington Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mental Health Issues in Response to Hurricanes Katrina and Rita</strong></td>
<td></td>
<td>National Institute of Mental Health</td>
</tr>
<tr>
<td>Chp.: Agnes E. Rupp, Ph.D.</td>
<td>Participants: Sheryl Kataoka, M.D., Lisa Jaycox Ph.D., Audra Langley, Ph.D., Michael Schoenbaum, Ph.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 24</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 144C, Level One, Washington Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Teaching on the Fly: Practical Tips for Teaching Medical Students One-to-One</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Andrea E. Waddell, M.D.</td>
<td>Participants: Lana Benedek, B.A., Kien Dang, M.D., Jodi Lofchy, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 25</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 150A, Level One, Washington Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Computer-Mediated Relationships: Blogs, Online Communities, and Virtual Worlds</strong></td>
<td></td>
<td>American Association for Technology in Psychiatry</td>
</tr>
<tr>
<td>Chp.: Robert C. Hsiung, M.D.</td>
<td>Participants: Steven Daviss, M.D., Jerald Block, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 26</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 150B, Level One, Washington Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fibromyalgia: Current Understanding and Future Directions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-Chps.: Alan Z. Manevitz, M.D., James Halper, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 27</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 151A, Level One, Washington Convention Center</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mid-to-Late Life Onset of Substance Use Disorders: Risk, Diagnosis, and Evidence-Based Treatment in an Ethno-Culturally Diverse Population</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-Chps.: Neeraj Gandotra, M.D., Louis A Trevisan, M.D.</td>
<td>Participants: Neeraj Gandotra M.D., Lily Arora M.D., Zinaida Boutaeva M.D., Denis Drubetskayi M.D., Raquel Lugo, M.D., Sergio Yero, M.D.</td>
<td></td>
</tr>
<tr>
<td>ISSUE WORKSHOP 28</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>ISSUE WORKSHOP 34</td>
</tr>
<tr>
<td>-------------------</td>
<td>---------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td><strong>Room 151B, Level One, Washington Convention Center</strong></td>
<td><strong>Room 160, Level One, Washington Convention Center</strong></td>
<td></td>
</tr>
<tr>
<td><strong>SEXUAL HISTORY: THE ART AND THE SCIENCE</strong></td>
<td><strong>PATHOLOGICAL GAMBLING IN SPECIAL POPULATIONS: MILITARY, PSYCHIATRIC CO-MORBIDITIES, AND INDIVIDUALS WITH INTELLECTUAL DISABILITY</strong></td>
<td></td>
</tr>
<tr>
<td>Chp.: Waguih W. IsHak, M.D.</td>
<td>Chp.: Lesley R. Dickson, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: Norana Caivano, M.D., Eugene Lee, M.D.</td>
<td>Participants: Coni Kalinowski, M.D., Zeba Hafeez, M.D., Rena Nora, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 29</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>ISSUE WORKSHOP 35</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Room 152A, Level One, Washington Convention Center</strong></td>
<td><strong>Room 201, Level Two, Washington Convention Center</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>THE MAN WHO CAN'T STOP SWALLOWING SHARP OBJECTS: MEDICAL ETHICS AND MANAGEMENT LIMITATIONS IN PATIENTS WITH CHRONIC FACTITIOUS DISORDER</strong></td>
<td><strong>HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE: PART 1</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-Chps.: Kahlil A. Johnson, M.D., Anton C. Trinidad, M.D.</td>
<td>Chp.: William E. Callahan, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants:</td>
<td>Participants: Martin Tracy, J.D., Marynell Hinton, Keith Young M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 30</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Room 152B, Level One, Washington Convention Center</strong></td>
<td></td>
</tr>
<tr>
<td><strong>LEADERSHIP DEVELOPMENT FOR EARLY CAREER WOMEN: FULFILLING YOUR DREAMS AND ASPIRATIONS</strong></td>
<td></td>
</tr>
<tr>
<td>Co-Chps.: Roslyn Seligman, M.D., June A. Powell, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 31</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Room 153, Level One, Washington Convention Center</strong></td>
<td></td>
</tr>
<tr>
<td><strong>THE DESIGN AND RENOVATION OF THERAPEUTIC SPACE IN AN OVERREGULATED AND UNDERFUNDED WORLD</strong></td>
<td></td>
</tr>
<tr>
<td>Chp.: Virginia L. Susman, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: Jaques Black, Philip Wilner M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 32</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Room 157, Level One, Washington Convention Center</strong></td>
<td></td>
</tr>
<tr>
<td><strong>BUILDING THE BRIDGES: REACHING THE SOUTH ASIAN COMMUNITY THROUGH RESEARCH AND EDUCATION</strong></td>
<td></td>
</tr>
<tr>
<td>Indo-American Psychiatric Association</td>
<td></td>
</tr>
<tr>
<td>Co-Chps.: Vani Rao, M.D., Geetha Jayaram, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participant: Sunil Khushalani, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUE WORKSHOP 33</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Room 158A/B, Level One, Washington Convention Center</strong></td>
<td></td>
</tr>
<tr>
<td><strong>THE SPECIAL UTILITY OF STANDARDIZED PATIENTS IN THE PSYCHIATRIC TRAINING OF INTERNATIONAL MEDICAL GRADUATES</strong></td>
<td></td>
</tr>
<tr>
<td>Co-Chps.: Jacob E. Sperber, M.D., Nyapati R. Rao, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participant: Anthony Errichetti, Ph.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSUES 28-34</th>
<th>9:00 a.m.-12:30 p.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ballroom C, Level Three, Washington Convention Center</strong></td>
<td></td>
</tr>
<tr>
<td><strong>ADVANCES IN (APPI SERIES) 2</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Current and Future Treatments for Non-Alzheimer’s Dementia</strong></td>
<td></td>
</tr>
<tr>
<td>Steven I. Dubovsky, M.D.</td>
<td></td>
</tr>
<tr>
<td><strong>Pharmacological and Psychological Treatments for the Component Symptoms of Schizophrenia</strong></td>
<td></td>
</tr>
<tr>
<td>Carol A. Tamminga, M.D.</td>
<td></td>
</tr>
<tr>
<td>Bryna Siegel, Ph.D.</td>
<td></td>
</tr>
<tr>
<td><strong>Advances in Treatment of Borderline Personality Disorder</strong></td>
<td></td>
</tr>
<tr>
<td>John G. Gunderson, M.D.</td>
<td></td>
</tr>
<tr>
<td><strong>Psychotherapy of Depression: An Update</strong></td>
<td></td>
</tr>
<tr>
<td>Michael E. Thase, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MEDIA WORKSHOP 3</th>
<th>9:00 a.m.-12 noon</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Room 140A, Level One, Washington Convention Center</strong></td>
<td></td>
</tr>
<tr>
<td><strong>GHOSTS OF ABU GHRAIB</strong></td>
<td></td>
</tr>
<tr>
<td>Chp.: David Rothstein, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: Stephen Xenakis, A.B., Jerrold Post, M.D.</td>
<td></td>
</tr>
</tbody>
</table>
MEDIA WORKSHOP 4  9:00 a.m.-12 noon
Room 140B, Level One, Washington Convention Center

ADDITION AND SEX: “SPUN” OUT OF CONTROL
APA Corresponding Committee on Treatment Services for Patients With Addictive Disorders
Chp.: Petros Levounis, M.D.
Co-Chp.: Jose Vito, M.D.
Participants: Steven Lee, M.D., Christopher Welsh, M.D.,
Marjorie Waldbaum, M.D., Sean Chappin, M.D., Cathy Cerullo

SYMPOSIA 26-27

SYMPOSIUM 26  9:00 a.m.-12:00 noon
Room 145A, Level One, Washington Convention Center

GENOMIC INVESTIGATIONS OF MOOD DISORDERS
Chp.: William E. Bunney, M.D.

A  Gene Expression in Limbic Thalamus and Cerebral Cortex in Mood Disorders
Edward G. Jones, M.D., Ph.D.

B  Biologic Intermediate Phenotypes for Major Depression and Suicidal Behavior
John J. Mann, M.D.

C  Genome-Wide Association Studies of Mood Disorders
Francis McMahon, M.D.

D  A New Integrative Strategy for the Investigation of Genetics and Imaging in Mood Disorder Patients
Steven G. Potkin, M.D., Jessica A. Turner, Ph.D., James Fallon, Ph.D., Guia Guffanti, Ph.D., David B. Keator, M.S.,
Anita Lakatos, M.D., Ph.D., Fabio Macciardi, M.D., Ph.D.

E  Expression Profiling in Mood Disorders Signaling and Metabolic Pathways
Stanley J. Watson, M.D.

Discussants: Francis McMahon, M.D., Steven Potkin, M.D.,
John J. Mann, M.D., Edward Jones, M.D., Stanley Watson, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 27  9:00 a.m.-12:00 noon
Room 145B, Level One, Washington Convention Center

THE VASCULAR DEPRESSION HYPOTHESIS: NEW FINDINGS TEN YEARS LATER
Chp.: George S. Alexopoulos, M.D.

A  Alterations in Functional Connectivity in Vascular Depression

B  Fronto-Striato-Limbic Abnormalities Linked to Late-Life Depression and to Treatment Resistance
George S. Alexopoulos, M.D., Faith Gunning-Dixon, Ph.D.,
Christopher Murphy, Ph.D., Matt Hopman, Ph.D., Kelvin O. Lim, M.D., John Foxe, Ph.D.

C  Repetitive Transcranial Magnetic Stimulation and Vascular Depression
Robert G. Robinson, M.D., Ricardo E. Jorge, M.D.,
David J. Moser, Ph.D.

D  The Role of Vascular Depression in Cognitive Decline and Dementia
David C. Steffens, M.D.

E  Support for the Vascular Depression Hypothesis: Neuropsychological and Neuroimaging Findings From a Prospective Treatment Trial in LLD
Yvette I. Sheline, M.D., Carl Pieper, Ph.D., Deanna M. Barch, Ph.D., Kathleen Welsh-Boehmer, Ph.D., Robert C. McKinstry, M.D., James R. McFall, M.D., Keith Garcia, M.D., Kenneth Ginsing, M.D., Ranga R. Krishnan, M.D.,
P. Murali Doraiswamy, M.D.

Discussants: George S. Alexopoulos, M.D., Howard J. Aizenstein, M.D., Yvette I. Sheline, M.D., Robert G. Robinson, M.D., David C. Steffens, M.D.
THIS SESSION WILL BE AUDIOTAPED.

COURSES 66-72
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 66  9:00 a.m.-4:00 p.m.
Room 2, Meeting Room Level, Renaissance Washington

BASIC CONCEPTS IN ADMINISTRATIVE PSYCHIATRY I

Co-Directors: Barry K. Herman, M.D., Arthur L. Lazarus, M.D.
Faculty: I. Mark Russakoff, M.D., Shivkumar S. Hatti, M.D.,
Stuart B. Silver, M.D., Sy A. Saeed, M.D.

COURSE 67  9:00 a.m.-4:00 p.m.
Room 3, Meeting Room Level, Renaissance Washington

GOING FROM THE BIO-BIO MODEL FORWARD TO BIO-PSYCHO-SOCIAL REASONING

Director: Paul R. McHugh, M.D
Faculty: Alan J. Romanoski, M.D., M.P.H., Glenn J. Treisman, M.D., Ph.D.
COURSE 68 9:00 a.m.-4:00 p.m.  
Room 4, Meeting Room Level, Renaissance Washington  
A PSYCHODYNAMIC APPROACH TO TREATMENT-RESISTANT MOOD DISORDERS: BREAKING THROUGH COMPLEX COMORBID TREATMENT RESISTANCE BY FOCUSING ON AXIS II  
Director: Eric M. Plakun, M.D.  
Faculty: David L. Mintz, M.D., Edward R. Shapiro, M.D.  

COURSE 69 9:00 a.m.-4:00 p.m.  
Room 13, Meeting Room Level, Renaissance Washington  
PERSONNEL MANAGEMENT FOR CLINICIAN-ADMINISTRATORS  
Director: Stephen M. Soltys, M.D.  
Faculty: Joseph J. Parks, M.D., Kay H. Titchenal, S.P.H.R., Alan Q. Radke, M.D.  

COURSE 70 9:00 a.m.-4:00 p.m.  
Room 14, Meeting Room Level, Renaissance Washington  
CHILD AND ADOLESCENT PSYCHIATRY FOR THE GENERAL PSYCHIATRIST  
Co-Directors: Robert L. Hendren, D.O., Malia A. McCarthy, M.D.  

COURSE 71 9:00 a.m.-4:00 p.m.  
Room 15, Meeting Room Level, Renaissance Washington  
ACHIEVING PSYCHOTHERAPY EFFECTIVENESS: PRACTICAL APPROACHES FOR CLINICIANS  
Co-Directors: Paula Ravitz, M.D., Molyn Leszcz, M.D.  
Faculty: Jon Hunter, M.D., Nancy L. McNaughton, M.Ed.  

COURSE 72 9:00 a.m.-4:00 p.m.  
Congressional Hall A, Ballroom Level, Renaissance Washington  
THE WAY OF YOGA AND HERBS AND NUTRIENTS IN THE TREATMENT OF DEPRESSION, ANXIETY, PTSD, COGNITIVE DYSFUNCTION, ADHD, AND SEXUAL DYSFUNCTION  
Co-Directors: Richard P. Brown, M.D., Patricia L. Gerbarg, M.D.  

THE IMPLICATIONS OF THE CURRENT INSOLUBILITY OF THE MIND-BRAIN PROBLEM FOR THE CONTEMPORARY PRACTICE OF PSYCHIATRY  
Chp.: Richard D. Chessick, M.D.  

11:00 a.m. Sessions  
LECTURES 16-19  
LECTURE 16  
Room 102 A/B, Level One, Washington Convention Center  
11:00 a.m.-12:30 p.m.  
E. Cameron Ritchie, M.D.  
PSYCHOLOGICAL EFFECTS OF WAR: FROM THE BATTLEFRONT TO THE HOME FRONT AND BACK AGAIN  
Chp.: Leah J. Dickstein, M.D.  
Co-Chp.: Christine E. Marx, M.D.  

COL Ritchie is currently the psychiatry consultant to the US Army Surgeon General and Director of the Propensity of Behavioral Health. She trained at Harvard, George Washington, Walter Reed, and the Uniformed Services University of the Health Sciences. Her assignments and other missions have taken her to Korea, Somalia, Iraq, and Vietnam. An internationally recognized expert, she brings a unique public health approach to the management of disaster and combat mental health issues. She has published numerous articles on forensic, disaster, and military operational psychiatry. In 2005 she received the William Porter and Bruno Lima awards. Her textbook, “Mental Health Interventions for Mass Violence and Disaster” was recently published by Guilford Press. Military Medicine published her supplement on Humanitarian Assistance and Health Diplomacy: Military-Civilian Partnership in the 2004 Tsunami Aftermath. She is currently the senior editor on a forthcoming text on Combat and Operational Mental Health.  
Marian I. (Mimi) Butterfield's Distinguished Psychiatrist Lecture Series  
THIS SESSION WILL BE AUDIOTAPED.  

9:30 a.m. Sessions  
FORUM 6  
FORUM 6  
9:30 a.m.-11:00 a.m.  
Room 146C/B, Level One, Washington Convention Center
PTSD AND TRAUMATIC STRESS: FROM GENE TO POLICY, INDIVIDUAL TO COMMUNITY, AND TRAUMA TO DISASTER

Chp.: Donald M. Hilty, M.D.
Co-Chp.: Robert W. Guynn, M.D.

Robert J. Ursano, M.D. is Professor and Chairman of the Department of Psychiatry at the Uniformed Services University School of Medicine, our nation’s only federal medical school. He is also Director of the Center for the Study of Traumatic Stress. Dr. Ursano is one of the world’s leaders in research and public health planning and policy development for psychological and behavioral effects of trauma, disasters, terrorism, and bioterrorism in particular. His research and publications on the effects of traumatic events on individuals and groups are widely recognized as having made fundamental contributions to our understanding of the distress and illness that can result from trauma, disasters, and terrorism. He is noted for bringing individual and public health issues together on critical issues. Dr. Ursano and his team have been lead collaborators and advisors in times of disaster to WHO, National Academy of Science Institute of Medicine, U.S Capitol, Department of Defense, corporations and businesses and numerous state and local agencies. His Textbook of Disaster Psychiatry (Cambridge University Press), was recently released and is the first textbook ever published on the topic. In addition Dr. Ursano is Editor in Chief of the distinguished psychiatric journal, Psychiatry: Interpersonal and Biological Processes, founded by Harry Stack Sullivan.

Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 17
11:00 a.m.-12:30 p.m.
Room 143 A/B/C, Level One
Washington Convention Center

Robert Ursano, M.D.

APA'S VESTERMARK AWARD LECTURE

Ronald D. Rieder, M.D.

What is Wrong With Our Patients?

Chp.: Frederick G. Guggenheim, M.D.

Ronald O. Rieder, M.D., has been a Director of Residency Education for the past 29 years, first at Columbia University and now at Mount Sinai School of Medicine. On the national level, he has been President of the Association of Directors of Psychiatric Residency Training, and Founding Chair of the Committee on Research Training of the APA. Dr. Rieder received his undergraduate and medical education at Harvard. His internship was at Johns Hopkins, and his psychiatric residency training at Albert Einstein. He then did a research fellowship in the Intramural Research Program of NIMH, working with Drs. David Rosenthal and Paul Wender. He remained at NIMH for six years as a Research Psychiatrist, and chaired education initiatives in the intramural program and the NIH’s Foundation for Advanced Education in the Sciences. His research focused on schizophrenia, including genetic and brain imaging studies. Dr. Rieder’s research background was unusual for those involved in residency training, and led to his focus on integrating neuroscience and research into the curricula for psychiatric trainees. At Columbia he developed NIMH-funded research fellowships and medical student research programs. For residents he initiated “neurobiological formulations” that related brain imaging and neuropsychological findings to clinical symptomatology.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSIONS 9-17

SCIENTIFIC AND CLINICAL REPORT SESSION 9
11:00 a.m.-12:30 p.m.
Room 101, Level One, Washington Convention Center

THE INTERNET AND PSYCHIATRY

Chp.: Dan Cotoman, M.D.

11:00 a.m.
25 Clinical Encounters With Internet Pornography
Thomas Kalman, M.D.

11:30 a.m.
26 Cybersuicide: "Pro" and "How to" Suicide Information on the Web
Patricia R. Recupero, M.D., J.D., Samara E. Harms, B.A., Jeffrey M. Noble, B.A.

12 noon
27 Self-Exploration and Identity Negotiation on the Internet
Lydia Sit, M.D.

THIS SESSION WILL NOT BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 10
11:00 a.m.-12:30 p.m.
Room 103A/B, Level One, Washington Convention Center

ALCOHOL AND CANNABIS DEPENDENCE

Chp.: Meera Vaswani, Ph.D.

11:00 a.m.
28 Long-Term Safety and Tolerability of Extended-Release Naltrexone in Alcohol- and/or Opioid-Dependent Patients: A Randomized, Active-Controlled Study
Kyle Kampman, M.D., Irina Gromov, M.D., Ph.D., Alan Sirota, M.D., Ph.D., Bernard Silverman, M.D., Xinjian Qiao, Sc.D., David R. Gastfriend, M.D.
11:30 a.m.
29 Integrated Group Therapy for Patients With Bipolar Disorder and Substance Dependence Can Be Successfully Delivered by Drug Counselors
Roger Weiss, M.D., Margaret L. Griffin, Ph.D., William B. Jaffee, Ph.D., Rachel E. Bender, B.A., Fiona Graff, B.A., Robert J. Gallop, Ph.D.

12 noon
30 Cannabis Withdrawal in Non-Treatment-Seeking Adult Cannabis Users
David Gorelick, M.D., Kenneth H. Levin, B.A., Marc L. Copersino, Ph.D., Stephen J. Heishman, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 11
11:00 a.m.-12:30 p.m.
Room 142, Level One, Washington Convention Center

GERIATRIC PSYCHIATRY
Chp.: Daniel P. Chapman, Ph.D.

11:00 a.m.
31 Association Between Frontal Lobe Cognitive and Executive Functions and Domains of Depressive Symptoms in Early Post-Stroke Patients
Matildes Sobreiro, Psy.D., Kátia O. Pinto, Ph.D., Luisa Terroni, M.D., Mara C. De Lucia, Ph.D., Gisela Tinone, Ph.D., Dan V. Iosifescu, M.D., Renêrio Fráguas, Ph.D., Milberto Scaf, Ph.D.

11:30 a.m.
32 Poor Sleep Quality Independently Predicts Depression in Community-Dwelling Older Adults
Hyong Cho, M.D., Michael R. Irwin, M.D.

12 noon
33 Feasibility and Effectiveness of Telemedicine for Psychiatric Consultation to Chinese Immigrants in a Nursing Home
Albert Yeung, M.D., Wan-Chen Claire Weng, Daniel Johnson, B.A., Maurizio Fava, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 12
11:00 a.m.-12:30 p.m.

WITHDRAWN

SCIENTIFIC AND CLINICAL REPORT SESSION 13
11:00 a.m.-12:30 p.m.
Room 150A, Level One, Washington Convention Center

ADULT BEHAVIORAL AND PERSONALITY DISORDERS

11:00 a.m.
36 Factor Structure and Diagnostic Efficiency of DSM-IV Criteria for Avoidant Personality Disorder in Hispanic Men and Women with Substance Use Disorders
Daniel Becker, M.D., Luis Miguel Añez, Psy.D., Manuel Paris, Psy.D., Luis Bedregal, Ph.D., Carlos M. Grilo, Ph.D.

11:30 a.m.
37 Tattoos and Antisocial Personality Disorder
William Cardasis, M.D., Alissa Huth-Bocks, Ph.D., Kenneth R. Silk, M.D.

12 noon
38 Results From A Randomized, Control Trial of an Integrated Treatment for Comorbid Anger and Gambling Problems
Lorne Korman, Ph.D., Jane Collins, B.Sc.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 14
11:00 a.m.-12:30 p.m.
Room 150B, Level One, Washington Convention Center

ANTIPSYCHOTIC MEDICATIONS IN BIPOLAR DISORDER AND SCHIZOPHRENIA

11:00 a.m.
39 Atypical Antipsychotic Agents, Neurocognitive Deficits, and Aggression in Schizophrenic Patients
Menahem Krakowski, M.D., Pal Czobor, Ph.D., Karen Nolan, Ph.D.

11:30 a.m.
40 Comparison of Intramuscular Ziprasidone, Olanzapine, or Aripiprazole for Agitation: A Quantitative Review of Efficacy and Safety
Leslie Citrome, M.D.,

12 noon
41 Gender-Specific Patterns in NMS Symptoms
Zack Cernovsky, Ph.D., Varadaraj Velamoor, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 15
11:00 a.m.-12:30 p.m.
Room 151A, Level One, Washington Convention Center

PSYCHOPHARMACOLOGY OF MOOD DISORDERS

11:00 a.m.
42 Quetiapine As Maintenance Therapy in Bipolar I Disorder
Trisha Suppes, M.D., Eduard Vieta, MD

11:30 a.m.
43 Efficacy of Desvenlafaxine Succinate 50 mg/d and 100 mg/d: Results From Two Placebo-Controlled, Fixed-Dose Studies in Depressed Outpatients
Michael Liebowitz, M.D., Stuart Montgomery, M.D., FRCPsych, Patrice Boyer, M.D., Ph.D., Amy L. Manley, Sudharshan K. Padmanabhan, Raj Tummala, M.D., Jean-Michel Germani, Ph.D., Claudine Brisard, M.D., Karen A. Tourian, M.D.

(Continued next page)
12 noon
44 Asenapine in Bipolar Disorder: An Overview of Clinical Trials in the Olympia Program
Roger McIntyre, M.D., Robert Hirschfeld, M.D., Joseph Calabrese, M.D., John Panagides, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 16
11:00 a.m.-12:30 p.m.
Room 151B, Level One, Washington Convention Center

CONSULTATION-LIAISON AND EMERGENCY PSYCHIATRY

11:00 a.m.
45 Depression and Subjective Incompetence as Separate Components of Demoralization
John de Figueiredo, M.D., Cheryl A. Cockram, Ph.D., John M. de Figueiredo, MD, Sc.D., Gheorghe Doros, Ph.D.

46 Influence of Depressive and Anxiety Symptoms on Survival in Patients With End-Stage Renal Disease
Klaas-jan Nauta, M.D., Robert Riezebos, M.D., Carl Siegert, M.D., Ph.D., Adriaan Honig, M.D., Ph.D.

12 noon
47 Psychiatric Emergencies on an Obstetrics Service: Agitation From Unrecognized Posttraumatic Stress Disorder Triggered by Routine Hospital Care
Anjuli Jindal, M.D., Lydia Sit, M.D., James L. Griffith, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 17
11:00 a.m.-12:30 p.m.
Room 152A, Level One, Washington Convention Center

ANXIETY SYNDROMES AND DISORDERS

Chp.: Derya Iren Akbiyik, M.D., Ph.D.

11:00 a.m.
48 Social Anxiety and Functional Impairment in Patients Seeking Surgical Evaluation for Hyperhidrosis
Franklin Schneier, M.D., Lyall Gorenstein, M.D., Catherine Whitman, B.A.

11:30 a.m.
49 Tapering Out Clonazepam in Panic Disorder Patients After at Least Three Years of Treatment
Antonio Nardi, M.D., Fabiana L. Lopes, M.D., Rafael C. Freire, M.D., Alexandre M. Valença, M.D., Isabella Nascimento, M.D., Valfrido I. de-Melo-Neto, M.D., André B. Veras, M.D., Arabella Rassi, M.D., Gastão L. Soares-Filho, M.D., Marco A. Mezzasalma, M.D., Anna Lucia King, Psy.D., Marcio Versiani, M.D.

12 noon
50 Evidence for the Existence of a Temporal Sequence In Comorbid Obsessive-Compulsive Disorder and Schizophrenia: Which Comes First?
Kavi Devulapalli, B.A., Henry A. Nasrallah M.D., Jeffrey A. Welge Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SMALL INTERACTIVE SESSIONS 10-12
11:00 a.m.-12:30 p.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

10 Robert Liberman, M.D., on Recovery from Disability: Rehabilitation is the Mission (Meet the Author)
Room 304, Level Three, Washington Convention Center

11 Thomas Insel, M.D., on Research in Mental Health
Room 305, Level Three, Washington Convention Center

12 David Mrazek, M.D., on Clinical Aspects of Genetics and Genomics
Room 306, Level Three, Washington Convention Center

ADVANCES IN MEDICINE 2
11:00 a.m.-12:30 noon
Room 147 A, Level One, Washington Convention Center

TRAUMATIC BRAIN INJURY: THE SILENT EPIDEMIC

Chp.: Julio Licinio, M.D.
Presenter: Ross Bullock, M.D.
THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 34-39

COMPONENT WORKSHOP 34 11:00 a.m.-12:30 p.m.
Room 141, Level One, Washington Convention Center

CAREER ADVANCEMENT IN ACADEMIC IN ACADEMIC PSYCHIATRY FOR EARLY CAREER PSYCHIATRISTS
APA Assembly Committee of Early Career Psychiatrists

Co-Chps.: Marina Goldman, M.D., Elisabeth J. Kunkel, M.D.
Participants: Michael Vergare, M.D., Michelle Riba, M.D., Kenneth Certa, M.D.

COMPONENT WORKSHOP 35 11:00 a.m.-12:30 p.m.
Room 148, Level One, Washington Convention Center

THE ROLE OF THE PSYCHIATRIST IN PALLIATIVE AND END-OF-LIFE CARE
APA Committee on Access and Effectiveness of Psychiatric Services for the Elderly

Co-Chps.: David A. Casey, M.D., Lina Shihabuddin, M.D.
Participants: Keith R. Stowell, M.D., Colleen Northcott, Ph.D., Mercedes Rodriguez-Suarez, M.D., Benjamin Woo, M.D.
COMPONENT WORKSHOP 36  11:00 a.m.-12:30 p.m.
Room 154A/B, Level One, Washington Convention Center

REACHING OUT: APPROACHES TO SUICIDE AMONGST THE PHYSICIAN POPULATION
APA Corresponding Committee on Physician Health, Illness, and Impairment

Chp.: Malkah T. Notman, M.D.
Participants: Derek Puddester, M.D., Penelope Ziegler, M.D.,
Michael Myers, M.D.

COMPONENT WORKSHOP 37  11:00 a.m.-12:30 p.m.
Room 155, Level One, Washington Convention Center

SHOULD WE HAVE A V-CODE FOR RESPONSE TO MILITARY OPERATIONAL STRESS?
APA Lifers

Co-Chps.: Sheila Hafter Gray, M.D., Edward Hanin, M.D.
Participants: Aaron Haney, M.D., Harold Kudler, M.D.,
Charles Hoge, M.D.

COMPONENT WORKSHOP 38  11:00 a.m.-12:30 p.m.
Room 156, Level One, Washington Convention Center

LANGUAGE ACCESS IN HEALTH CARE: CHALLENGES AND INITIATIVES FOR PSYCHIATRY
APA Council on Minority Mental Health and Health Disparities

Co-Chps.: Francis G. Lu, M.D., Andres J. Pumariega, M.D.
Participants: Mara Youdelman, J.D., Sandra Walker, M.D.,
Annelle Primm M.D.

COMPONENT WORKSHOP 39  11:00 a.m.-12:30 p.m.
Room 160, Level One, Washington Convention Center

BREAKING BARRIERS: EMPOWERING PROVIDERS AND PATIENTS
APA/SAMHSA Minority Fellows

Co-Chps.: Eugene Lee, M.D., Otis Anderson, III, M.D.
Participants: Russell Lim, M.D., Shirley Liu, B.A., Jimmark
Aboener, M.D., Aeva Gaymon-Doones, M.D., Helen Witte,
M.D., Karinn Glover, M.D., Alexander Huang, M.D.

ISSUES 36-44

ISSUE WORKSHOP 36  11:00 a.m.-12:30 p.m.
Room 144C, Level One, Washington Convention Center

TO WORK OR NOT TO WORK: WHAT IS THE QUESTION?
APA Corresponding Committee on Psychiatry in the Workplace

Chp.: Andrea Stolar, M.D.
Participants: Marie-Claude Rigaud, M.D., Marcia Scott, M.D.,
Marilyn Price, M.D.

ISSUE WORKSHOP 37  11:00 a.m.-12:30 p.m.
Room 152B, Level One, Washington Convention Center

QUALITY OF LIFE OF PATIENTS WITH MAJOR DEPRESSION IN A NATURAL CLINICAL SETTING

Co-Chps.: Waguih W. IsHak, M.D., Mark H. Rapaport, M.D.

ISSUE WORKSHOP 38  11:00 a.m.-12:30 p.m.
Room 153, Level One, Washington Convention Center

REDUCING SUICIDE RISK IN A SMALL COMMUNITY: A PROJECT UPDATE

Chp.: Alex N. Sabo, M.D.
Participants: Sharon Mozian, M.D., Brenda Bahnson, M.S.W.

ISSUE WORKSHOP 39  11:00 a.m.-12:30 p.m.
Room 157, Level One, Washington Convention Center

FAMILY-INCLUSIVE TREATMENT FOR BIPOLAR DISORDER: HAS THE TIME ARRIVED FOR FAMILY PSYCHIATRIST?

Co-Chps.: Igor Galynker, M.D., Susan Tross, Ph.D.
Participants: Allison Lee, M.D., Philip Yanowitch, M.D.

ISSUE WORKSHOP 40  11:00 a.m.-12:30 p.m.
Room 158A/B, Level One, Washington Convention Center

COGNITIVE AND BEHAVIORAL TECHNIQUES TO IMPROVE BRIEF PHARMACOTHERAPY SESSIONS

Chp.: Donna M. Sudak, M.D.
Participants: Judith Beck, Ph.D., Jesse Wright, M.D.

ISSUE WORKSHOP 41  11:00 a.m.-12:30 p.m.
Room 159A/B, Level One, Washington Convention Center

METABOLIC SCREENING OF PATIENTS ON ANTIPSYCHOTIC MEDICATIONS: PROGRESS OF A QUALITY IMPROVEMENT PROGRAM IN AN URBAN TRAINING CLINIC

Co-Chps.: Diane Gottlieb, M.D., April S. Ladavac, M.D.
Participants: Elizabeth Tien, M.D., Kathleen Diller, M.D.,
Shaneek Johnson, M.D., Chioma Iheagwara, D.O.,
Neil Sanuck, M.D.

ISSUE WORKSHOP 42  11:00 a.m.-12:30 p.m.
Room 201, Level Two, Washington Convention Center

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE: PART 2

Co-Chps.: William E. Callahan, M.D., Keith W. Young, M.D.
Participants: Tracy Gordy, M.D., Chester Schmidt, M.D.
TUESDAY

ISSUE WORKSHOP 43 11:00 a.m.-12:30 p.m.
Room 207A, Level Two, Washington Convention Center

THE THEORY AND UTILIZATION OF YOGA AND MEDITATION AS IT RELATES TO WELL BEING, HUMAN RELATIONSHIPS, AND GLOBAL SOCIETY

Co-Chps.: Norana I. Caivano, M.D., Karl Goodkin, M.D.
Participant: Tara Klein, M.D.

ISSUE WORKSHOP 44 11:00 a.m.-12:30 p.m.
Room 207B, Level Two, Washington Convention Center

IMPLEMENTING A COGNITIVE THERAPY FOR PSYCHOSIS PROGRAM IN THE USA: CHALLENGES AND REWARDS

Chp.: Page Burkholder, M.D.
Participants: Peter Weiden, M.D., David Kingdom, M.D., Yulia Landa, Psy.D.

FORUMS 7-8

FORUM 7
11:00 a.m.-12:30 p.m.
Room 147 B, Level One, Washington Convention Center

CAREER DEVELOPMENT IN ACADEMIC PSYCHIATRY: SO WHAT'S AN OFFER FOR ME?

Chp.: Peter F. Buckley, M.D.

FORUM 8
11:00 a.m.-12:30 p.m.
Room 149A/B, Level One, Washington Convention Center

SUPPORTING MILITARY MEMBERS AND THEIR FAMILIES DURING TIMES OF WAR: NEEDS, CHALLENGES, AND OPPORTUNITIES

Chp.: David M. Benedek, M.D.

12:00 noon Sessions

FORUMS 9-10

FORUM 9
12 noon-1:30 p.m.
Room 144A/B, Level One, Washington Convention Center

PHARMACOLOGICAL PERSPECTIVES AMONG UNITED STATES ETHNIC MINORITIES

Chp.: Pedro Ruiz, M.D.
Presenters: William Lawson, M.D., Edmond Pi, M.D., Tarek Okasha, M.D.

FORUM 10
12 noon-1:30 p.m.
Room 146C, Level One, Washington Convention Center

READY OR NOT-COMING SOON TO A DESKTOP NEAR YOU: PSYCHIATRY AND INFORMATION

Chp.: Robert Kolodner, M.D.
Presenters: Steven Altchuler, M.D., Karen Bell, M.D., John Boronow, M.D., Sarah Wattenberg, M.S.W.

NEW RESEARCH POSTER SESSION 4: SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS

12 noon-2:00 p.m.
West Lobby, Level One, Washington Convention Center

For further information on New Research submissions, please refer to the New Research Program Book included in your registration packet.

1:00 p.m Sessions

COURSES 73-78

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 73 1:00 p.m.-5:00 p.m.
Rooms 8/9, Meeting Room Level, Renaissance Washington

MELATONIN AND LIGHT TREATMENT OF SAD, SLEEP, AND OTHER BODY CLOCK DISORDERS

Director: Alfred J. Lewy, M.D.

COURSE 74 1:00 p.m.-5:00 p.m.
Room 10/11, Meeting Room Level, Renaissance Washington

CHILD MURDER BY PARENTS

Director: Phillip J. Resnick, M.D.

COURSE 75 1:00 p.m.-5:00 p.m.
Room 12, Meeting Room Level, Renaissance Washington

A DEVELOPMENTAL APPROACH TO CONTEMPORARY ISSUES IN PSYCHOTHERAPY WITH GAY MEN

Director: Marshall Forstein, M.D.
Faculty: Robert M. Kertzner, M.D., Stewart L. Adelson, M.D., Jeffrey S. Akman, M.D.
COURSE 76  1:00 p.m.-5:00 p.m.
Room 16, Meeting Room Level, Renaissance Washington

MOTIVATIONAL THERAPY FOR INDIVIDUALS WITH CONCURRENT DISORDERS

Director: Arvinder K. Grewal, M.A., Shimi Kang, M.D.
Faculty: Jennifer Toomey, R.P.N., Linda J. Barker, M.S.W., Marilyn Herie, Ph.D., Shaohua Lu, M.D.

COURSE 77  1:00 p.m.-5:00 p.m.
Renassiance Ballroom West A, Ballroom Level, Renaissance Washington

ADVANCED ASSESSMENT AND TREATMENT OF ADD

Director: Thomas E. Brown, Ph.D.
Faculty: Jefferson B. Prince, M.D., Anthony Rostain, M.D.

COURSE 78  1:00 p.m.-5:00 p.m.
Congressional Hall B, Ballroom Level, Renaissance Washington

STREET DRUGS AND MENTAL DISORDERS: OVERVIEW AND TREATMENT

Director: John W. Tsuang, M.D.
Faculty: Karen Miotto, M.D., Timothy W. Fong, M.D., Stephen Ross, M.D.

2:00 p.m Session

LECTURES 19-22

LECTURE 19  
2:00 p.m.-3:30 p.m.
Room 103 A/B, Level One, Washington Convention Center

James H. Meadow-Woodruff, M.D.

SCHIZOPHRENIA AS A DISORDER OF RECEPTOR TRAFFICKING

Chp.: Christine Marx, M.D.

Dr. Meadow-Woodruff received his B.S. in Chemistry from the University of Richmond, and his M.D. from the Medical College of Virginia. He then moved to Ann Arbor, and completed a combined residency in psychiatry and a research fellowship at the University of Michigan. After completing his research training, he joined the faculty of the Department of Psychiatry and the Mental Health Research Institute at the University of Michigan. He left Michigan in April 2006 to become the Heman E. Drummond Professor and Chairman of the Department of Psychiatry of University of Alabama at Birmingham (UAB). His research has been continuously funded by NIH since 1989. His laboratory’s primary research interest is on understanding how different parts of the brain communicate with other parts via a variety of chemical signals, and how this communication is disrupted in schizophrenia. His current focus is on studying the expression of genes associated with glutamatergic neurotransmission within individual cells in the nervous system. He also has a longstanding interest in teaching and mentorship, including serving on the APA Corresponding Committee on Research Training, which he chaired in 2006; is a frequent faculty participant at the annual APA Research Colloquium for Junior Investigators; and was the director of the University of Michigan's Psychiatry residency research track, holding one of the first NIH grants designed to fund such programs. Nearly 100 trainees have rotated through his lab. He is Editor-in-Chief of the journal Neuropsychopharmacology.

Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 20  
2:00 p.m.-3:30 p.m.
Room 143 A/B/C, Level One, Washington Convention Center

Maria Oquendo, M.D.

Suicidal Behavior in Disorder: Risk Factors and Interventions

Chp.: David Baron, D.O.

Maria A. Oquendo, M.D. is Professor of Clinical Psychiatry at Columbia University and Vice-Chair for Education in the Department of Psychiatry at Columbia University and the New York State Psychiatric Institute (NYSPI). She is also Director of the Clinical Evaluation Core of the Silvio O. Conte Center for the Neurobiology of Mental Disorders at NYSPI. Her areas of expertise include the diagnosis, pharmacologic treatment, and neurobiology of bipolar disorder and major depression, with a special focus on suicidal behavior as well as cross cultural psychiatry. Dr. Oquendo graduated summa cum laude and Phi Beta Kappa from Tufts University in 1980. She received her M.D. from the College of Physicians and Surgeons at Columbia University in 1984. She completed her residency in Psychiatry at the Payne Whitney Psychiatric Clinic in the New York Hospital-Cornell Medical Center. Dr. Oquendo is the principal investigator on a high-risk study of suicide attempters with bipolar disorder and on a prospective study of suicidal behavior in patients with affective and psychotic disorders. She is also a co-investigator on four other NIMH-funded research studies examining the neurobiology of suicidal behavior. She is the Co-Principal Investigator on a Developing Center for Interventions to Prevent Suicide. She is the recipient of a grant from the American Foundation for Suicide Prevention for the study of serotonin transporter binding using PET in bipolar suicide attempters, non-attempters, and healthy volunteers. Dr. Oquendo teaches at Columbia University. Dr. Oquendo is a member of the American Psychiatric Association, the American College of Neuropsychopharmacology, the APA SAMHSA Fellowship and Selection Corresponding Committee, Group for the

(Continued next page)
Advancement of Psychiatry, Association of Women Psychiatrists, and the American Board of Psychiatry and Neurology, on which she also functions as an examiner. She is the president-elect of the American Society of Hispanic Psychiatry. She is an associate editor of the American Journal of Psychiatry and serves on the Scientific Advisory Council of the American Foundation for Suicide Prevention. She is a member of the NIMH scientific review committee, Interventions and Treatment of Mood and Anxiety Disorders (ITMA) responsible for providing peer review of applications for federally funded grants. She has authored or co-authored over 150 peer-reviewed articles, chapters, and editorials. She is the recipient of several awards including Exemplary Psychiatrist Award from the National Alliance for the Mentally Ill (1993); award from the National Alliance for the Mentally Ill for Commitment to Multicultural and Underserved Communities (2002); Travel Award from American Foundation for Suicide Prevention (2003); the Marian Butterfield Early Career Psychiatrist Award from the Association of Women Psychiatrists (2004); and the Gerald Klerman Award from the Depression and Bipolar Support Alliance (2005).

Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 21
2:00 p.m.-3:30 p.m.
Room 146 A/B, Level One,
Washington Convention Center

APA'S JUDD MARMOR AWARD LECTURE
Charles Nemeroff, M.D.

The Neurobiology of Child Abuse and Neglect: Implications for the Prevention and Treatment of Mood and Anxiety Disorders

Chp.: Stuart C. Yudofsky, M.D.

Dr. Nemeroff was born in New York City and educated in the New York City Public School System. After graduating from the City College of New York in 1970, he received a Master's degree in biology from Northeastern University in 1973, and his M.D. and Ph.D. (Neurobiology) degrees from the University of North Carolina at Chapel Hill. His residency training in psychiatry was conducted at both the University of North Carolina and at Duke University, after which he joined the faculty of Duke University. At Duke he was Professor of Psychiatry and Pharmacology and Chief of the Division of Biological Psychiatry before relocating in 1991 to Emory University School of Medicine in Atlanta, Georgia, where he is the Reunette W. Harris Professor and Chairman of the Department of Psychiatry and Behavioral Sciences. His research has concentrated on the biological basis of affective and anxiety disorders. In recent years he has begun to elucidate the neurobiological mechanisms that mediate the increased risk for depression and post traumatic stress disorder in victims of child abuse. Dr. Nemeroff has received numerous honors during his career, including the A.E. Bennett Award from the Society of Biological Psychiatry (1979) the Kempf Award in Psychobiology (1989), and the APA's Samuel Hibbs Award (1990), and the Gold Medal Award and the Research Prize (1996) from the Society of Biological Psychiatry. He was the recipient of the Gerald Klerman Award from the National Depressive and Manic-Depressive Disorders Association and the Selo Prize from the National Alliance for Research in Schizophrenia and Depression (1997). He has received the Research Award in Mood Disorders, the Bowis Award, and the Dean Award from the American College of Psychiatrists (ACP), the Menninger Prize (2000) from the American College of Physicians, the Research Award from the American Foundation for Suicide Prevention (AFSP) in 2001, and the Burlingame Prize from the Institute of Living (2002). In 2006 he received the APA Research Mentoring Award and the Vestermark Award. Dr. Nemeroff served as the Editor-in-Chief of Neuropsychopharmacology (2001-2006). With Alan F. Schatzberg, M.D., he is co-Editor of the Textbook of Psychopharmacology. He has served on the Mental Health Advisory Council of the NIMH. He is past President of the American College of Neuropsychopharmacology and the ACP. He is the current President of the AFSP. He is chair of the APA Committee on Research Training. In 2002 he was elected to membership in the Institute of Medicine of the National Academy of Sciences. He is the recipient of four research grants from the NIH and has published more than 875 research reports and reviews.

THIS SESSION WILL BE AUDIOTAPED.

PRESIDENTIAL SYMPOSIA 1-2

PRESIDENTIAL SYMPOSIUM 1
2:00 p.m.-5:00 p.m.
Room 152 A, Level One, Washington Convention Center

TODAY'S DYNAMIC PSYCHOTHERAPY: NOT YOUR GRANDPARENTS' PSYCHOANALYSIS

Chp.: Joseph P. Merlino, M.D.

A Dynamic Psychopharmacology: You ARE Doing Therapy
Cesar A. Alfonso, M.D.

B The “Y” Model: Integrated, Evidence-Based Teaching of Psychotherapy Competencies
Eric M. Plakun, M.D.

C Psychodynamics of Women’s Sexuality
Jennifer I. Downey, M.D

D Psychodynamics of Women's Sexuality
Richard C. Friedman

C Combining Psychotherapies: a Rational Approach to the Order of Operations
Sherry P Katz-Bearnot, M.D.

D Psychoanalyst: Internist of the Mind
Sylvia W. Olarte, M.D.

THIS SESSION WILL BE AUDIOTAPED.

58
TUESDAY

PRESIDENTIAL SYMPOSIUM 2
2:00 p.m.-5:00 p.m.
Room 152 B, Level One, Washington Convention Center

THE LAST 25 YEARS OF WOMEN IN PSYCHIATRY

Chp.: Tana A. Grady-Weliky, M.D.

A Women's Progress: Promises and Problems Revisited
Carolyn B. Robinowitz, M.D.

B The Challenge of Change: Perspectives on Family, Work, and Education in 1983, 2008, and 2033
Carol C. Nadelson, M.D.

C The Necessity of “New Ways of Working”
Sheila Hollins, M.B.

D Women as the Key to Integration and Wellness in Psychiatric Practice
Mary Jane England, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 28-49

SYMPOSIUM 28 2:00 p.m.-5:00 p.m.
Room 101, Level One, Washington Convention Center

CATATONIA: TREATMENT AND FUTURE RESEARCH

Chp.: Vincent R. Kirkhart, Ph.D.
Co-Chp.: Brendan T. Carroll, M.D.

A Katatonia- A New Conceptual Understanding of Catatonia and a New Rating Scale
Brendan T. Carroll, M.D., Rob Kirkhart, Ph.D., PA-C.

B Catatonia A NeuroPsychiatric Syndrome
Jose Ramirez, M.D., Jose Ramirez, M.D.
Rob Kirkhart, Ph.D., PA-C.

C Common Medical Complications Secondary to Catatonic States
Harold W. Goforth, M.D., Xavier Preud'homme, M.D., Sarah Rivelli, M.D.

D Pharmacotherapy of Catatonic Symptoms in Schizophrenia
Joseph W. Lee, M.D., Brendan Carroll, M.D., Rebecca A. Talbert, Pharm.D., Rob Kirkhart, Ph.D.

E Directions for Future Catatonia Research
William W. McDaniel, M.D., Brendan Carroll, M.D.
Rebecca Talbert, Pharm.D., Rob Kirkhart, Ph.D.

Discussants: Brendan Carroll M.D., Joseph W. Lee M.D., Jose Ramirez M.D., Harold Goforth M.D., William McDaniel, M.D.

SYMPOSIUM 29 2:00 p.m.-5:00 p.m.
Room 103A/B, Level One, Washington Convention Center

SCHOOL SHOOTINGS: THREAT RECOGNITION AND PREVENTION

Chp.: Jerald J. Block, M.D.

A Reassessing Columbine: Virtual and Real Rage
Jerald J. Block, M.D.

B Why Terrible Things Happen in Perfect Places
Katherine S. Newman, Ph.D.

C School Shootings and Threat Assessment
Terri E. Royster, B.S., Jerald J. Block, M.D., Katherine A. Newman, Ph.D., Terri E. Royster, M.A.

Discussants: Katherine Newman, Ph.D., Jerald Block, M.D., Terri Royster, B.S.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 30 2:00 p.m.-5:00 p.m.
Room 140A, Level One, Washington Convention Center

VIOLENCE IN MINORITY GROUPS: WHAT CAN BE DONE?

Chp.: Gail Robinson, M.D.
Co-Chp.: Stephen A. McLeod-Bryant, M.D.

A Violence Against Ourselves: Suicide Among Native American Youth
Brian T. Benton, M.D.

B Preventing Violence Against Women
Gail E. Robinson, M.D.

C Domestic Violence Among South Asians: An Example of Response of the Community
Jagannathan Srinivasaraghavan, M.D., Surinder Nand, M.D.

D The Epidemiology and Mental Health Consequences of Violence Against Lesbian, Gay, Bisexual, and Transgendered (LGBT) People
Philip A. Bialer, M.D.

E Violence in Black Youth
Rahn K. Bailey, M.D.

Discussants: Rahn Bailey, M.D., Philip A. Bialer, M.D., Jagannathan Srinivasaraghavan M.D., Gail E. Robinson, M.D., Brian T. Benton, M.D.

THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 31  2:00 p.m.-5:00 p.m.
Room 140B, Level One, Washington Convention Center

COMPARISON OF THREE PSYCHODYNAMIC TREATMENTS OF BORDERLINE PERSONALITY DISORDER

Chp.: Robert J. Gregory, M.D.

A  Mentalization Based Therapy (MBT) for Borderline Personality Disorder – Recent Developments
   Prof. Anthony W. Bateman, M.D., F.R.C.Psych.

B  Dynamic Deconstructive Psychotherapy: Neurocognitive Remediation for Treatment-Resistant Borderline PD
   Robert J. Gregory, M.D.

C  An Object Relations Treatment for Patients With Borderline Personality Disorder
   John F. Clarkin, Ph.D.

Discussants: John Oldham, M.D., Anthony Bateman, M.D., John F. Clarkin, Ph.D., Robert J. Gregory, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 32  2:00 p.m.-5:00 p.m.
Room 144A/B, Level One, Washington Convention Center

CHRONIC PAIN AND THE PRESCRIPTION OPIOID EPIDEMIC: WHY PSYCHIATRISTS MUST GET INVOLVED

Chp.: Alex N. Sabo, M.D.

A  Chronic Pain and the Prescription Opioid Epidemic: Why Psychiatrists Must Get Involved
   Alex N. Sabo, M.D., John Rogers, Esq, Jennifer Michaels, M.D., Ronald Hayden, M.D., John Harrington, Ph.D., Rocco Iannucci, M.D., Ann MacDonald

B  Safe and Effective Treatment for Chronic Pain: Combined Cognitive-Behavioral Therapy and Exercise
   John J. Harrington, Ph.D., Douglas Molin, M.D.

C  Positive Options and Preliminary Findings: Wraparound Buprenorphine Treatment, Chronic Pain, and Addiction
   Jennifer L. Michaels, M.D.

D  An Experiment in the Field: A Community-Based Pain Management Project in Berkshire County, Massachusetts
   John F. Rogers, Esq., Alex N. Sabo, M.D., Donald P. Burt, M.D.


Discussants: Alex Sabo, M.D., John Rogers, Esq., John Harrington, Ph.D., Jennifer Michaels, M.D., Nathaniel P. Katz, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 33  2:00 p.m.-5:00 p.m.
Room 144C, Level One, Washington Convention Center

MEN: POSTPARTUM DEPRESSION AND OTHER ISSUES RELATED TO CHILDBIRTH

Chp.: Thomas S. Newmark, M.D.

A  The Therapist's Entrance Into Fatherhood and its Impact on Psychotherapy
   April E. Fallon, Ph.D., Virginia Brabender, Ph.D., Mark Famador, M.D., Ryan Kuehner, M.A.

B  The Psychological Impact of Infertility and the Psychological Stress on Male Fertility
   Consuelo C. Cagande, M.D.

C  The Silent Partner: Depression in Fathers Postpartum and in Early Parenthood
   James F. Paulson, Ph.D.

D  Men and Peripartum, an Overview
   R. Rao Gogineni, M.D.

Discussants: Nada L. Stotland, M.D., Elisabeth Kunkel, M.D., R. Rao Gogineni M.D., James F. Paulson, Ph.D., Consuelo C. Cagande, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 34  2:00 p.m.-5:00 p.m.
Room 145A, Level One, Washington Convention Center

NEURODEVELOPMENT AND ITS RELEVANCE TO PSYCHIATRIC DISORDERS

Chp.: Jay N. Giedd, M.D.

A  Childhood-Onset Schizophrenia: Insights From Neuroimaging
   Nitin Gogtay, M.D.

B  Trajectories of Brain Development in Healthy Children and Adolescents
   Jay N. Giedd, M.D.

C  Imaging the Developing Brain In Autism
   Joseph Pivan, M.D.

D  Genes, Clinical Outcome and Neurodevelopment in ADHD
   Wallace Shaw, M.D.
Discussions: Joseph Pivan, M.D., Wallace Shaw, M.D.,
Jay N. Giedd, M.D., Nitin Gogtay, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 35 2:00 p.m.-5:00 p.m.
Room 145A, Level One, Washington Convention Center

RESEARCH ADVANCES: BRAIN MECHANISMS OF
BIPOLAR DISORDER AND MAJOR DEPRESSION

Chp.: Ellen Leibenluft, M.D.

A Neural Circuits Underlying the Pathophysiology of
Major Depressive Disorder
Wayne C. Drevets, M.D.

B Advances in Understanding the Brain Circuitry of
Bipolar Disorder
Hilary P. Blumberg, M.D., Fei Wang, M.D., Ph.D.; Jessica
H. Kalmar, Ph.D., Lara G. Chepenik, M.D., Ph.D.

C Brain Mechanisms Mediating Bipolar Disorder and
Severe Irritability in Youth
Ellen Leibenluft, M.D., Melissa Brotman, Ph.D., Brendan
Rich, Ph.D., Ken Towbin, M.D., Daniel Pine, M.D.

D Dysregulation of Stress-Regulated Neurotransmitter
Systems in Major Depression
Jon-Kar Zubieta, M.D.

Discussions: Jon-Kar Zubieta M.D., Wayne C. Drevets, M.D.,
Hilary P. Blumberg, M.D., Ellen Leibenluft, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 36 2:00 p.m.-5:00 p.m.
Room 146C, Level One, Washington Convention Center

HEALTH CARE FINANCING REFORM: THE GOOD,
THE BAD AND THE NECESSARY

Chp.: Leslie H. Gise, M.D.
Co-Chp.: Steven S. Sharfstein, M.D.

A 2008 Presidential Candidates’ Health Care Proposals:
An Analysis
Harvey Fernbach, M.D.

B Working Under a Universal Health Care Plan
Jon Davine, M.D., C.C.F.P., F.R.C.P.

C Overview and Principles of Health Care Financing
Reform: Who’s Afraid of Single-Payer?
Leslie H. Gise, M.D.

D Why Psychiatrists Should Advocate for Single Payer
Steven S. Sharfstein, M.D.

Discussions: Jim McDermott, M.D., James H. Seully, Jr., M.D., Leslie
H. Gise, M.D., Steven Sharfstein, M.D., Harvey Fernbach, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 37 2:00 p.m.-5:00 p.m.
Room 147A, Level One, Washington Convention Center

CHANGING CONCEPTIONS OF THE PERSONALITY
DISORDERS

Chp.: James H. Reich, M.D.

A Dimensional Personality Traits and Maladaptive
Outcomes
Paul T. Costa, Jr. Ph.D., Gerald Nestadt, M.D.

B The "Forgotten" Personality Disorders
Donald W. Black, M.D.

C State and Trait in Personality Disorders
James H. Reich, M.D.

D Changing Biological Conceptions of Personality
Disorders
Chandra Sekhar Sripada, M.D., Kenneth R. Silk, M.D.

E Categorical and Dimensional Models of Personality
Disorders: Toward Integration
Simone S. Kool, Ph.D., Robert A. Schoevers, Ph.D., M.D.

F Evolving Relationships Between Bipolar Disorder and
Borderline Personality Disorder
Terence A. Ketter, M.D., Po W. Wang, M.D., Jenifer L.
Culver, Ph.D.

Discussions: Peter Tyrer, M.D., Kenneth R. Silk M.D., James H.
Reich, M.D., Paul Costa, Ph.D., Simone Kool, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 38 2:00 p.m.-5:00 p.m.
Room 147B, Level One, Washington Convention Center

CHOOSING THE RIGHT TREATMENT FOR
SUBSTANCE ABUSE

Chp.: Herbert D. Kleber, M.D.

A Choosing the Right Treatment for Cocaine Dependence
Adam Bisaga, M.D.

B Psychosocial Interventions for Substance Dependence
and Common Principles for Promoting Behavior
Change
Ken Carpenter, Ph.D.

C Choosing Treatment for Cannabis Dependence
Frances R. Levin, M.D.

D Choosing the Right Treatment for Opioid Dependence
Herbert D. Kleber, M.D.

E Integrating Psychosocial Interventions With
Medications in the Treatment of Substance Dependence
Edward V. Nunes, M.D.
TUESDAY

**SYMPHOSIUM 39**
2:00 p.m.-5:00 p.m.
Room 149A/B, Level One, Washington Convention Center

**ANTIDEPRESSANTS IN BIPOLAR DISORDER: TOWARDS A RESEARCH BASED CONSENSUS**

Chp.: S. Nassir Ghaemi, M.D.
Co-Chp.: Lori L. Altshuler, M.D.

**A** Maintenance Treatment of Bipolar Depression: Open and Randomized Trials
Lori L. Altshuler, M.D.

**B** A Randomized Clinical Trial of Antidepressants in Acute Bipolar Depression: Predictors of Response and Manic Induction
Mark Frye, M.D., Trisha Suppes, M.D., Ph.D., Susan L. McElroy, M.D., Willem A. Nolen, M.D., Lori Altshuler, M.D., Paul E. Keck, Jr. M.D., Gabriele S. Leverich, L.C.S.W., Ralph Kupka, MD., Ph.D., Heinz Grunze, M.D., Jim Mintz, Ph.D., Robert M. Post, M.D.

**C** Antidepressant Effect on Long-Term Mood Morbidity in Bipolar Disorder
S. Nassir Ghaemi, M.D., M.P.H, Riff S. El-Mallakh, M.D., Claudia F. Baldassano, M.D., Michael J. Ostacher, M.D., Megan M. Filkowski, B.A., Vanessa A. Stan, Gary Sachs, M.D., R.J. Baldessarini

**D** A STEP-BD Double-Blind-Randomized Study: Effectiveness of Standard Antidepressants for Acute Bipolar Depression
Gary Sachs, M.D.

**Discussants:** Robert Post, M.D., Frederick Goodwin, M.D., Mark Frye, M.D., Gary Sachs, M.D., S. Nassir Ghaemi M.D.

**SYMPHOSIUM 40**
2:00 p.m.-5:00 p.m.
Room 150B, Level One, Washington Convention Center

**WOMEN AND SUBSTANCE ABUSE TREATMENT: EXPLORING WOMEN-FOCUSED TREATMENTS AND SERVICES**

Chp.: Shelly F. Greenfield, M.D.
Co-Chp.: Carmen L. Rosa, M.S.

**A** NIDA's Clinical Trials Network “Women and Trauma” Study
Denise Hien, Ph.D., Aimee Campbell, M.S.S.W., Gloria Miele, Ph.D., Lisa Cohen, Ph.D., Ned Nunes, M.D.

**B** Assessment and Treatment of Co-Occurring Eating Disorders in Publicly Funded Addiction Treatment Programs
Susan M. Gordon, Ph.D., Aaron Johnson, Ph.D., Shelly Greenfield, M.D., Lisa Cohen, Ph.D., Theresa Killeen, Ph.D., Paul Roman, Ph.D.

**C** The Women’s Recovery Study: A Stage I Trial of Women-Focused Group Therapy for Substance Use Disorders Mixed-Gender Group Drug Counseling
Shelly F. Greenfield, M.D., Elisa Trucuito, B.A., Rebecca Kate McHugh, B.A., M. Lincoln, B.A., Robert J. Gallop, Ph.D.

**D** HIV/STD Safer Sex Skills Groups For Women in Drug Treatment Programs in the NIDA Clinical Trials Network: Primary Outcome Results
Susan Tross, Ph.D., Aimee Campbell, M.S.S.W., Lisa Cohen, Ph.D., Martina Pavlicova, Ph.D., Edward Nunes, M.D., Donald Calsyn, Ph.D., Mary Hatch-Maillette, Ph.D., Gloria Miele, Ph.D., Louise Haynes, Mei-Chen Hu, Ph.D., Nancy Nugent, M.S., Wejin Gan, M.P.H.

**Discussants:** Kathleen Brady, M.D., Shelly Greenfield, M.D., Denise Hien, Ph.D., Susan Tross, Ph.D., Susan Gordon, Ph.D.

**SYMPHOSIUM 41**
2:00 p.m.-5:00 p.m.
Room 150A, Level One, Washington Convention Center

**CHILDREN AND WAR**

Chp.: Siham Muntasser, M.D.

**A** Psychiatric Problems Among War Displaced Children in Darfur
Abdullah Abdulrahman, M.D., Eldin Elmahdi

**B** Short-and Long-Term Psychiatric Consequences of Exposure to War and Terror on Israeli Children and Adolescents
Esti Galili-Weissstub, M.D.

**C** Mental Health Promotion Among Adolescents in Palestinian and Israeli Communities
Sami Hamdan, M.Psy., Harvey Skinner, Ph.D., Alan Apter, M.D

**D** Mental Health and Psychosocial Support for Children in Post Conflict Areas in Low-Income Countries: A Public Mental Health Model
Peter Ventevogel, M.D., Mark J.D. Jordans, Wietse A. Tol, Ivan H. Komproe, Ph.D., Joop T.V.M. de Jong, M.D., Ph.D.

**Discussants:** Elie Karam, M.D., Sami Hamdan, M.Psy., Esti Galili-Weissstub, M.D., Peter Ventevogel, M.D., Abdullah Abdulrahman M.D.

**THIS SESSION WILL BE AUDIOTAPED.**
SYMPOSIUM 42  2:00 p.m.-5:00 p.m.
Room 151A, Level One, Washington Convention Center

THE LONG-TERM COURSE OF THE MAJOR AFFECTIVE DISORDERS: NEW FINDINGS FROM A 25-YEAR HIGH-INTENSITY FOLLOW-UP

Chp.: William Coryell, M.D.

A  An Empirical Typology of Bipolar I Mood Episodes
   David A. Solomon, M.D.

B  Are Rapid Shifts in Mood the Final Common Pathway of Suicidality?
   Hagop A. Akiskal, M.D.

C  Cardiovascular Disease in the Collaborative Depression Study
   Jess G. Fiedorowicz, M.D.

D  The 20-Year Symptomatic Course of BP-I and BP-II: Chronicity, Dimensionality, and Relapse
   Lewis L. Judd, M.D.

E  Does Major Affective Disorder Change With Age?
   William Coryell, M.D.

Discussants: Lewis Judd, M.D., William Coryell, M.D., Hagop Akiskal, M.D., David Solomon, M.D., Jess Fiedorowicz, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 43  2:00 p.m.-5:00 p.m.
Room 151B, Level One, Washington Convention Center

INTERNATIONAL SYMPOSIUM ON BULLYING ACROSS THE LIFESPAN: ASSOCIATED HEALTH RISKS, DETECTION, AND PREVENTION

Chp.: Jorge C. Srabstein, M.D.
Co-Chp.: Carl C. Bell, M.D.

A  Workplace Bullying: What We Know, What We Think We Know and What We Don’t Know
   Loraleigh Keashly, Ph.D.

B  Bullying Among Prisoners: Theoretical and Practical Advances From a Decade of Research
   Jane Ireland, M.S.C.

C  School Bullying and Related Health Risks: Detection, Prevention, and Advocacy
   Jorge C. Srabstein, M.D.

D  Bullying–In the Context of War and Terrorism
   Paramjit Joshi, M.D.

Discussants: Carl Bell, M.D., Paramjit Joshi, M.D., Jorge Srabstein, M.D., Loraleigh Keashly, Ph.D., Jane Ireland, M.S.C.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 44  2:00 p.m.-5:00 p.m.
Room 154A/B, Level One, Washington Convention Center

LIFE WITHOUT PAROLE: SENTENCING FOR JUVENILE OFFENDERS

Chp.: Donna M. Norris, M.D.

A  The Increasingly Paradoxical Nature of Juvenile Life Sentences
   David M. Siegel, J.D.

B  Life Sentences for Juveniles: Developmental Considerations
   Diane H. Schetky, M.D.

C  Cyntoia: A 16-Year-Old Girl Sentenced to Life in Prison
   William Bernet, M.D.

Discussants: David Siegel, J.D., Diane Schetky, M.D., William Bernet, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 45  2:00 p.m.-5:00 p.m.
Room 158A/B, Level One, Washington Convention Center

SAFETY AND RECENT RESEARCH IN NON-CONVENTIONAL THERAPIES

Chp.: James H. Lake, M.D.

A  Safety Considerations When Considering Complementary and Alternative Therapies
   James H. Lake, M.D.

B  Vitamins and Minerals in the Treatment of Psychiatric Disorders: A Review of the Evidence
   Garry M. Vickar, M.D.

C  Adventure Therapy Counseling in at Risk Youth
   James Fleming, M.D.

D  Using Technology to Enhance the Effectiveness of Hypnosis, Entrainment, and EEG Biofeedback
   Jonathan H. Holt, M.D.

E  Uses of Experiential Therapies in Psychiatry: A Review of the Evidence
   Chris C. Streeter, M.D.

Discussants: James H. Lake, M.D., James Fleming, M.D., Garry Vickar, M.D., Chris C. Streeter, M.D., Jonathan H. Holt, M.D.

THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 46  2:00 p.m.-5:00 p.m.
Room 159A/B, Level One, Washington Convention Center

RECENT ADVANCES IN CROSS-CULTURAL, ETHNIC AND ETHNOPSYPHARMACOLOGICAL ASPECTS OF MOOD DISORDERS

Chp.: Shamsah B. Sonawalla, M.D.
Co-Chp.: Gregory L. Fricchione, M.D.

A  Culturally Sensitive Treatment of Depressed Chinese Americans in Primary Care
Albert Yeung, M.D.

B  Ethnopsychopharmacology Update
David C. Henderson, M.D.

C  Psychiatric Management of Hispanic Patients: Cross-cultural Issues and Ethnopsychopharmacology
David Mischoulon, M.D.

D  Challenges in the Treatment of Mood and Anxiety Disorders: Considerations in the Asian Indian Population
Rajesh M. Parikh, M.D., Shamsah B. Sonawalla, MD

E  Cultural Considerations in the Diagnosis and Treatment of Mood Disorders in Women
Shamsah B. Sonawalla, M.D., Albert Yeung, M.D., PH.D., Rajesh Parikh, MD

Discussants: Gregory Fricchione, M.D., David Henderson, M.D., David Mischoulon, M.D., Albert Yeung, M.D., Rajesh Parikh, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 47  2:00 p.m.-5:00 p.m.
Room 201, Level Two, Washington Convention Center

HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE: PART 3

Chp.: William E. Callahan, M.D.
Co-Chp.: Keith W. Young, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 48  2:00 p.m.-5:00 p.m.
Room 207A, Level Two, Washington Convention Center

TREATING DEPRESSION IN PATIENTS WITH SCHIZOPHRENIA

Chp.: Sidney Zisook, M.D.
Co-Chp.: John W. Kasckow, M.D.

A  Effects of Antidepressant Augmentation on Subsyndromal Depressive Symptoms in Older Patients With Schizophrenia on Positive and Negative Symptoms
Ipsit Vahia, M.D., Nicole Lanouette, M.D. Sidney Zisook, M.D.

B  Antidepressant Augmentation in Middle Age and Older Adults With Schizophrenia and Depressive Symptoms: Effects on Functioning and Service Utilization
John W. Kasckow, M.D., Ph.D., Thomas Patterson, Ph.D., Ian Fellows, M.S., Shah Golshan, Ph.D., Ellen Solorzano, B.S., S. Zickmund, Ph.D., Somaia Mohamed, M.D., Ph.D., Sidney Zisook, M.D.

C  The Spectrum of Depressive Syndromes and Treatment Outcomes in Patients With Schizophrenia
Nicole M. Lanouette, M.D. Ipsit Vahia, M.D., Sidney Zisook, M.D.

D  Cognitive Functioning in Middle Aged and Older Adults With Schizophrenia and Depressive Symptoms
Somaia Mohamed, M.D., Ph.D., Shah Golshan, Ph.D., John W. Kasckow, M.D., Ph.D., Thomas Patterson, Ph.D., Ellen Solorzano, M.S., Ian Fellows, M.S., Sidney Zisook, M.D.

E  Antidepressant Augmentations of Subsyndromal Depressive Symptoms in Middle Age and Older Patients With Schizophrenia
Sidney Zisook, M.D., M.D., John W. Kasckow, M.D., Ph.D., Somaia Mohamed, M.D., Ph.D., Shah Golshan, Ph.D., Ian Fellows, M.S., Ellen Solorzano, B.S., Somaia Mohamed, M.D., Ph.D., Ian Lehman, M.D.

Discussants: Carl Cohen, M.D., Somaia Mohamed, M.D., Nicole Lanouette, M.D., Sidney Zisook, M.D., Ipsit Vahia, M.D.

THIS SESSION WILL BE AUDIOTAPED.
ADVANCES IN (APPI SERIES) 3

ADVANCES IN EATING DISORDERS
2:00 p.m.-5:30 p.m.
Ballroom C, Level Three, Washington Convention Center

Chp.: Joel Yager, M.D.
Co-Chp.: Pauline S. Powers, M.D.

A Diagnosis and Assessment of Eating Disorders
David B. Herzog, M.D.

B Management of Anorexia Nervosa in Inpatient and Partial Hospital Settings
Katherine A. Halmi, M.D.

C Bulimia Nervosa and BED
James E. Mitchell, M.D.

D Weight, Eating Disorders, and Medications
Pauline S. Powers, M.D.

E Managing Patients With Chronic, Intractable Eating Disorders
Joel Yager, M.D.

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 5
3:00 p.m.-5:00 p.m.
West Lobby, Level One, Washington Convention Center

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

5:00 p.m. Session

MIND GAMES
5:00 p.m.-6:00 p.m.
Room 202A/B, Level Two, Washington Convention Center

Our Host and Moderator: Glen Gabbard, M.D.

Mind Games is a national team competition for residents at the APA Annual Meeting. The game pits top game-scoring residency programs against each other in a final competition testing the depth and breadth of their knowledge of psychiatry.

Finalists for the 2008 Championship are:
- Carilion Health Center
- New York Medical College (Richmond) Program at Richmond University Medical Center
- University of Texas - Houston

7:00 p.m Sessions

INDUSTRY SUPPORTED SYMPOSIA 22-24

INDUSTRY-SUPPORTED SYMPOSIUM 22
7:00 p.m.-10:00 p.m.
Ballroom A/B, Level Three, Washington Convention Center

ORGANIZING THE EVIDENCE: OBSESSIVE COMPULSIVE RELATED DISORDERS: NEW PERSPECTIVES TOWARD DSM-V
Supported by: Jazz Pharmaceuticals, Inc.

Chp.: Lorrin Koran, M.D.

Brain Imaging in the Obsessive Compulsive Spectrum Disorders
Dan J. Stein, M.D.

A Obsessive Compulsive Related Disorders: Overview and Developmental Disorders
Eric Hollander, M.D.

B New Treatment Developments for Obsessive, Compulsive and Related Disorders
Zohar Joseph, M.D.

C Establishing Endophenotypes for Obsessive-Compulsive Disorders
Naomi Fineberg, M.A.

D Muscle Dysphoria and Anabolic Steroid Use
Thomas M. Mick, M.D.

INDUSTRY SUPPORTED SYMPOSIUM 23
7:00 p.m.-10:00 p.m.
Grand Ballroom, Ballroom Level, Renaissance Washington

UNDERSTANDING THE ENDOCANNABINOID SYSTEM: KEY LINKS BETWEEN MIND, BODY AND NEUROPSYCHIATRY
Supported by: Sanofi-Aventis

Chp.: Gary Sachs, M.D.

A Potential Relevance to the Unmet Needs of Patients with Psychiatric Disorders
Gary Sachs, M.D., Dan W. Haupt, M.D.

B The Metabolic Perspective-Current and Emerging Therapies for Metabolic Disorders: Effects on Mind and Body
Louis Aronne, M.D.

C The Cardiovascular Perspective: Inflammation, Visceral Fat, and the ECS
Jorge Plutzky, M.D.

D The Endocannabinoid System: Impact on Metabolism and Mood
Stephen Woods, Ph.D., R. Andrew Chambers, M.D.
INDUSTRY-SUPPORTED SYMPOSIUM 24
7:00 p.m.-10:00 p.m.
Independence Ballroom, Independence Level, Grand Hyatt
Washington

REAL-WORLD SCHIZOPHRENIA: THE COMPLEXITY
OF REAL WORLD CARE
Supported by: Janssen Pharmaceutica and Research

Chp.: Herbert Y. Meltzer, M.D.

A  Reasons for Non-Adherence and Strategies for
Improvement in Patients With Schizophrenia
  Dawn I. Velligan, Ph.D.

B  Utilizing Medication and Psychotherapy to, Overcome
Schizophrenia: A Patient's Perspective
  Elyn R. Saks, J.D.

C  Achieving Optimal Outcome in Schizophrenia
  Herbert Y. Meltzer, M.D.
  (Continued next page)

D  Evaluating All the Evidence for Antipsychotic Efficacy:
CATIE and Beyond
  Philip D. Harvey, Ph.D.

E  Metabolic Side Effects of Antipsychotic Drugs
  William V. Bobo, M.D.
7:00 a.m. Session

PART 1 OF INDUSTRY-SUPPORTED BREAKFAST, SYMPOSIUM 25

INDUSTRY SUPPORTED BREAKFAST SYMPOSIUM 25, PART 1
7:00 a.m.-8:30 a.m.
Ballroom A/B, Level Three, Washington Convention Center

PLAQUES AND TANGLES: APPLYING GENETICS AND MOLECULAR TARGETS TO UNRAVEL STRATEGIES FOR ALZHEIMER’S DISEASE
Supported by: Esai

Chp.: Jacobo E. Mintzer, M.D.
Co-Chp.: Richard Mayeux, M.D.

A Molecular and Genetic Markers for AD: Is There a Role for Screening?
Lindsay A. Farrer, Ph.D.

B Current Treatment Strategies for AD
Jacobo E. Mintzer, M.D.

C Molecular Mechanisms of Neurodegenerative Diseases
Peter H. St. George-Hyslop, M.D.

D Challenges Faced by Psychiatrists in the Management of AD: Ethnic, Genetic, and Environmental Factors
Jessica L. Broadway, M.D.

E Epidemiology of AD: Unraveling the Tangle of Information
Richard Mayeux, M.D.

8:00 a.m. Sessions

COURSES 79-83
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 79 8:00 a.m.-12 noon
Room 3, Meeting Room Level, Renaissance Washington
HOME TREATMENT FOR ACUTE MENTAL DISORDERS: AN ALTERNATIVE TO HOSPITALIZATION
Director: David S. Heath, M.B.

COURSE 80 8:00 a.m.-12 noon
Room 10/11, Meeting Room Level, Renaissance Washington
ASSESSING POSITIVE AND NEGATIVE SYMPTOMS WITH THE POSITIVE AND NEGATIVE SYNDROME SCALE
Co-Directors: Lewis A. Opler, M.D., Paul M. Ramirez, Ph.D.

COURSE 81 8:00 a.m.-12 noon
Room 12, Meeting Room Level, Renaissance Washington
TREATING PHYSICIANS INVOLVED IN SEXUAL MISCONDUCT
Co-Directors: Gene G. Abel, M.D., Tracey I. Marks, M.D.

COURSE 82 8:00 a.m.-12 noon
Room 15, Meeting Room Level, Renaissance Washington
PSYCHIATRIC ROLES IN ASSESSING AND TREATING ADULT AND ADOLESCENT SEX OFFENDERS
Co-Directors: Bradley R. Johnson, M.D., Judith V. Becker, Ph.D.

COURSE 83 8:00 a.m.-5:00 p.m.
Congressional Hall B, Ballroom Level, Renaissance Washington
OFFICE-BASED BUPRENORPHINE TREATMENT FOR OPIOID-DEPENDENT PATIENTS
Director: Gerardo Gonzalez, M.D.,
Faculty: Andrew J. Saxon, M.D., Eric C. Strain, M.D., Laura McNicholas, M.D.

9:00 a.m. Sessions

LECTURES 22-23

LECTURE 22
9:00 a.m.-10:30 a.m.
Room 143A/B/C, Level One
Washington Convention Center
APA’S OSKAR PFISTER AWARD LECTURE
Dan G. Blazer, M.D.
Prozac and the Spiritual Self

(Continued next page)
Chp.: John R. Peteet, M.D.

Dr. Blazer is former Dean of Medical Education and currently J.P. Gibbons Professor of Psychiatry and Behavioral Sciences and Vice Chair for Education and Academic Affairs at Duke University Medical Center. He is a Professor of Community and Family Medicine at Duke and Head of the University Council on Aging and Human Development. He also serves as Adjunct Professor in the Department of Epidemiology, School of Public Health, University of North Carolina. He received his M.D. degree from the University of Tennessee and his MPH and Ph.D. degrees from the University of North Carolina at Chapel Hill. He is the author or editor of 30 books, author or co-author of over 180 published abstracts and over 330 peer-reviewed articles. He is also the author or co-author of over 150 book chapters. Many of the book chapters and scientific articles are on the topics of depression, epidemiology, and consultation-liaison psychiatry, and religion and psychiatry, especially with the elderly. He is listed by the ISI among the most highly cited authors in both psychiatry and the social sciences. He was selected for the Distinguished Alumni Award at the School of Public Health, University of North Carolina in 1989, the Rema LaPouse Award from the American Public Health Association in 2001, the First Annual Geriatric Psychiatry Research Award from the American College of Psychiatrists in 2004, the Kleemeier Award from the Gerontological Society of America and, the Distinguished Faculty Award from Duke Medical School in 2005. He was elected to the Institute of Medicine, National Academy of Sciences in 1995 where he chaired the membership committee for two years (2005-2007). He currently serves on the editorial board of the Archives of General Psychiatry. Dr. Blazer has a career-long interest in the association of psychiatry and religion. He has authored or co-authored a number of articles on depression and spirituality and authored Freud vs. God: How Psychiatry Lost its Soul and Christianity Lost its Mind (1998) as well as The Age of Melancholy: Major Depression and its Social Origins (2005), books which explore the social influence upon the self, especially the spiritual self.

THIS SESSION WILL BE AUDIOTAPED.

LECTURE 23
9:00 a.m.-10:30 a.m.
Room 146A/B, Level One
Washington Convention Center

Terry Cline, M.D.

Chp.: Annelle Primm, M.D.

Terry Cline, Ph.D., was nominated by President George W. Bush on November 13, 2006, and confirmed by the U.S. Senate on December 9, 2006, as Administrator for the Substance Abuse and Mental Health Services Administration (SAMHSA). As SAMHSA Administrator, Dr. Cline reports to Health and Human Services Secretary Michael O. Leavitt and leads the $3.3 billion agency responsible for improving the accountability, capacity and effectiveness of the nation’s substance abuse prevention, addictions treatment, and mental health service delivery systems. Throughout his career, Dr. Cline has championed the principle that mental health and freedom from substance abuse are fundamental to overall health and well-being and that mental and substance use disorders should be treated with the same urgency as any other health condition. Prior to his appointment as SAMHSA Administrator, Dr. Cline put these core values to work as Oklahoma’s Secretary of Health, a position he was appointed to by Governor Brad Henry in 2004. At the same time, he served as Oklahoma’s Commissioner of the Department of Mental Health and Substance Abuse Services, a position he held since January 2001. He actively participated in and supported the creation of grassroots coalitions to improve the health status of local communities. During his tenure in Oklahoma, Dr. Cline built strong collaborative relationships among the multiple constituency groups and government agencies that touch the lives of people with substance abuse and mental health problems. As a result of these partnerships significant advances were made in transforming the state’s service delivery systems, including the creation of Oklahoma’s Integrated Services Initiative which creates a holistic approach to treatment needs, a wide expansion of drug courts throughout the state, and the introduction of mental health courts into Oklahoma along with a statewide focus on recovery and recovery support services. Dr. Cline has extensive experience in overseeing health and human services at the state level. He has also served as a provider through an earlier post as the Clinical Director of the Cambridge Youth Guidance Center in Cambridge, Massachusetts, and as a Staff Psychologist at McLean Hospital in Belmont, Massachusetts. His professional history also includes a six-year appointment as a clinical instructor in the Department of Psychiatry at Harvard Medical School and Chairman of the governing board for a Harvard teaching hospital in Cambridge, Massachusetts. A native of Ardmore, Oklahoma, Dr. Cline attended the University of Oklahoma, where he earned a bachelor’s degree in psychology in 1980. He then received both a master’s degree and a doctorate in clinical psychology from Oklahoma State University. Dr. Cline has involved himself in community service, including membership on a number of local, state, and national committees and boards with a focus on improving the overall health of the community and the nation.

THIS SESSION WILL BE AUDIOTAPED.

SMALL INTERACTIVE SESSIONS 13-14
9:00 a.m.-10:30 a.m.

These sessions are limited to 25 participants on a first-come, first-served basis.

13 Robert Findling, M.D., on Child and Adolescent Psychopharmacology (Meet the Author)
Room 304, Level Three, Washington Convention Center

14 Fred Goodwin, M.D., on Integrating the Old With the New in the Long-Term Management of Recurrent Affective Disorders
Room 305, Level One, Washington Convention Center
WEDNESDAY

CASE CONFERENCE 3
9:00 a.m.-10:30 a.m.
Room 154A/B, Level One, Washington Convention Center

TREATMENT-RESISTANT ANOREXIA NERVOSA: A MATTER OF LIFE AND DEATH

Moderator: Charles B. Nemeroff, M.D.
Presenters: Elizabeth DeOreo, M.D., Steven A. Garlow, M.D., Ph.D., Michael Burke, M.D., Timothy Walsh, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

WORKSHOPS

COMPONENTS 40-49

COMPONENT WORKSHOP 40 9:00 a.m.-10:30 a.m.
Room 102A/B, Level One, Washington Convention Center

ADVOCACY: WHAT MEDICAL STUDENTS, RESIDENTS, AND EARLY CAREER PSYCHIATRISTS NEED TO KNOW TO EFFECT CHANGE IN THE POLITICAL PROCESS
APA Assembly Committee of Area Member-in-Training Representatives

Co-Chps.: Jose Vito, M.D., Bob Kearley, M.D.
Participants: Catherine Finley, Carolyn B. Robinowitz MD, Daniel Bober D.O.

COMPONENT WORKSHOP 41 9:00 a.m.-10:30 a.m.
Room 103A/B, Level One, Washington Convention Center

ONE PSYCHIATRIST'S VIOLATION MAY BE ANOTHER'S AREA OF WORK
APA Assembly Allied Organization Liaisons

Chp.: Lee Combrinck-Graham, M.D.
Participants: Rachel Glick, M.D., David Brook, M.D., Anita Everett, M.D., Robert Pyles, M.D.

COMPONENT WORKSHOP 42 9:00 a.m.-10:30 a.m.
Room 144A/B, Level One, Washington Convention Center

GRASSROOTS IN ACTION: DISTRICT BRANCH INITIATIVES AND APA GRANT FUNDING UNITE IN MAKING A DIFFERENCE
APA Council on Member and District Branch Relations

Co-Chps.: Nioaka N. Campbell, M.D., Jeffrey S. Akman, M.D.
Participants: Beverly Sheehan, M.B.A., Janet Shaw, B.S.

COMPONENT WORKSHOP 43 9:00 a.m.-10:30 a.m.
Room 146C, Level One, Washington Convention Center

FOSTER CARE: ARE WE DOING OUR BEST FOR THE CHILDREN?
APA Committee on Family Violence and Abuse

Chp.: Gail Robinson, M.D.
Participants: Sandra Kaplan, M.D.

COMPONENT WORKSHOP 44 9:00 a.m.-10:30 a.m.
Room 147A, Level One, Washington Convention Center

PREVENTING INCARCERATION OF THE MENTALLY III: THE ROLE OF PSYCHIATRY
APA Assembly Allied Organization Liaisons

Chp.: Steven K. Hoge, M.D.
Participants: Erik Roskes, M.D., Alec Buchanan, Ph.D.

COMPONENT WORKSHOP 45 9:00 a.m.-10:30 a.m.
Room 149A/B, Level One, Washington Convention Center

CPT CODING AND DOCUMENTATION UPDATE
APA Committee on RBRVS, Codes, and Reimbursements

Co-Chps.: Ronald M. Burd, M.D., David K. Nace, M.D.
Participants: Edward Gordon, M.D., Allan Anderson, M.D., A. Evan Eyler, M.D., Napoleon Higgins, Jr., M.D., Jeremy Mushet, M.D., Tracy Gordy, M.D., Chester Schmidt, M.D.

COMPONENT WORKSHOP 46 9:00 a.m.-10:30 a.m.
Room 151A, Level One, Washington Convention Center

PSYCHIATRIC SERVICES IN JAILS AND PRISONS: IT'S TIME TO REVISE THE APA GUIDELINES!
APA Caucus of Psychiatrists Working in Correctional Settings

Chp.: Henry C. Weinstein, M.D.
Participants: Kathryn Burns, M.D., Cassandra Newkirk, M.D.

COMPONENT WORKSHOP 47 9:00 a.m.-10:30 a.m.
Room 153, Level One, Washington Convention Center

WHY BUSINESS NEEDS PSYCHIATRY AND WHY PSYCHIATRY NEEDS BUSINESS: LESSONS LEARNED FROM THE CABR MODEL
APA Committee on APA/Business Relationships

Chp: Alan M. Langlieb, M.D., M.P.H, M.B.A.
Participants: Dauda Griffin, M.D., Gabriela Cora, M.D., M.B.A.
COMPONENT WORKSHOP 48  9:00 a.m.-10:30 a.m.
Room 156, Level One, Washington Convention Center

NEW APA PRACTICE GUIDELINES: MDD AND BIPOLAR DISORDER
*APA Steering Committee on Practice Guidelines*

Chp.: John S. McIntyre, M.D.
Participants: Alan Gelenberg, M.D., Robert Hirschfeld, M.D., Laura Fochtmann, M.D.

COMPONENT WORKSHOP 49  9:00 a.m.-10:30 a.m.
Room 207B, Level Two, Washington Convention Center

MENTAL HEALTH OF LATINAS: CHANGING ROLES AND NEEDS
*APA Committee of Hispanic Psychiatrists*

Chp.: Andres J. Pumariega, M.D.
Participants: Natalie Weder, M.D., Daniel Castellanos, M.D., Sarah Huertas-Goldman, M.D., Tatiana Falcone, M.D., Carlos Rodriguez M.D.

ISSUES 45-61

ISSUE WORKSHOP 45  9:00 a.m.-10:30 a.m.
Room 101, Level One, Washington Convention Center

TRAINING FOR ALL PSYCHIATRIC RESIDENTS AND SCHOLARLY ACTIVITY

Co-Chps.: Milton Kramer, M.D., Michele Pato, M.D.
Participants: Jerald Kay, M.D., Mantosh J. Dewan M.D.

ISSUE WORKSHOP 46  9:00 a.m.-10:30 a.m.
Room 141, Level One, Washington Convention Center

INFERTILITY: WHAT TO EXPECT WHEN YOU ARE NOT EXPECTING

Co-Chps.: Joyce A. Spurgeon, M.D., Julianne Flynn, M.D.

ISSUE WORKSHOP 47  9:00 a.m.-10:30 a.m.
Room 142, Level One, Washington Convention Center

CREATING A BUPRENORPHINE WRAP-AROUND PROGRAM IN YOUR COMMUNITY: LESSONS LEARNED AND WHAT WORKS

Chp.: Jennifer L. Michaels, M.D.
Participants: Alex Sabo, M.D.

ISSUE WORKSHOP 48  9:00 a.m.-10:30 a.m.
Room 147B, Level One, Washington Convention Center

LEADERSHIP IN PSYCHIATRY

Co-Chps.: Julian Beezhold, M.D., Victor J. Buwalda, M.D.
Participant: Abigail Donovan, M.D.

ISSUE WORKSHOP 49  9:00 a.m.-10:30 a.m.
Room 148, Level One, Washington Convention Center

USING INTERPERSONAL PSYCHOTHERAPY WITH GERIATRIC PATIENTS

Co-Chps.: Mark D. Miller, M.D., Gregory A. Hinrichsen, Ph.D.

ISSUE WORKSHOP 50  9:00 a.m.-10:30 a.m.
Room 150A, Level One, Washington Convention Center

COGNITIVE THERAPY FOR PSYCHOSIS IN PRACTICE BY PSYCHIATRISTS: BASIC TECHNIQUES

Chp.: Shanaya Rathod, M.D.
Participants: Douglas Turkington M.D., David Kingdon M.D.

ISSUE WORKSHOP 51  9:00 a.m.-10:30 a.m.
Room 150B, Level One, Washington Convention Center

COGNITIVE THERAPY FOR PERSONALITY DISORDERS

Chp.: Judith S. Beck, Ph.D.

ISSUE WORKSHOP 52  9:00 a.m.-10:30 a.m.
Room 151B, Level One, Washington Convention Center

PHANTOMS OF THE MIND: THE ROLE OF NARCISSISM IN THERAPIST BOUNDARY-CROSSING

Chp.: Howard E. Book, M.D.
Participants: Gary Schoener, M.A., Carolyn Quadrio, M.D

ISSUE WORKSHOP 53  9:00 a.m.-10:30 a.m.
Room 152A, Level One, Washington Convention Center

THE AIR FORCE SUICIDE PREVENTION PROGRAM: A COMMUNITY AND ORGANIZATIONAL APPROACH TO PREVENTION

Chp.: Steven E. Pflanz, M.D.

ISSUE WORKSHOP 54  9:00 a.m.-10:30 a.m.
Room 152B, Level One, Washington Convention Center

TEACHING RESIDENTS IN CONSULTATION-LIAISON SERVICE TO RECOGNIZE AND MANAGE COUNTERTRANSFERENCE

Co-Chps.: Damir Huremovic, M.D., Nyapati R. Rao, M.D.
Participants: Jacob Sperber M.D., Aleksandar Micevski, M.D.
ISSUE WORKSHOP 55  9:00 a.m.-10:30 a.m.  
Room 155, Level One, Washington Convention Center

QUALITY IMPROVEMENT INTERVENTION FOR DEPRESSION IN PRIMARY CARE
National Institute of Mental Health

Chp.: Agnes E. Rupp, Ph.D.
Participants: Jeanne Miranda, Ph.D., Kenneth Wells, M.D., Cathy Sherbourne, Ph.D., David Kennedy, Ph.D.

ISSUE WORKSHOP 56  9:00 a.m.-10:30 a.m.  
Room 157, Level One, Washington Convention Center

FORGIVENESS AND INDIVIDUAL PSYCHOTHERAPY: TO ERR IS HUMAN, TO FORGIVE DIVINE, OR IS IT?

Chp.: Janet L. Lewis, M.D.

ISSUE WORKSHOP 57  9:00 a.m.-10:30 a.m.  
Room 158A/B, Level One, Washington Convention Center

KATRINA'S LONG-TERM IMPACT ON MENTAL HEALTH AND EDUCATION

Co-Chps.: Phbe M. Tucker, M.D., Harold M. Ginzburg, M.D.
Participants: Richard Dalton, M.D., Janet Johnson, M.D.

ISSUE WORKSHOP 58  9:00 a.m.-10:30 a.m.  
Room 159A/B, Level One, Washington Convention Center

MAKING THE MOST OF YOUR CHIEF YEAR: CHIEF RESIDENTS' FORUM, PART I

Co-Chps.: Amy W. Poon, M.D., Carolyn I. Rodriguez, M.D.
Participants: Christina Mangurian, M.D., Shirley Liu, B.A., Violeta Tan, M.D., Anjali D. Souza, M.D., S. Shane Konrad, M.D.

ISSUE WORKSHOP 59  9:00 a.m.-10:30 a.m.  
Room 160, Level One, Washington Convention Center

DELIVERING PSYCHIATRIC AID TO IRAQ: HOW CAN AMERICAN PSYCHIATRISTS HELP IN A CONFLICT ZONE?

Chp.: Amir Afkhami, M.D.
Participants: James Griffith, M.D., Saman Anwar, M.D., Saman Halabjayi, M.D.

ISSUE WORKSHOP 60  9:00 a.m.-10:30 a.m.  
Room 201, Level Two, Washington Convention Center

THE PHYSICIAN AS PATIENT: HOW CAN WE HELP?
Co-Chps.: Michael F. Myers, M.D., Glen O. Gabbard, M.D.

ISSUE WORKSHOP 61  9:00 a.m.-10:30 a.m.  
Room 207A, Level Two, Washington Convention Center

PSYCHIATRY IN ASIA: PROBLEMS, PRIORITIES AND SOLUTIONS

Co-Chps.: Pedro Ruiz, M.D., Bruce S. Singh, Ph.D.
Participants: Pichet Udomratn, M.D., Tsuyoshi Akiyama, M.D., Haroon Chaudhry, M.B.B.S, Chiao-Chicy Chen, M.D.

MEDIAS 5-7
MEDIA WORKSHOP 5  9:00 a.m.-12 noon  
Room 140A, Level One, Washington Convention Center

MICHAEL MOORE'S SICKO

Chp.: Steven S. Sharfstein, M.D.

MEDIA WORKSHOP 6  9:00 a.m.-12 noon  
Room 140B, Level One, Washington Convention Center

RED WITHOUT BLUE: A FILM ABOUT GAY AND TRANSGENDER IDENTICAL TWINS
American Academy of Child and Adolescent Psychiatry

Chp.: Richard R. Pleak, M.D.
Co-Chp.: Edgardo J. Menvielle, M.D.

MEDIA WORKSHOP 7  9:00 a.m.-12 noon  
Room 144C, Level One, Washington Convention Center

SHAME AND SILENCE: UNDERSTANDING THE STIGMA OF MENTAL ILLNESS IN ASIAN AMERICANS

Chp.: Francis G. Lu, M.D.
Co-Chp.: Elizabeth J. Kramer, S.M.

SYMPOSIA 50-51
SYMPOSIUM 50  9:00 a.m.-12 noon  
Room 145A, Level One, Washington Convention Center

ADVANCES IN EARLY DETECTION, TREATMENT, AND PREVENTION OF PSYCHOSIS: FINDINGS FROM THE NORTH AMERICAN PRODROME LONGITUDINAL STUDY

Chp.: Robert K. Heinssen, Ph.D.
Co-Chp.: Thomas H. McGlashan, M.D.

A  Risk of Mania in Persons at Heightened Clinical Risk for Psychosis
Diana O. Perkins, M.D., Scott W. Woods, M.D.

B  Psychosocial Treatments for the Psychosis Prodrome
Jean M. Addington, Ph.D., Irvine Epstein, M.D., Robert Zipursky, M.D.

(Continued next page)
C  Cannabis Misuse and Risk for Psychosis in a Prodromal Sample  
Kristin S. Cadenhead, M.D., Robert Heinssen, Ph.D., A.B.P.P.

D  Predicting Psychosis Onset in Youth at High Clinical Risk: The Effects of Prodromal Symptoms, Neurocognition, and Family History  
Larry J. Seidman, Ph.D., Tyrone D. Cannon, Ph.D., Ming Tsuang, M.D.

E  The Relation of Antipsychotics and SSRIs With Baseline Symptoms and Symptom Progression in Prodromal Subjects: A Naturalistic Study  
Elaine Walker, Ph.D., Barbara Cornblatt, Ph.D.

F  Should the Psychosis Prodrome Be Included in DSM-V?  
Scott W. Woods, M.D., Thomas H. McGlashan, M.D.

Discussants: Ming Tsuang, M.D., Larry Seidman, Ph.D., Diana Perkins, M.D., Kristin Cadenhead, M.D., Elaine Walker, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 51  
Room 145B, Level One, Washington Convention Center

TREATING PTSD IN A VIOLENT WORLD

Chp.: Robert J. Ursano, M.D.  
Co-Chp.: Arshad Husain, M.D.

A  Treatment and Prevention Research, Part 2: The Jerusalem Trauma Outreach and Early Prevention Study  
Arieh Y. Shalev, M.D., Barbara Rothbaum, Ph.D.

B  Cutting-Edge Treatment and Prevention Research  
Barbara O. Rothbaum, Ph.D.

C  Prevalence and Treatment of PTSD  
Charles R. Marmar, M.D.

D  Developing and Implementing PTSD Interventions in Real-World Settings  
Douglas F. Zatzick, M.D., Peter Roy-Byrne, M.D., Frederick Rivara, M.D., M.P.H., Gregory Jurkovich, M.D., Joan Russo, Ph.D., Chris Dunn, Ph.D., Amy Wagner, Ph.D., Sandro Galea, M.D., Dr.P.h., Wayne Katon, M.D.

E  Integrating Bio-Psycho-Social Factors Mediating Risk and Resiliency in PTSD  
Kerry J. Ressler, MD, PhD

Discussants: Charles Marmar, M.D., Douglas F. Zatzick, M.D., Barbara Rothbaum, Ph.D., Arieh Shalev, M.D., Kerry Ressler, M.D.

THIS SESSION WILL BE AUDIOTAPED.
Co-Directors: Richard P. Brown, M.D., Patricia L. Gerbarg, M.D.

**11:00 a.m. Sessions**

**LECTURE 24**

**LECTURE 24**
11:00 a.m.-12:30 P.m.  
Room 143A/B/C, Level One  
Washington Convention Center  

**APA'S KUN-PO SOO AWARD LECTURE**

Wen-Shing Tseng, M.D.

Cultural Psychiatry in Asia

Chp.: Mona H. Gill, M.D.

Wen-Shing Tseng, M.D., has been a professor of psychiatry at the University of Hawai`i, School of Medicine since 1972. He was trained in psychiatry at the Department of Psychiatry at the National Taiwan University Hospital in Taipei, and later at the Massachusetts Mental Health Center of Harvard Medical School in Boston. He holds a position as guest professor at the Institute of Mental Health, Peking University, Beijing, China, since 1987. He served as Chairman of the Transcultural Psychiatry Section of the World Psychiatric Association for two terms, from 1983 to 1993. Since 2005, he has served as the President of the World Association of Cultural Psychiatry. Throughout his career, Prof. Tseng has conducted research on the cultural aspects of mental health, psychopathology, and psychotherapy in Asia. He has published nearly 20 books in English and 30 books in Chinese. His book Handbook of Cultural Psychiatry, published in 2001, was regarded as a landmark text in the field of cultural psychiatry, and received the Creative Scholarship Award from the Society for Study of Psychiatry and Culture in 2002.

**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSIONS 18-26**

**SCIENTIFIC AND CLINICAL REPORT SESSION 18**
11:00 a.m.-12:30PM  
Room 101, Level One, Washington Convention Center  

**CONVERSION, SOMATIZATION, AND CHRONIC FATIGUE**

11:00 a.m.  
51 Demographic, Clinical, and Treatment, Outcome Profiles in 71 Consecutive, Prospectively Studied Patients With Conversion Disorder(CD)  
Patricia Rosebush, M.D., Michael F. Mazurek, M.D.

11:30 a.m.  
52 Somatization Increases Role Impairment and Disability Independent of Psychiatric and Medical Comorbidity  
Arthur J. Barsky, M.D., Ashley M. Harris, M.D., E. John Orav, Ph.D., David W. Bates, M.D., MSc.

12 noon  
53 The Comparative Epidemiology of Chronic Fatigue Between Brazilian and British Primary Care: Prevalence, Reporting, Recognition, and Labeling,  
Hyong Cho, M.D.,

**THIS SESSION WILL BE AUDIOTAPED.**

**SCIENTIFIC AND CLINICAL REPORT SESSION 19**
11:00 a.m.-12:30 p.m.  
Room 103A/B, Level One, Washington Convention Center  

**MANAGING BEHAVIOR IN PATIENTS AND PSYCHIATRISTS**

Chp.: Britta Ostermeyer, M.D.

11:00 a.m.  
54 First Mailed Educational Intervention to Physicians Reduced Pharmacy, Hospital, and Outpatient Costs  
Harold Carmel, M.D., Jeffrey Veach, M.S., Jack Gorman, M.D., Joseph J. Parks, M.D., Richard Surles, Ph.D., John Docherty, M.D.

11:30 a.m.  
55 Clinical Trial Reports in Psychiatry Before and After the CONSORT Statement  
Changsu Han, M.D., Chi-Un Pae, M.D., Kamal Bhatia, M.D., David Marks, M.D., Clement Ogudejofo, M.D., Prakash S. Masand, M.D., Ashwin A. Patkar, M.D.

12 noon  
56 Attachment, Contemporary Interpersonal Theory, and IPT: An Integration of Theoretical, Clinical, and Empirical Perspectives  
Paula Ravitz, M.D., Robert Maunder, MD, Carolina McBride, Ph.D.

**THIS SESSION WILL BE AUDIOTAPED.**
WEDNESDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 20
11:00 a.m.-12:30 p.m.
Room 142, Level One, Washington Convention Center

SIDE EFFECTS OF PSYCHOPHARMACOLOGICAL TREATMENT

11:00 a.m.
57 Long-Term Follow Up of Patients With Major Depressive Disorder: Changes in Symptoms, Treatment, and Side Effects
John Goethe, M.D., Stephen B. Woolley, D.Sc., Alex A. Cardoni, M.S. Pharm., Brenda A. Woznicki, B.S., Deborah A. Piez, M.S.

11:30 a.m.
58 Identification and Attribution of Side Effects of Antidepressants by Self-Report and Psychiatrist Interview
Rajnish Mago, M.D., Nancy Diazgranados, M.D., Constantine Daskalakis, Sc.D., Scott Waldman, M.D., Ph.D., David Oslin, M.D., Barry Rovner, M.D., Michael Thase, M.D.

12 noon
59 Antipsychotic-Induced Extrapyramidal Side Effects in Bipolar Disorder and Schizophrenia
Keming Gao, M.D., Joseph R. Calabrese, M.D., Stephen J. Ganocy, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 21
11:00 a.m.-12:30 p.m.
Room 147B, Level One, Washington Convention Center

BIOLOGICAL PSYCHIATRY

Chp.: Meera Vaswani, Ph.D.

11:00 a.m.
60 Normalization of Immune Cell Imbalance After Pharmacological Treatments of Patients Suffering From Obsessive-Compulsive Disorder
Donatella Marazziti, M.D., Giorgio Consoli, M.D., Mario Catena Dell'Osso, M.D., Stefano Baroni, Ph.D.

11:30 a.m.
61 Ventral Capsular/Ventral Striatal Gamma Capsulotomy for Obsessive-Compulsive Disorder: First Results of a Double-Blind, Randomized, Controlled Trial
Antonio Lopes, M.D., Maria E. de Mathis, Psy.D., Anita Taub, Psy.D., Carina C. D’Alcante, Psy. D., Miguel M. Canetras, M.D., Marcelo Q. Hoexter, M.D., Fernando S. Gouvea, M.D., Benjamin D. Greenberg, M.D., Georg Norén, M.D., Eurípedes C. Miguel, M.D., Ph.D.

12 noon
62 Alterations of the Dopamine Transporter in Lymphocytes of Patients With Different Psychotic Disorders
Giorgio Consoli, M.D., D. Marazziti, M.D., Catena Dell'Osso, M.D., S. Baroni, Ph.D., I. Masala, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 22
11:00 a.m.-12:30 p.m.
Room 150A, Level One, Washington Convention Center

SOCIAL AND COMMUNITY PSYCHIATRY

Chp.: Daniel P. Chapman, Ph.D.
Co-Chp: Derya Iren Akbiyik, M.D., Ph.D.

11:00 a.m.
63 Treating Obesity: Interventions for Improving Body Mass Index and Increasing Fitness in an Inner-City Hispanic and African-American SPMI Population
Joanne Caring, M.D.

11:30 a.m.
64 FACT, A Dutch Version of ACT (Assertive Community Treatment)
J. Remmers van Veldhuizen, M.D.

12 noon
65 Psychiatric Housing: Correlates of Community Interaction
Allison Zippay, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 23
11:00 a.m.-12:30 p.m.
Room 150B, Level One, Washington Convention Center

DIAGNOSIS

Chp.: Jacob Moussai, M.D.

11:00 a.m.
66 Threats to Validity in Causality Research Using Psychiatric Diagnoses
Stephen Shanfield, M.D., Stephen B. Shanfield, M.D.

11:30 a.m.
67 Is Bipolar Disorder Overdiagnosed?
Mark Zimmerman, M.D., Camilo J. Ruggero, Ph.D., Iwona Chelminki, Ph.D., Diane Young, Ph.D.

12 noon
68 What Can We Learn From Valid Diagnoses?
Roger Peele, M.D., Enrico Suardi, M.D.

THIS SESSION WILL BE AUDIOTAPED.
TREATMENT DECISIONS AND OUTCOME IN DEPRESSION

11:00 a.m.
69 Disease Management for Patients With Difficult-to-Treat Depression
Gabor Keitner, M.D., Christine E. Ryan, Ph.D, David A. Solomon, M.D., Stephen Bishop, Ph.D, Joan Kelley

11:30 a.m.
70 Evidence-Based Medicine and Outcome: Three-Month Follow Up of Inpatients With MDD

12 noon
71 A Clinically Useful Depression Outcome Scale
Mark Zimmerman, M.D., Iwona Chelminski, Ph.D., Joseph B. McGlinchey, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

STUDIES IN THE COURSE OF SCHIZOPHRENIA

72 Separable Developmental Trajectories in Schizophrenia From Womb to Grave: Results From the Northern Finland 1966 Birth Cohort
Matti Isohanni, Ph.D., Jouko Miettunen, Ph.D., Antti Alaräisänen, Irene Isohanni, Ph.D., Erika Lauronen, M.D., Ph.D.

73 Predicting Schizophrenia Spectrum Disorders With Psychological Scales: The Northern Finland 1966 Birth Cohort
Jouko Miettunen, Ph.D., Juha Veijola, M.D., Ph.D., Matti Isohanni, M.D., Ph.D., Tiina Paunio, M.D., Ph.D., Nelson Freimer, M.D., Ph.D., Erika Lauronen, M.D., Ph.D., Jesper Ekelund, M.D., Ph.D., Leena Peltonen, M.D., Ph.D., Matti Joukamaa, M.D., Ph.D., Dirk Lichtermann, M.D.

74 Recovery From Schizophrenia: A Meta-Analysis
Erika Lauronen, B. Med., Juha Veijola, M.D., Ph.D., John McGrath, M.D., Ph.D., Sukanta Saha, M.Sc., Johanna Heikkinen, M.A., Matti Isohanni, M.D., Ph.D., Jouko Miettunen, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 50-54

COMPONENT WORKSHOP 50  11:00 a.m.-12:30 p.m.
Room 146 A/B/C, Level One, Washington Convention Center

RELIGION AND PSYCHIATRY IN THE POST-FREUDIAN AGE
APA Corresponding Committee on Religion, Spirituality, and Psychiatry
Chp.: John Peteet, M.D.

COMPONENT WORKSHOP 51  11:00 a.m.-12:30 p.m.
Room 155, Level One, Washington Convention Center

PSYCHIATRIC ASPECTS OF BARIATRIC SURGERY
APA Caucus on Eating Disorders
Co-Chps.: Daniel I. Bober, D.O., Jodi E. Star, M.D.

COMPONENT WORKSHOP 52  11:00 a.m.-12:30 p.m.
Room 157, Level One, Washington Convention Center

ONE IN A MILLION? SAFETY OF TRAINEES IN THE PSYCHIATRIC SETTING
APA/GlaxoSmithKline Fellows
Co-Chps.: Umee A. Davae, D.O., Han-chun Liang, M.D.
COMPONENT WORKSHOP 53  11:00 a.m.-12:30 p.m.
Room 158A/B, Level One, Washington Convention Center

MENTAL HEALTH EFFECTS OF DISASTERS AMONG ETHNIC MINORITY ELDERLY
*APA Committee on Ethnic Minority Elderly*

Co-Chps.: Maria Llorente, M.D., Iqbal Ahmed, M.D.
Participants: Carl Cohen, M.D., Moises Martinez, M.D., Shunda McGahee, M.D., Vernon Nathaniel M.D., Alveth Young M.D., Mary Bret, M.D.

COMPONENT WORKSHOP 54  11:00 a.m.-12:30 p.m.
Room 207B, Level Two, Washington Convention Center

HOT ISSUES IN PSYCHIATRY AND LAW
*APA Council on Psychiatry and Law*

Co-Chps.: Paul S. Appelbaum, M.D., Steven K. Hoge, M.D.
Participant: Debra Pinals, M.D.

ISSUE WORKSHOP 62  11:00 a.m.-12:30 p.m.
Room 141, Level One, Washington Convention Center

(HU)MANUALIZED CBT WITH CHILDREN: INNOVATION AND IMPROVISATION IN TREATMENT

Chp.: Robert D. Friedberg, Ph.D.
Participants: Fauzia Mahr, M.D., Ellen Flannery-Schroeder, Ph.D., Angela Gorman, Ph.D., Jolene Garcia, M.D., Elizabeth Gosch

ISSUE WORKSHOP 63  11:00 a.m.-12:30 p.m.
Room 148, Level One, Washington Convention Center

INTEGRATING PSYCHIATRY AND PRIMARY CARE: A RATIONAL RESPONSE TO CONTINUING MENTAL HEALTH NEEDS FOLLOWING HURRICANE KATRINA

Co-Chps.: Julia Z Frank, M.D., Catherine S. May, M.D.
Participants: Robert Titzler, M.D., Lorna Mayo M.D.

ISSUE WORKSHOP 64  11:00 a.m.-12:30 p.m.
Room 149A/B, Level One, Washington Convention Center

WHAT TIME DOES NOT HEAL: ACHIEVING FUNCTIONAL RECOVERY IN PSYCHIATRIC ILLNESS

Co-Chps.: Marcia Scott, M.D., Paul Pendler, Psy.D.
Participants: Marilyn Price M.D., Andrea Stolar M.D.

ISSUE WORKSHOP 65  11:00 a.m.-12:30 p.m.
Room 152B, Level One, Washington Convention Center

ELVIN SEMRAD'S INTERVIEWING FUNDAMENTALS FOR HIGH-PRESSURE CLINICAL, FORENSIC, AND EDUCATIONAL CONTEXTS

Chp.: Robindra K. Paul, M.D.
Participants: Max Day, M.D., Jason Rafferty, B.S., Beata Zolovska, M.D., Harold J. Bursztajn, M.D.

ISSUE WORKSHOP 66  11:00 a.m.-12:30 p.m.
Room 153, Level One, Washington Convention Center

TRANSITION-AGE YOUTH: AN OVERVIEW ON PSYCHOLOGICAL DEVELOPMENT, SERVICE DELIVERY, AND TREATMENT MODELS

Chp.: Brooke A. Goldner, M.D.
Participants: Joel Sherrill, Ph.D., Maryann Davis, Ph.D.

ISSUE WORKSHOP 67  11:00 a.m.-12:30 p.m.
Room 154A/B, Level One, Washington Convention Center

THE PORTRAYAL OF PSYCHIATRY IN RECENT AMERICAN FILM

Chp.: Steven E. Pflanz, M.D.

ISSUE WORKSHOP 68  11:00 a.m.-12:30 p.m.
Room 156, Level One, Washington Convention Center

PARTNERSHIPS IN THE AMERICAS: UPDATE FROM THE WORLD PSYCHIATRIC ASSOCIATION

American Psychiatric Association and the World Psychiatric Association

Co-Chps.: Michelle B. Riba, M.D., Lawrence Hartmann, M.D.
Participants: Rodolfo Fahrer, M.D., Roger Montenegro, M.D., Julio Arboleda-Florez, M.D.

ISSUE WORKSHOP 69  11:00 a.m.-12:30 p.m.
Room 159A/B, Level One, Washington Convention Center

MAKING THE MOST OF YOUR CHIEF YEAR: CHIEF RESIDENTS’ FORUM, PART II

Co-Chps.: Amy W. Poon, M.D., Carolyn I. Rodriguez, M.D.
Participants: Christina Mangurian, M.D., Violeta Tan, M.D., Shirley Liu B.A., Anjali D. Souza, M.D., S. Shane Konrad, M.D.

ISSUE WORKSHOP 70  11:00 a.m.-12:30 p.m.
Room 160, Level One, Washington Convention Center

NAVIGATING TERRORISM AND ITS RELATION TO MENTAL HEALTH: MIDDLE EAST PERSPECTIVE

Co-Chps.: Mostafa K. Ismail, M.D., Zeinab Bishry, M.D.
Participants: Yasser Elsayed, M.D., Mohamed Ghanem, M.D., Afaf Khalil, M.D., Abdel Naser Omar, M.D.
1:00 p.m. Sessions

COURSES 90-93

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 90
1:00 p.m.-5:00 p.m.
Room 3, Meeting Room Level, Renaissance Washington

FUNCTIONAL FAMILY THERAPY FOR BEHAVIOR DISORDERED ADOLESCENTS WITH PSYCHIATRIC COMORBIDITY

Director: René E. Breuk, M.D., Thomas L. Sexton, Ph.D.
Faculty: Lillian Smits, M.D.

COURSE 91
1:00 p.m.-5:00 p.m.
Room 12, Meeting Room Level, Renaissance Washington

BIOETHICS 2008

Director: Edmund G. Howe, M.D.

COURSE 92
1:00 p.m.-5:00 p.m.
Room 15, Meeting Room Level, Renaissance Washington

PSYCHIATRIC CARE OF THE HEPATITIS C PATIENT

Co-Directors: Muhamad Aly Rifai, M.D., Peter Hauser, M.D.
Faculty: David Indest, M.D., Julie Nelligan, Ph.D, Eric Dieperink, M.D.

COURSE 93
1:00 p.m.-5:00 p.m.
Room 16, Meeting Room Level, Renaissance Washington

INSANITY DEFENSE EVALUATIONS

Director: Phillip J. Resnick, M.D.

2:00 p.m. Sessions

FORUM 14

FORUM 14
12:00 noon-1:30 p.m.
Room 143A/B/C, Level One, Washington Convention Center

MILITARY PSYCHIATRY TODAY

Chp.: Elspeth C. Ritchie, M.D.
Participants: Capt. Robert Koffman, Lt. Col. Steve Pflanz
WEDNESDAY

PRESIDENTIAL SYMPOSIA 3-4

PRESIDENTIAL SYMPOSIUM 3
2:00 p.m.-5:00 p.m.
Room 152A, Level One, Washington Convention Center

THE MYTH OF THE MED CHECK

Chp.: Glen O. Gabbard, M.D.
Co-Chp.: Charles B. Nemeroff, M.D.

A The Myth of Med Check in Psychopharmacology
Charles B. Nemeroff, M.D.

B Deconstructing the Med Check
Glen O. Gabbard, M.D.

C Brief Medication Visits: When and How?
Alan F. Schatzberg, M.D.

D Using Targeted General Health Screening and Monitoring to Improve Outcomes and Reduce Adverse Events During Psychiatric Treatment
John W. Newcomer, M.D.

THIS SESSION WILL BE AUDIOTAPED.

PRESIDENTIAL SYMPOSIUM 4
2:00 p.m.-5:00 p.m.
Room 152B, Level One, Washington Convention Center

ADVOCATING WITH ONE VOICE FOR MENTAL HEALTH CARE IN THE UNITED STATES AND THE UNITED KINGDOM

Chp.: Sheila Hollins, M.D.
Co-Chp.: Carolyn B. Robinowitz, M.D.

A Advocating for Mental Health in Primary Care
Roger Banks, M.D.

B Advocacy as an Aspect of Professionalism
Dinesh Bhugra, M.D.

C Advocacy Through Partnerships With Users, Carers, and Non-Governmental Organizations
Sue Bailey, M.D.

D Advocacy for Government Support for Research and Funding of Mental Health Programs in the United States
Steven Sharfstein, M.D.

E Enhancing Public Awareness on Mental Health by Working With the Media in the U.S.
Nada Stotland, M.D.

F Anti-Stigma Campaigns With the Aid of Patient/Consumer Groups and High-Profile Individuals in the U.S.
Donna Norris, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 52-75

SYMPOSIUM 52
2:00 p.m.-5:00 p.m.
Room 101, Level One, Washington Convention Center

AN INTERSTATE COMPARISON OF EXCLUSIONS TO INVOLUNTARY CIVIL COMMITMENT LAWS: HAS A BIOETHICS SUCCESS COME UNDONE?

Chp.: Claire L. Pouncey, M.D.

A Ethical and Conceptual Issues
Claire L. Pouncey, M.D.

B Psychiatric Limitations of the Mental Retardation Exclusion
Fayez A. El Gabalawi, M.D.

C Legal Issues Raised by Exclusions in Civil Commitment Statutes
Karoline K. Adler, Esq.

D Policy Issues
Lawrence A. Real, M.D.

Discussants: Paul S. Appelbaum, M.D., Karoline Adler, Esq., Fayez El Gabalawi, M.D., Claire Pouncey, M.D., Lawrence Real, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 53
2:00 p.m.-5:00 p.m.
Room 102A/B, Level One, Washington Convention Center

DIMENSIONAL MODELS FOR PERSONALITY DISORDER ASSESSMENT

Chp.: Andrew E. Skodol, M.D.
Co-Chp.: Donna S. Bender, Ph.D.

A Persistence of Personality Disorder Psychopathology and Functional Impairment Over Time
Andrew E. Skodol, M.D., Maria E. Pagano, Ph.D., Donna S. Bender, Ph.D.

B Six-Year Stability of DSM-IV Schizotypal, Borderline, Avoidant, and Obsessive-Compulsive Personality Disorder Constructs
Charles A. Sanislow, Ph.D., Todd D. Little, Ph.D., Emily B. Ansell, Ph.D., Carlos M. Grilo, Ph.D., Thomas H. McGlashan, M.D.
C Prevalence and Persistence of Criteria for Schizotypal, Borderline, Avoidant, and Obsessive-Compulsive Personality Disorders at Six-year Follow-up
Emily B. Ansell, Ph.D., Charles A. Sanislow, Ph.D., Carlos M. Grilo, Ph.D., Robert L. Stout, Ph.D., Thomas H. McGlashan, M.D.

D T雷达tedness as an Indicator of Incremental Validity in the Five-Factor Model of PD Assessment
Megan B. Warner, Ph.D., Leslie C. Morey, Ph.D. Tracie M. Shea, Ph.D., Andrew E. Skodol, M.D., Carlos M. Grilo, Ph.D., Charles A. Sanislow, Ph.D., John C. Markowitz, M.D., Mary C. Zanarini, Ed.D.

E Predictors of Change in Personality Traits
Sara E. Lowmaster, M.S., Leslie C. Morey, Ph.D.
Discussants: John Oldham, M.D., Emily Ansell, Ph.D., Charles Sanislow, Ph.D., Andrew Skodol, M.D., Megan Warner, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 54 2:00 p.m.-5:00 p.m.
Room 103A/B, Level One, Washington Convention Center

GENE-ENVIRONMENT-DEVELOPMENT INTERACTIONS: IMPLICATIONS FOR PSYCHIATRIC AND ADDICTIVE DISORDERS
National Institute on Drug Abuse

Chp.: Jonathan D. Pollock, Ph.D.

A Role of MEF2 in Cocaine-Induced Synaptic and Behavioral Plasticity
Christopher W. Cowan, Ph.D., Suprabha Pulliparacharuvil, Ph.D., William Renthall, M.D., Carly Hale, M.D., Colleen Dewey, Avind Kumar, Ph.D., Eric Nestler, M.D., Ph.D.

B Epigenetic Influence of the Early Environment
Frances A. Champagne, Ph.D.

C MAOA by Maltreatment Gene x Environment Interaction and Children's Behavior Problems
Julia Kim-Cohen, Ph.D.

D How Gene X Environment Interactions Can Shape the Development of Emotional Regulation in Primates
Stephen Suomi, Ph.D.
Discussants: Stephen Suomi, Ph.D., Julia Kim-Cohen, Ph.D., Christopher Cowan, Ph.D., Frances A. Champagne, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 55 2:00 p.m.-5:00 p.m.
Room 140A, Level One, Washington Convention Center

UPDATE ON NEUROLEPTIC MALIGNANT SYNDROME WITH CASE REVIEWS

Chp.: Andrew J. Francis, M.D.

A Complications of Neuroleptic Malignant Syndrome (NMS)
Dora D. Kohen, M.D.

B The Pathophysiology and Treatment of NMS: Current Perspectives
Ronald J. Gurrera, M.D.

C A Naturalistic, Prospective Study of 53 Patients with Neuroleptic Malignant Syndrome (NMS) Secondary to Typical and Atypical Anti-psychotic Drugs
Patricia Rosebush, M.D., Michael Mazurek, M.D.

Discussants: Stanley Caroff, M.D., Ronald Gurrera, M.D., Dora Kohen, M.D., Patricia Rosebush, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 56 2:00 p.m.-5:00 p.m.
Room 144A/B, Level One, Washington Convention Center

DEMORALIZATION AND PSYCHOTHERAPY: RESEARCH ADVANCES AND CLINICAL IMPLICATIONS

Chp.: John M. de Figueiredo, M.D.

A Psychotherapy for Demoralization in the Physically Ill
David M. Clarke, M.B., M.B.BS., Ph.D.

B Psychotherapeutic Interventions for Mobilizing Hope in Demoralized Patients
James L. Griffith, M.D.

C Demoralization and the Course of PTSD: Two Years After Hurricane Mitch
Robert Kohn, M.D., Itzhak Levav, M.D.

Discussants: Julia Frank, M.D., Robert Kohn, M.D., David Clarke, M.B., James Griffith, M.D.

THIS SESSION WILL BE AUDIOTAPED.
WEDNESDAY

SYMPOSIUM 58 2:00 p.m.-5:00 p.m.
Room 144C, Level One, Washington Convention Center

DRUG ABUSE, HIV, HCV, AND THE BRAIN

Chp.: Lynda Erinoff, Ph.D.

A Pathogenesis of Hepatitis C Virus Coinfection in the Brains of Patients Infected With HIV
Eliezer Masliah, M.D.

B Neuroeconomics: New Approaches to Risky Decision Making
Gregory S. Berns, M.D., Ph.D.

C Neurologic and Psychiatric Complications of ART and Drug Interactions
Glenn J. Treisman, M.D., Ph.D.

D Methamphetamine and HIV: CNS Effects
Igor Grant, M.D.

E A New Basic Approach to Understand Dysregulation of Reward Systems in Substance Use
Martin P. Paulus, M.D., Kathryn L. Lovero, B.S., Jennifer Aron, B.S.

Discussions: Igor Grant, M.D., Eliezer Masliah, M.D., Glenn Treisman, M.D., Gregory Berns, M.D., Martin Paulus, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 59 2:00 p.m.-5:00 p.m.
Room 145A, Level One, Washington Convention Center

TREATMENT OF ADOLESCENT DEPRESSION: RESULTS FROM RECENT TRIALS AND IMPLICATIONS FOR PRACTICE

Chp.: Joel T. Sherrill, Ph.D.

A The Treatment of SSRI-Resistant Depression in Adolescents (TORDIA)
David A. Brent, M.D., Graham Emslie, M.D., Greg Clarke, Ph.D., Karen Wagner, M.D., Joan Asarnow, Ph.D., Marty Keller, M.D., Ben Vitiello, M.D., Louise Ritz, Ph.D.

B Delivering Evidence-Based Psychotherapy for Teen Depression in Primary care, With and Without Pharmacotherapy: Approaches, Issues, and Outcomes
Greg Clarke, Ph.D.

C Exporting Evidence-Based Depression Treatment to Primary Care Clinics: Impact on Adolescent Depression Outcomes
Joan R. Asarnow, Ph.D., Lisa Jaycox, Ph.D., Jeanne Miranda, Ph.D., Kenneth Wells, M.D., M.P.H

D The Treatment for Adolescents With Depression Study (TADS): Implications for Practice
John S. March, M.D., and the TADS Team

Discussions: Benedetto Vitiello, M.D., John S. March, M.D., David Brent, M.D., Joan Asarnow Ph.D., Greg Clarke Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 60 2:00 p.m.-5:00 p.m.
Room 145B, Level One, Washington Convention Center

RESEARCH UPDATE: CURRENT PROSPECTS FOR ENHANCED TREATMENTS FOR SCHIZOPHRENIA, MOOD DISORDERS, ANXIETY DISORDERS, AND SUBSTANCE ABUSE

Chp.: Husseini Manji, M.D.

A Treatments for Schizophrenia: Current Limitations and Future Promises
Jeffrey A. Lieberman, M.D.

B Translational Studies in Anxiety Disorders: New Insights and Treatments
Kerry Ressler, M.D., Ph.D.

C Genomic Approaches to the Treatment of Alcoholism
Charles O'Brien, M.D.

D Developing Improved Therapeutics for Refractory Mood Disorders
Carlos A. Zarate, Jr., M.D., Husseini K. Manji, M.D.

Discussions: Carlos Zarate, M.D., Kerry Ressler, M.D., Jeffrey Lieberman M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 61 2:00 p.m.-5:00 p.m.
Room 146C, Level One, Washington Convention Center

CARDIOMETABOLIC RISK DURING TREATMENT WITH ANTIPSYCHOTIC MEDICATIONS

Chp.: John W. Newcomer, M.D.

A Effects if Antipsychotic Medications on Metabolic End Points in the Adult Population
John W. Newcomer, M.D.

B Antipsychotic Medications and Metabolic and Cardiovascular Risk in Older Patients
Dilip V. Jeste, M.D.

C Clinician-Level Approaches
Michael J. Sernyak, M.D.

D Treatment Strategies to Prevent Weight Gain, Produce Weight Loss, or Improve Insulin Sensitivity in Response to Psychiatric Medications
Tonya Cohn, M.B.

Discussions: Dilip V. Jeste, M.D., Tonya Cohn, M.B., Michael Sernyak, M.D.
THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 62 2:00 p.m.-5:00 p.m.
Room 147A, Level One, Washington Convention Center

Chp.: John A. Talbott, M.D.
Co-Chp.: Francois C. Petitjean, M.D.

MOOD DISORDERS THROUGH THE LIFE CYCLE IN FRANCE AND THE UNITED STATES: “VIVE LA DIFFERENCE!”

A From the French Paradox to the French Program Against Depression
Frederic Rouillon, M.D.,

B How Well Do We Know How to Recognize and Address Infant and Early Childhood Depression?
Gisèle Apter-Danon, M.D.

C Reducing Suicidal Ideation and Depression in Older Primary Care Patients: Two-Year Outcomes of the Prospect Study
George S. Alexopoulos, M.D., Martha L. Bruce, Ph.D., Ira R. Katz, M.D., Ph.D., Charles F. Reynolds III, M.D., Thomas Ten Have, Ph.D., and the PROSPECT Group

D STAR*D: What Are the Take-Home Messages for Clinicians?
A. John Rush, M.D.

E Functional Neuroimaging Findings in Youth with Bipolar Disorder
Ellen Leibenluft, M.D., Brendan Rich, Ph.D., Melissa Brotman, Ph.D., Eric Nelson, Ph.D., Ken Towbin, M.D., Daniel Pine, M.D.

F Treating Mental Disorders of the Elderly in France: A Daring Fight or a Lost Cause?
Thierry Gallarda, M.D.

Discussants: Gisèle Apter-Danon M.D., Ellen Leibenluft M.D., Frederic Rouillon M.D., A. John Rush M.D., Thierry Gallarda M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 63 2:00 p.m.-5:00 p.m.
Room 147B, Level One, Washington Convention Center

STOP IT: YOU’RE MAKING ME SICK REVISITED: LANDMARKS IN THE STRUGGLE TO NORMALIZE LESBIAN AND GAY LIVES

Chp.: Gene A. Nakajima, M.D.
Co-Chp.: Serena Y. Volpp, M.D.

A Sexual Orientation and Psychiatric Diagnosis: Current Issues in DSM-IV and Moving Towards DSM-V
Benjamin H. McCommon, M.D.

B Strike While the Iron is Hot! Science and Social Forces and Ego-Dystonic Homosexuality
Robert P. Cabaj, M.D.

C How it all Started
Franklin Kameny, M.D.

D Eliminating Anti-Gay Diagnoses in the WHO’s International Classification of Disorders (ICD)
Gene A. Nakajima, M.D.

E From Disorder to Distonia: DSM-II and DSM-III
Richard C. Pillard, M.D.

Discussants: William Narrow, M.D., Nada L. Stotland, M.D., Franklin Kameny, M.D., Richard Pillard, M.D., Robert Cabaj, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 64 2:00 p.m.-5:00 p.m.
Room 149A/B, Level One, Washington Convention Center

DEPRESSION AMONG EMERGENCY DEPARTMENT PATIENTS IN LATIN-AMERICAN COUNTRIES

Chp.: Ruby C. Castilla-Puentes, M.D.
Co-Chp.: Carlos A. Leon-Andrade, M.D.

A Challenges in the Diagnosis of Depression in Emergency Departments
Arturo P. Grau, M.D.

B The Burden of Comorbid Depression in Emergency Departments in Latin America
Carlos Sanchez-Russi, Ph.D., Jorge Calle, M.D., Nuri Pena, MD., Wilma Castilla, M.D., Sandra Castilla, M.D., Ivan Gomez, M.D.

C Depression and Medical Comorbidity in Emergency Departments in Latin America
Ricardo Secin, M.D.

D Underlying Differences Between Depressed and Non-Depressed Patients in Emergency Departments
Roxana B. Galeno, M.D., Ruby Castilla, M.D., Ricardo Secin, M.D., Arturo Grau, MD, Marcelo de Mello,MD, Nuri Pena, MD.

Discussants: Bernardo Ng, M.D., Roxana Galeno, M.D., Ricardo O. Secin, M.D., Arturo Grau, M.D., Carlos Sanchez-Russi, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 65  2:00 p.m.-5:00 p.m.  
Room 150A, Level One, Washington Convention Center

COGNITIVE DYSFUNCTION IN BIPOLAR DISORDER

Chp.: Joseph F. Goldberg, M.D.  
Co-Chp.: Katherine E. Burdick, Ph.D.

A  A Clinician-Friendly Approach to Neurocognitive Assessment  
   Katherine E. Burdick, Ph.D.

B  Neurocognitive Deficits Across Illness Phases in Bipolar Disorder  
   Eduard Vieta, M.D., Ph.D., Anabel Martinez-Aran, Ph.D., 
   Carla Torrent, Ph.D.

C  Neurocognition as an Endophenotype in Bipolar Disorder  
   David Glahn, Ph.D., Carrie E. Bearden, Ph.D.

D  Beneficial and Adverse Cognitive Effects of Psychotropic Medications for Bipolar Disorder  
   Joseph F. Goldberg, M.D.

E  Attention and Cognitive Dysfunction in Pediatric Bipolar Disorder  
   Paula Shear, Ph.D., Melissa P. DelBello, M.D.

Discussants: Katherine Burdick, Ph.D., Eduard Vieta, M.D., 
   David Glahn, Ph.D., Joseph Goldberg, M.D., Paula Shear, Ph.D.  
   THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 66  2:00 p.m.-5:00 p.m.  
Room 150B, Level One, Washington Convention Center

THE SCIENTIFIC BASIS OF INTERPERSONAL DYSFUNCTION IN BORDERLINE PERSONALITY DISORDER

Chp.: Lois W. Choi-Kain, M.D.  
Co-Chp.: John G. Gunderson, M.D.

A  The Intrapsychic and Neurocognitive Basis of Interpersonal Dysfunction in BPD Patients  
   John F. Clarkin, Ph.D.

B  A Prospective Longitudinal View of Genetic Vulnerability and Quality of Early Care as Contributors to Borderline Features  
   Karlen Lyons-Ruth, Ph.D.

C  Interpersonal Stress Reactivity, Attachment, and Borderline Personality Disorder  
   Lois W Choi-Kain, M.D.

D  Can a Deficit in Mentalization Explain the Interpersonal Dysfunction in BPD?  
   Peter Fonagy, Ph.D.

E  BPD Relationships as a Phenotype  
   John G Gunderson, M.D.

Discussants: Glen Gabbard, M.D., John Clarkin, Ph.D., 
   Karlen Lyons-Ruth, Ph.D., Lois Choi-Kain, M.D., Peter Fonagy, Ph.D.  
   THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 67  2:00 p.m.-5:00 p.m.  
Room 151A, Level One, Washington Convention Center

DSM V: PHILOSOPHICAL AND CLINICAL CONSIDERATIONS

Chp.: Rodrigo A. Munoz, M.D.

A  Are Relational Problems Mental Disorders and Should They Be in DSM-V?  
   Christian D. Perring, Ph.D.

B  Vice in DSM-IV Diagnostic Criteria  
   John Sadler, M.D.

C  What is Moody? What is Bipolar?  
   S. Nassir Ghaemi, M.D.

D  Are Personality Disorders Infected With Moral Norms? Considerations From Virtue Theory  
   Peter Zachar, Ph.D.

Discussants: John Sadler, M.D., Peter Zachar, Ph.D., Christian Perring, Ph.D., 
   S. Nassir Ghaemi, M.D., Harold Eist, M.D.  
   THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 68  2:00 p.m.-5:00 p.m.  
Room 151B, Level One, Washington Convention Center

PHARMACOTHERAPY OF UNIPOLAR PSYCHOTIC DEPRESSION: RESULTS FROM THE NATIONAL INSTITUTE OF MENTAL HEALTH STOP-PD TRIAL

Chp.: Barnett S. Meyers, M.D.

A  Design Issues Related to Recruiting, Protecting, and Retaining Patients With Psychotic Depression in a Randomized, Controlled Pharmacotherapy Trial  
   Alastair J. Flint, M.B., Barnett Meyers, M.D., Benoit Mulsant, M.D., 
   Anthony Rothschild, M.D., Ellen Whyte, M.D., Ayal Schaffer, M.D., 
   Shelley Brook, M.D., Nathan Herrmann, M.D., Jose Silveira, M.D., 
   Kate Peasley Miklus, Ph.D., Moonseong Heo, Ph.D., Sonja Kasapinovic, M.Sc., 
   Camila Andrade, B.A., for the STOP-PD Study Group

B  Tolerability of Intensive Pharmacotherapy and Predictors of Attrition  
   Benoit H. Mulsant, M.D., Alastair Flint, M.B., Anthony J. Rothschild, M.D., 
   Ellen Whyte, M.D., Ariel Gildengers, M.D., Nancy McLaughlin, R.N., B.S.N., 
   Kate Peasley Miklus, Ph.D., Moonseong Heo, Ph.D., Barnett Meyers, M.D., 
   for the STOP-PD Study Group

82
C The Efficacy of Combination Pharmacotherapy Compared to Atypical Antipsychotic Monotherapy for Major Depression With Psychotic Features
Barnett S. Meyers, M.D., Alastair J. Flint, MB, ChB, Anthony J. Rothschild, M.D, Benoit H. Mulsant, M.D., Ellen M. Whyte, M.D., Catherine Peasley-Miklus, Ph.D., Eros Papademetriou, M.A., Moonseong Heo, Ph.D.

D Challenges in the Diagnosis and Treatment of Psychotic Depression
Anthony J. Rothschild, M.D., Alastair Flint, M.B., Benoit Mulsant, M.D., Ellen Whyte, M.D., Barnet Meyers, M.D., Jayendra Patel, M.D., Eric Smith, M.D., Nancy Byatt, M.D., Richard Cook, M.D., Kristina Deligiannidis, M.D., Philip Burke, M.D., Catherine Peasley-Miklus, Ph.D., Moonseong Heo, Ph.D., Susan Fratoni, B.A., R.N., Michelle Martin, B.A., Constance Wood, M.S.W., for the STOP-PD Study Group

E Neuropsychological Functioning in Patients With Psychotic Major Depression
Ellen M. Whyte, M.D., Alastair Flint, M.B., Benoit H. Mulsant, M.D., Anthony Rothschild, M.D., Kate Peasley-Miklus, Ph.D., Moonseong Heo, Ph.D., Eros Papademetriou, Faith Gunning-Dixon Ph.D., Barnet Meyers, M.D., for the STOP-PD Study Group

Discussants: Anthony J. Rothschild M.D., Alastair Flint, M.B., Barnet Mulsant M.D., Ellen Whyte, M.D., Barnett Meyers M.D., Benoit Mulsant M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 69 2:00 p.m.-5:00 p.m.
Room 154A/B, Level One, Washington Convention Center
PRIVACY AND FRAUD POLICIES AND ELECTRONIC HEALTH RECORDS

Chp.: Zebulon Taintor, M.D.
Co-Chp.: Richard K. Harding, M.D.

A Model Anti-Fraud Requirements for Electronic Health Records
Colleen McCue, Ph.D.

B Privacy and Electronic Health Records
Deborah C. Peel, M.D.

C Psychiatric Health Records as Sensitive Information
Mark A. Rothstein, J.D.

D National Health IT Agenda: Privacy and Security
Robert Kolodner, M.D.

E What the Certification Commission for Health Information Technology Might Do
Zebulon Taintor, M.D.

Discussants: Richard Harding, M.D., Robert Kolodner, M.D., Mark Rothstein, J.D., Colleen McCue, Ph.D., Zebulon Taintor, M.D.

THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 72  2:00 p.m.-5:00 p.m.  
Room 159A/B, Level One, Washington Convention Center  

TRANSFORMING THE PROVISION OF MENTAL HEALTH SERVICES: THE CalMEND PROJECT  

Chp.: Penny Knapp, M.D.  
Co-Chp.: Neal H. Adams, M.D.  

A CalMEND: An Initiative to Rationalize Care for Mentally Ill Persons Across State Systems in California  
Barry E. Handon, M.D., M.P.H.  

B Identifying Antipsychotic Polypharmacy and the Collaborative Performance Improvement Project  
Douglas Del Paggio, Pharm.D., M.P.H., Pauline Chan, R.Ph.  

C Antipsychotic Treatment Decisions: Who Determines Recovery of Function?  
Pauline Chan, R.Ph., Neal Adams, M.D., Ahn Thu Bui, M.D., Kim Tallian, Pharm.D.  

D Incorporating Both Family Support and Evidence-Based Practices in Treatment for Children  
Penelope K. Knapp, M.D.  

E Devising a Durable Treatment Plan Who Decides?  
Thu A. Bui, M.D., Neal Adams, M.D.  

Discussants: Barry Handon, M.D., Thu Bui, M.D., Penelope Knapp, M.D., Douglas Del Paggio, Pharm.D., Pauline Chan, R.Ph.  

THIS SESSION WILL BE AUDIOTAPED.  

SYMPOSIUM 73  2:00 p.m.-5:00 p.m.  
Room 201, Level Two, Washington Convention Center  

AFFECTIVE INSTABILITY IN BORDERLINE PERSONALITY DISORDER  
Chp.: Joel Paris, M.D.  

A Neural Correlates of Affective Instability in Borderline Personality Disorder  
Harold W. Koenigsberg, M.D., Larry J. Siever, M.D., Hedok Lee, Ph.D., Antonia S. New, M.D., Marianne Goodman, M.D., Hu Cheng, Ph.D., Janine Flory, Ph.D., Isak Prohovnik, Ph.D.  

B Stability and Variability of Affective Experience and Interpersonal Behavior in Borderline Personality Disorder  
Jennifer J. Russell, Ph.D., Moskowitz, D.S., Ph.D., David C. Zuroff, Ph.D., Debbie Sookman, Ph.D., Joel Paris, M.D.  

C The Interface Between BPD and Bipolar Disorder  
Joel Paris, M.D., John Gunderson, M.D., Igor Weinberg, Ph.D.  

D Clarifying the Nature of Affective Instability in Borderline Personality Disorder  
Paul S. Links, M.D., Rahel Eynan, M.A., Marnin J. Heisel, Ph.D., Rosane Nisenbaum, Ph.D., Denise Sum, B.A.  

Discussants: John Livesley, M.D., Jennifer Russell, Ph.D., Paul Links, M.D., Harold Koenigsberg, M.D., Joel Paris, M.D.  

SYMPOSIUM 74  2:00 p.m.-5:00 p.m.  
Room 207A, Level Two, Washington Convention Center  

COGNITIVE EFFECTS OF SECOND GENERATION ANTIPSYCHOTICS: EXPERIENCES FROM FIRST EPISODE STUDIES  
Chp.: Delbert Robinson, M.D.  

A Using Translational Cognitive Neuroscience Paradigms To Explore The Effects Of Second Generation Agents  
John A. Sweeney, Ph.D., Margret S. H. Harris, M.S., Scot K. Hill, Ph.D., James L. Reilly, Ph.D.  

B The Cognitive Effects of Risperidone, Olanzapine and Quetiapine In Patients With First Episode Psychosis  
Richard S. Keefe, Ph.D.  

C Multi-Dimensional Outcomes of Treatment of First Episode Schizophrenia With Second Generation Antipsychotics  
Delbert Robinson, M.D.  

D Cognitive Change With Treatment: Real Or Practice Effects?  
Terry E. Goldberg, Ph.D.  

Discussants: Philip D. Harvey, Ph.D., Delbert Robinson, M.D., Terry Goldberg, Ph.D., John Sweeney, Ph.D., Richard Keefe, Ph.D.  

SYMPOSIUM 75  2:00 p.m.-5:00 p.m.  
Room 207B, Level Two, Washington Convention Center  

MOOD DISORDERS AND MEDICAL COMORBIDITY, CAUSES AND CONSEQUENCES  
Chp.: Claus H. Sorensen, M.D.  

A Mood Disorders and Medical Comorbidity, Causes and Consequences  
Claus H. Sorensen, M.D.  

B Depression and Diabetes: Current Challenges and Future Directions  
Dominique L. Musselman, M.D.  

C Post Stroke Depression  
Grethe Andersen, M.D.
D Can Treatment of Depression Reduce Cardiac Risk
   Steven P. Roose, M.D.

Discussants: Claus Sørensen, M.D., Grethe Andersen, M.D.,
   Steven Roose, M.D., Dominique L. Musselman, M.D.

3:00 p.m. Session

NEW RESEARCH POSTER SESSION 7
3:00 p.m.-5:00 p.m.
West Lobby, Level One, Washington Convention Center

For further information on New Research submissions, please refer to the New Research Program Book included in your registration packet.

7:00 p.m. Session

INDUSTRY-SUPPORTED SYMPOSIA 26-29

INDUSTRY-SUPPORTED SYMPOSIUM 26
7:00 p.m.-10:00 p.m.
Ballroom A/B, Level Three, Washington Convention Center

NOVEL PERSPECTIVES TOWARDS A BETTER UNDERSTANDING OF MAJOR DEPRESSION DISORDER
Supported by: Bristol-Myers Squibb Company and Otsuka American Pharmaceuticals

A Combining Antidepressants: Is There Evidence for Synergy?
   Craig Nelson

B The Role of Glutamate in MDD Nonresponsive to Standard Therapies
   Sanacora Gerad, M.D.

C Augmentation Strategies in Treatment-Resistant Depression
   Maurizio Fava, M.D.

D The Role of Pharmacogenetics in Treatment-Resistant Depression
   Roy H. Perlis, M.D.

E Neurostimulation Approaches to Treatment-Resistant Depression
   Sarah Lisanby, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 27
7:00 p.m.-10:00 p.m.
Hall D, Level Two, Washington Convention Center

INDIVIDUALIZING TREATMENT PLANS FOR TOTAL HEALTH IN PATIENTS WITH BIPOLAR DISORDER
Supported by: Organon Pharmaceuticals USA Inc.

Chp.: Joseph R. Calabrese, M.D.

A Long-Term Treatment Strategies Tailored for Comorbid Presentations
   David Kemp, M.D.

B The Importance of Early Recognition and Treatment of Bipolar Disorder
   Karen D. Wagner, M.D., Ph.D.

C Improving Treatment Outcomes in Bipolar Disorder
   Robert M. Hirschfeld, M.D.

D Evidence-Based Approaches to Tailoring Individual Treatment Plan
   Terry Ketter, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 28
7:00 p.m.-10:00 p.m.
Grand Ballroom, Ballroom Level, Renaissance Washington

ADVANCING SCIENCE AND PRACTICE IN THE MANAGEMENT OF ADHD FROM CHILD TO ADULT: AN INTERACTIVE CASE PRESENTATION
Supported by Shire US, Inc.

Chp.: Joel Young, M.D.

A How Well Do We Recognize and Diagnose ADHD in Children and Adults?
   Aude Henin, Ph.D.

B Putting Our Voice to Action in the Management of Childhood ADHD
   Richard D'Alli, M.D.

C Adult ADHD: How Well Do We Recognize and Manage the Condition?
   Joel Young, M.D.

D What Is the Role of Non-Pharmacologic Therapy In ADHD?
   Scott H Kollins, Ph.D.
INDUSTRY-SUPPORTED SYMPOSIUM 29
7:00 p.m.-10:00 p.m.
Independence Ballroom, Independence Level, Grand Hyatt
Washington

BEYOND PAIN TO “FIBROFOG” AND SLEEP IMPAIRMENTS: IMPLICATIONS FOR NEUROCIRCUITRY AND TREATMENTS IN FIBROMYALGIA
Supported by: Pfizer Inc.

Chp.: Stephen M. Stahl, M.D.

A Managing Pain Symptoms in Fibromyalgia
Stephen M. Stahl, M.D., Ph.D., Sonia Ancoli-Israel, Ph.D,
Nikhil D. Nihalani, MD, Daniel J. Clauw, M.D.

B “Fibrofog”: Identifying and Treating Cognitive Dysfunction in Fibromyalgia
Stephen M. Stahl, M.D., Ph.D., Daniel J. Clauw, M.D.,
Nikhil D. Nihalani, M.D.

C Fibromyalgia and Sleep Impairment: How They Relate
Stephen M. Stahl, M.D., Ph.D., Daniel J. Clauw, M.D.,
Nikhil Nihalani, M.D., Sonia Ancoli-Israel, Ph.D.

D Indications of Fibromyalgia Origin and Mechanisms of Action of Treatment Options
Sonia Ana, M.D., Daniel J. Clauw, M.D., Nikhil Nihalani,
M.D., Stephen M. Stahl, M.D.
THURSDAY, MAY 8, 2008

161ST ANNUAL MEETING

7:00 a.m. Session

PART 2 OF INDUSTRY SUPPORTED BREAKFAST SYMPOSIA 25

INDUSTRY SUPPORTED BREAKFAST SYMPOSIUM 25, PART 2
7:00 a.m.- 8:30 a.m.
Ballroom A/B, Level Three, Washington Convention Center

PLAQUES AND TANGLES: APPLYING GENETICS AND MOLECULAR TARGETS TO UNRAVEL STRATEGIES FOR ALZHEIMER’S DISEASE
Supported by: Eisai

Chp.: Jacobo E. Mintzer, M.D.
Co-Chp.: Richard Mayeux, M.D.

A Molecular and Genetic Markers for AD: Is There a Role for Screening?
   Lindsay A. Farrer, Ph.D.

B Current Treatment Strategies for AD
   Jacobo E. Mintzer, M.D.

C Molecular Mechanisms of Neurodegenerative Diseases
   Peter H. St. George-Hyslop, M.D.

D Challenges Faced by Psychiatrists in the Management of AD: Ethnic, Genetic and Environmental Factors
   Jessica L. Broadway, M.D.

E Epidemiology of AD: Unraveling the Tangle of Information
   Richard Mayeux, M.D.

8:00 a.m. Sessions

COURSES 94-95
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 94 8:00 a.m.-12 noon
Room 3, Meeting Room Level, Renaissance Washington

SYSTEMIC THERAPIES FOR SUBSTANCE ABUSE DISORDERS

Co-Directors: Peter Steinglass, M.D., Marc Galanter, M.D.

COURSE 95 8:00 a.m.-12 noon
Room 4, Meeting Room Level, Renaissance Washington

HOW TO PRACTICE BRIEF PSYCHODYNAMIC PSYCHOTHERAPY: THE CORE CONFLICTUAL RELATIONSHIP THEME METHOD

Director: Howard E. Book, M.D.

9:00 a.m. Sessions

WORKSHOPS

ISSUES 73-99

ISSUE WORKSHOP 73 9:00 a.m.-10:30 a.m.
Room 101, Level One, Washington Convention Center

THE HISTORY OF WORLD PSYCHIATRY: CONTENT AND CONSEQUENCES

Chp.: Milton Kramer, M.D.
Participants: Prakash Desai, M.D., Douglas Lehrer, M.D.

ISSUE WORKSHOP 74 9:00 a.m.-10:30 a.m.
Room 102A/B, Level One, Washington Convention Center

THE FUTURE OF PSYCHIATRY: UTILIZING A NEURODEVELOPMENTAL MODEL FOR CASE FORMULATION

Co-Chps.: Jennifer L. McLaren, M.D., Robert L. Hendren, D.O.
Participants: Daniel Weinberger, M.D., Charles Nemeroff, M.D., Jean Frazier M.D.

ISSUE WORKSHOP 75 9:00 a.m.-10:30 a.m.
Room 103A/B, Level One, Washington Convention Center

AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY UPDATE: CERTIFICATION AND MAINTENANCE OF CERTIFICATION IN PSYCHIATRY AND ITS SUBSPECIALTIES

Chp.: Larry R. Faulkner, M.D.
Participants: Barbara Schneiderman M.D., Burton V. Reifler M.D., Naleen Andrade, M.D., David Mrazek, M.D., Victor Reus, M.D.
THURSDAY

ISSUE WORKSHOP 76 9:00 a.m.-10:30 a.m.  
Room 140A, Level One, Washington Convention Center  
DEVELOPMENTS IN THE ASSESSMENT OF CAPACITY, STATUTORY CHANGES, AND ADMINISTRATIVE AIDS: THE ROAD TO LESS LITIGATION  
Co-Chps.: Michael J. Wise, M.D., Julian Beezhold, M.D.

ISSUE WORKSHOP 77 9:00 a.m.-10:30 a.m.  
Room 140B, Level One, Washington Convention Center  
CONTROVERSIES IN BIPOLAR DISORDER: A CLINICAL PERSPECTIVE  
Chp.: Gary E. Miller, M.D.  
Participant: Richard Noel, M.D.

ISSUE WORKSHOP 78 9:00 a.m.-10:30 a.m.  
Room 141, Level One, Washington Convention Center  
ATHEROGENIC DYSLIPIDEMIA IN PATIENTS TREATED WITH ATYPICAL ANTIPSYCHOTICS  
Chp.: Peter Manu, M.D.  
Participant: Mariana Roida, M.D.

ISSUE WORKSHOP 79 9:00 a.m.-10:30 a.m.  
Room 142, Level One, Washington Convention Center  
PATIENT SIMULATION: BRITISH AND AMERICAN ADAPTATIONS FOR PSYCHIATRIC EDUCATION OF MEDICAL STUDENTS  
Co-Chps.: Julia Z. Frank, M.D., Subodh Dave, M.D.

ISSUE WORKSHOP 80 9:00 a.m.-10:30 a.m.  
Room 144C, Level One, Washington Convention Center  
MEDICAL LEGAL ASPECTS OF PSYCHIC TRAUMA: A FAMILY APPROACH  
Co-Chps.: Michael Hughes, M.D., Jon A. Shaw, M.D.

ISSUE WORKSHOP 81 9:00 a.m.-10:30 a.m.  
Room 146C, Level One, Washington Convention Center  
IRAQ ON THE GROUND: THE REAL STORY THROUGH A PSYCHIATRIST’S LENS  
Chp.: Anita S. Everett, M.D.  
Participants: Mohammed Al-Zuri, M.D., Allen Dyer, M.D.

ISSUE WORKSHOP 82 9:00 a.m.-10:30 a.m.  
Room 147A, Level One, Washington Convention Center  
ENHANCING THE MILIEU DEVELOPMENT OF A COMPREHENSIVE INPATIENT CBT PROGRAM  
Co-Chps.: Katherine L. Lynch, Ph.D., Jean Kim, M.D.  
Participants: Virginia Susman, M.D., Courtney Berry, M.A.

ISSUE WORKSHOP 83 9:00 a.m.-10:30 a.m.  
Room 147B, Level One, Washington Convention Center  
SECOND CHANCE PROGRAM: TEN YEARS OF SUCCESSFULLY TREATING THE TREATMENT REFRACTORY PATIENT WITH SCHIZOPHRENIA  
Chp.: Adam J. Savitz, M.D.  
Participants: Andrew Bloch, M.S.W., Barbara-Ann Bybel, B.S.N., Steven Silverstein, Ph.D.

ISSUE WORKSHOP 84 9:00 a.m.-10:30 a.m.  
Room 150A, Level One, Washington Convention Center  
IS THERE A ROLE FOR COMPLEMENTARY AND ALTERNATIVE MEDICINE IN THE TREATMENT OF DEPRESSION?  
Chp.: Meera Narasimhan, M.D.  
Participants: Shilpa Srinivasan, M.D., Travis Bruce, M.D.

ISSUE WORKSHOP 85 9:00 a.m.-10:30 a.m.  
Room 150B, Level One, Washington Convention Center  
INSECURITY, VIOLENCE, AND TRAUMA IN HAITI: CLINICAL IMPLICATIONS  
Haitian-American Psychiatric Association  
Co-Chps.: Jacques Vital-Herne, M.D., Pierre Jean-Noel, M.D.  
Participants: Joseph Clerisme, M.D., Georges Casimir, M.D.

ISSUE WORKSHOP 86 9:00 a.m.-10:30 a.m.  
Room 151A, Level One, Washington Convention Center  
THE CLINICIAN’S ROLE IN CHANGING THE LIGHT BULB  
Co-Chps.: Marcia Scott, M.D., Paul Pendler, Psy.D.  
Participants: Marilyn Price, M.D., Dennis Egnatz, A.B.

ISSUE WORKSHOP 87 9:00 a.m.-10:30 a.m.  
Room 151B, Level One, Washington Convention Center  
REDUCING INPATIENT SUICIDE FOR KIDS: PRACTICAL STRATEGIES FOR THE INPATIENT TEAM  
Co-Chps.: Meena Ramani, M.D., Nyapati R. Rao, M.D.  
Participants: Sadaf Javaid, M.D., Nicholas Forlenza, Ph.D., Noumana Hameed, M.D.
ISSUE WORKSHOP 88 9:00 a.m.-10:30 a.m.  
Room 152A, Level One, Washington Convention Center  
RISK MANAGEMENT ISSUES IN PSYCHIATRIC PRACTICE  
Co-Chps.: Jacqueline M. Melonas, J.D., Martin G. Tracy, J.D.  
Participants: Charles Cash, J.D., Donna Vanderpool, J.D.

ISSUE WORKSHOP 89 9:00 a.m.-10:30 a.m.  
Room 152B, Level One, Washington Convention Center  
ADOPTION PSYCHIATRIST ON THE MOVE  
Co-Chps.: Victor J. Buwalda, M.D., Michelle Riba, M.D.  
Participants: Christine Van Boeijen, M.D.

ISSUE WORKSHOP 90 9:00 a.m.-10:30 a.m.  
Room 153, Level One, Washington Convention Center  
THE CHILD PSYCHIATRIST AS GRANDPARENT: GRAND JOYS AND GRAND CHALLENGES  
Co-Chps.: Ellen H. Sholevar, M.D., G. Pirooz Sholevar, M.D.

ISSUE WORKSHOP 91 9:00 a.m.-10:30 a.m.  
Room 155, Level One, Washington Convention Center  
THE SCIENCE OF LIFE: THE APPLICATION OF AYURVEDA IN MENTAL HEALTH  
Co-Chps.: Aravinda Kolan, M.D., Karl Goodkin, M.D.  
Participants: Tara Klein, M.D., Norana Caivano, M.D.

ISSUE WORKSHOP 92 9:00 a.m.-10:30 a.m.  
Room 156, Level One, Washington Convention Center  
COGNITIVE DYSFUNCTION IN SUBSTANCE DEPENDENCE: TYPES OF DEFICITS AND THEIR POSSIBLE MODULATION  
National Institute on Drug Abuse  
Chp.: Frank J. Voci, Ph.D.  
Participants: Warren Bickel, Frederick Moeller, M.D., Anna Rose Childress, Ph.D., William Fals-Stewart, Ph.D.

ISSUE WORKSHOP 93 9:00 a.m.-10:30 a.m.  
Room 157, Level One, Washington Convention Center  
BRAIN SUBSTRATES OF IMPAIRED ERROR DETECTION, MORAL JUDGMENT, AND AGENCY AS CORE DEFICITS IN SUBSTANCE ABUSE  
National Institute on Drug Abuse  
Chp.: Steven Grant, Ph.D.  
Participants: Kent Kiehl, Ph.D., Janet Metcalfe, Ph.D., Jordan Grafman, Ph.D., Hugh Garavan

ISSUE WORKSHOP 94 9:00 a.m.-10:30 a.m.  
Room 158A/B, Level One, Washington Convention Center  
PRACTITIONER FEEDBACK ON NIMH's CLINICAL TREATMENT TRIALS  
National Institute of Mental Health  
Co-Chps.: John K Hsiao, M.D., Barry D. Lebowitz, Ph.D.  
Participants: A. John Rush, M.D., Barry D. Lebowitz, Ph.D., Thomas Stroup M.D., Andrew A. Nierenberg, M.D.

ISSUE WORKSHOP 95 9:00 a.m.-10:30 a.m.  
Room 159A/B, Level One, Washington Convention Center  
PRIMARY CARE DEPRESSION MANAGEMENT: THE DESIGN AND IMPLEMENTATION OF A FOCUSED ACUTE PHASE MEDICATION MANAGEMENT QUALITY IMPROVEMENT PROGRAM  
Chp.: Robert C. Joseph, M.D.  
Participants: Amy Bauer, M.D., Carleen Riselli, R.N.C.

ISSUE WORKSHOP 96 9:00 a.m.-10:30 a.m.  
Room 160, Level One, Washington Convention Center  
INSIGHT AND AWAKENING MINDFULNESS AND PSYCHOTHERAPY  
Co-Chps.: Anjali C. Dsouza, M.D., James L. Griffith, M.D.  
Participants: Anjali Dsouza M.D.

ISSUE WORKSHOP 97 9:00 a.m.-10:30 a.m.  
Room 201, Level Two, Washington Convention Center  
TRANSFORMING THE LOCAL MENTAL HEALTH SYSTEM: A PERSON-CENTERED PROGRAM  
Chp.: John S. McIntyre, M.D.  
Participants: Adele Gorges, B.A., Lloyd Sederer, M.D.

ISSUE WORKSHOP 98 9:00 a.m.-10:30 a.m.  
Room 207A, Level Two, Washington Convention Center  
SO YOU WANT TO BE A CLINICAL INVESTIGATOR!  
Chp.: Arthur L. Lazarus, M.D.  
Participants: Andrew Cutler, M.D., Katherine Wisner ,M.D., S. Charles Schulz, M.D.

ISSUE WORKSHOP 99 9:00 a.m.-10:30 a.m.  
Room 207B, Level Two, Washington Convention Center  
BIOPSYCHOSOCIAL AND SPIRITUAL ASPECTS OF TREATING OUR PHYSICIAN COLLEAGUES  
Chp.: Monisha R. Vasa, M.D.  
Participants: Syed Naqvi, M.D., Amy Dewar, M.D., Alicia Ruelaz, M.D., Michael Myers, M.D.
THURSDAY

SYMPOSIA 76-77

SYMPOSIUM 76 9:00 a.m.-12:00 noon
Room 145A, Level One, Washington Convention Center

TRANSLATIONAL RESEARCH ON OBSESSIVE-COMPULSIVE DISORDER

Chp.: Benjamin D. Greenberg, M.D.

A  DBS of the Ventral Internal Capsule/Ventral Striatum for OCD: Experience, Effects and Potential Mechanisms
Benjamin D. Greenberg, M.D., Ph.D., Loes Gabriels, M.D. Ph.D., Donald Malone, M.D., Nathan A. Shapira, M.D., Ph.D., Michael Okun, M.D., Ph.D., Gerhard Friehs, M.D., Ali Rezai, M.D., Kelly Foote, M.D., Ph.D., Donald Malone, M.D., Nathan A. Shapira, M.D., Ph.D., Michael Okun, M.D., Ph.D., Gerhard Friehs, M.D., Ali Rezai, M.D., Kelly Foote, M.D., Ph.D., Paul Cosyns, M.D., Cynthia Kubu, Ph.D., Paul Malloy, Ph.D., Stephen Salloway, M.D., Ph.D., Wayne Goodman, M.D., Bart Nuttin M.D., Ph.D., Steven Rasmussen, M.D.

B  The Utility of Genetic Research to Identify Etiologically Distinct Syndromes Amenable to Advancing Treatment Options
Gerald Nestadt, M.D., M.P.H.

C  The Potential and Pitfalls of Animal Models of OCD: A Clinical Perspective
Helen Blair Simpson, M.D., Stephanie Dulawa, Ph.D., Abby Fyer, M.D., Rene Hen, Ph.D., David Leonardo, M.D., Ph.D., Michael Liebowitz, M.D., Susanne Ahmari, M.D., Ph.D.

D  Targeting Glutamate: Novel Treatment Interventions for OCD
Vladimir Coric, M.D.

Discussants: Steven Rasmussen, M.D., Gerald Nestadt, M.D., M.P.H., Benjamin Greenberg, M.D., Helen Blair Simpson, M.D., Vladimir Coric, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 77 9:00 a.m.-12:00 noon
Room 145B, Level One, Washington Convention Center

ASSESSING AND REDUCING RISK OF VIOLENCE AMONG PEOPLE WITH SCHIZOPHRENIA AND OTHER MENTAL DISORDERS

Chp.: John Monahan, Ph.D.

A  Facilitating Treatment Engagement to Lower Risk of Violence
Eric B. Elbogen, Ph.D.

B  Schizophrenia and Risk Factors for Community Violence: Does Antipsychotic Treatment Reduce Risk?
Jeffrey W. Swanson, Ph.D.

C  Violence Risk and Mandated Community Treatment
Marvin S. Swartz, M.D.

Discussants: Paul S. Appelbaum, M.D., Jeffrey Swanson, Ph.D., Marvin Swartz, M.D., Eric Elbogen, Ph.D.

CASE CONFERENCE 4
9:00 a.m.-12 noon
Room 149A/B, Level One, Washington Convention Center

PSYCHODYNAMIC PSYCHOTHERAPY: EROTIC TRANSFERENCE AND THE FEMALE THERAPIST

Moderator: Glen O. Gabbard, M.D.
Ppresenters: Gabrielle S. Hobday, M.D., Lisa A. Mellman, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

11:00 a.m. Sessions

ADVANCES IN MEDICINE 4
11:00 a.m.-12:30 p.m.
Room 147A, Level One, Washington Convention Center

INTERNAL MEDICINE UPDATE 2007: A JOURNAL ROUNDPUP

Chp.: Robert J. Boland, M.D.
Presenter: Monique Yohanan, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSIONS 27-29

SCIENTIFIC AND CLINICAL REPORT SESSION 27 11:00 a.m.-12:30 p.m.
Room 101, Level One, Washington Convention Center

PSYCHOPHARMACOLOGY OF SCHIZOPHRENIA

78  Racial Differences in Prescribing Practices in the Treatment of Schizophrenia
Karen Bullock, Ph.D., Bonnie L. Szarek, R.N., John W. Goether, M.D.

79  Risperidone Alone Versus Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility
Leslie Citrome, M.D., Constance B. Shope, Ph.D., Karen A. Nolan, Ph.D., Pal Czobor, Ph.D., Jan Volavka, M.D., Ph.D.
80  Asenapine in Schizophrenia: An Overview of Clinical Trials in the Olympia Program
Steven G. Potkin, M.D., John M. Kane, M.D., Robin A. Emsley, M.D., Dieter Naber, M.D., John Panagides, Ph.D.

SCIENTIFIC AND CLINICAL REPORT SESSION 28
11:00 a.m.-12:30 p.m.
Room 140A, Level One, Washington Convention Center

ATTENTION DEFICIT DISORDER IN ADULTS
81  Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
Lenard Adler, M.D., David W. Goodman, M.D., Scott H. Kollins, Ph.D., Richard Weisler, M.D., Suma Krishnan, M.S., M.B.A., Yuxin Zhang, Ph.D., Joseph Biederman, M.D.

82  Adult Attention-Deficit/Hyperactivity Disorder in an Anxiety Disorders Population
Michael Van Ameringen, M.D., Catherine Mancini M.D., F.R.C.P.C., Beth Patterson, B.ScN., B.Ed., Bill Simpson, B.Sc., Wendy Freeman, Ph.D.

83  Inattention and Hyperactivity Symptoms in Individuals at Risk for Psychosis
Juha M. Veijola, Ph.D., Mervi Ilmarinen, Marika Kaakinca, B.A., Jouko Miettunen, Ph.D., Irma Moilanen, M.D., Anja Taanila, Ph.D., Hanna Ebeling, M.D., Tuula Hurtig, Ph.D., Pirjo Mäki, M.D., Erika Lauronen, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 29
11:00 a.m.-12:30 p.m.
Room 140B, Level One, Washington Convention Center

TOPICS IN MOOD DISORDERS
84  Patients’ Involvement in Treatment Decisions and Antidepressant Discontinuation
Stephen Woolley, D.Sc., Lisa Fredman, Ph.D., John W. Goethe, M.D., Alisa Lincoln, Ph.D., Timothy Heeren, Ph.D.

85  Prevalence and Characteristics of Bipolar Mixed Depression in STEP-BD Patients
Joseph Goldberg, M.D., Roy H. Perlis, M.D., S. Nassir Ghaemi, M.D., Lauren Marangell, M.D., Andrew A. Nierenberg, M.D., Gary S. Sachs, M.D., Michael E. Thase, M.D.

86  Depressive Symptoms Predispose Females to Metabolic Syndrome: A Population-Based 7-Year Follow-Up Study
Hannu Koponen, M.D., Mauno Vanhala, M.D., Jari Jokelainen, M.Sc., Sirkka Keinänen-Kiukaanniemi, M.D., Esko Kumpusalo, M.D.

THIS SESSION WILL BE AUDIOTAPED.
ISSUE WORKSHOP 105 11:00 a.m.-12:30 p.m.
Room 150B, Level One, Washington Convention Center
WHERE IS THE LINE DRAWN? IS THERE A CLINICAL INTERFACE BETWEEN AUTISM SPECTRUM DISORDERS AND BIPOLAR DISORDER IN CHILDREN AND ADOLESCENTS?
Chp.: Michelle S. Guchereau, M.D.
Participants: Gabrielle Carlson, M.D., Fred Volkmar, M.D., Jay Salpekar, M.D.

ISSUE WORKSHOP 106 11:00 a.m.-12:30 p.m.
Room 151A, Level One, Washington Convention Center
TRANSFORMING MENTAL HEALTH CARE IN SOUTH CAROLINA: A PERSPECTIVE ON STRENGTHENING PARTNERSHIPS BETWEEN ACADEMIA AND THE DEPARTMENT OF MENTAL HEALTH
Chp.: Richard K. Harding, M.D.
Participants: Ronald Prier, M.D., Meera Narasimhan, M.D., Brenda Ratliff, M.D.

ISSUE WORKSHOP 107 11:00 a.m.-12:30 p.m.
Room 152A, Level One, Washington Convention Center
CHILDREN OF PSYCHIATRISTS
Co-Chps.: Michelle B. Riba, M.D., Leah J. Dickstein, M.D.
Participants: Kevin McIntyre, M.D., William Raskin, Hanna Stotland, A.B.

ISSUE WORKSHOP 108 11:00 a.m.-12:30 p.m.
Room 152B, Level One, Washington Convention Center
INFLAMMATION, PSYCHOSIS, AND THE BRAIN: WHAT DO WE REALLY KNOW?
Chp.: Tatiana Falcone, M.D.
Participants: Damir Janigro, Ph.D., Kathleen Franco, M.D., Omar Fattal, M.D., Matthias Rothermundt, M.D.

ISSUE WORKSHOP 109 11:00 a.m.-12:30 p.m.
Room 153, Level One, Washington Convention Center
STRESS RESPONSE AND WOMEN'S HEALTH: A LITERATURE REVIEW AND BIOPSYCHOSOCIAL PERSPECTIVE
Chp.: Lucila Sloninsky, M.D.

ISSUE WORKSHOP 110 11:00 a.m.-12:30 p.m.
Room 154A/B, Level One, Washington Convention Center
IMPROVING, INTERFERING, OR INANE: CURRENT LESSONS FROM FORMAL PATIENT FEEDBACK TO PSYCHIATRISTS
Chp.: Jacob E. Sperber, M.D.
Participants: Aleksandar Micevski, M.D., Nyapati Rao, M.D., Amandeep Nagra, M.D.

ISSUE WORKSHOP 111 11:00 a.m.-12:30 p.m.
Room 155, Level One, Washington Convention Center
MY PATIENT IS STALKING ME: MANAGEMENT OF EROTOMANIA IN RESIDENCY AND BEYOND
Chp.: Kenneth M. Certa, M.D.
Participants: Amy McAndrew, M.D., Kathleen Dougherty, M.D.

ISSUE WORKSHOP 112 11:00 a.m.-12:30 p.m.
Room 156, Level One, Washington Convention Center
APPLICATION OF CULTURAL VARIABLES FOR EFFECTIVE PSYCHOTHERAPY OF THE MIGRANT ASIAN POPULATION IN THE US
Co-Chps.: Vijoy K. Varma, M.D., Nitin Gupta, M.D.

ISSUE WORKSHOP 113 11:00 a.m.-12:30 p.m.
Room 157, Level One, Washington Convention Center
WOMEN SERVING LIFE SENTENCES: CRIME, PUNISHMENT, AND TREATMENT
Co-Chps.: Sharon S. Snow, Psy.D., Daun H. Martin, Ph.D.
Participants: Lori Williams, Ph.D.

ISSUE WORKSHOP 114 11:00 a.m.-12:30 p.m.
WITHDRAWN

ISSUE WORKSHOP 115 11:00 a.m.-12:30 p.m.
Room 160, Level One, Washington Convention Center
INNOVATIVE MODELS FOR EXTENDING PSYCHIATRIC CARE TO CHILDREN
Chp.: Radmila Bogdanich, M.A.
Participants: Mary Dobbins M.D., John Record, M.A., Deborah Seale, B.A., Nicole Roberts, Ph.D., Sandra Vicari, Ph.D.

ISSUE WORKSHOP 116 11:00 a.m.-12:30 p.m.
Room 201, Level Two, Washington Convention Center
A FEDERAL PERSPECTIVE ON REDUCING MENTAL HEALTH DISPARITIES: HOW CAN PSYCHIATRY PARTICIPATE
Substance Abuse and Mental Health Services Administration
Co-Chps.: Francis G. Lu, M.D., Lark Huang, Ph.D.
Participants: Kenneth Thompson, M.D., Kana Enomoto, M.A.
ISSUE WORKSHOP 117 11:00 a.m.-12:30 p.m.
Room 207A, Level Two, Washington Convention Center

PSYCHIATRY TRAINING FOR PRIMARY CARE PHYSICIANS: AN ONGOING CHALLENGE

Chp.: Hoyle Leigh, M.D.
Participants: Don Lipsitt, M.D., Seth Powsner, M.D., Jon Streltzer, M.D.

ISSUE WORKSHOP 118 11:00 a.m.-12:30 p.m.
Room 207B, Level Two, Washington Convention Center

HUMOR AND HUMANS: A NEW TREATMENT MODALITY FOR PATIENTS WITH DEPRESSION

Co-Chps.: Anna Bokarius, B.A., Waguih W. IsHak, M.D.
Participants: Ed Dunkelblau, Ph.D.

12:00 noon Sessions

FORUM 15-16

FORUM 15 12:00 noon-1:30 p.m.
Room 102A/B, Level One, Washington Convention Center

HOW TO DECIDE WHETHER TO, WHAT, AND HOW TO SUBMIT TO THE APA ANNUAL MEETING: UNDERSTANDING MEMBERS' INTERESTS AND DIFFERENT FORMATS

Chp.: Donald M. Hilty, M.D.
Co-Chp.: Deborah Spitz, M.D.
Presenters: Deborah Spitz, M.D., Michele T. Pato, M.D., Kenneth M. Silk, M.D., Donald M. Hilty, M.D.

FORUM 16 12:00 noon-1:30 p.m.
Room 144A/B, Level One, Washington Convention Center

GRADING THE STATE PSYCHIATRIC SYSTEMS

Chp.: Anand Pandya, M.D.
Participants: Laudan Aron, B.S.C., Ronald Honberg, J.D., Kenneth S. Duckworth M.D.

2:00 p.m. Sessions

SYMPOSIA 78-98

SYMPOSIUM 78 2:00 p.m.-5:00 p.m.
Room 101, Level One, Washington Convention Center

AIDS PSYCHIATRY IN 2008
Chp.: Mary Ann Cohen, M.D.
Co-Chp.: Marshall Forstein, M.D.

A Methamphetamine and HIV Treatment
   Antoine Douaihy, M.D.

B Update on HIV Treatment in Severally Mentally Ill
   Francine Cournos, M.D.

C HIV-Associated Sleep Disorders: A Comprehensive Approach
   Harold W. Goforth, M.D.

D A Biopsychosocial Approach to AIDS: The 27th Year
   Mary Ann Cohen, M.D.

E Psychotherapeutic Aspects of Lipodystrophy in Persons with AIDS
   Marshall Forstein, M.D.

F HIV-Associated Neurocognitive Disorders: An Update
   Steve Ferrando, M.D.

Discussants: Mary Ann Cohen, M.D., Harold W. Goforth, M.D., Steve Ferrando, M.D., Francine Cournos, M.D., Marshall Forstein, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 79 2:00 p.m.-5:00 p.m.
Room 102A/B, Level One, Washington Convention Center

Chp.: James L. Griffith, M.D.

RELIGION THAT HEALS, RELIGION THAT HARMS: WHAT IS THE PLACE OF PSYCHIATRY?

A When Religion Does Harm: How Do I Respond As a Clinician?
   James L. Griffith, M.D.

B Killing in the Name of God
   Jerrold M. Post, M.D.

C Working With the Religious Aspect of Patients' Moral Concerns
   John Peteet, M.D.

D Cults: Faith, Healing and Coercion
   Marc Galanter, M.D.

Discussants: James Griffith, M.D., Jerrold Post, M.D., John Peteet, M.D., Marc Galanter, M.D.
THIS SESSION WILL BE AUDIOTAPED.
Symposium 80  2:00 p.m.–5:00 p.m.
Room 103A/B, Level One, Washington Convention Center

**Behavioral and Psychological Symptoms of Dementia (BPSD): An Update**

Chp.: Kirsten M. Wilkins, M.D.
Co-Chp.: Rajesh R. Tampi, M.D.

A  Inappropriate Sexual Behaviors in Dementia: A Review
   Karin E. Kerfoot, M.D.

B  Behavioral and Psychological Symptoms of Dementia: An Evidence-Based Review
   Kirsten M. Wilkins, M.D.

C  Risk of Stroke and Death in Elderly Demented Patients Treated With Atypical Antipsychotics: A Review of Published Data
   Rehan Aziz, M.D.

**Discussants:** Kirsten M. Wilkins, M.D., Karin Kerfoot, M.D., Rehan Aziz, M.D.

**This Session Will Be Audiorecorded.**

Symposium 81  2:00 p.m.–5:00 p.m.
Room 140A, Level One, Washington Convention Center

**Mentalizing as a Framework for Effective Psychotherapy**

Chp.: Jon G. Allen, Ph.D.
Co-Chp.: John M. Oldham, M.D.

A  Promoting Mentalizing in Individual and Group Psychotherapy
   Prof. Anthony W. Bateman, M.D., F.R.C.Psych.

B  What Is Distinctive About Mentalizing?
   Jon G. Allen, Ph.D.

C  What Does Mentalizing Leave Out? A Cognitive-Behavior Therapist’s Perspective
   Thöröstr Björgvinsson, Ph.D., John Hart, M.A.

D  Mentalization and Developmental Psychopathology
   Peter Fonagy

**Discussants:** Jon Allen, Ph.D., Peter Fonagy, Anthony Bateman M.D., Thöröstr Björgvinsson Ph.D.

**This Session Will Be Audiorecorded.**

Symposium 82  2:00 p.m.–5:00 p.m.
Room 140B, Level One, Washington Convention Center

**Parasomnias, Violence and the Law**

Chp.: Clarence Watson, J.D.

A  Overview of Parasomnias I: A Review for Psychiatric Practice
   Dimitri Markov, M.D., Karl Doghramji, M.D.

B  Sexsomnia: Phenomenology and Forensic Implications
   Elena delBusto, M.D.

C  Evaluation of Childhood Parasomnias as a Predictor for Future Sleep Violence
   Nicole Foubister, M.D.

D  Overview of Parasomnias II: A Review for Psychiatric Practice
   Karl Doghramji, M.D., Dimitri Markov, M.D.

E  Sleep Disorders, Violence and Criminal Responsibility
   Kenneth J. Weiss, M.D.

**Discussants:** Clarence Watson, J.D., Dimitri Markov, M.D., Karl Doghramji, M.D., Nicole Foubister, M.D., Elena delBusto, M.D.

**This Session Will Be Audiorecorded.**

Symposium 83  2:00 p.m.–5:00 p.m.
Room 144C, Level One, Washington Convention Center

**Quality and Outcome Assessment in Diverse Clinical Settings**

Chp.: Victor J. Buwalda, M.D.
Co-Chp.: Richard C. Hermann, M.D.

A  Implementation and Use of Outcome Assessments as Quality Indicators in Long Term Mental Health Care
   Annet A. Nugter, Ph.D., W. Teer, M.D.

B  Health of the Nation Outcome Scales and Questionnaire: Tools for Routine Clinical Outcome Measures for Moderate to Severe Mental Illnesses
   Victor J. A. Buwalda, M.D., Jan H. Smit, PhD, Jan A. Swinkels, M.D., Ph.D., Willem van Tilburg, M.D., Ph.D.

C  Is the Effectiveness of Quality Improvement Associated With Organizational Fit?
   Richard C. Hermann, M.D., Susan Stockdale, Ph.D., Jeff Chan, B.A., Debra Lerner, Ph.D., Paul Barreira, M.D., Gail Tsimpria, Ph.D., Benjamin Liptzin, M.D., Paul Summergrad, MD.

**Discussants:** Lloyd Sederer, M.D., Richard C. Hermann, M.D., Victor J.A. Buwalda, M.D., Annet Nugter, Ph.D.

**This Session Will Be Audiorecorded.**

Symposium 84  2:00 p.m.–5:00 p.m.
Room 145A, Level One, Washington Convention Center

**Pharmacogenetics in Psychiatry**

Chp.: Anil K. Malhotra, M.D.
THURSDAY

A Pharmacogenetics in Bipolar Disorder
John R. Kelsoe, M.D.

B Overview of Genetic and Pharmacogenetic Approaches in Psychiatry
Todd Lencz, Ph.D.

C Pharmacogenetics of Schizophrenia
Anil K. Malhotra, M.D.

D Pharmacogenetics of Antidepressants
Francis McMahon, M.D.

Discussants: Todd Lencz, Ph.D., John Kelsoe, M.D., Francis McMahon, M.D., Anil Malhotra, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 85 2:00 p.m.-5:00 p.m.
Room 145B, Level One, Washington Convention Center

APA'S GOLDWATER RULE: ETHICS OF SPEAKING PUBLICLY ABOUT PUBLIC FIGURES

Chp.: Jerome L. Kroll, M.D.
Co-Chp.: Claire L. Pouncey, M.D.

A The Psychiatrist in the Community: A Broader Ethical Perspective
Claire L. Pouncey, M.D.

B Legal Issues Behind the Goldwater Rule
Lisa Dagostino, M.D.

C When Psychiatrists Speak Out About Public Figures: Legal Liability, Medical Ethics, and Private Conscience
Jerome L. Kroll, M.D.

D A Prudent and Professional Position Is Often Challenging
William Arroyo, M.D.

Discussants: Lisa Dagostino, M.D., William Arroyo, M.D., Claire L. Pouncey, M.D., Jerome L. Kroll, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 86 2:00 p.m.-5:00 p.m.
Room 146C, Level One, Washington Convention Center

NEUROETHICS: ETHICAL CHALLENGES AT THE CUTTING EDGE OF NEUROSCIENCE

Chp.: Paul S. Appelbaum, M.D.
Co-Chp.: Laura B. Dunn, M.D.

A Ethical Issues in Research on Deep Brain Stimulation for Treatment-Resistant Depression
Laura B. Dunn, M.D., Paul Holtzheimer, M.D.
Helen Mayberg, M.D., Laura Weiss Roberts, M.D., M.A.
Paul Appelbaum, M.D.

B The New Lie Detectors: Neuroscience in the Courts
Paul S. Appelbaum, M.D.

C Genes, Blame, Responsibility and the Brain: Views of Patients
Robert L. Klitzman, M.D.

D Determinism and the Death of Folk Psychology: Two Challenges to Responsibility From Neuroscience
Stephen J. Morse, J.D.

E Building Better Brains: The Ethics of Neuroenhancement
Paul R. Wolpe, Ph.D.

Discussants: Henry Greely, J.D., Robert Klitzman, M.D., Laura B. Dunn, M.D., Paul S. Appelbaum, M.D., Stephen J. Morse, J.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 87 2:00 p.m.-5:00 p.m.
Room 147A, Level One, Washington Convention Center

INDIGENOUS MODELS OF MIND AND MENTAL HEALTH

Chp.: Lewis Mehl-Madrona, M.D.

A Huichole Ideas of Mind and Mental Health
Bruce W. Scotton, M.D.

B Mind and Mental Health Within the Mayan Cultures: Comparisons With Conventional Psychiatric Models
Anne-Marie Chaisson, M.D.

C Models of Mind and Health From the Southeastern U.S.: What can We Learn?
Robert Crocker, M.D.

D Narrative Philosophy: A Bridge Between Conventional Psychiatry and Aboriginal Idea of Mind and Mental Health
Lewis Mehl-Madrona, M.D.

E Indigenous Mental Health With Particular Reference to Akadian and Mikmac Cultures
Margaret Williams, M.D.

Discussants: Lewis Mehl-Madrona M.D., Margaret Williams M.D., Robert Crocker, M.D., Anne-Marie Chaisson, M.D., Bruce Scotton, M.D.
THIS SESSION WILL BE AUDIOTAPED.
THURSDAY

SYMPOSIUM 88 2:00 p.m.-5:00 p.m. 
Room 147B, Level One, Washington Convention Center

TECHNOLOGIES TO IMPROVE PSYCHOTHERAPY TRAINING AND OUTCOMES

Chp.: Mantosh J. Dewan, M.D.
A Computer-assisted Cognitive-Behavior Therapy in Clinical Practice  
Jesse H. Wright, M.D.
B Through the Looking Glass With Supervision: Video Recording Two  
John Manning, M.D.
C Simulation Based Assessment and Training in Psychotherapy  
Usha Satish, Ph.D., John Manning, MD, Mantosh J. Dewan, M.D., Gregory Robert, M.D.
D Web-based Learning in Psychotherapy: A Demonstration!  
Priyanthy Weerasekera, M.D., M.Ed.

Discussants: Jesse H. Wright M.D., Usha Satish Ph.D., Priyanthy Weerasekera M.D., M.Ed., John Manning M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 89 2:00 p.m.-5:00 p.m. 
Room 150A, Level One, Washington Convention Center

CHILDREN OF IMMIGRANTS DEVELOPMENT AND MENTAL HEALTH NEEDS

Chp.: Andres J. Pumariega, M.D.
Co-Chp.: R. Rao Gogineni, M.D.
A Culture and identity development of Asian Indian Children  
Aradhana Sood, M.D.
B Mental Health of Children of Latino Immigrants in the U.S.  
Andres J. Pumariega, M.D.
C The Health and Well-Being of Children of Immigrants  
Randolph Capps, Ph.D.
D Identity Formation in Children of Immigrants  
R. Rao Gogineni, M.D.

Discussants: R. Rao Gogineni, M.D., Andres Pumariega, M.D., Aradhana Sood, M.D., Randolph Capps, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 90 2:00 p.m.-5:00 p.m. 
Room 150B, Level One, Washington Convention Center

DSM V: FROM RESEARCH TO CLINICAL ISSUES

Chp.: Rodrigo A. Munoz, M.D.
A Mental Disorder Versus Understandable Mental Suffering: Is the Difference Clear? Is It Relevant to Treatment Decisions?  
Mario Maj, M.D.
B Increasing the Validity in DSM-V  
Roger Peele, M.D., D.L.F.A.P.A., Enrico Suardi, M.D.
C Public Health Implications of Changing Classification of Mental Disorders  
Norman Sartorius, M.D.

Discussants: Mario Maj, M.D., Norman Sartorius, M.D., Roger Peele, M.D., Harold Eist, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 91 2:00 p.m.-5:00 p.m. 
Room 151A, Level One, Washington Convention Center

STUCK IN THE BLACK BOX: A PATIENT SAFETY APPROACH TO PRESCRIBING ANTIDEPRESSANTS

Chp.: Geetha Jayaram, M.D.
Co-Chp.: Alfred Herzog, M.D.
A Making It to Morning: A Resident's Perspective  
Jason G. Roof, M.D.
B Uses of Genetic Testing  
John W. Goethe, M.D.

Discussant: Yad Jabbarpour, M.D., John Goethe, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 92 2:00 p.m.-5:00 p.m. 
Room 151B, Level One, Washington Convention Center

POVERTY AND MENTAL ILLNESS AROUND THE WORLD

Chp.: Nigel Bark, M.D.
Co-Chp.: Rachel Jenkins, M.D.
A The Effects of Poverty on Mental Illness Around the World: The African Perspective  
Frank G. Njenga, M.D., F.R.C.Psych.
B Abstract: The High Cost of Poverty: Mental Health Perspectives From The Caribbean Diaspora  
Frederick W. Hickling, D.M., M.R.C.Psych.
C A Pilot Intervention to Promote Mental Health Among Widows of Injecting Drug Users in North-East India  
Helen E. Herman, M.B.B.S., M.D., Michelle Kermode, Ph.D., Alexandra Devine, B.Sc., Prabha Chandra, M.B.B.S, M.D., Bernadette Dzuvichu, B.Sc., Thomghood Gilbert, B.Sc.
D Poverty, Maternal Depression and Infant Morbidity in the Developing World: Can the Vicious Circle be Broken?
John L. Cox, M.D.

E Everyday Emotional Disturbances in Mexican Urban Populations with Low Financial Resources
Maria Elena Medina-Mora, Psy.D., Ph.D., Shoshana Berenson, Ph.D., Jazmín Mora-Ríos, Ph.D., María A. Lara Ph.D.

F Impact of Poverty on Mental Health in the Middle East
Nasser N Loza, M.D., Nael Hasan, M.D.

Discussants: Professor Sam Tyano, M.D., John Cox, M.D., Frank Njenga, M.D., Maria Elena Medina-Mora, Psy.D., Ph.D., Helen Herman, M.B.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 93 2:00 p.m.-5:00 p.m.
Room 152A, Level One, Washington Convention Center

BEYOND THE WALLS: CAN PRINCIPLES OF MORAL TREATMENT BE APPLIED TO CONTEMPORARY MENTAL HEALTH SYSTEMS?

Chp.: Virginia L. Susman, M.D.

A Moral Treatment in Contemporary Practice
Christopher J. Holman, M.B.

B All Things Old Are New Again: The Impact of Moral Treatment on Contemporary Psychiatry
Gregory A. Miller, M.D.

C The Paradox of Moral Treatment in Modern Times
Harold I. Schwartz, M.D.

D Echoes of Moral Treatment in the Planetree Movement
Virginia L. Susman, M.D., Philip J. Wilner, M.D.

Discussants: Robert Michels, M.D., Virginia L. Susman, M.D., Christopher Holman, M.B., Gregory Miller, M.D., Harold I. Schwartz, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 94 2:00 p.m.-5:00 p.m.
Room 154A/B, Level One, Washington Convention Center

HORMONES, IDENTITIES AND CULTURES: CLINICAL ISSUES IN TRANSGENDER YOUTH

Chp.: Richard R. Pleak, M.D.
Co-Chp.: Edgardo J. Menvielle, M.D.

A Transgender Children: Clinical and Ethical Issues in Pre-Pubertal Presentations
Edgardo J. Menvielle, M.D.

B An Endocrine Perspective on the Care of Transgender Adolescents
Norman Spack, M.D.

C Formation of Transgender Identities in Adolescence
Richard R Pleak, M.D.

D Issues in Working With Female to Male Transgender Youth
Sarah E. Herbert, M.D.

E African-American and Latino Transgender Youth
Vernon A. Rosario, M.D.

Discussants: Richard R. Pleak, M.D., Edgardo J. Menvielle, M.D., Sarah E. Herbert, M.D., Vernon A. Rosario, M.D., Norman Spack, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 95 2:00 p.m.-5:00 p.m.
Room 156, Level One, Washington Convention Center

IMPULSIVE-COMPULSIVE SPECTRUM DISORDERS: RECOGNITION AND CLINICAL MANAGEMENT

Chp.: Jon E. Grant, M.D.

A Obsessive-Compulsive Disorder, Its Relationship to Impulsivity, and Available Treatments
Dan J. Stein, M.D.

B Impulsive-Compulsive Spectrum Disorders: Diagnostic Issues
Eric Hollander, M.D., Heather Berlin, Ph.D., Daphne Simeon, M.D., Stefano Pallanti, M.D., Jennifer Bartz, Ph.D., Andrea Allen, Ph.D.

C Update on the Clinical Features and Treatment of Trichotillomania and Pathologic Skin Picking
Jon E. Grant, M.D.

D Body Dysmorphic Disorder
Katharine A. Phillips, M.D.

E Clinical Advances in Understanding and Treating Impulse Control Disorders
Marc N. Potenza, M.D., Ph.D.

Discussants: Eric Hollander, M.D., Dan Stein, M.D., Katharine Phillips, M.D., Jon Grant, M.D., Marc Potenza, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 96 2:00 p.m.-5:00 p.m.
Room 158A/B, Level One, Washington Convention Center

PSYCHIATRIC EMERGENCY SERVICES: MEDICO LEGAL IN CRISIS CARE

Chp.: Anthony T. Ng, M.D.

(Continued next page)
A Medicolegal Issues Faced by Psychiatric Emergency Physicians
Avrim B. Fishkind, M.D.

B The Lived Experience of Medico Legal Issues in ER's
Edward L. Knight, Ph.D.

C Legal Liability Pitfalls in Psychiatric Emergency Care
and Practical Suggestions to Avoid Them
Steven R. Smith, B.A., Esq.

D Psychiatric Emergency Services: Medico Legal Issues in Crisis Care
Susan Stefan, J.D.

Discussants: Glenn Currier, M.D., Avrim Fishkind, M.D.,
Susan Stefan, J.D., Steven Smith, B.A., Edward Knight Ph.D.

SYMPOSIUM 97 2:00 p.m.-5:00 p.m.
Room 159 A/B, Level One, Washington Convention Center

ADHD UPDATE: MANAGEMENT OF NEW COMPLEXITIES AND ONGOING CHALLENGES
Chp.: Gabriel Kaplan, M.D.

A Minimizing Growth Effects of ADHD Medication in Clinical Practice
Christopher Kratochvil, M.D.

B Neurobiology and Management of Tic Disorders
Robert D. Hunt, M.D.

C Childhood ADHD and Risk for Adolescent Substance Abuse
Iliyan Ivanov, M.D.

D Diagnosis and Treatment of ADHD and Bipolar Spectrum Disorders in Youth
Jeffrey H. Newcorn, M.D.

E Stimulant Use and Cardiovascular Issues
Stephen E. Kimmel, M.D.

SYMPOSIUM 98 2:00 p.m.-5:00 p.m.
Room 201, Level Two, Washington Convention Center

ADVANCES IN DIAGNOSIS AND TREATMENT OF FREQUENTLY ASSOCIATED COMORBID CONDITIONS IN YOUTH WITH PERVERSIVE DEVELOPMENT DISORDERS
Chp.: Gagan Joshi, M.D.
Co-Chp.: Robert L. Doyle, D.D.S

A Treating Attention-Deficit/Hyperactivity Disorder Symptoms in Pervasive Developmental Disorders
David J. Posey, M.D., Craig A. Erickson, M.D.,
Christopher J. McDougle, M.D.

B Genetic Studies of Pervasive Developmental Disorders and Related Disorders of Cognitive Development
Eric M. Morrow, M.D., Seung-Yun Yoo, Ph.D., Russell J.
Ferland, Ph.D., Robert Sean, Hill, Ph.D, Adria Bodell, M.S.,
C.G.C., Kira A. Apse, M.S., Samira Al-Saad, Ph.D., Asif
Hashmi, M.D, Soher Balkhy, M.D., Generoso Gascon,
M.D., Sabri Herguner, M.D., Nahit Motavalli Mukaddes,
M.D., Christopher A. Walsh, M.D., Ph.D.

C Comorbidity in Asperger's Disorder and High Functioning Autism
Fred R. Volkmar, M.D.

D Response to Second Generation Neuroleptics in Youth with Comorbid Pervasive Developmental Disorder and Bipolar Disorder
Gagan Joshi, M.D., Joseph Biederman, M.D., Robert
Doyle, M.D., Nora Sullivan, B.A., Paul Hammerness, M.D.,
Eric Morrow, M.D., Janet Wozniak, M.D., Eric Mick, Sc.D.

Discussants: James McCracken, M.D., Gagan Joshi, M.D., Fred
Volkmar, M.D., Eric Morrow, M.D., David Posey, M.D.

THIS SESSION WILL BE AUDIOTAPED.
2009 CALL FOR PAPERS

PRESIDENT'S THEME:
Shaping Our Future: Science and Service

Nada L. Stotland, M.D.
President

Josepha A. Cheong, M.D., Chairperson
Scientific Program Committee

THE SUBMISSION SCHEDULE

<table>
<thead>
<tr>
<th>Format</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry-Supported Symposia</td>
<td>August 07, 2008</td>
</tr>
<tr>
<td>Courses</td>
<td>August 28, 2008</td>
</tr>
<tr>
<td>Scientific &amp; Clinical Reports Symposia</td>
<td></td>
</tr>
<tr>
<td>Workshops (Issue &amp; Media)</td>
<td></td>
</tr>
<tr>
<td>Component Workshops</td>
<td>September 19, 2008</td>
</tr>
<tr>
<td>New Research / Young Investigator Posters</td>
<td>December 09, 2008</td>
</tr>
</tbody>
</table>

Submissions are accepted ONLINE ONLY!

For format descriptions, instructions, guidelines, and to submit your program or poster proposal, consult the 2009 Annual Meeting information available on the APA home page (www.psych.org).
2008 ANNUAL MEETING
TOPIC AREAS FOR THE SCIENTIFIC PROGRAM

Addiction Psychiatry
AIDS and HIV-Related Disorders
Alcohol and Drug-Related Disorders
Anxiety Disorders
Attention Spectrum Disorders
Behavior and Cognitive Therapies
Biological Psychiatry and Neuroscience and Neuropsychiatry
Brain Imaging
Child and Adolescent Psychiatry and Disorders
Cognitive Disorders (Delirium, Dementia, Amnestic, etc.)
Community and Social Psychiatry
Computers
Consultation/Liaison Psychiatry
Couple and Family Therapies
Creativity and the Arts
Cross-Cultural and Minority Issues
Diagnostic Issues
Eating Disorders
Electronic Medical Records
Ethics and Human Right
Forensic Psychiatry
Gender Issues
Genetics
Geriatric Psychiatry
Health Services Research
Historical Issues
Individual Psychotherapies
Information Technology
Internet
Lesbian/Gay/Bisexual/Transgender Issues
Managed Care and Health Care Funding
Men’s Issues
Neuropsychiatry

Mental Retardation (Child/Adolescent/Adult)
Mood Disorders
Other Somatic Therapies
Pain Management
Personality Disorders
Political Questions
Presidential Theme: “Our Voice In Action: Advancing Science, Care, And The Profession”
Professional and Personal Issues
Psychiatric Administration and Services: Public, Private, and University
Psychiatric Education
Psychiatric Rehabilitation
Psychoanalysis
Psychoimmunology
Psychopharmacology
Religion, Spirituality, and Psychiatry
Research Issues
Resident and Medical Student Issues
Schizophrenia and Other Psychotic Disorders
Sexual and Gender Identity Disorders
Sleep Disorders
Social and Community Psychiatry
Somatoform Disorders
Stigma/Advocacy
Stress
Suicide
Telepsychiatry
Treatment Techniques and Outcome Studies
Violence, Trauma, and Victimization
Women’s Health Issues

GUIDE TO USING THE TOPIC INDEX

Use this index to find sessions of interest to you. Under each topic listed above, you will find a list of formats (types of sessions) listed alphabetically underneath. Within each format, you will find the title of the individual session listed by number. The listing will also show the page number that the session appears on. You should refer to the page number in this Program Book to obtain further details about the session.
## TOPIC INDEX

### ADDICTION PSYCHIATRY

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>31</td>
<td>Advances In Series 1</td>
</tr>
<tr>
<td>27</td>
<td>Clinical Report 13</td>
</tr>
<tr>
<td>27</td>
<td>Clinical Report 14</td>
</tr>
<tr>
<td>27</td>
<td>Clinical Report 15</td>
</tr>
<tr>
<td>53</td>
<td>Clinical Report 29</td>
</tr>
<tr>
<td>53</td>
<td>Clinical Report 38</td>
</tr>
<tr>
<td>27</td>
<td>Clinical Report 13</td>
</tr>
<tr>
<td>27</td>
<td>Clinical Report 14</td>
</tr>
<tr>
<td>27</td>
<td>Clinical Report 15</td>
</tr>
<tr>
<td>53</td>
<td>Clinical Report 29</td>
</tr>
<tr>
<td>53</td>
<td>Clinical Report 38</td>
</tr>
<tr>
<td>29</td>
<td>Component Workshop 20</td>
</tr>
<tr>
<td>47</td>
<td>Component Workshop 25</td>
</tr>
<tr>
<td>57</td>
<td>Course 76</td>
</tr>
<tr>
<td>67</td>
<td>Course 83</td>
</tr>
<tr>
<td>87</td>
<td>Course 94</td>
</tr>
<tr>
<td>30</td>
<td>Forum 4</td>
</tr>
<tr>
<td>23</td>
<td>Issue Workshop 10</td>
</tr>
<tr>
<td>23</td>
<td>Issue Workshop 12</td>
</tr>
<tr>
<td>29</td>
<td>Issue Workshop 17</td>
</tr>
<tr>
<td>48</td>
<td>Issue Workshop 27</td>
</tr>
<tr>
<td>49</td>
<td>Issue Workshop 34</td>
</tr>
<tr>
<td>70</td>
<td>Issue Workshop 47</td>
</tr>
<tr>
<td>89</td>
<td>Issue Workshop 93</td>
</tr>
<tr>
<td>50</td>
<td>Media Workshop 4</td>
</tr>
<tr>
<td>20</td>
<td>Small Interactive Session 2</td>
</tr>
<tr>
<td>33</td>
<td>Symposium 3</td>
</tr>
<tr>
<td>60</td>
<td>Symposium 32</td>
</tr>
<tr>
<td>61</td>
<td>Symposium 38</td>
</tr>
<tr>
<td>62</td>
<td>Symposium 40</td>
</tr>
<tr>
<td>79</td>
<td>Symposium 54</td>
</tr>
</tbody>
</table>

### AIDS AND HIV-RELATED DISORDERS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>24</td>
<td>Advances In Medicine 1</td>
</tr>
<tr>
<td>21</td>
<td>Component Workshop 9</td>
</tr>
<tr>
<td>1</td>
<td>Course 7</td>
</tr>
<tr>
<td>80</td>
<td>Symposium 58</td>
</tr>
<tr>
<td>93</td>
<td>Symposium 78</td>
</tr>
</tbody>
</table>

### ALCOHOL AND DRUG-RELATED DISORDERS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>52</td>
<td>Clinical Report 28</td>
</tr>
<tr>
<td>53</td>
<td>Clinical Report 30</td>
</tr>
<tr>
<td>57</td>
<td>Course 78</td>
</tr>
<tr>
<td>89</td>
<td>Issue Workshop 72</td>
</tr>
<tr>
<td>77</td>
<td>Issue Workshop 92</td>
</tr>
<tr>
<td>67</td>
<td>Lecture 23</td>
</tr>
<tr>
<td>24</td>
<td>Symposium 2</td>
</tr>
<tr>
<td>80</td>
<td>Symposium 58</td>
</tr>
<tr>
<td>80</td>
<td>Symposium 60</td>
</tr>
</tbody>
</table>

### ANXIETY DISORDERS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>18</td>
<td>Case Conferences 1</td>
</tr>
<tr>
<td>54</td>
<td>Clinical Report 48</td>
</tr>
<tr>
<td>54</td>
<td>Clinical Report 49</td>
</tr>
<tr>
<td>54</td>
<td>Clinical Report 50</td>
</tr>
<tr>
<td>91</td>
<td>Clinical Report 82</td>
</tr>
<tr>
<td>31</td>
<td>Focus Live 3</td>
</tr>
<tr>
<td>65</td>
<td>Industry-Supported Symp. 22</td>
</tr>
</tbody>
</table>
## TOPIC INDEX

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>48</td>
<td>Issue Workshop 22</td>
<td>Vietnam Veterans and the Iraq War</td>
</tr>
<tr>
<td>58</td>
<td>Lecture 21</td>
<td>The Neurobiology of Child Abuse and Neglect</td>
</tr>
<tr>
<td>39</td>
<td>NR Posters Session 3</td>
<td>Anxiety and Mood Disorders</td>
</tr>
<tr>
<td>33</td>
<td>Symposium 4</td>
<td>Traumatic Stress, Hormones and Depression</td>
</tr>
<tr>
<td>35</td>
<td>Symposium 11</td>
<td>Depression and Generalized Anxiety: Research Planning for the DSM-V</td>
</tr>
<tr>
<td>37</td>
<td>Symposium 18</td>
<td>The Application of Translational Affective Neuroscience to Anxiety Disorders</td>
</tr>
<tr>
<td>72</td>
<td>Symposium 51</td>
<td>Treating PTSD in a Violent World</td>
</tr>
<tr>
<td>80</td>
<td>Symposium 60</td>
<td>Research Update: Current Prospects for Enhanced Treatments for Schizophrenia, Mood Disorders, Anxiety Disorders and Substance Abuse</td>
</tr>
<tr>
<td>90</td>
<td>Symposium 76</td>
<td>Translational Research on Obsessive-Compulsive Disorder</td>
</tr>
</tbody>
</table>

## ANXIETY DISORDERS (cont.)

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>91</td>
<td>Clinical Report 81</td>
<td>Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With ADHD</td>
</tr>
<tr>
<td>91</td>
<td>Clinical Report 82</td>
<td>Adult Attention-Deficit/Hyperactivity Disorder in an Anxiety Disorders Population</td>
</tr>
<tr>
<td>91</td>
<td>Clinical Report 83</td>
<td>Inattention and Hyperactivity Symptoms in Individuals at Risk for Psychosis</td>
</tr>
<tr>
<td>5</td>
<td>Course 23</td>
<td>ADD in Children and Adolescents</td>
</tr>
<tr>
<td>18</td>
<td>Course 44</td>
<td>ADD in Adults</td>
</tr>
<tr>
<td>57</td>
<td>Course 77</td>
<td>Advanced Assessment and Treatment of ADHD</td>
</tr>
<tr>
<td>4</td>
<td>Industry-Supported Symp. 6</td>
<td>Pediatric and Adolescent ADHD</td>
</tr>
<tr>
<td>5</td>
<td>Industry-Supported Symp. 8</td>
<td>Advances in Neuroimaging and Genetics in ADHD</td>
</tr>
<tr>
<td>85</td>
<td>Industry-Supported Symp. 28</td>
<td>Advancing Science and Practice in the Management of ADHD from Child to Adult: An Interactive Case Presentation</td>
</tr>
<tr>
<td>96</td>
<td>Symposium 97</td>
<td>ADHD Update: Management of New Complexities and Ongoing Challenges</td>
</tr>
</tbody>
</table>

## ATTENTION SPECTRUM DISORDERS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Course 15</td>
<td>Cognitive-Behavior Therapy for Schizophrenia</td>
</tr>
<tr>
<td>5</td>
<td>Course 20</td>
<td>Cognitive-Behavior Therapy for Severe Mental Disorders</td>
</tr>
<tr>
<td>6</td>
<td>Course 25</td>
<td>Introduction to Cognitive-Behavioral Therapy</td>
</tr>
<tr>
<td>6</td>
<td>Course 31</td>
<td>Cognitive Therapy on the Fly</td>
</tr>
<tr>
<td>30</td>
<td>Course 52</td>
<td>Engaging Resistant and Difficult-to-Treat Patients</td>
</tr>
<tr>
<td>72</td>
<td>Course 88</td>
<td>Overview of Dialectical Behavior Therapy</td>
</tr>
<tr>
<td>56</td>
<td>Issue Workshop 44</td>
<td>Implementing a Cognitive Therapy for Psychosis Program</td>
</tr>
<tr>
<td>70</td>
<td>Issue Workshop 50</td>
<td>Cognitive Therapy For Psychosis in Practice by Psychiatrists</td>
</tr>
<tr>
<td>76</td>
<td>Issue Workshop 62</td>
<td>(H)umanized CBT with Children</td>
</tr>
<tr>
<td>88</td>
<td>Issue Workshop 82</td>
<td>Enhancing the milieu: Development of a Comprehensive Inpatient CBT Program</td>
</tr>
</tbody>
</table>

## BEHAVIOR AND COGNITIVE THERAPIES

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Course 12</td>
<td>Neuroanatomy of Emotions</td>
</tr>
<tr>
<td>5</td>
<td>Course 23</td>
<td>Understanding the Endocannabinoid System</td>
</tr>
<tr>
<td>72</td>
<td>Issue Workshop 074</td>
<td>The Future of Psychiatry: Using a Neurodevelopmental Model for Case Formulation</td>
</tr>
<tr>
<td>52</td>
<td>Lecture 18</td>
<td>What Is Wrong With Our Patients</td>
</tr>
<tr>
<td>38</td>
<td>Lecture 21</td>
<td>The Neurobiology of Child Abuse and Neglect</td>
</tr>
<tr>
<td>23</td>
<td>Symposium 1</td>
<td>Epigenetic Mechanisms of Depression and Antidepressant Action</td>
</tr>
<tr>
<td>50</td>
<td>Symposium 26</td>
<td>Genomic Investigations of Mood Disorders</td>
</tr>
<tr>
<td>61</td>
<td>Symposium 35</td>
<td>Research Advances; Brain Mechanisms of Bipolar Disorder and Major Depression</td>
</tr>
<tr>
<td>90</td>
<td>Symposium 76</td>
<td>Translational Research on Obsessive-Compulsive Disorder</td>
</tr>
<tr>
<td>94</td>
<td>Symposium 84</td>
<td>NIMH Research Track: Pharmacogenetics in Psychiatry</td>
</tr>
<tr>
<td>95</td>
<td>Symposium 86</td>
<td>Neuroethics: Ethical Challenges at the Cutting Edge of Neuroscience</td>
</tr>
</tbody>
</table>

## BIOLOGICAL PSYCHIATRY AND NEUROSCIENCE AND NEUROPSYCHIATRY

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>74</td>
<td>Clinical Report 61</td>
<td>Ventral Capsular/Ventral Striatal Gamma Capsulotomy for Obsessive-Compulsive Disorder</td>
</tr>
<tr>
<td>74</td>
<td>Clinical Report 62</td>
<td>Alterations of the Dopamine Transporter in Lymphocytes of Patients With Different Psychotic Disorders</td>
</tr>
<tr>
<td>2</td>
<td>Course 12</td>
<td>Neuroanatomy of Emotions</td>
</tr>
<tr>
<td>65</td>
<td>Industry-Supported Symp. 23</td>
<td>The Future of Psychiatry: Using a Neurodevelopmental Model for Case Formulation</td>
</tr>
<tr>
<td>52</td>
<td>Lecture 18</td>
<td>What Is Wrong With Our Patients</td>
</tr>
<tr>
<td>38</td>
<td>Lecture 21</td>
<td>The Neurobiology of Child Abuse and Neglect</td>
</tr>
<tr>
<td>23</td>
<td>Symposium 1</td>
<td>Epigenetic Mechanisms of Depression and Antidepressant Action</td>
</tr>
<tr>
<td>50</td>
<td>Symposium 26</td>
<td>Genomic Investigations of Mood Disorders</td>
</tr>
<tr>
<td>61</td>
<td>Symposium 35</td>
<td>Research Advances; Brain Mechanisms of Bipolar Disorder and Major Depression</td>
</tr>
<tr>
<td>90</td>
<td>Symposium 76</td>
<td>Translational Research on Obsessive-Compulsive Disorder</td>
</tr>
<tr>
<td>94</td>
<td>Symposium 84</td>
<td>NIMH Research Track: Pharmacogenetics in Psychiatry</td>
</tr>
<tr>
<td>95</td>
<td>Symposium 86</td>
<td>Neuroethics: Ethical Challenges at the Cutting Edge of Neuroscience</td>
</tr>
</tbody>
</table>

## BRAIN IMAGING

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>54</td>
<td>Advances In Medicine 2</td>
<td>Traumatic Brain Injury: The Silent Epidemic</td>
</tr>
<tr>
<td>7</td>
<td>Course 33</td>
<td>Traumatic Brain Injury: Neuropsychiatric Assessment</td>
</tr>
<tr>
<td>60</td>
<td>Symposium 34</td>
<td>Neurodevelopment and Its Relevance to Psychiatric Disorders</td>
</tr>
</tbody>
</table>
TOPIC INDEX

Page #  Session

CHILD AND ADOLESCENT PSYCHIATRY AND DISORDERS

26  Clinical Report 6  High Frequency of Undiagnosed Cognitive Disorders in Inner-City Children and Adolescents Hospitalized for Disruptive Behavior
21  Component Workshop 2  Early Childhood Feeding Disorders
21  Component Workshop 5  School Mental Health
22  Component Workshop 12  The New Orleans School Recovery District
22  Component Workshop 13  Role of International Health Organizations in Promoting Global Child and Adolescent Health
28  Component Workshop 19  Reducing Juvenile Delinquency through Prevention
69  Component Workshop 43  Foster Care: Are we Doing Our Best for the Children
51  Course 70  Child and Adolescent Psychiatry for the General Psychiatrist
67  Course 82  Psychiatric Roles in Assessing and Treating Adult and Adolescent Sex Offenders
77  Course 90  Functional Family Therapy for Behavior Disordered Adolescents with Psychiatric Comorbidity
4  Industry-Supported Symp. 6  Pediatric and Adolescent ADHD
8  Industry-Supported Symp. 12  Treatment of Children and Adolescents with Psychiatric Disorders
85  Industry-Supported Symp. 28  Advancing Science and Practice in the Management of ADHD from Child to Adult: An Interactive Case Presentation
29  Issue Workshop 19  Children and Trauma (Military, Natural Disaster, etc.)
76  Issue Workshop 62  Manualized CBT with Children
76  Issue Workshop 66  Transition-Age Youth
89  Issue Workshop 89  Adoption Psychiatrist on the Move
89  Issue Workshop 90  The Child Psychiatrist as Grandparent: Grand Joys and Grand Challenges
92  Issue Workshop 105  Where Is the Line Drawn? Is There a Clinical Interface Between Autism Spectrum Disorders and Bipolar Disorder?
92  Issue Workshop 107  Children of Psychiatrists
92  Issue Workshop 115  Innovative Models for Extending Psychiatric Care to Children
58  Lecture 21  The Neurobiology of Child Abuse and Neglect
7  Presidential AACAP Institute: Practicing Pediatric Psychopharmacology
68  Small Interactive Session 13  Child and Adolescent Psychopharmacology
47  Small Interactive Session 13  Meet the Author, Child and Adolescent
34  Symposium 06  Recent Advances in Prevention Science: Implications for Practice and DSM-V
34  Symposium 08  Externalizing Disorders of Childhood: A DSM-V Research Agenda
35  Symposium 10  Safety Issues in Child and Adolescent Psychopharmacology
36  Symposium 15  Global Gaps in Psychiatry: The Mental Health Needs of Child Soldiers
59  Symposium 29  School Shootings: Threat Recognition and Prevention
62  Symposium 41  Children and War
63  Symposium 44  Life Without Parole: Sentencing for Juvenile Offenders
80  Symposium 59  Treatment of Adolescent Depression
83  Symposium 71  Features of Autism in Adulthood
96  Symposium 89  Children of Immigrants: Developmental and Mental Health Needs
97  Symposium 94  Hormones, Identities and Cultures: Clinical Issues in Transgender Youth
96  Symposium 98  Advances in Diagnosis and Treatment of Frequently Associated Comorbid Conditions in Youth With Pervasive Developmental Disorders

COGNITIVE DISORDERS (DELIRIUM, DEMENTIA, AMNESTIC, ETC.)

49  Advances In Series 02  Advances in Treatments of Psychiatric Disorder
45  Course 64  The Evaluation, Identification, and Treat of the Major Dementias
2  Industry-Supported Symp. 3  Recent Advances in Alzheimer's Disease
67, 87  Industry-Supported Symp. 25  Plaques & Tangles: Applying Genetics and Molecular Targets to Unravel Strategies for Alzheimer's Disease
82  Symposium 65  Cognitive Dysfunction in Bipolar Disorder
94  Symposium 80  Behavioral and Psychological Symptoms of Dementia (BPSD)

COMPUTERS (See also: Electronic Medical Records; Information Technology; Internet)

18  Course 43  Exploring Technologies in Psychiatry

CONSULTATION/LIAISON PSYCHIATRY

90  Advances In Medicine 4  Internal Medicine Update 2007: A Journal Roundup
54  Clinical Report 45  Depression and Subjective Incompetence as Separate Components of Demoralization
54  Clinical Report 46  Influence of Depressive and Anxiety Symptoms on Survival in Patients With End-Stage Renal Disease
54  Clinical Report 47  Psychiatric Emergencies on an Obstetrics Service: Agitation From Unrecognized Posttraumatic Stress Disorder Triggered by Routine Hospital Care
28  Component Workshop 15  Assessing Suicide Risk in the General Hospital
1  Course 3  Dynamic Psychotherapy for Cancer Patients and Their Spouses
3  Course 14  Psychiatrists' Role in Disaster Management
CONSULTATION/LIAISON PSYCHIATRY (cont.)

Course 92  Psychiatric Care of the Hepatitis C Patient
Issue Workshop 16  Teaching and Learning at the Medical-Psychiatric Interface: A Residency Training Perspective
Issue Workshop 20  Off-Label Use of Psychotropic Medications in C/L Psychiatry
Issue Workshop 29  The Man Who Can't Stop Swallowing Sharp Objects (Chronic Factitious Disorder)
Issue Workshop 54  Teaching Residents in Consultation-Liaison Service to Recognize and Manage Countertransference
Issue Workshop 76  Developments in the Assessment of Capacity, Statutory Changes, and Administrative Aids: The Road to Less Litigation

Issue Workshop 95  Primary Care Depression Management
Issue Workshop 117  Psychiatry Training for Primary Care Physicians: An Ongoing Challenge
Symposium 21  Pharmacogenetics of Tamoxifen and other Chemotherapeutic Agents and SSRIs
Symposium 64  Depression Among Emergency Department Patients in Latin-american Countries
Symposium 96  Psychiatric Emergency Services: Medico-Legal Issues in Crisis Care

COUPLE AND FAMILY THERAPIES

Course 55  Fostering Collaborative Therapeutic Alliance During the Initial Encounters with a Couple
Course 90  Functional Family Therapy for Behavior Disordered Adolescents with Psychiatric Comorbidity

CREATIVITY AND THE ARTS

Course 54  Teaching Psychiatry? Let Hollywood Help
Forum 5  Music and Mood Disorders: Tchaikovsky
Issue Workshop 14  Poets, Psychiatric Treatment, and the Creative Process
Issue Workshop 67  The Portrayal of Psychiatry in Recent American Film

CROSS-CULTURAL AND MINORITY ISSUES

Clinical Report 53  The Comparative Epidemiology of Chronic Fatigue Between Brazilian and British Primary Care
Clinical Report 63  Treating Obesity: Interventions for Improving Body Mass Index and Increasing Fitness in an Inner-City Hispanic and African-American SPMI Population
Clinical Workshop 78  Racial Differences in Prescribing Practices in the Treatment of Schizophrenia
Component Workshop 27  Better Luck Tomorrow: Gambling in Asian Americans
Component Workshop 29  Does Culture Matter?
Component Workshop 38  Language Access in Health Care
Component Workshop 39  Breaking Barriers: Empowering Providers and Patients
Component Workshop 49  Mental Health of Latinas: Changing Roles and Needs
Component Workshop 53  Mental Health Effects of Disasters Among Ethnic Minority Elderly
Course 41  DSM-IV-TR Cultural Formulations
Forum 9  Pharmacological Perspectives Among USA Ethnic Minorities
Forum 11  APA and APAL: Building Bridges, Finding Routes
Issue Workshop 4  Cross-Cultural Validation of Self-report Questionnaire in Non-Western Post-Conflict Settings
Issue Workshop 32  Building the Bridges: Reaching the South Asian Community
Issue Workshop 33  The Special Utility of Standardized Patients in the Psychiatric Training of IMGs
Issue Workshop 61  Psychiatry in Asia: Problems, Priorities, Solutions
Issue Workshop 68  Partnerships in the Americas: Update from the WPA
Issue Workshop 70  Navigating Terrorism And Its Relation To Mental Health: Middle East Perspective
Issue Workshop 81  IRAQ on the Ground: The Real Story Through a Psychiatrist's Lens
Issue Workshop 89  Adoption Psychiatrist on the Move
Issue Workshop 112  Application of Cultural Variables for Effective Psychotherapy of the Migrant Asian Population in the US
Issue Workshop 116  A Federal Perspective on Reducing Mental Disparities: How Can Psychiatry Participate?
Lecture 24  Kun-Po Soo Award Lecture: Cultural Psychiatry in Asia
Media Workshop 7  Shame and Silence: Understanding the Stigma of Mental Illness in Asian Americans
Symposium 30  Violence in Minority Groups: What Can Be Done
Symposium 46  Recent Advances in Cross-Cultural, Ethnic and Ethnopsychopharmacological Aspects of Mood Disorders
Symposium 64  Depression Among Emergency Department Patients in Latin-american Countries
Symposium 79  Religion that Heals, Religion that Harms: What Is the Place of Psychiatry?
Symposium 87  Indigenous Models of Mind and Mental Health
Symposium 89  Children of Immigrants: Developmental and Mental Health Needs
Symposium 92  Poverty and Mental Illness Around the World
## DIAGNOSTIC ISSUES

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>74</td>
<td>Clinical Report 67</td>
<td>Is Bipolar Disorder Overdiagnosed?</td>
</tr>
<tr>
<td>74</td>
<td>Clinical Report 68</td>
<td>What Can We Learn From Valid Diagnoses?</td>
</tr>
<tr>
<td>50</td>
<td>Course 67</td>
<td>Going From the Bio-Bio-Bio Model Forward to Bio-Psycho-Social Reasoning</td>
</tr>
<tr>
<td>33</td>
<td>International Symposium 1</td>
<td>The Emergence of Subthreshold Psychiatry</td>
</tr>
<tr>
<td>28</td>
<td>Small Interactive Session 4</td>
<td>Autism and Impulse Control</td>
</tr>
<tr>
<td>34</td>
<td>Symposium 8</td>
<td>Externalizing Disorders of Childhood: A DSM-V Research Agenda</td>
</tr>
<tr>
<td>35</td>
<td>Symposium 11</td>
<td>Depression and Generalized Anxiety: Research Planning for the DSM-V</td>
</tr>
<tr>
<td>36</td>
<td>Symposium 14</td>
<td>Somatic Presentations of Mental Disorders</td>
</tr>
<tr>
<td>82</td>
<td>Symposium 67</td>
<td>DSM V: Philosophical and Clinical</td>
</tr>
<tr>
<td>97</td>
<td>Component Workshop 95</td>
<td>Impulsive-Compulsive Spectrum Disorders: Recognition and Clinical Management</td>
</tr>
</tbody>
</table>

## EATING DISORDERS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>24</td>
<td>Advances In Research 1</td>
<td>Research Advances in Psychiatry</td>
</tr>
<tr>
<td>65</td>
<td>Advances In Series 3</td>
<td>Advances in Eating Disorders</td>
</tr>
<tr>
<td>69</td>
<td>Case Conferences 3</td>
<td>Treatment-Resistant Anorexia Nervosa</td>
</tr>
<tr>
<td>26</td>
<td>Clinical Report 5</td>
<td>Overvaluation of Shape and Weight in Binge-Eating Disorder and Overweight Controls: Refinement of BED as a Diagnostic Construct</td>
</tr>
<tr>
<td>74</td>
<td>Clinical Report 63</td>
<td>Treating Obesity: Interventions for Improving Body Mass Index and Increasing Fitness in an Inner-City Hispanic and African-American SPMI Population</td>
</tr>
<tr>
<td>75</td>
<td>Component Workshop 51</td>
<td>Psychiatric Aspects of Bariatric Surgery</td>
</tr>
<tr>
<td>1</td>
<td>Course 9</td>
<td>Therapeutic Interventions in Eating Disorders</td>
</tr>
</tbody>
</table>

## ELECTRONIC MEDICAL RECORDS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>48</td>
<td>Component Workshop 31</td>
<td>Electronic Health Records in Psychiatry</td>
</tr>
<tr>
<td>83</td>
<td>Symposium 69</td>
<td>Privacy and Fraud Policies and Electronic Health Records</td>
</tr>
</tbody>
</table>

## ETHICS AND HUMAN RIGHT

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>29</td>
<td>Component Workshop 21</td>
<td>Ethical Dilemmas in Clinical Practice:</td>
</tr>
<tr>
<td>69</td>
<td>Component Workshop 41</td>
<td>One Psychiatrist's Boundary Violation May Be Another's Area of Work</td>
</tr>
<tr>
<td>77</td>
<td>Course 91</td>
<td>Bioethics Update 2008</td>
</tr>
<tr>
<td>29</td>
<td>Issue Workshop 15</td>
<td>Complexities of Post-termination Relationships</td>
</tr>
<tr>
<td>29</td>
<td>Issue Workshop 18</td>
<td>Do-Not-Resuscitate Orders in Suicidal Patients</td>
</tr>
<tr>
<td>70</td>
<td>Issue Workshop 52</td>
<td>Phantoms of the Mind: The Role of Narcissism in Therapist Boundary-Crossing</td>
</tr>
<tr>
<td>91</td>
<td>Issue Workshop 101</td>
<td>Innovations in the Evaluation of Professionals Who Engage in Boundary Violations</td>
</tr>
<tr>
<td>46</td>
<td>Lecture 14</td>
<td>Conflicts of Interest in Psychiatric Practice and Research</td>
</tr>
<tr>
<td>49</td>
<td>Media Workshop 3</td>
<td>Ghosts of Abu Ghraib</td>
</tr>
<tr>
<td>20</td>
<td>Small Interactive Session 1</td>
<td>Professionalism and Ethics</td>
</tr>
<tr>
<td>78</td>
<td>Symposium 52</td>
<td>An Interstate Comparison of Exclusions to Involuntary Civil Commitment Laws</td>
</tr>
<tr>
<td>95</td>
<td>Symposium 85</td>
<td>APA's Goldwater Rule: Ethics of Speaking Publically About Public Figures</td>
</tr>
<tr>
<td>95</td>
<td>Symposium 86</td>
<td>Neuroethics: Ethical Challenges at the Cutting Edge of Neuroscience</td>
</tr>
</tbody>
</table>

## FORENSIC PSYCHIATRY

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td>Clinical Report 1</td>
<td>The Validity of Psychiatric Impairment Assessment: A Comparison of Two Systems in Clinical Practice</td>
</tr>
<tr>
<td>26</td>
<td>Clinical Report 2</td>
<td>Profile of Perpetrators With Impulsive Violent Behavior</td>
</tr>
<tr>
<td>26</td>
<td>Clinical Report 3</td>
<td>Fathers Who Kill Their Children</td>
</tr>
<tr>
<td>48</td>
<td>Component Workshop 32</td>
<td>Demystifying the System: Eliminating Barriers to Effective Treatment of Mentally Ill in Jails and Prisons</td>
</tr>
<tr>
<td>69</td>
<td>Component Workshop 44</td>
<td>Preventing Incarceration of the Mentally Ill</td>
</tr>
<tr>
<td>69</td>
<td>Component Workshop 46</td>
<td>Psychiatric Services in Jails and Prisons</td>
</tr>
<tr>
<td>76</td>
<td>Component Workshop 54</td>
<td>Hot Issues in Psychiatry and Law</td>
</tr>
<tr>
<td>18</td>
<td>Course 45</td>
<td>Detection of Malingered Mental Illness</td>
</tr>
<tr>
<td>31</td>
<td>Course 59</td>
<td>The Psychiatrist as Expert Witness</td>
</tr>
<tr>
<td>45</td>
<td>Course 65</td>
<td>Risk Assessment for Violence</td>
</tr>
<tr>
<td>67</td>
<td>Course 81</td>
<td>Treating Physicians Involved in Sexual Misconduct</td>
</tr>
<tr>
<td>77</td>
<td>Course 93</td>
<td>Insanity Defense Evaluations</td>
</tr>
<tr>
<td>22</td>
<td>Issue Workshop 1</td>
<td>Paraphilias, Personality Disorders, and Pharmaceuticals</td>
</tr>
<tr>
<td>22</td>
<td>Issue Workshop 3</td>
<td>Malpractice: A Defendant's Primer</td>
</tr>
<tr>
<td>Page #</td>
<td>Session</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>Issue Workshop 18</td>
<td>Do-Not-Resuscitate Orders in Suicidal Patients</td>
</tr>
<tr>
<td>48</td>
<td>Issue Workshop 20</td>
<td>Off-Label Use of Psychotropic Medications in C/L Psychiatry</td>
</tr>
<tr>
<td>76</td>
<td>Issue Workshop 65</td>
<td>Elvin Semrad's Interviewing Fundamentals for High-Pressure Clinical, Forensic and Educational Contexts</td>
</tr>
<tr>
<td>88</td>
<td>Issue Workshop 76</td>
<td>Developments in the Assessment of Capacity, Statutory Changes, and Administrative Aids: The Road to Less Litigation</td>
</tr>
<tr>
<td>88</td>
<td>Issue Workshop 80</td>
<td>Medical Legal Aspects of Psychic Trauma: A Family Approach</td>
</tr>
<tr>
<td>89</td>
<td>Issue Workshop 88</td>
<td>Risk Management Issues in Psychiatric Practice</td>
</tr>
<tr>
<td>91</td>
<td>Issue Workshop 101</td>
<td>Innovations in the Evaluation of Professionals Who Engage in Boundary Violations</td>
</tr>
<tr>
<td>92</td>
<td>Issue Workshop 111</td>
<td>My Patient Is Stalking Me: Management of Erotomania in Residency and Beyond</td>
</tr>
<tr>
<td>92</td>
<td>Issue Workshop 113</td>
<td>Women Serving Life Sentences: Crime, Punishment and Treatment</td>
</tr>
<tr>
<td>9</td>
<td>Lecture 1</td>
<td>Critique of Pure Risk: Assessment</td>
</tr>
<tr>
<td>63</td>
<td>Symposium 44</td>
<td>Life Without Parole: Sentencing for Juvenile Offenders</td>
</tr>
<tr>
<td>90</td>
<td>Symposium 77</td>
<td>Assessing and Reducing Risk of Violence Among People With Schizophrenia and Other Mental Disorders</td>
</tr>
<tr>
<td>94</td>
<td>Symposium 82</td>
<td>Parasomnias, Violence and the Law</td>
</tr>
<tr>
<td>97</td>
<td>Symposium 96</td>
<td>Psychiatric Emergency Services: Medico-Legal Issues in Crisis Care</td>
</tr>
<tr>
<td>53</td>
<td>Clinical Report 41</td>
<td>Gender-Specific Patterns in NMS Symptoms</td>
</tr>
<tr>
<td>47</td>
<td>Component Workshop 30</td>
<td>Novel Careers in Psychiatry: Women Who Have Made Their Own Way</td>
</tr>
<tr>
<td>49</td>
<td>Issue Workshop 30</td>
<td>Leadership Development for Early Career Women</td>
</tr>
<tr>
<td>59</td>
<td>Presidential Symposium 2</td>
<td>The Last 25 Years of Women In Psychiatry</td>
</tr>
<tr>
<td>73</td>
<td>Advances In Medicine 3</td>
<td>Obesity: The Confluence of Genetics and Environment Leading to a National Epidemic</td>
</tr>
<tr>
<td>24</td>
<td>Advances In Research 1</td>
<td>Research Advances in Psychiatry</td>
</tr>
<tr>
<td>26</td>
<td>Clinical Report 7</td>
<td>Genes, Memes, and an Infection Model of Mental Illness</td>
</tr>
<tr>
<td>26</td>
<td>Clinical Report 8</td>
<td>Combinatorial CYP450 Genotyping for Depressed Inpatients</td>
</tr>
<tr>
<td>26</td>
<td>Clinical Report 9</td>
<td>Pharmacogenomics: Therapeutic and Diagnostic Applications of Chromatin Remodeling Agents in Mental Illness</td>
</tr>
<tr>
<td>3</td>
<td>Course 17</td>
<td>Psychiatric Genomics: Applications for Clinical Practice</td>
</tr>
<tr>
<td>32</td>
<td>Lecture 9</td>
<td>Frontiers for Science</td>
</tr>
<tr>
<td>54</td>
<td>Small Interactive Session 12</td>
<td>Clinical Aspects of Genetics and Genomics</td>
</tr>
<tr>
<td>75</td>
<td>Small Interactive Session 15</td>
<td>Psychiatric Genetics: Applications in Clinical Practice</td>
</tr>
<tr>
<td>35</td>
<td>Symposium 12</td>
<td>Psychiatric Genetics: New Discoveries Knocking at the Clinic Door</td>
</tr>
<tr>
<td>37</td>
<td>Symposium 20</td>
<td>The Psychoses Fused: The Kraepelinian Dichotomy</td>
</tr>
<tr>
<td>50</td>
<td>Symposium 26</td>
<td>Genomic Investigations of Mood Disorders</td>
</tr>
<tr>
<td>79</td>
<td>Symposium 54</td>
<td>Gene-Environment-Developmental Interactions: Implications for Psychiatric and Addictive Disorders</td>
</tr>
<tr>
<td>53</td>
<td>Clinical Report 32</td>
<td>Poor Sleep Quality Independently Predicts Depression in Community-Dwelling Older Adults</td>
</tr>
<tr>
<td>54</td>
<td>Component Workshop 35</td>
<td>The Role of the Psychiatrist in Palliative and End-of-Life Care</td>
</tr>
<tr>
<td>76</td>
<td>Component Workshop 53</td>
<td>Mental Health Effects of Disasters Among Ethnic Minority Elderly</td>
</tr>
<tr>
<td>1</td>
<td>Course 2</td>
<td>Psychiatric Consultation in Long-Term Care: Basic Course</td>
</tr>
<tr>
<td>5</td>
<td>Course 19</td>
<td>Psychiatric Consultation in Long Term Care: Advanced Course</td>
</tr>
<tr>
<td>67</td>
<td>Industry-Supported Symp. 25</td>
<td>Plaques &amp; Tangles: Applying Genetics and Molecular Targets to Unravel Strategies for Alzheimer's Disease</td>
</tr>
<tr>
<td>70</td>
<td>Issue Workshop 49</td>
<td>Using Interpersonal Psychotherapy (IPT) With Geriatric Patients</td>
</tr>
<tr>
<td>50</td>
<td>Symposium 27</td>
<td>The Vascular Depression Hypothesis</td>
</tr>
<tr>
<td>94</td>
<td>Symposium 80</td>
<td>Behavioral and Psychological Symptoms of Dementia (BPSD)</td>
</tr>
<tr>
<td>48</td>
<td>Issue Workshop 23</td>
<td>Mental Health Issues in Response to Hurricanes Katrina and Rita</td>
</tr>
<tr>
<td>71</td>
<td>Issue Workshop 55</td>
<td>Quality Improvement Intervention for Depression in Primary Care</td>
</tr>
<tr>
<td>88</td>
<td>Issue Workshop 78</td>
<td>Atherogenic Dyslipidemia in Patients With Atypical Antipsychotics</td>
</tr>
<tr>
<td>94</td>
<td>Symposium 83</td>
<td>Quality and Outcome Assessment in Diverse Clinical Settings</td>
</tr>
</tbody>
</table>
### HISTORICAL ISSUES

<table>
<thead>
<tr>
<th>Page</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>87</td>
<td>Issue Workshop 73</td>
</tr>
<tr>
<td>25</td>
<td>Lecture 5</td>
</tr>
<tr>
<td>81</td>
<td>Symposium 63</td>
</tr>
<tr>
<td>97</td>
<td>Symposium 93</td>
</tr>
</tbody>
</table>

### INDIVIDUAL PSYCHOTHERAPIES

<table>
<thead>
<tr>
<th>Page</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>90</td>
<td>Case Conferences 4</td>
</tr>
<tr>
<td>73</td>
<td>Clinical Report 56</td>
</tr>
<tr>
<td>28</td>
<td>Component Workshop 16</td>
</tr>
<tr>
<td>2</td>
<td>Course 10</td>
</tr>
<tr>
<td>2</td>
<td>Course 11</td>
</tr>
<tr>
<td>5</td>
<td>Course 22</td>
</tr>
<tr>
<td>6</td>
<td>Course 28</td>
</tr>
<tr>
<td>20</td>
<td>Course 47</td>
</tr>
<tr>
<td>30</td>
<td>Course 57</td>
</tr>
<tr>
<td>44</td>
<td>Course 60</td>
</tr>
<tr>
<td>51</td>
<td>Course 68</td>
</tr>
<tr>
<td>51</td>
<td>Course 71</td>
</tr>
<tr>
<td>56</td>
<td>Course 75</td>
</tr>
<tr>
<td>87</td>
<td>Course 95</td>
</tr>
<tr>
<td>23</td>
<td>Issue Workshop 8</td>
</tr>
<tr>
<td>55</td>
<td>Issue Workshop 40</td>
</tr>
<tr>
<td>70</td>
<td>Issue Workshop 49</td>
</tr>
<tr>
<td>70</td>
<td>Issue Workshop 52</td>
</tr>
<tr>
<td>71</td>
<td>Issue Workshop 56</td>
</tr>
<tr>
<td>92</td>
<td>Issue Workshop 112</td>
</tr>
<tr>
<td>58</td>
<td>Presidential Symposium 1</td>
</tr>
<tr>
<td>38</td>
<td>Symposium 22</td>
</tr>
<tr>
<td>79</td>
<td>Symposium 57</td>
</tr>
<tr>
<td>94</td>
<td>Symposium 81</td>
</tr>
<tr>
<td>96</td>
<td>Symposium 88</td>
</tr>
</tbody>
</table>

### INFORMATION TECHNOLOGY

<table>
<thead>
<tr>
<th>Page</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>56</td>
<td>Forum 10</td>
</tr>
<tr>
<td>83</td>
<td>Symposium 69</td>
</tr>
</tbody>
</table>

### INTERNET

<table>
<thead>
<tr>
<th>Page</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>52</td>
<td>Clinical Report 25</td>
</tr>
<tr>
<td>52</td>
<td>Clinical Report 26</td>
</tr>
<tr>
<td>52</td>
<td>Clinical Report 27</td>
</tr>
<tr>
<td>48</td>
<td>Issue Workshop 25</td>
</tr>
</tbody>
</table>

### LESBIAN/GAY/BISEXUAL/TRANSGENDER ISSUES

<table>
<thead>
<tr>
<th>Page</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>29</td>
<td>Component Workshop 22</td>
</tr>
<tr>
<td>56</td>
<td>Course 75</td>
</tr>
<tr>
<td>71</td>
<td>Media Workshop 6</td>
</tr>
<tr>
<td>39</td>
<td>Symposium 25</td>
</tr>
<tr>
<td>81</td>
<td>Symposium 63</td>
</tr>
<tr>
<td>97</td>
<td>Symposium 94</td>
</tr>
</tbody>
</table>

### MANAGED CARE AND HEALTH CARE FUNDING

<table>
<thead>
<tr>
<th>Page</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>22</td>
<td>Component Workshop 11</td>
</tr>
<tr>
<td>28</td>
<td>Component Workshop 17</td>
</tr>
<tr>
<td>69</td>
<td>Component Workshop 45</td>
</tr>
<tr>
<td>30</td>
<td>Course 58</td>
</tr>
<tr>
<td>72</td>
<td>Course 86</td>
</tr>
<tr>
<td>71</td>
<td>Media Workshop 5</td>
</tr>
<tr>
<td>36</td>
<td>Symposium 36</td>
</tr>
</tbody>
</table>
MEN'S ISSUES
Symposium 33  Men: Post Partum Depression and Other Issues

MENTAL RETARDATION (CHILD/adolescent/adult)
Component Workshop 14  Anxiety, Impulsivity, and Aggression: Diagnostic and Treatment Issues in Intellectual Disability

MOOD DISORDERS
NR Posters Session 3  Anxiety and Mood Disorders
Advances In Research 1  Research Advances in Psychiatry
Advances In Series 2  Advances in Treatments of Psychiatric Disorder
Case Conferences 2  Mood Disorders
Clinical Report 4  Adverse Effects on Gestational and Neonatal Outcomes: From Depression or Antidepressant Drugs?
Clinical Report 32  Poor Sleep Quality Independently Predicts Depression in Community-Dwelling Older Adults
Clinical Report 42  Quetiapine as Maintenance Therapy in Bipolar I Disorder
Clinical Report 43  Efficacy of Desvenlafaxine Sustained 50 mg/d and 100 mg/d
Clinical Report 58  Antipsychotic-Induced Extrapyramidal Side Effects in Bipolar Disorder and Schizophrenia
Clinical Report 67  Is Bipolar Disorder Overdiagnosed?
Clinical Report 69  Disease Management for Patients With Difficult-to-Treat Depression
Clinical Report 70  Evidence-Based Medicine and Outcome: Three-Month Follow-Up of Inpatients With MDD
Clinical Report 71  A Clinically Useful Depression Outcome Scale
Clinical Report 84  Patients’ Involvement in Treatment Decisions and Antidepressant Discontinuation
Clinical Report 85  Prevalence and Characteristics of Bipolar Mixed Depression in STEP-BD Patients
Clinical Report 86  Depressive Symptoms Predispose Females to Metabolic Syndrome
Component Workshop 48  New APA Practice Guidelines: MDD and Bipolar Disorder
Course 18  Mood Disorders in Later Life
Course 68  A Psychodynamic Approach to Treatment Resistant Mood Disorders
Course 73  Melatonin and Light Treatment of SAD, Sleep, and Other Body Clock Disorders
Focus Live 1  Major Depressive Disorder
Forum 5  Music and Mood Disorders: Tchaikovsky
Forum 13  "Out of the Shadows": The Many Faces of Depression
Industry-Supported Symp. 5  Addressing Unmet Clinical Needs in Severe Depression
Industry-Supported Symp. 10  Better Understanding of Treatment of MDD
Industry-Supported Symp. 13  Optimizing Treatment of Depression in the Presence of Comorbidities
Industry-Supported Symp. 17  Understanding Bipolar Disorder
Industry-Supported Symp. 26  Novel Perspectives Towards a Better Understanding of Major Depression Disorder
Industry-Supported Symp. 27  Individualizing Treatment Plans for Total Health in Patients With Bipolar Disorder
Issue Workshop 6  Treating the Chronically Depressed Patient Using the Cognitive-Behavioral Analysis System of Psychotherapy
Issue Workshop 37  Quality Of Life Of Patients With Major Depression in a Natural Clinical Setting
Issue Workshop 39  Family-Inclusive Treatment (FIT) For Bipolar Disorder
Issue Workshop 55  Quality Improvement Intervention for Depression in Primary Care
Issue Workshop 77  Controversies in Bipolar Disorder: A Clinical Perspective
Issue Workshop 84  Is There A Role For Complementary and Alternative Medicine in the Treatment of Depression
Issue Workshop 95  Primary Care Depression Management
Issue Workshop 105  Where Is the Line Drawn? Is There a Clinical Interface Between Autism Spectrum Disorders and Bipolar Disorder?
Issue Workshop 118  Humor and Humans: A New Treatment Modality for Patients With Depression
Lecture 4  Deep Brain Stimulation for Treatment of Resistant Depression
Lecture 13  Cellular Plasticity Cascades: A Window into Mood Disorders
Lecture 20  Suicidal Behavior in Bipolar Disorder
Lecture 21  The Neurobiology of Child Abuse and Neglect
Small Interactive Session 9  How Neuroimaging Had Changed Our View of Depression
Small Interactive Session 14  Long-Term Management of Recurrent Affective Disorders
Symposium 11  Depression and Generalized Anxiety: Research Planning for the DSM-V
Symposium 20  The Psychoses Fused: The Kraepelinian Dichotomy
Symposium 26  Genomic Investigations of Mood Disorders
Symposium 33  Men: Post Partum Depression and Other Issues
Symposium 35  Research Advances: Brain Mechanisms of Bipolar Disorder and Major Depression
Symposium 39  Antidepressants in Bipolar Disorder
Symposium 42  The Long-Term Course of the Major Affective Disorders
Symposium 46  Recent Advances in Cross-Cultural, Ethnic and Ethnopsychopharmacological Aspects of Mood Disorders
Symposium 48  Treating Depression in Patients with Schizophrenia
Symposium 59  Treatment of Adolescent Depression
Symposium 60  Research Update: Current Prospects for Enhanced Treatments for Schizophrenia, Mood Disorders, Anxiety Disorders and Substance Abuse
Symposium 62  Mood Disorders through the Life Cycle in France and the US
Symposium 64  Depression Among Emergency Department Patients in Latin-American Countries
### MOOD DISORDERS (cont.)

- 82 Symposium 65: Cognitive Dysfunction in Bipolar Disorder
- 82 Symposium 68: Pharmacotherapy of Unipolar Psychotic Depression (NIMH STOP-PD Trial)
- 84 Symposium 75: Mood Disorders and Medical Comorbidity, Causes and Consequences
- 96 Symposium 91: Stuck in the Black Box: A Patient Safety Approach to Prescribing Antidepressants

### NEUROPSYCHIATRY (See also: Biological Psychiatry and Neuroscience)

- 53 Clinical Report 31: Association Between Frontal Lobe Cognitive and Executive Functions and Domains of Depressive Symptoms in Early Poststroke Patients
- 73 Clinical Report 51: Demographic, Clinical, and Treatment Outcome Profiles in 71 Consecutive, Prospectively Studied Patients With Conversion Disorder
- 7 Course 33: Traumatic Brain Injury: Neuropsychiatric Assessment
- 7 Course 35: Advanced Interviewing Techniques
- 20 Course 50: Advances in Neuropsychiatry
- 17, 44 Industry-Supported Symp. 18: Genetics, Brain Imaging, and Pharmacology
- 25 Lecture 6: Neurotransmitters, Drugs and the Brain: Historical Perspectives
- 40 Lecture 11: William C. Menninger Memorial Lecture
- 59 Symposium 28: Catatonia: Treatment and Future Research

### OTHER SOMATIC THERAPIES

- 1 Course 5: EEG Neurofeedback in Psychiatry
- 72 Course 89: Yoga of the East and West: Integrating Breath
- 35 Symposium 9: Continuation Treatments to Preventing Relapse Following ECT

### PAIN MANAGEMENT

- 7 Course 36: Multidisciplinary Treatment of Chronic Pain
- 3 Industry-Supported Symp. 4: Fibromyalgia
- 6 Industry-Supported Symp. 9: Recent Advances in Diagnosis and Treatment of Fibromyalgia
- 86 Industry-Supported Symp. 29: Beyond Pain to "Fibrofog" and Sleep Impairments
- 45 Lecture 12: Frontiers of Science Lecture
- 47 Small Interactive Session 7: An Overview of the Role of Psychiatrists in Pain Medicine
- 60 Symposium 32: Chronic Pain and the Prescription Opioid Epidemic

### PERSONALITY DISORDERS

- 49 Advances In Series 2: Advances in Treatments of Psychiatric Disorder
- 26 Clinical Report 11: Prediction of Time-to-Accomplishment of Good Psychosocial Functioning for Borderline Patients Followed Prospectively for 10 Years
- 26 Clinical Report 12: The 10-Year Course of Dissociation Reported by Patients With Borderline Personality Disorder
- 53 Clinical Report 36: Factor Structure and Diagnostic Efficiency of DSM-IV Criteria for Avoidant Personality Disorder in Hispanic Men and Women With Substance Use Disorders
- 53 Clinical Report 37: Tattoos and Antisocial Personality Disorder William Cardasis, MD
- 75 Clinical Report 75: Trauma and Psychopathology in Patients With Borderline Personality Disorder and Their Sisters
- 75 Clinical Report 76: Specificity of Glutamatergic Neurotransmission and Borderline Personality Disorder
- 75 Clinical Report 77: Pain in Borderline Personality Disorder: Examining the Role of NMDA Neurotransmission
- 6 Course 27: Recognition and Treatment of Social Phobia
- 20 Course 49: Treating Borderline Personality Disorder With The Stepps* Model (*Systems Training For Emotional Predictability And Problem Solving)
- 21 Course 51: Psychotherapy for Personality Disorder
- 72 Course 88: Overview of Dialectical Behavior Therapy
- 60 Symposium 31: Comparison of Three Psychodynamic Treatments of BPD
- 61 Symposium 37: Changing Conceptions of the Personality Disorders
- 78 Symposium 53: Dimensional Models for Personality Disorder Assessment
- 82 Symposium 66: The Scientific Basis of Interpersonal Dysfunction in Borderline Personality Disorder
- 84 Symposium 73: Affective Instability in Borderline Personality Disorder
TOPIC INDEX

Page # Session

POLITICAL QUESTIONS

21 Component Workshop 1 The Bigger Picture: Psychiatrists As Physician Advocates
72 Course 85 Personality and Political Behavior
71 Issue Workshop 59 Delivering Psychiatric Aid to Iraq
76 Issue Workshop 70 Navigating Terrorism And Its Relation To Mental Health: Middle East Perspective
71 Media Workshop 5 Michael Moore's SICKO
78 Presidential Symposium 3 Advocating with One Voice for Mental Health Care in the US and UK
95 Symposium 85 APA's Goldwater Rule: Ethics of Speaking Publicly About Public Figures

PRESIDENTIAL THEME: “OUR VOICE IN ACTION: ADVANCING SCIENCE, CARE, AND THE PROFESSION”

55 Component Workshop 37 Should We Have a V-Code for Response to Military Operational Stress
69 Component Workshop 42 Grassroots In Action: District Branch Initiative and APA Grant Funding
92 Issue Workshop 115 Innovative Models for Extending Psychiatric Care to Children
18 Lecture 3 Planning, Organization and Evaluation of Mental Health Services
59 Presidential Symposium 2 The Last 25 Years of Women In Psychiatry
78 Presidential Symposium 3 Advocating with One Voice for Mental Health Care in the US and UK
28 Small Interactive Session 6 The Psychiatrist as Advocate for Family
82 Symposium 67 DSM V: Philosophical and Clinical
96 Symposium 90 DSM V: From Research to Clinical Issues

PROFESSIONAL AND PERSONAL ISSUES

90 Case Conferences 4 Psychodynamic Psychotherapy: Erotic Transference and the Female Therapist
21 Component Workshop 6 Practical Tips On How To Be A Successful Author
21 Component Workshop 7 Mentoring 101: A Survival Guide for IMGs
47 Component Workshop 26 Workplace Psychiatry 101
47 Component Workshop 28 American Psychiatry: Care Quality, Access, Ethics, and Advocacy
47 Component Workshop 30 Novel Careers in Psychiatry: Women Who Have Made Their Own Way
54 Component Workshop 34 Career Advancement in Academic Psychiatry for ECPs
55 Component Workshop 36 Reaching Out: Approaches to Suicide Among the Physician Population
69 Component Workshop 41 One Psychiatrist's Boundary Violation May Be Another's Area of Work
1 Course 6 A Practical Approach to Risk Assessment
7 Course 32 Money Matters I: Using Theory in Clinical Practice
18 Course 42 Treating Medical Students and Physicians
20 Course 48 Hope for the Distressed and Disruptive Physician
45 Course 63 Improve Your Presentation Skills: A Coaching Approach
51 Course 69 Personnel Management for Clinician-Administrators
67 Course 81 Treating Physicians Involved in Sexual Misconduct
56 Forum 7 Career Development in Academic Psychiatry
77 Forum 14 Military Psychiatry Today
93 Forum 15 How to Decide Whether to, What, and How to Submit to the APA Annual Meeting
22 Issue Workshop 2 Maintenance of Certification for Diplomats of the ABPN
23 Issue Workshop 9 Jumping off a Cliff, or the Road Not Taken (Career Choices)
49 Issue Workshop 30 Leadership Development for Early Career Women
49 Issue Workshop 35 How to Launch a Successful Private Practice
55 Issue Workshop 42 How to Launch a Successful Private Practice
70 Issue Workshop 48 Leadership in Psychiatry
71 Issue Workshop 60 The Physician As Patient: How Can We Help?
76 Issue Workshop 67 The Portrayal of Psychiatry in Recent American Film
77 Issue Workshop 71 Psychiatrists Who Have Been in Treatment: Part II
89 Issue Workshop 75 American Board of Psychiatry and Neurology Update: Certification and Maintenance of Certification
89 Issue Workshop 88 Risk Management Issues in Psychiatric Practice
89 Issue Workshop 90 The Child Psychiatrist as Grandparent: Grand Joys and Grand Challenges
89 Issue Workshop 98 So You Want To Be A Clinical Investigator?
89 Issue Workshop 99 Biopsychosocial and Spiritual Aspects of Treating Our Physician Colleagues
91 Issue Workshop 101 Innovations in the Evaluation of Professionals Who Engage in Boundary Violations
91 Issue Workshop 103 Responding to theImpact of Suicide on Clinicians
92 Issue Workshop 107 Children of Psychiatrists
92 Issue Workshop 111 My Patient Is Stalking Me: Management of Erotomania in Residency and Beyond
18 Lecture 2 What Women Want
32 Lecture 10 Administrative Psychiatry Award Lecture
59 Presidential Symposium 2 The Last 25 Years of Women In Psychiatry
28 Small Interactive Session 5 Career Versus Job in Psychiatry
47 Small Interactive Session 8 Career Issues for the Academic Psychiatrist
36 Symposium 16 European and American Psychiatry: Identity and Priorities
38 Symposium 23 The Relationships Between the APA Annual Meeting and the Pharmaceutical Industry
64 Symposium 47 How to Launch a Successful Private Practice, Part 3
# TOPIC INDEX

## PSYCHIATRIC ADMINISTRATION AND SERVICES: PUBLIC, PRIVATE, AND UNIVERSITY

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>73</td>
<td>Clinical Report 54</td>
<td>First Mailed Educational Intervention to Physicians Reduced Pharmacy, Hospital, and Outpatient Costs</td>
</tr>
<tr>
<td>21</td>
<td>Component Workshop 3</td>
<td>From Bedside to Balance Sheet (Administrative Psychiatry)</td>
</tr>
<tr>
<td>22</td>
<td>Component Workshop 10</td>
<td>The Beginning and the End of Transinstitutionalization</td>
</tr>
<tr>
<td>50</td>
<td>Course 66</td>
<td>Basic Concepts in Administrative Psych I</td>
</tr>
<tr>
<td>51</td>
<td>Course 69</td>
<td>Personnel Management for Clinician-Administrators</td>
</tr>
<tr>
<td>72</td>
<td>Course 84</td>
<td>Basic Concepts in Administrative Psychiatry II</td>
</tr>
<tr>
<td>93</td>
<td>Forum 16</td>
<td>Grading the State Psychiatric Systems</td>
</tr>
<tr>
<td>49</td>
<td>Issue Workshop 31</td>
<td>The Design and Renovation of Therapeutic Space in an Over-regulated and Underfunded World</td>
</tr>
<tr>
<td>89</td>
<td>Issue Workshop 97</td>
<td>Transforming the Local Mental Health System: A Person-Centered Program</td>
</tr>
<tr>
<td>92</td>
<td>Issue Workshop 106</td>
<td>Transforming Mental Health Care in South Carolina: Partnership Between Academia and Mental Health Departments</td>
</tr>
<tr>
<td>64</td>
<td>Symposium 49</td>
<td>The Virginia Tech Tragedy's Influence on Virginia's Mental Health System</td>
</tr>
<tr>
<td>84</td>
<td>Symposium 72</td>
<td>Transforming the Provision of Mental Health Services: CalMEND Project</td>
</tr>
</tbody>
</table>

## PSYCHIATRIC EDUCATION

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
<td>Component Workshop 4</td>
<td>Ripple Effect of Psychiatric Stigma In Medicine</td>
</tr>
<tr>
<td>28</td>
<td>Component Workshop 18</td>
<td>Evaluating Competency in Psychosomatic</td>
</tr>
<tr>
<td>1</td>
<td>Course 1</td>
<td>DSM-IV Rating Scales to Increase the Effectiveness of Your Psychiatric Practice</td>
</tr>
<tr>
<td>5</td>
<td>Course 21</td>
<td>How to Give a More Effective Lecture</td>
</tr>
<tr>
<td>6</td>
<td>Course 26</td>
<td>Seeing the Forest and the Trees: A Biopsychosocial Approach to the Oral Board Examination</td>
</tr>
<tr>
<td>6</td>
<td>Course 29</td>
<td>What is Psychiatry? Philosophies and Practices</td>
</tr>
<tr>
<td>18</td>
<td>Course 40</td>
<td>Reel Psychiatry</td>
</tr>
<tr>
<td>20</td>
<td>Course 46</td>
<td>Understanding the Person Behind the Illness</td>
</tr>
<tr>
<td>30</td>
<td>Course 54</td>
<td>Teaching Psychiatry? Let Hollywood Help</td>
</tr>
<tr>
<td>22</td>
<td>Issue Workshop 5</td>
<td>Making Your Talks More Interactive</td>
</tr>
<tr>
<td>48</td>
<td>Issue Workshop 21</td>
<td>Pearls and Pitfalls in Negotiating Your First Job</td>
</tr>
<tr>
<td>48</td>
<td>Issue Workshop 24</td>
<td>Teaching on the Fly: Practical Tips for Teaching Medical Students 1-to-1</td>
</tr>
<tr>
<td>70</td>
<td>Issue Workshop 45</td>
<td>Training for All Psychiatric Residents and Scholarly Activity</td>
</tr>
<tr>
<td>88</td>
<td>Issue Workshop 79</td>
<td>Patient Simulation: British and American Adaptations for Psychiatric Education of Medical Students</td>
</tr>
<tr>
<td>91</td>
<td>Issue Workshop 104</td>
<td>Size Matters: Teaching Medical Students in Small Groups</td>
</tr>
<tr>
<td>20</td>
<td>Small Interactive Session 10</td>
<td>Graduation and the PGY 4 Resident</td>
</tr>
<tr>
<td>37</td>
<td>Symposium 19</td>
<td>Comparing Notes: International Experiences in Evaluating Residents' Skills</td>
</tr>
</tbody>
</table>

## PSYCHIATRIC REHABILITATION

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>Industry-Supported Symp. 15</td>
<td>Using a Chronic Disease Model When Managing Patients</td>
</tr>
<tr>
<td>55</td>
<td>Issue Workshop 36</td>
<td>To Work or Not to Work, What is the Question</td>
</tr>
<tr>
<td>88</td>
<td>Issue Workshop 86</td>
<td>The Clinician's Role in Changing the Light</td>
</tr>
<tr>
<td>54</td>
<td>Small Interactive Session 10</td>
<td>Recovery From Disability: Rehabilitation Is the Mission</td>
</tr>
<tr>
<td>83</td>
<td>Symposium 70</td>
<td>Does Peer Support Have a Role in Psychiatry</td>
</tr>
</tbody>
</table>

## PSYCHOANALYSIS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Course 16</td>
<td>Dream Translation: One Empirically-Based Approach</td>
</tr>
<tr>
<td>51</td>
<td>Forum 6</td>
<td>The Implications of the Current Insolubility of the Mind-Brain Problem</td>
</tr>
<tr>
<td>76</td>
<td>Issue Workshop 65</td>
<td>Elvin Semrad's Interviewing Fundamentals for High-Pressure Clinical, Forensic and Educational Contexts</td>
</tr>
<tr>
<td>58</td>
<td>Presidential Symposium 1</td>
<td>Today's Dynamic Psychotherapy: Not Your Grandfather's Psychoanalysis</td>
</tr>
</tbody>
</table>

## PSYCHOIMMUNOLOGY

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>74</td>
<td>Clinical Report 60</td>
<td>Normalization of Immune Cell Imbalance After Pharmacological Treatments of Patients Suffering From Obsessive-Compulsive Disorder</td>
</tr>
<tr>
<td>92</td>
<td>Issue Workshop 108</td>
<td>Inflammation, Psychosis and the Brain: What Do We Really Know?</td>
</tr>
</tbody>
</table>

## PSYCHOPHARMACOLOGY

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>28</td>
<td>Clinical Report 24</td>
<td>A Comparison of the Effects of Modafinil on Olanzapine-Associated Eating Behaviors in Normal Human Subjects</td>
</tr>
<tr>
<td>53</td>
<td>Clinical Report 39</td>
<td>Atypical Antipsychotic Agents, Neurocognitive Deficits, and Aggression in Schizophrenia Patients</td>
</tr>
<tr>
<td>53</td>
<td>Clinical Report 40</td>
<td>Comparison of Intramuscular Ziprasidone, Olanzapine, or Aripiprazole for Agitation</td>
</tr>
<tr>
<td>53</td>
<td>Clinical Report 41</td>
<td>Gender-Specific Patterns in NMS Symptoms</td>
</tr>
<tr>
<td>73</td>
<td>Clinical Report 55</td>
<td>Clinical Trial Reports in Psychiatry Before and After the CONSORT Statement</td>
</tr>
<tr>
<td>74</td>
<td>Clinical Report 57</td>
<td>Long-Term Follow-Up of Patients With Major Depressive Disorder</td>
</tr>
<tr>
<td>74</td>
<td>Clinical Report 58</td>
<td>Antipsychotic-Induced Extrapyramidal Side Effects in Bipolar Disorder and Schizophrenia</td>
</tr>
</tbody>
</table>
PSYCHOPHARMACOLOGY (cont.)

74 Clinical Report 59  Identification and Attribution of Side Effects of Antidepressants by Self Report and Psychiatrist Interview
72 Course 87  Drug Interaction Principles Course: Update 2008
5 Industry-Supported Symp. 7  Treating Patients Early: Updates on the Controversy
8 Industry-Supported Symp.12  Treatment of Children and Adolescents with Psychiatric Disorders
88 Issue Workshop 84  Is There A Role For Complementary and Alternative Medicine in the Treatment of Depression
7 Presidential Symposium 3  The Myths of the Med Check
68 Small Interactive Session 13  Child and Adolescent Psychopharmacology
35 Symposium 10  Safety Issues in Child and Adolescent Psychopharmacology
36 Symposium 13  Psychopharmacology in the Athlete
64 Symposium 46  Recent Advances in Cross-Cultural, Ethnic and Ethnopsychopharmacological Aspects of Mood Disorders
79 Symposium 56  Update on Neuroleptic Malignant Syndrome With Case Reviews

RELIGION, SPIRITUALITY, AND PSYCHIATRY

75 Component Workshop 50  Religion and Psychiatry in the Post-Freudian Age
1 Course 8  Spirituality and Worldview in Clinical Practice
6 Course 24  Transpersonal and Spiritual Aspects of the Practice of Psychiatry
7 Course 34  Spirituality in Psychiatry
23 Issue Workshop 11  The Wrath of God: A Faith-Based Survival Paradigm (Earthquake Survivors)
56 Issue Workshop 43  The Theory and Utilization of Yoga and Meditation As It Relates to Well Being, Human Relationships, and Global Society
89 Issue Workshop 91  The Science of Life: The Application of Ayurveda in Mental Health
89 Issue Workshop 96  Insight and Awakening: Mindfulness and Psychotherapy
89 Issue Workshop 99  Biopsychosocial and Spiritual Aspects of Treating Our Physician Colleagues
31 Lecture 8  Should Psychiatry Embrace a Psycho-spiritual Approach to Patient Care?
67 Lecture 22  Prozac and the Spiritual Self
39 Symposium 25  Homosexuality and Therapy: The Religious Dimension
93 Symposium 79  Religion that Heals, Religion that Harms: What Is the Place of Psychiatry?

RESEARCH ISSUES

74 Clinical Report 66  Threats to Validity in Causality Research Using Psychiatric Diagnoses
30 Course 56  Research and Publishing on a Shoestring Budget
30 Forum 3  Research Planning for DSM-V
89 Issue Workshop 94  Practitioner Feedback on NIMH's Clinical Treatment Trials
89 Issue Workshop 98  So You Want To Be A Clinical Investigator?
46 Lecture 14  Conflicts of Interest in Psychiatric Practice and Research
46 Lecture 15  Rethinking Mental Disorders: How Research Will Change Practice
20 NR Posters Session 1  Young Investigators
31 NR Posters Session 2  Young Investigators
39 NR Posters Session 3  Anxiety and Mood Disorders
56 NR Posters Session 4  Schizophrenia and Other Psychotic Disorders
65 NR Posters Session 5  DSM V: From Research to Clinical Issues
85 NR Posters Session 7  DSM V: From Research to Clinical Issues
54 Small Interactive Session 11  Research in Mental Health
63 Symposium 45  Safety and Recent Research in Non-Conventional Therapies
82 Symposium 67  DSM V: Philosophical and Clinical
96 Symposium 90  DSM V: From Research to Clinical Issues

RESIDENT AND MEDICAL STUDENT ISSUES

75 Component Workshop 52  One in a Million? Safety of Trainees in the Psychiatric Setting
30 Forum 2  The World Association of Young Psychiatrist
23 Issue Workshop 7  Impact of Patient Suicide on Psychiatry Residents
71 Issue Workshop 58  Making the Most of Your Chief Year: Chief Residents' Forum, Part I
76 Issue Workshop 69  Making the Most of Your Chief Year: Chief Residents' Forum, Part II
92 Issue Workshop 111  My Patient Is Stalking Me: Management of Erotomania in Residency and Beyond
## TOPIC INDEX

### SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>24</td>
<td>Advances In Research 1</td>
</tr>
<tr>
<td>49</td>
<td>Advances In Series 2</td>
</tr>
<tr>
<td>27</td>
<td>Clinical Report 16</td>
</tr>
<tr>
<td>27</td>
<td>Clinical Report 17</td>
</tr>
<tr>
<td>27</td>
<td>Clinical Report 18</td>
</tr>
<tr>
<td>27</td>
<td>Clinical Report 19</td>
</tr>
<tr>
<td>27</td>
<td>Clinical Report 20</td>
</tr>
<tr>
<td>27</td>
<td>Clinical Report 21</td>
</tr>
<tr>
<td>27</td>
<td>Clinical Report 22</td>
</tr>
<tr>
<td>28</td>
<td>Clinical Report 23</td>
</tr>
<tr>
<td>54</td>
<td>Clinical Report 44</td>
</tr>
<tr>
<td>54</td>
<td>Clinical Report 50</td>
</tr>
<tr>
<td>74</td>
<td>Clinical Report 58</td>
</tr>
<tr>
<td>75</td>
<td>Clinical Report 72</td>
</tr>
<tr>
<td>75</td>
<td>Clinical Report 73</td>
</tr>
<tr>
<td>75</td>
<td>Clinical Report 74</td>
</tr>
<tr>
<td>90</td>
<td>Clinical Report 78</td>
</tr>
<tr>
<td>90</td>
<td>Clinical Report 79</td>
</tr>
<tr>
<td>27</td>
<td>Clinical Report 80</td>
</tr>
<tr>
<td>8</td>
<td>Course 39</td>
</tr>
<tr>
<td>67</td>
<td>Course 80</td>
</tr>
<tr>
<td>24</td>
<td>Focus Live 2</td>
</tr>
<tr>
<td>2</td>
<td>Industry-Supported Symp. 2</td>
</tr>
<tr>
<td>8</td>
<td>Industry-Supported Symp. 11</td>
</tr>
<tr>
<td>8</td>
<td>Industry-Supported Symp. 12</td>
</tr>
<tr>
<td>40</td>
<td>Industry-Supported Symp. 19</td>
</tr>
<tr>
<td>66</td>
<td>Industry-Supported Symp. 24</td>
</tr>
<tr>
<td>55</td>
<td>Issue Workshop 41</td>
</tr>
<tr>
<td>56</td>
<td>Issue Workshop 44</td>
</tr>
<tr>
<td>70</td>
<td>Issue Workshop 50</td>
</tr>
<tr>
<td>88</td>
<td>Issue Workshop 78</td>
</tr>
<tr>
<td>88</td>
<td>Issue Workshop 83</td>
</tr>
<tr>
<td>56</td>
<td>NR Posters Session 4</td>
</tr>
<tr>
<td>64</td>
<td>Symposium 48</td>
</tr>
<tr>
<td>71</td>
<td>Symposium 50</td>
</tr>
<tr>
<td>80</td>
<td>Symposium 60</td>
</tr>
<tr>
<td>85</td>
<td>Symposium 61</td>
</tr>
<tr>
<td>84</td>
<td>Symposium 74</td>
</tr>
<tr>
<td>90</td>
<td>Symposium 77</td>
</tr>
</tbody>
</table>

### SEXUAL AND GENDER DISORDERS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>Course 30</td>
</tr>
<tr>
<td>67</td>
<td>Course 81</td>
</tr>
<tr>
<td>67</td>
<td>Course 82</td>
</tr>
<tr>
<td>49</td>
<td>Issue Workshop 28</td>
</tr>
<tr>
<td>50</td>
<td>Media Workshop 4</td>
</tr>
</tbody>
</table>

### SLEEP DISORDERS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>53</td>
<td>Clinical Report 32</td>
</tr>
<tr>
<td>56</td>
<td>Clinical Report 73</td>
</tr>
<tr>
<td>17, 44</td>
<td>Industry-Supported Symp. 16</td>
</tr>
<tr>
<td>41</td>
<td>Industry-Supported Symp. 21</td>
</tr>
<tr>
<td>86</td>
<td>Industry-Supported Symp. 29</td>
</tr>
<tr>
<td>94</td>
<td>Symposium 82</td>
</tr>
</tbody>
</table>

---

113
### Social and Community Psychiatry

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>74</td>
<td>Clinical Report 63</td>
<td>Treating Obesity: Interventions for Improving Body Mass Index and Increasing Fitness in an Inner-City Hispanic and African-American SPMI Population</td>
</tr>
<tr>
<td>74</td>
<td>Clinical Report 64</td>
<td>FACT, A Dutch Version of ACT (Assertive Community Treatment)</td>
</tr>
<tr>
<td>74</td>
<td>Clinical Report 65</td>
<td>Psychiatric Housing: Correlates of Community Interaction</td>
</tr>
<tr>
<td>69</td>
<td>Component Workshop 44</td>
<td>Preventing Incarceration of the Mentally Ill</td>
</tr>
<tr>
<td>57</td>
<td>Course 79</td>
<td>Home Treatment for Acute Mental Disorders: An Alternative to Hospitalization</td>
</tr>
<tr>
<td>24</td>
<td>Forum 1</td>
<td>The Disposable Americans</td>
</tr>
<tr>
<td>56</td>
<td>Issue Workshop 63</td>
<td>Integrating Psychiatry and Primary Care (Response Following … Katrina)</td>
</tr>
<tr>
<td>76</td>
<td>Issue Workshop 66</td>
<td>Transition-Age Youth</td>
</tr>
<tr>
<td>91</td>
<td>Issue Workshop 100</td>
<td>Facts about FACT (a Dutch Version of Assertive Community Treatment)</td>
</tr>
<tr>
<td>51</td>
<td>Lecture 16</td>
<td>Psychological Effects of War</td>
</tr>
<tr>
<td>34</td>
<td>Symposium 5</td>
<td>The Social Responsibility of Universities for the Mental Health of Students and Community Safety</td>
</tr>
<tr>
<td>59</td>
<td>Symposium 29</td>
<td>School Shootings: Threat Recognition and Prevention</td>
</tr>
<tr>
<td>96</td>
<td>Symposium 92</td>
<td>Poverty and Mental Illness Around the World</td>
</tr>
</tbody>
</table>

### Somatoform Disorders

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>73</td>
<td>Clinical Report 52</td>
<td>Somatization Increases Role Impairment and Disability Independent of Psychiatric and Medical Comorbidity</td>
</tr>
<tr>
<td>48</td>
<td>Issue Workshop 26</td>
<td>Fibromyalgia: Current Understanding and Future Directions</td>
</tr>
<tr>
<td>34</td>
<td>Symposium 7</td>
<td>Medical Conundrums: A Guide for the Treating Psychiatrist</td>
</tr>
</tbody>
</table>

### Stigma/Advocacy

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>55</td>
<td>Component Workshop 39</td>
<td>Breaking Barriers: Empowering Providers and Patients</td>
</tr>
<tr>
<td>69</td>
<td>Component Workshop 40</td>
<td>Advocacy: What Medical Students, Residents, and ECPs Need to Know</td>
</tr>
<tr>
<td>69</td>
<td>Component Workshop 42</td>
<td>Grassroots In Action: District Branch Initiative and APA Grant Funding</td>
</tr>
<tr>
<td>71</td>
<td>Media Workshop 5</td>
<td>Michael Moore’s SICKO</td>
</tr>
<tr>
<td>71</td>
<td>Media Workshop 7</td>
<td>Shame and Silence: Understanding the Stigma of Mental Illness in Asian Americans</td>
</tr>
<tr>
<td>78</td>
<td>Presidential Symposium 3</td>
<td>Advocating with One Voice for Mental Health Care in the US and UK</td>
</tr>
</tbody>
</table>

### Suicide

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td>Clinical Report 10</td>
<td>Prospective Predictors of Suicidal Behavior in Borderline Personality Disorder</td>
</tr>
<tr>
<td>27</td>
<td>Clinical Report 20</td>
<td>Pathways Leading to Suicide in Schizophrenia</td>
</tr>
<tr>
<td>52</td>
<td>Clinical Report 26</td>
<td>Cybersuicide: &quot;Pro&quot; and &quot;How To?&quot; Suicide Information on the Web</td>
</tr>
<tr>
<td>47</td>
<td>Component Workshop 24</td>
<td>Lethal Beauty: The Golden Gate Bridge</td>
</tr>
<tr>
<td>55</td>
<td>Component Workshop 36</td>
<td>Reaching Out: Approaches to Suicide Among the Physician Population</td>
</tr>
<tr>
<td>8</td>
<td>Course 38</td>
<td>Losing a Patient to Suicide</td>
</tr>
<tr>
<td>29</td>
<td>Issue Workshop 18</td>
<td>Do-Not-Resuscitate Orders in Suicidal Patients</td>
</tr>
<tr>
<td>55</td>
<td>Issue Workshop 38</td>
<td>Reducing Suicide Risk in a Small Community</td>
</tr>
<tr>
<td>70</td>
<td>Issue Workshop 53</td>
<td>The Air Force Suicide Prevention Program</td>
</tr>
<tr>
<td>88</td>
<td>Issue Workshop 87</td>
<td>Reducing Inpatient Suicide for Kids (RISK): Practical Strategies for the Inpatient Team</td>
</tr>
<tr>
<td>91</td>
<td>Issue Workshop 103</td>
<td>Responding to the Impact of Suicide on Clinicians</td>
</tr>
<tr>
<td>57</td>
<td>Lecture 20</td>
<td>Suicidal Behavior in Bipolar Disorder</td>
</tr>
</tbody>
</table>

### Telepsychiatry

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>53</td>
<td>Clinical Report 33</td>
<td>Feasibility and Effectiveness of Telemedicine for Psychiatric Consultation to Chinese Immigrants in a Nursing Home</td>
</tr>
</tbody>
</table>

### Treatment Techniques and Outcome Studies

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>49</td>
<td>Advances In Series 2</td>
<td>Advances in Treatments of Psychiatric Disorder</td>
</tr>
<tr>
<td>3</td>
<td>Course 13</td>
<td>Brain Stimulation Therapies in Psychiatry</td>
</tr>
<tr>
<td>8</td>
<td>Course 37</td>
<td>Introduction to Tranccranial Magnetic Stimulation</td>
</tr>
<tr>
<td>45</td>
<td>Course 62</td>
<td>Creative Use of Boundary Crossings in Therapy Instead of Slippery Slopes</td>
</tr>
<tr>
<td>51</td>
<td>Course 72</td>
<td>The Way of Yoga, Herbs, and Nutrients in the Treatment of Depression, Anxiety, PTSD, Cognitive Dysfunction, ADHD and Sexual Dysfunction</td>
</tr>
<tr>
<td>40</td>
<td>Industry-Supported Symp. 20</td>
<td>Novel and Current Antidepressants</td>
</tr>
<tr>
<td>76</td>
<td>Issue Workshop 64</td>
<td>What Time Does Not Heal: Achieving Functional Recovery in Psychiatric Illness</td>
</tr>
<tr>
<td>92</td>
<td>Issue Workshop 110</td>
<td>Improving, Interfering, or Inane: Current Lessons from Formal Patient Feedback to Psychiatrists</td>
</tr>
<tr>
<td>93</td>
<td>Issue Workshop 118</td>
<td>Humor and Humans: A New Treatment Modality for Patients With Depression</td>
</tr>
</tbody>
</table>
### TOPIC INDEX

#### VIOLENCE, TRAUMA, AND VICTIMIZATION

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
<td>Component Workshop 8</td>
</tr>
<tr>
<td>48</td>
<td>Component Workshop 33</td>
</tr>
<tr>
<td>75</td>
<td>Component Workshop 52</td>
</tr>
<tr>
<td>76</td>
<td>Component Workshop 53</td>
</tr>
<tr>
<td>30</td>
<td>Course 53</td>
</tr>
<tr>
<td>45</td>
<td>Course 61</td>
</tr>
<tr>
<td>45</td>
<td>Course 65</td>
</tr>
<tr>
<td>56</td>
<td>Course 74</td>
</tr>
<tr>
<td>67</td>
<td>Course 82</td>
</tr>
<tr>
<td>56</td>
<td>Forum 8</td>
</tr>
<tr>
<td>77</td>
<td>Forum 12</td>
</tr>
<tr>
<td>71</td>
<td>Issue Workshop 57</td>
</tr>
<tr>
<td>76</td>
<td>Issue Workshop 63</td>
</tr>
<tr>
<td>76</td>
<td>Issue Workshop 70</td>
</tr>
<tr>
<td>88</td>
<td>Issue Workshop 81</td>
</tr>
<tr>
<td>88</td>
<td>Issue Workshop 85</td>
</tr>
<tr>
<td>51</td>
<td>Lecture 16</td>
</tr>
<tr>
<td>52</td>
<td>Lecture 17</td>
</tr>
<tr>
<td>58</td>
<td>Lecture 21</td>
</tr>
<tr>
<td>23</td>
<td>Media Workshop 1</td>
</tr>
<tr>
<td>23</td>
<td>Media Workshop 2</td>
</tr>
<tr>
<td>36</td>
<td>Media Workshop 3</td>
</tr>
<tr>
<td>36</td>
<td>Symposium 15</td>
</tr>
<tr>
<td>38</td>
<td>Symposium 24</td>
</tr>
<tr>
<td>59</td>
<td>Symposium 29</td>
</tr>
<tr>
<td>59</td>
<td>Symposium 30</td>
</tr>
<tr>
<td>62</td>
<td>Symposium 41</td>
</tr>
<tr>
<td>63</td>
<td>Symposium 43</td>
</tr>
<tr>
<td>64</td>
<td>Symposium 49</td>
</tr>
<tr>
<td>72</td>
<td>Symposium 51</td>
</tr>
<tr>
<td>90</td>
<td>Symposium 77</td>
</tr>
</tbody>
</table>

#### WOMEN'S HEALTH ISSUES

<table>
<thead>
<tr>
<th>Page #</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>29</td>
<td>Component Workshop 23</td>
</tr>
<tr>
<td>70</td>
<td>Component Workshop 49</td>
</tr>
<tr>
<td>1</td>
<td>Course 4</td>
</tr>
<tr>
<td>2</td>
<td>Industry-Supported Symp. 1</td>
</tr>
<tr>
<td>9</td>
<td>Industry-Supported Symp. 14</td>
</tr>
<tr>
<td>23</td>
<td>Issue Workshop 13</td>
</tr>
<tr>
<td>70</td>
<td>Issue Workshop 46</td>
</tr>
<tr>
<td>37</td>
<td>Symposium 17</td>
</tr>
<tr>
<td>62</td>
<td>Symposium 40</td>
</tr>
<tr>
<td>Name</td>
<td>Page</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Ancoli-Israel, Sonia</td>
<td>86</td>
</tr>
<tr>
<td>Abdulrahman, Abdullah</td>
<td>63</td>
</tr>
<tr>
<td>Abel, Gene</td>
<td>67</td>
</tr>
<tr>
<td>Al-Sarraf, Abdallah</td>
<td>17</td>
</tr>
<tr>
<td>Adams, Neal</td>
<td>84</td>
</tr>
<tr>
<td>Adelson, Stewart</td>
<td>57</td>
</tr>
<tr>
<td>Afzal, Amir</td>
<td>71</td>
</tr>
<tr>
<td>Ahmed, Iqbal</td>
<td>70</td>
</tr>
<tr>
<td>Akhtar, Sahab</td>
<td>23</td>
</tr>
<tr>
<td>Akiskal, Hapog</td>
<td>63</td>
</tr>
<tr>
<td>Akman, Jeffrey</td>
<td>69</td>
</tr>
<tr>
<td>Alarcon, Renato D</td>
<td>3</td>
</tr>
<tr>
<td>Albright, Suzanne</td>
<td>48</td>
</tr>
<tr>
<td>Alexopoulos, George</td>
<td>50</td>
</tr>
<tr>
<td>Alfonso, Cesar</td>
<td>59</td>
</tr>
<tr>
<td>Ali, Farhana</td>
<td>38</td>
</tr>
<tr>
<td>Allen, Jon</td>
<td>94</td>
</tr>
<tr>
<td>Altshuler, Lori</td>
<td>62</td>
</tr>
<tr>
<td>Al-Zait, Mohammed</td>
<td>88</td>
</tr>
<tr>
<td>Andersen, Grethe</td>
<td>84</td>
</tr>
<tr>
<td>Anderson, Allan</td>
<td>30</td>
</tr>
<tr>
<td>Anderson III, Otis</td>
<td>23</td>
</tr>
<tr>
<td>Andrade, Naleen</td>
<td>71</td>
</tr>
<tr>
<td>Arnett, Emily</td>
<td>79</td>
</tr>
<tr>
<td>Amara, Sami</td>
<td>48, 65, 70, 78, 90</td>
</tr>
<tr>
<td>Appelbaum, Paul</td>
<td>37, 81</td>
</tr>
<tr>
<td>Arboleda-Florez, Julio</td>
<td>76</td>
</tr>
<tr>
<td>Arnold, Lesley</td>
<td>8</td>
</tr>
<tr>
<td>Aronne, Louis</td>
<td>65</td>
</tr>
<tr>
<td>Arroyo, William</td>
<td>92</td>
</tr>
<tr>
<td>Atkins, Robert</td>
<td>72</td>
</tr>
<tr>
<td>Bahnbruck, Brenda</td>
<td>55</td>
</tr>
<tr>
<td>Bailey, Rahn</td>
<td>29</td>
</tr>
<tr>
<td>Barker, Linda</td>
<td>57</td>
</tr>
<tr>
<td>Barsky, Arthur J</td>
<td>34</td>
</tr>
<tr>
<td>Bass, Judith</td>
<td>82</td>
</tr>
<tr>
<td>Bateman, Anthony</td>
<td>60</td>
</tr>
<tr>
<td>Bauer, Amy</td>
<td>89</td>
</tr>
<tr>
<td>Baum, Antonia</td>
<td>36</td>
</tr>
<tr>
<td>Beardslee, William</td>
<td>34</td>
</tr>
<tr>
<td>Beck, Judith</td>
<td>70</td>
</tr>
<tr>
<td>Becker, Judith</td>
<td>67</td>
</tr>
<tr>
<td>Beezhold, Julian</td>
<td>88</td>
</tr>
<tr>
<td>Belcher, Myron</td>
<td>87</td>
</tr>
<tr>
<td>Bell, Carl</td>
<td>36</td>
</tr>
<tr>
<td>Bender, Donna</td>
<td>78</td>
</tr>
<tr>
<td>Benedek, Elissa</td>
<td>29</td>
</tr>
<tr>
<td>Benedek, Lana</td>
<td>48</td>
</tr>
<tr>
<td>Benton, Brian T</td>
<td>60</td>
</tr>
<tr>
<td>Berkowitz, Steven</td>
<td>29</td>
</tr>
<tr>
<td>Bernet, William</td>
<td>63</td>
</tr>
<tr>
<td>Bernstein, Carol</td>
<td>30</td>
</tr>
<tr>
<td>Berrettini, Wade</td>
<td>38</td>
</tr>
<tr>
<td>Bhagta, Dinesh</td>
<td>37</td>
</tr>
<tr>
<td>Bieler, Philip</td>
<td>60</td>
</tr>
<tr>
<td>Bickel, W.</td>
<td>89</td>
</tr>
<tr>
<td>Biederman, Joseph</td>
<td>5</td>
</tr>
<tr>
<td>Billick, Stephen</td>
<td>28</td>
</tr>
<tr>
<td>Bishay, Zeinab</td>
<td>76</td>
</tr>
<tr>
<td>Black, Donald W</td>
<td>61</td>
</tr>
<tr>
<td>Black, Jacques</td>
<td>49</td>
</tr>
<tr>
<td>Blair, James</td>
<td>37</td>
</tr>
<tr>
<td>Blair, Katrina</td>
<td>37</td>
</tr>
<tr>
<td>Blazer, Dan</td>
<td>37, 67</td>
</tr>
<tr>
<td>Bluestein, Jared</td>
<td>48, 59</td>
</tr>
<tr>
<td>Blumberg, Hilary</td>
<td>61</td>
</tr>
<tr>
<td>Bober, Daniel</td>
<td>69</td>
</tr>
<tr>
<td>Bocho, William</td>
<td>66</td>
</tr>
<tr>
<td>Bohn, Paul</td>
<td>8</td>
</tr>
<tr>
<td>Bokarius, Vladimir</td>
<td>7</td>
</tr>
<tr>
<td>Book, Howard</td>
<td>45, 70</td>
</tr>
<tr>
<td>Booty, Andrew</td>
<td>22</td>
</tr>
<tr>
<td>Borus, Jonathan</td>
<td>47</td>
</tr>
<tr>
<td>Boyer, Edward</td>
<td>77</td>
</tr>
<tr>
<td>Bradford, John</td>
<td>31</td>
</tr>
<tr>
<td>Brady, Kathleen</td>
<td>31, 62</td>
</tr>
<tr>
<td>Brendel, David H</td>
<td>6</td>
</tr>
<tr>
<td>Brent, David</td>
<td>80</td>
</tr>
<tr>
<td>Breuk, Rene</td>
<td>77</td>
</tr>
<tr>
<td>Brod, Thomas M</td>
<td>1</td>
</tr>
<tr>
<td>Brown, Richard</td>
<td>73</td>
</tr>
<tr>
<td>Brown, Thomas E</td>
<td>5</td>
</tr>
<tr>
<td>Bruce, Travis</td>
<td>88</td>
</tr>
<tr>
<td>Buckley, Peter</td>
<td>24</td>
</tr>
<tr>
<td>Buie, Stephen E</td>
<td>14</td>
</tr>
<tr>
<td>Bunney, William</td>
<td>50</td>
</tr>
<tr>
<td>Burd, Ronald</td>
<td>69</td>
</tr>
<tr>
<td>Burdick, Katherine</td>
<td>82</td>
</tr>
<tr>
<td>Burgholter, Page</td>
<td>56</td>
</tr>
<tr>
<td>Burroughs, Tracee</td>
<td>22</td>
</tr>
<tr>
<td>Burt, Donald</td>
<td>23</td>
</tr>
<tr>
<td>Burt, Vivien</td>
<td>6</td>
</tr>
<tr>
<td>Busch, Alissa</td>
<td>17</td>
</tr>
<tr>
<td>Butler, Jeremy</td>
<td>30</td>
</tr>
<tr>
<td>Buyvala, Victor</td>
<td>30, 70, 89</td>
</tr>
<tr>
<td>Buyssse, Daniel</td>
<td>17</td>
</tr>
<tr>
<td>Caba, Robert</td>
<td>81</td>
</tr>
<tr>
<td>Caiano, Norama</td>
<td>49, 89</td>
</tr>
<tr>
<td>Callahan, William</td>
<td>49, 56, 64</td>
</tr>
<tr>
<td>Camarena, Enrique</td>
<td>77</td>
</tr>
<tr>
<td>Campbell, Aimee</td>
<td>62</td>
</tr>
<tr>
<td>Campbell, Jamie</td>
<td>48</td>
</tr>
<tr>
<td>Campbell, William</td>
<td>1, 48, 72</td>
</tr>
<tr>
<td>Capps, Randolph</td>
<td>96</td>
</tr>
<tr>
<td>Carlson, Gabrielle</td>
<td>92</td>
</tr>
<tr>
<td>Carpenter, Ken</td>
<td>62</td>
</tr>
<tr>
<td>Carpenter, Linda</td>
<td>3</td>
</tr>
<tr>
<td>Carroll, Brendan</td>
<td>59</td>
</tr>
<tr>
<td>Carter, Dana</td>
<td>1</td>
</tr>
<tr>
<td>Cash, Charles</td>
<td>63</td>
</tr>
<tr>
<td>Castellanos, Daniel</td>
<td>70</td>
</tr>
<tr>
<td>Cesta, Kenneth</td>
<td>92</td>
</tr>
<tr>
<td>Cerullo, Cathy</td>
<td>50</td>
</tr>
<tr>
<td>Chan, Carlyle</td>
<td>18</td>
</tr>
<tr>
<td>Chang, Kiki</td>
<td>17</td>
</tr>
<tr>
<td>Chatter, Irene</td>
<td>21</td>
</tr>
<tr>
<td>Chen, David</td>
<td>21</td>
</tr>
<tr>
<td>Chessick, Richard</td>
<td>51</td>
</tr>
<tr>
<td>Choi-Kain, Lois</td>
<td>82</td>
</tr>
<tr>
<td>Clarke, David</td>
<td>79</td>
</tr>
<tr>
<td>Clarkson, John</td>
<td>21, 82</td>
</tr>
<tr>
<td>Clay, Daniel</td>
<td>3, 6</td>
</tr>
<tr>
<td>Clemens, Joseph</td>
<td>88</td>
</tr>
<tr>
<td>Cohen, Lee S</td>
<td>10</td>
</tr>
<tr>
<td>Cohen, Mary Ann</td>
<td>93</td>
</tr>
<tr>
<td>Cohen, Carl</td>
<td>65</td>
</tr>
<tr>
<td>Cohn, Tonya</td>
<td>80</td>
</tr>
<tr>
<td>Colenda, Christopher</td>
<td>22</td>
</tr>
<tr>
<td>Combrink-Graham, Lee</td>
<td>69</td>
</tr>
<tr>
<td>Compton III, Wilson</td>
<td>23</td>
</tr>
<tr>
<td>Condon, Timothy</td>
<td>77</td>
</tr>
<tr>
<td>Conley, Robert R</td>
<td>10</td>
</tr>
<tr>
<td>Cora, Gabriella</td>
<td>69</td>
</tr>
<tr>
<td>Cordoba, Rodrigo</td>
<td>77</td>
</tr>
<tr>
<td>Comblatt, Barbara</td>
<td>5</td>
</tr>
<tr>
<td>Coryell, William</td>
<td>63</td>
</tr>
<tr>
<td>Costa, Paul</td>
<td>61</td>
</tr>
<tr>
<td>Coutons, Francine</td>
<td>22</td>
</tr>
<tr>
<td>Cowan, Christopher</td>
<td>79</td>
</tr>
<tr>
<td>Cozza, Kelly</td>
<td>72</td>
</tr>
<tr>
<td>Crocker, Robert</td>
<td>95</td>
</tr>
<tr>
<td>Crowe, Samantha</td>
<td>37</td>
</tr>
<tr>
<td>Cummings, Jeffrey</td>
<td>70</td>
</tr>
<tr>
<td>Cutler, Andrew</td>
<td>89</td>
</tr>
<tr>
<td>D</td>
<td></td>
</tr>
<tr>
<td>Dadhaby, Dina</td>
<td>6</td>
</tr>
<tr>
<td>D’Alli, Richard</td>
<td>85</td>
</tr>
<tr>
<td>Dang, Kien</td>
<td>91</td>
</tr>
<tr>
<td>Davae, Umeic</td>
<td>29</td>
</tr>
<tr>
<td>Dave, Subodhi</td>
<td>88</td>
</tr>
<tr>
<td>Davidson, Larry</td>
<td>17</td>
</tr>
<tr>
<td>Davine, Jon</td>
<td>22</td>
</tr>
<tr>
<td>Davis, Jeri</td>
<td>72</td>
</tr>
<tr>
<td>Davis, Rachel</td>
<td>26</td>
</tr>
<tr>
<td>Daviss, Steven</td>
<td>28, 48</td>
</tr>
<tr>
<td>de Figueiredo, John</td>
<td>28</td>
</tr>
<tr>
<td>DeFrancis, Lisa, Lea</td>
<td>29</td>
</tr>
<tr>
<td>Dell, Mary</td>
<td>1</td>
</tr>
<tr>
<td>Desai, Abhishash</td>
<td>1</td>
</tr>
<tr>
<td>Desai, Prakash</td>
<td>87</td>
</tr>
<tr>
<td>Dewan, Mantosh</td>
<td>30, 96</td>
</tr>
<tr>
<td>Dewar, Amy</td>
<td>89</td>
</tr>
<tr>
<td>Dick, Danielle</td>
<td>8</td>
</tr>
<tr>
<td>Dickson, Lesley</td>
<td>49</td>
</tr>
<tr>
<td>Dickstein, Leah</td>
<td>49</td>
</tr>
<tr>
<td>Dimsdale, Joel</td>
<td>36</td>
</tr>
<tr>
<td>Dobins, Mary</td>
<td>92</td>
</tr>
<tr>
<td>Doghramji, Karl</td>
<td>94</td>
</tr>
<tr>
<td>Douanh, Antoine</td>
<td>93</td>
</tr>
<tr>
<td>Dougherty, Darin</td>
<td>8</td>
</tr>
<tr>
<td>Douglas, Carolyn</td>
<td>22</td>
</tr>
<tr>
<td>Dressman, Douglas</td>
<td>34</td>
</tr>
<tr>
<td>D’Souza, Anjali</td>
<td>89</td>
</tr>
<tr>
<td>Dubovsky, Steven</td>
<td>49</td>
</tr>
<tr>
<td>Dunn, Laura B.</td>
<td>95</td>
</tr>
<tr>
<td>Name</td>
<td>Page(s)</td>
</tr>
<tr>
<td>---------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Posey, David</td>
<td>98</td>
</tr>
<tr>
<td>Post, Jerrold</td>
<td>38, 50</td>
</tr>
<tr>
<td>Post, Robert</td>
<td>62</td>
</tr>
<tr>
<td>Potash, James</td>
<td>35</td>
</tr>
<tr>
<td>Potkin, Steven</td>
<td>50</td>
</tr>
<tr>
<td>Pourceu, Claire</td>
<td>78, 95</td>
</tr>
<tr>
<td>Powers, Pauline</td>
<td>65</td>
</tr>
<tr>
<td>Powsner, Seth</td>
<td>93</td>
</tr>
<tr>
<td>Price, Marlyn</td>
<td>88</td>
</tr>
<tr>
<td>Prieto, Ronald</td>
<td>92</td>
</tr>
<tr>
<td>Prince, Jefferson</td>
<td>18, 57</td>
</tr>
<tr>
<td>Puchalski, Christina</td>
<td>7</td>
</tr>
<tr>
<td>Pumariega, Andres</td>
<td>96</td>
</tr>
<tr>
<td>Pumariega, Andres</td>
<td>70</td>
</tr>
<tr>
<td>Pyles, Robert</td>
<td></td>
</tr>
</tbody>
</table>

R

<table>
<thead>
<tr>
<th>Name</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rabins, Peter V.</td>
<td>2</td>
</tr>
<tr>
<td>Rafferty, Jason</td>
<td>76</td>
</tr>
<tr>
<td>Ramani, Meena</td>
<td>88</td>
</tr>
<tr>
<td>Ramati, Luiz</td>
<td></td>
</tr>
<tr>
<td>Raminie, Paul</td>
<td>67</td>
</tr>
<tr>
<td>Rao, Nyapati</td>
<td>70, 92</td>
</tr>
<tr>
<td>Rapaport, Mark</td>
<td>18, 24</td>
</tr>
<tr>
<td>Raskin, Williams</td>
<td>92</td>
</tr>
<tr>
<td>Rathod, Shanaya</td>
<td></td>
</tr>
<tr>
<td>Ratliff, Brenda</td>
<td>92</td>
</tr>
<tr>
<td>Real, Lawrence</td>
<td>78</td>
</tr>
<tr>
<td>Regier, Darrel A.</td>
<td>30</td>
</tr>
<tr>
<td>Reich, James</td>
<td>61</td>
</tr>
<tr>
<td>Reid, William</td>
<td>72</td>
</tr>
<tr>
<td>Reifler, Burton V.</td>
<td>87</td>
</tr>
<tr>
<td>Reiss, David</td>
<td>34</td>
</tr>
<tr>
<td>Resnick, Phillip</td>
<td>6, 31, 18</td>
</tr>
<tr>
<td>Ressler, Kerry</td>
<td>80</td>
</tr>
<tr>
<td>Reus, Victor</td>
<td>87</td>
</tr>
<tr>
<td>Reyes, Raymond</td>
<td>77</td>
</tr>
<tr>
<td>Ribas, Michelle</td>
<td>54, 89</td>
</tr>
<tr>
<td>Richeimer, Steven</td>
<td>7</td>
</tr>
<tr>
<td>Rifai, Mahmad Aly</td>
<td>77</td>
</tr>
<tr>
<td>Rigaud, Marie-Claude</td>
<td>55</td>
</tr>
<tr>
<td>Ritchie, Elspeth</td>
<td>51</td>
</tr>
<tr>
<td>Roberts, Laura W.</td>
<td>20</td>
</tr>
<tr>
<td>Robinowitz, Carolyn B.</td>
<td>69</td>
</tr>
<tr>
<td>Robinson, David</td>
<td>18</td>
</tr>
<tr>
<td>Robinson, Delbert</td>
<td>84</td>
</tr>
<tr>
<td>Robinson, Gail</td>
<td>37, 45, 60, 79</td>
</tr>
<tr>
<td>Rodriguez, Carlos</td>
<td>70</td>
</tr>
<tr>
<td>Rodriguez, Carolyn</td>
<td>76</td>
</tr>
<tr>
<td>Rogers, John</td>
<td>23</td>
</tr>
<tr>
<td>Romanowski, Alan</td>
<td>51</td>
</tr>
<tr>
<td>Roose, Steven</td>
<td>85</td>
</tr>
<tr>
<td>Rosario, Vernon</td>
<td>97</td>
</tr>
<tr>
<td>Roskes, Erik</td>
<td>69</td>
</tr>
<tr>
<td>Ross, Stephen</td>
<td>57</td>
</tr>
<tr>
<td>Rostain, Anthony</td>
<td>18</td>
</tr>
<tr>
<td>Rothbaum, Barbara</td>
<td>72</td>
</tr>
<tr>
<td>Rothermundi, Matthias</td>
<td>92</td>
</tr>
<tr>
<td>Rothschild, Anthony J.</td>
<td>82</td>
</tr>
<tr>
<td>Rothstein, David</td>
<td>23</td>
</tr>
<tr>
<td>Rothstein, Mark</td>
<td>83</td>
</tr>
<tr>
<td>Roua, Samuel</td>
<td>1</td>
</tr>
<tr>
<td>Rudorfer, Matthew</td>
<td>35</td>
</tr>
<tr>
<td>Ruiz, Pedro</td>
<td>36, 56</td>
</tr>
<tr>
<td>Rundell, James</td>
<td>3</td>
</tr>
<tr>
<td>Rupp, Agnes</td>
<td>48</td>
</tr>
<tr>
<td>Rush, A. John</td>
<td>89</td>
</tr>
</tbody>
</table>

S

<table>
<thead>
<tr>
<th>Name</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sabo, Alex</td>
<td>23, 55</td>
</tr>
<tr>
<td>Sachs, Gary</td>
<td>17, 62, 65</td>
</tr>
<tr>
<td>Sadler, John</td>
<td>82</td>
</tr>
<tr>
<td>Saeid, Sy</td>
<td>50</td>
</tr>
<tr>
<td>Saks, Elyn R.</td>
<td>66</td>
</tr>
<tr>
<td>Salah, Rima</td>
<td>22</td>
</tr>
<tr>
<td>Samenow, Charles</td>
<td>20</td>
</tr>
<tr>
<td>Sampson, Stirlene</td>
<td>8</td>
</tr>
<tr>
<td>Sanchez-Russi, Carlos</td>
<td>81</td>
</tr>
<tr>
<td>Sanislow, Charles</td>
<td>78</td>
</tr>
<tr>
<td>Sanuck, Neil</td>
<td>56</td>
</tr>
<tr>
<td>Sarthorius, Norman</td>
<td>96</td>
</tr>
<tr>
<td>Satis, Usha</td>
<td>96</td>
</tr>
<tr>
<td>Saxon, Andrew</td>
<td>67</td>
</tr>
<tr>
<td>Seast, David</td>
<td>39</td>
</tr>
<tr>
<td>Schatzberg, Alan</td>
<td>3</td>
</tr>
<tr>
<td>Schiffer, Randolph</td>
<td></td>
</tr>
<tr>
<td>Schmidt, Chester</td>
<td>30, 69</td>
</tr>
<tr>
<td>Schoenbaum, Michael</td>
<td></td>
</tr>
<tr>
<td>Schoener, Gary</td>
<td>70</td>
</tr>
<tr>
<td>Schoevers, Robert A.</td>
<td>61</td>
</tr>
<tr>
<td>Schooff, Kenneth</td>
<td>21</td>
</tr>
<tr>
<td>Schulz, S. Charles</td>
<td>5, 89</td>
</tr>
<tr>
<td>Schwartz, Harold</td>
<td>97</td>
</tr>
<tr>
<td>Scott, Maria</td>
<td>55, 76</td>
</tr>
<tr>
<td>Scott, Bruce</td>
<td>8</td>
</tr>
<tr>
<td>Seely, Jr., James H.</td>
<td>61</td>
</tr>
<tr>
<td>Seale, Deborah</td>
<td>92</td>
</tr>
<tr>
<td>Sederer, Lloyd</td>
<td>94</td>
</tr>
<tr>
<td>Seidman, Larry</td>
<td>72</td>
</tr>
<tr>
<td>Seligman, Roslyn</td>
<td>23</td>
</tr>
<tr>
<td>Septon, Sandra</td>
<td>33</td>
</tr>
<tr>
<td>Sexton, Thomas</td>
<td>77</td>
</tr>
<tr>
<td>Shaffer, Davi</td>
<td>34</td>
</tr>
<tr>
<td>Shalev, Anel</td>
<td>72</td>
</tr>
<tr>
<td>Shaprio, Edward</td>
<td>51, 91</td>
</tr>
<tr>
<td>Shaffstein, Steven</td>
<td>61, 78</td>
</tr>
<tr>
<td>Shaw, Janet</td>
<td>69</td>
</tr>
<tr>
<td>Shaw, Jon</td>
<td>88</td>
</tr>
<tr>
<td>Shear, Shawn</td>
<td>7</td>
</tr>
<tr>
<td>Sheehan, Beverly</td>
<td>69</td>
</tr>
<tr>
<td>Shen, Hong</td>
<td>21</td>
</tr>
<tr>
<td>Sherbourne, Cathy</td>
<td>71</td>
</tr>
<tr>
<td>Sherrill, Joel</td>
<td>76</td>
</tr>
<tr>
<td>Shibley, Heather</td>
<td>21</td>
</tr>
<tr>
<td>Sholevar, Ellen</td>
<td>89</td>
</tr>
<tr>
<td>Siegel, Bryna</td>
<td>49</td>
</tr>
<tr>
<td>Sikkie, Limmarie</td>
<td>35</td>
</tr>
<tr>
<td>Silberman, Edward</td>
<td>23</td>
</tr>
<tr>
<td>Silk, Kenneth R.</td>
<td>8</td>
</tr>
<tr>
<td>Silverstein, Steven</td>
<td>88</td>
</tr>
<tr>
<td>Simon, Robert</td>
<td>8</td>
</tr>
<tr>
<td>Singh, Bruce</td>
<td>71</td>
</tr>
<tr>
<td>Sizoo, Bram</td>
<td>83</td>
</tr>
<tr>
<td>Skotol, Andrew</td>
<td>78</td>
</tr>
<tr>
<td>Slattery, Marcia</td>
<td>21</td>
</tr>
<tr>
<td>Smolin, Lucina</td>
<td>92</td>
</tr>
<tr>
<td>Smith, J.D.</td>
<td>29</td>
</tr>
<tr>
<td>Smuts, Lilian</td>
<td>77</td>
</tr>
<tr>
<td>Snow, Sharon</td>
<td>92</td>
</tr>
<tr>
<td>Solomon, David</td>
<td>63</td>
</tr>
<tr>
<td>Solitys, Stephen</td>
<td>51</td>
</tr>
</tbody>
</table>

Sonawalla, Shamshah        | 64      |
| Sorel, Elior              | 22, 37  |
| Sorensen, Claus           | 84      |
| Sostre, Samuel            | 28      |
| Spieber, Jacob            | 49, 92  |
| Spiegel, David            | 33      |
| Spitz, Deborah            | 23      |
| Sprinz, Melanie           | 77      |
| Srbstein, Jorge           | 63      |
| Srinivasan, Shilp         | 88      |
| Sripada, Chandra Sekhar   | 61      |
| Stahl, Stephen            | 17, 86  |
| Stankowski, Joay          | 22      |
| Star, Jodi                | 75      |
| Steenfeldt-Foss, Otto W.  | 19      |
| Steffens, David           | 50      |
| Stein, Dan                | 97      |
| Stenglass, Peter          | 87      |
| Stewart, Donna            | 21      |
| Stodland, Frederick       | 28      |
| Stolar, Andra             | 55      |
| Stolland, Hanna           | 92      |
| Stolland, Nada L.         | 78      |
| Stowell, Keith R.         | 55      |
| Strain, Eric              | 67      |
| Sreditzer, Jon            | 93      |
| Suardi, Enrico            | 48      |
| Sudak, Donna              | 55      |
| Summers, Richard          | 37      |
| Susman, Virginia          | 49, 97  |
| Swanson, Jeffrey          | 80      |
| Schwartz, Harold. I.     | 97      |
| Sweeney, John             | 40      |
| Swiggart, William         | 20      |

T

<table>
<thead>
<tr>
<th>Name</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taimtor, Zebulon</td>
<td>83</td>
</tr>
<tr>
<td>Talbott, John</td>
<td>81</td>
</tr>
<tr>
<td>Tammenga, Carol</td>
<td>49</td>
</tr>
<tr>
<td>Tan, Violetta</td>
<td>71</td>
</tr>
<tr>
<td>Tandon, Rajiv</td>
<td></td>
</tr>
<tr>
<td>Taylor, Janet</td>
<td>48</td>
</tr>
<tr>
<td>Terhakopian, Artin</td>
<td>21</td>
</tr>
<tr>
<td>Terr, Lenore</td>
<td>38</td>
</tr>
<tr>
<td>Thase, Michael</td>
<td>40, 49</td>
</tr>
<tr>
<td>Thompson, Kenneth</td>
<td>92</td>
</tr>
<tr>
<td>Tien, Elizabeth</td>
<td>56</td>
</tr>
<tr>
<td>Titchenal, Kay</td>
<td>51</td>
</tr>
<tr>
<td>Tivnan, Patricia</td>
<td>22</td>
</tr>
<tr>
<td>Toomey, Jennifer</td>
<td>57</td>
</tr>
<tr>
<td>Tracey, Martin</td>
<td>89</td>
</tr>
<tr>
<td>Treisman, Glenn</td>
<td>51</td>
</tr>
<tr>
<td>Trimble, Michael</td>
<td>20</td>
</tr>
<tr>
<td>Tross, Susan</td>
<td>55</td>
</tr>
<tr>
<td>Tschan, Werner</td>
<td>79</td>
</tr>
<tr>
<td>Tseng, Wen-Shing</td>
<td>73</td>
</tr>
<tr>
<td>Tsuang, John</td>
<td>57</td>
</tr>
<tr>
<td>Tucker, Phebe</td>
<td>91</td>
</tr>
<tr>
<td>Turkingston, Douglas</td>
<td>5</td>
</tr>
<tr>
<td>Tyano, Professor Sam</td>
<td>97</td>
</tr>
</tbody>
</table>

U

<table>
<thead>
<tr>
<th>Name</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Udomratn, Pichet</td>
<td>71</td>
</tr>
<tr>
<td>Ursano, Robert</td>
<td>52, 72</td>
</tr>
</tbody>
</table>
PARTICIPANT INDEX

V
Van, Henricus ............................................................ 44
Van Boeijen, Christine .............................................. 89
van Putten, Marijke ................................................ 91
van Wijngaarden-Cremers, Patricia ........................ 83
Varma, Vijoy .............................................................. 92
Vavrusova, Livia ..................................................... 37
Velligan, Dawn ......................................................... 66
Ventevogel, Peter .................................................... 22
Vergare, Michael .................................................. 54
Vickar, Gary .......................................................... 63
Vierteloff, Jeff ....................................................... 39
Vigueras, Adele ........................................................ 10
Vaswani, Ramaswamy ........................................... 48
Vitiello, Benedetto ................................................ 35
Vito, Jose ............................................................... 50
Voci, Frank ............................................................ 89
Vogels-Scibilia, Suzanne E. ................................ 28
Volkmar, Fred ........................................................ 92
Volpp, Serena ........................................................ 29

W
Waddell, Andrea .................................................... 48
Wagner, Karen ..................................................... 85
Waldbaum, Marjorie .............................................. 50
Walker, Sandra ........................................................... 55
Wapenj, Khakasa .................................................. 21
Watson, Clarence .................................................. 94
Watson, Stanley ..................................................... 50
Weder, Natalie ....................................................... 70
Weeckesker, Priyamby ............................................ 37
Weiden, Peter ......................................................... 40
Weine, Stevan M. .................................................. 39
Weinstein, Henry ................................................... 48
Weishrot, Deborah ........... ................................. 1
Weiss, Kenneth ..................................................... 94
Weker, Jonathan .................................................. 22
Wells, Kenneth ..................................................... 71
Wessely, Simon ..................................................... 36
Wiel, Paul .............................................................. 22
Wilens, Timothy ................................................... 4
Wilkins, Kirsten ..................................................... 94
Williams, Lori ........................................................... 92
Williams, Margaret ................................................... 6
Wilonack, Sharon ................................................... 2
Winstead, Daniel ................................................... 47
Wise, Michael ........................................................ 88
Witte, Helen .......................................................... 55
Wolfe, Mary Kay ................................................... 8
Woo, Benjamin ..................................................... 54
Woods, Stephen ..................................................... 65
Woddy, George .................................................... 33
Wright, Jesse ......................................................... 3, 55
Wulsin, Lawson ..................................................... 28

Y
Yaari, Roy .............................................................. 3
Yager, Joel ............................................................. 65
Yanowitz, Philip ................................................... 55
Yeomans, Frank ................................................... 21
Yeung, Albert ......................................................... 64
Young, Joel .......................................................... 85
Young, Keith ......................................................... 49, 64
Yudofsky, Stuart .................................................... 17

Z
Zachar, Peter .......................................................... 82
Zaretsky, Ari ........................................................... 6
Ziegler, Penelope .................................................. 55
Zisook, Sidney ..................................................... 64
Zolovska, Beata ..................................................... 76
Zubieta, Jon-Kar ...................................................... 61